Compare Experiments Report,Mon Nov 17 13:39:42 2025,,,,,,,,,,,,,,TFS,Probe Count,,TFS,Probe Count,,TFS,Probe Count,,TFS,Probe Count,,TFS,Probe Count,,,,,
Platform,Species,Probe Count,Sequences Loaded,,,,,,,,,,,,,615,,2.02,24,,12.0022,13,,11.1101,5,,13.2022,1,,,,,
04_Mouse_RNA-Seq_76K-RefSeqLncRNA_edgeR_TPM,Mouse-mm9,75798,0,,,,,,,,,,,,8.0001,143,,4.002,23,,10.0101,11,,3.11,4,,,,,,,,
Exp. no.,|FC| >,P-value used,P <,Study,Exp. info,Exp. samples,,,,,,,,,8.0002,89,,10.0202,21,,1.1,10,,7.222,4,,,,,,,,
1540,2,1,0.05,G174-G178_SexDiffs_76K_Liver subfractionation,76K_FullGeneBody_TPM_EdgeR_FeatureCounts_pval1:padj_pval2:pval,Male_Cytoplasm_G174_M1M2M3_FullGeneBody/Female_Cytoplasm_G174_M7M8M9_FullGeneBody,,,,,,,,,15.2222,52,,1.2,20,,12.0011,9,,5.202,4,,,,,,,,
1544,2,1,0.05,G174-G178_SexDiffs_76K_Liver subfractionation,76K_FullGeneBody_TPM_EdgeR_FeatureCounts_pval1:padj_pval2:pval,Male_Nucleus_G175_M1M2M3_FullGeneBody/Female_Nucleus_G175_M7M8M9_FullGeneBody,,,,,,,,,14.0222,41,,2.01,18,,3.22,7,,9.2002,3,,,,,,,,
1548,2,1,0.05,G174-G178_SexDiffs_76K_Liver subfractionation,76K_FullGeneBody_TPM_EdgeR_FeatureCounts_pval1:padj_pval2:pval,Male_Nucleoplasm_G176_M1M2M3_FullGeneBody/Female_Nucleoplasm_G176_M7M8M9_FullGeneBody,,,,,,,,,15.1111,37,,4.001,17,,7.111,7,,9.1001,2,,,,,,,,
1556,2,1,0.05,G174-G178_SexDiffs_76K_Liver subfractionation,76K_FullGeneBody_TPM_EdgeR_FeatureCounts_pval1:padj_pval2:pval,Male_Chromatin_polyA_G178_M1M2M3_FullGeneBody/Female_Chromatin_polyA_G178_M7M8M9_FullGeneBody,,,,,,,,,14.0111,26,,6.022,15,,6.011,7,,11.2202,2,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Up:,65,115,103,233,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Down:,93,166,153,222,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,1540:Male_Cytoplasm_G174_M1M2M3_FullGeneBody/Female_Cytoplasm_G174_M7M8M9_FullGeneBody,,,,,1544:Male_Nucleus_G175_M1M2M3_FullGeneBody/Female_Nucleus_G175_M7M8M9_FullGeneBody,,,,,1548:Male_Nucleoplasm_G176_M1M2M3_FullGeneBody/Female_Nucleoplasm_G176_M7M8M9_FullGeneBody,,,,,1556:Male_Chromatin_polyA_G178_M1M2M3_FullGeneBody/Female_Chromatin_polyA_G178_M7M8M9_FullGeneBody,,,,
Probe ID,TFS,1540:FS,1544:FS,1548:FS,1556:FS,Max. Intensity,Comment,Probe Note,Mapping Location(s),Accession No.,Gene Name/Desc.,GO terms,Gene Symbol,1540: Ratio,1540: FC,1540: Intensity-1,1540: Intensity-2,1540: P-1,1544: Ratio,1544: FC,1544: Intensity-1,1544: Intensity-2,1544: P-1,1548: Ratio,1548: FC,1548: Intensity-1,1548: Intensity-2,1548: P-1,1556: Ratio,1556: FC,1556: Intensity-1,1556: Intensity-2,1556: P-1
NC_AS_C11_9447,9.2002,1.2,0,0,8.0002,13.189681,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:7,050,611-7,052,603",,"lnc_as_chr11_9447, ",,lnc_as_chr11_9447,0.032828557,-30.4612841,5.9174731,0.16337278,0.000140655,0.10311803,-9.6976248,6.4186532,0.70319534,0.14429993,0.083739948,-11.9417318,5.6295746,0.41073884,0.20832347,0.028851873,-34.6597947,13.189681,0.29598013,0.003674919
CYP3A16,9.2002,1.2,0,0,8.0002,22.170776,,"[Minus], [# of exons: 13], [Gene type: NM]","chr5:146,197,178-146,226,307 chr5:146,228,336-146,228,429 chr5:146,230,439-146,230,592",NM_007820,"Cyp3a16, cytochrome P450, family 3, subfamily a, polypeptide 16, cytochrome P450 3A16|CYPIIIA16|cytochrome P450, 3a16, Predicted to have demethylase activity; retinoic acid 4-hydroxylase activity; and steroid hydroxylase activity. Predicted to be involved in oxidative demethylation and steroid metabolic process. Predicted to localize to endoplasmic reticulum membrane. Is expressed in liver. Human ortholog(s) of this gene implicated in B-lymphoblastic leukemia/lymphoma; acute lymphoblastic leukemia; chronic myeloid leukemia; and essential hypertension. Orthologous to several human genes including CYP3A5 (cytochrome P450 family 3 subfamily A member 5).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); endoplasmic reticulum (GO:0005783); endoplasmic reticulum membrane (GO:0005789); steroid metabolic process (GO:0008202); steroid hydroxylase activity (GO:0008395); retinoic acid 4-hydroxylase activity (GO:0008401); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); heme binding (GO:0020037); demethylase activity (GO:0032451); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); testosterone 6-beta-hydroxylase activity (GO:0050649); aromatase activity (GO:0070330); oxidative demethylation (GO:0070989); estrogen 16-alpha-hydroxylase activity (GO:0101020)",Cyp3a16,0.12506096,-7.9961007,22.170776,2.4257927,0.000790303,0.34061931,-2.9358288,8.7242745,3.113901,0.13734169,0.51592988,-1.9382479,16.410879,8.6120478,1,0.2003343,-4.9916565,4.127947,0.63453019,0.00205379
BMPER,9.2002,1.2,0,0,8.0002,2.1736332,,"[~1%  IN BLACKLIST], [Plus], [# of exons: 15], [Gene type: NM]","chr9:23,027,520-23,289,659",NM_028472,"Bmper, BMP-binding endothelial regulator, BMP-binding endothelial regulator protein|bone morphogenetic protein-binding endothelial cell precursor-derived regulator|crossveinless-2, Predicted to be an extracellular matrix structural constituent. Involved in inner ear development; negative regulation of BMP signaling pathway; and ureteric bud development. Localizes to extracellular region. Is expressed in several structures, including axial skeleton cervical region; branchial arch; embryo mesenchyme; nervous system; and neural ectoderm. Orthologous to human BMPER (BMP binding endothelial regulator).",blood vessel development (GO:0001568); ureteric bud development (GO:0001657); blood vessel endothelial cell proliferation involved in sprouting angiogenesis (GO:0002043); extracellular matrix structural constituent (GO:0005201); protein binding (GO:0005515); extracellular region (GO:0005576); extracellular space (GO:0005615); regulation of endothelial cell migration (GO:0010594); negative regulation of BMP signaling pathway (GO:0030514); extracellular matrix (GO:0031012); endothelial cell activation (GO:0042118); regulation of angiogenesis (GO:0045765); inner ear development (GO:0048839); regulation of pathway-restricted SMAD protein phosphorylation (GO:0060393); collagen-containing extracellular matrix (GO:0062023); positive regulation of ERK1 and ERK2 cascade (GO:0070374); positive regulation of sprouting angiogenesis (GO:1903672),Bmper,0.27531611,-3.6321885,0.061572954,0.015881092,0.043905837,0.50764616,-1.969876,0.17249087,0.092939894,0.21147438,0.71432063,-1.3999316,0.17761906,0.13265521,1,0.28832362,-3.4683249,2.1736332,0.49799631,0.003439286
NC_AS_C11_20789,9.1001,1.1,0,0,8.0001,1.5998687,,"[Minus], [# Lnc isoforms: 17], [# of exons: 7], [Gene type: lncRNA]","chr11:76,716,194-76,743,336",,"lnc_as_chr11_20789, ",,lnc_as_chr11_20789,59.71307,59.7130699,0,0.082961178,0.030158212,9.1274497,9.1274497,0.021703014,0.20127399,0.11673133,5.9984596,5.9984596,0.047212486,0.37682929,0.078141553,6.9214454,6.9214454,0.30737802,1.5998687,0.003090645
COL5A3,9.1001,1.1,0,0,8.0001,21.520786,,"[Minus], [# of exons: 67], [Gene type: NM]","chr9:20,574,501-20,619,511",NM_001317388 NM_016919,"Col5a3, collagen, type V, alpha 3, collagen alpha-3(V) chain|Pro-alpha3(V)|procollagen, type V, alpha 3, Exhibits heparin binding activity. Involved in cell-matrix adhesion. Localizes to collagen type V trimer. Is expressed in several structures, including bone; embryo mesenchyme; extraembryonic component; placenta; and tongue. Orthologous to human COL5A3 (collagen type V alpha 3 chain).",structural molecule activity (GO:0005198); extracellular matrix structural constituent (GO:0005201); collagen type V trimer (GO:0005588); extracellular space (GO:0005615); cell-matrix adhesion (GO:0007160); heparin binding (GO:0008201); extracellular matrix structural constituent conferring tensile strength (GO:0030020); extracellular matrix organization (GO:0030198); extracellular matrix (GO:0031012); proteoglycan binding (GO:0043394); collagen-containing extracellular matrix (GO:0062023),Col5a3,6.3028395,6.3028395,0.15099768,1.0089055,0.048057458,3.4952459,3.4952459,1.195257,4.5554785,0.16848747,3.4927278,3.4927278,1.2617077,4.4675564,0.87835395,5.687766,5.687766,4.5851684,21.520786,0.003439286
NC_INTER_C10_17890,8.0002,0,0,0,8.0002,85.29288,,"[Minus], [# Lnc isoforms: 10], [# of exons: 1], [Gene type: lncRNA]","chr10:4,625,483-4,626,813",,"lnc_inter_chr10_17890, ",,lnc_inter_chr10_17890,0.22576938,-4.4292985,1.115166,0.23133527,1,0.2728304,-3.6652806,3.953275,1.01729,1,0.080809482,-12.3747854,7.5871745,0.65452562,0.28113789,0.13588894,-7.3589506,85.29288,8.7812066,0.048675206
NC_INTER_C12_10681,8.0002,0,0,0,8.0002,1.8102481,,"[Minus], [# Lnc isoforms: 12], [# of exons: 3], [Gene type: lncRNA]","chr12:78,139,528-78,146,418",XR_004937633 XR_381704 XR_872834,"Gm35189, predicted gene, 35189; lnc_inter_chr12_10681, ",,Gm35189 lnc_inter_chr12_10681,8.1721735,8.1721735,0,0.034057135,1,0.033806957,-29.5797101,0.21298018,0,0.75330921,0.2403229,-4.1610683,0.45202726,0.095144255,1,0.093085851,-10.7427712,1.8102481,0.11717451,0.018039418
NC_INTER_C1_15689,8.0002,0,0,0,8.0002,109.71011,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr1:13,391,280-13,392,520",,"lnc_inter_chr1_15689, ",,lnc_inter_chr1_15689,1,1,0,0,1,0.24697489,-4.0489946,2.2506969,0.6331127,1,0.16037741,-6.2352921,2.5208823,0.39643177,0.60558166,0.11216052,-8.9157934,109.71011,8.52041,1.05E-05
NC_INTER_C1_53,8.0002,0,0,0,8.0002,14.127546,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr1:13,385,641-13,388,927",,"lnc_inter_chr1_53, ",,lnc_inter_chr1_53,1,1,0,0,1,0.037673558,-26.5438163,0.40266903,0,0.77169406,0.56314526,-1.7757408,0.15312117,0.099798248,1,0.15824452,-6.3193344,14.127546,1.5720379,0.001474953
NC_INTER_C10_18070,8.0002,0,0,0,8.0002,223.50262,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr10:17,351,780-17,352,244",,"Gm47771, ; lnc_inter_chr10_18070, ",,Gm47771 lnc_inter_chr10_18070,1,1,0,0,1,0.24578989,-4.0685156,6.739803,1.7476923,0.57208145,0.11247221,-8.8910852,3.6869201,0.35266887,1,0.13310193,-7.5130388,223.50262,19.842409,0.000261624
NC_INTER_C11_21075,8.0002,0,0,0,8.0002,42.42421,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:94,578,114-94,579,102",,"lnc_inter_chr11_21075, ",,lnc_inter_chr11_21075,1,1,0,0,1,0.028096239,-35.5919523,1.5006709,0,1,0.3283547,-3.0454871,0.50926736,0.16596004,1,0.011559449,-86.5093163,42.42421,0.22038456,0.005585043
NC_INTER_C11_21076,8.0002,0,0,0,8.0002,25.088181,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:94,579,242-94,581,353",,"lnc_inter_chr11_21076, ",,lnc_inter_chr11_21076,0.28665961,-3.488458,0.042137155,0,1,0.078001749,-12.8202253,0.26877501,0,1,0.040305547,-24.8104808,0.5988949,0,1,0.00932366,-107.2540198,25.088181,0.1031454,0.003106153
NC_INTER_C11_21077,8.0002,0,0,0,8.0002,41.483859,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:94,585,779-94,588,683",,"lnc_inter_chr11_21077, ",,lnc_inter_chr11_21077,1,1,0,0,1,0.053937105,-18.5401125,1.0082288,0.046291793,0.35441054,0.030815897,-32.4507837,0.57396421,0,1,0.00723281,-138.2588614,41.483859,0.18667366,0.000768825
NC_INTER_C11_21079,8.0002,0,0,0,8.0002,12.249649,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:94,590,743-94,592,106",,"lnc_inter_chr11_21079, ",,lnc_inter_chr11_21079,0.28665973,-3.4884566,0.06526158,0,1,0.26411638,-3.7862098,0.39270418,0.098629029,1,0.036094481,-27.7050669,1.1584111,0,1,0.00814135,-122.8297574,12.249649,0,0.036566185
NC_INTER_C14_25085,8.0002,0,0,0,8.0002,24.299634,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr14:19,190,556-19,191,645",,"lnc_inter_chr14_25085, ",,lnc_inter_chr14_25085,0.056266118,-17.7726853,0.72900153,0,1,0.28455353,-3.5142772,0.55099444,0.099518958,1,0.030975789,-32.2832781,1.5059939,0,0.75017275,0.085324538,-11.719958,24.299634,1.6785175,0.004425112
NC_INTER_C14_26164,8.0002,0,0,0,8.0002,10.631087,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr14:112,765,528-112,766,444",,"lnc_inter_chr14_26164, ",,lnc_inter_chr14_26164,0.28544382,-3.5033163,0.092585076,0,1,1.0587133,1.0587133,0.80085869,0.85211024,1,0.37928763,-2.6365215,0.52007799,0.23432859,1,0.045816675,-21.8261148,10.631087,0.23770736,0.023758338
NC_INTER_C15_26833,8.0002,0,0,0,8.0002,39.200827,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr15:60,709,466-60,712,951",,"lnc_inter_chr15_26833, ",,lnc_inter_chr15_26833,0.24133832,-4.1435609,0.051201844,0,1,0.01987324,-50.3189217,0.71136212,0,0.21871882,0.035299926,-28.3286711,0.53073822,0,1,0.000829162,-1206.036819,39.200827,0,1.08E-10
NC_INTER_C15_26835,8.0002,0,0,0,8.0002,29.636089,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr15:60,717,636-60,718,879",,"lnc_inter_chr15_26835, ",,lnc_inter_chr15_26835,1,1,0,0,1,0.03298715,-30.3148351,1.1629075,0,0.94758175,0.040938675,-24.4267796,1.1974671,0,0.92394651,0.011244453,-88.9327393,29.636089,0.17517292,0.003763919
NC_INTER_C15_26837,8.0002,0,0,0,8.0002,106.54602,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr15:60,724,696-60,724,998",,"lnc_inter_chr15_26837, ",,lnc_inter_chr15_26837,1,1,0,0,1,0.076546533,-13.063949,1.8078318,0,1,0.10667819,-9.3739875,1.332864,0,1,0.003605665,-277.3413587,106.54602,0,1.17E-06
NC_INTER_C2_33450,8.0002,0,0,0,8.0002,81.610414,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr2:52,228,394-52,229,212",,"lnc_inter_chr2_33450, ",,lnc_inter_chr2_33450,1,1,0,0,1,0.59818812,-1.6717149,1.0342074,0.69452531,1,0.38859769,-2.5733555,2.7220545,1.1873004,1,0.28536077,-3.5043359,81.610414,17.533025,0.012017963
NC_INTER_C2_34810,8.0002,0,0,0,8.0002,9.1011536,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr2:160,047,682-160,051,895",,"lnc_inter_chr2_34810, ",,lnc_inter_chr2_34810,1,1,0,0,1,0.42346315,-2.3614806,0.38788432,0.17345806,1,0.62488505,-1.6002943,0.085114186,0.03884129,1,0.20463549,-4.8867379,9.1011536,1.427971,0.035380149
NC_INTER_C4_38545,8.0002,0,0,0,8.0002,10.253059,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr4:109,299,827-109,301,488",,"lnc_inter_chr4_38545, ",,lnc_inter_chr4_38545,1,1,0,0,1,0.043780352,-22.8412966,0.72280948,0,1,0.041992962,-23.8135144,0.68866755,0,1,0.10976128,-9.1106807,10.253059,0.84101433,0.020394099
NC_INTER_C6_5136,8.0002,0,0,0,8.0002,2.7556866,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr6:51,612,113-51,614,949",,"lnc_inter_chr6_5136, ",,lnc_inter_chr6_5136,1,1,0,0,1,0.06481684,-15.4280894,0.25489321,0,1,0.074169012,-13.4827198,0.32137835,0,1,0.014644663,-68.2842613,2.7556866,0,0.044526549
NC_INTER_C6_5773,8.0002,0,0,0,8.0002,606.88607,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr6:144,319,659-144,319,886",,"lnc_inter_chr6_5773, ",,lnc_inter_chr6_5773,3.7030425,3.7030425,0,0.45180015,1,0.92493549,-1.0811565,0.68499166,0.47742795,1,0.18642243,-5.3641613,0.88661878,0,1,0.24094633,-4.1503019,606.88607,112.30481,0.000528375
NC_INTER_C7_43723,8.0002,0,0,0,8.0002,13.332275,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr7:3,207,784-3,212,775",,"lnc_inter_chr7_43723, ",,lnc_inter_chr7_43723,1,1,0,0,1,1.908892,1.908892,0.25862189,0.62395988,1,0.3794431,-2.6354413,0.48849361,0.19705088,1,0.28484495,-3.5106819,13.332275,2.8229545,0.018039418
NC_INTER_C7_43809,8.0002,0,0,0,8.0002,14.661486,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr7:7,077,284-7,078,697",,"lnc_inter_chr7_43809, ",,lnc_inter_chr7_43809,0.96444842,-1.0368621,0.12628339,0.074701422,1,0.41128176,-2.4314231,0.7318639,0.26697727,1,0.26613357,-3.7575116,2.5160536,0.69508867,1,0.089369771,-11.1894658,14.661486,1.0304693,0.003175999
NC_INTER_C7_44068,8.0002,0,0,0,8.0002,25.591403,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr7:27,080,664-27,081,850",,"lnc_inter_chr7_44068, ",,lnc_inter_chr7_44068,1,1,0,0,1,0.2680628,-3.7304691,0.13110717,0,1,0.23712936,-4.2171075,0.67879414,0.18098229,1,0.10049763,-9.9504834,25.591403,2.0882178,0.005823227
NC_INTER_C7_6006,8.0002,0,0,0,8.0002,10.306528,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr7:27,085,745-27,087,356",,"lnc_inter_chr7_6006, ",,lnc_inter_chr7_6006,1,1,0,0,1,0.25013032,-3.9979159,0.083062662,0,1,0.18887599,-5.2944791,0.58511132,0.10178058,1,0.073987796,-13.5157425,10.306528,0.56732017,0.01739692
NC_INTER_C6_43605,8.0002,0,0,0,8.0002,66.077447,,"[Minus], [# Lnc isoforms: 25], [# of exons: 1], [Gene type: lncRNA]","chr6:144,484,138-144,491,424",,"lnc_inter_chr6_43605, ",,lnc_inter_chr6_43605,2.221705,2.221705,0.011639848,0.032206102,1,0.33142375,-3.0172853,0.69622176,0.23747386,0.62651213,0.35402499,-2.8246593,0.41478176,0.15726031,1,0.27090906,-3.6912755,66.077447,13.181232,0.001573916
NC_INTER_C8_46399,8.0002,0,0,0,8.0002,34.859021,,"[Minus], [# Lnc isoforms: 25], [# of exons: 1], [Gene type: lncRNA]","chr8:58,042,842-58,045,059",,"lnc_inter_chr8_46399, ",,lnc_inter_chr8_46399,0.52885714,-1.8908698,0.91069981,0.43911837,1,0.48415701,-2.0654457,1.7250642,0.9272596,1,0.36339953,-2.7517922,5.9593627,2.3029004,0.38971244,0.21660494,-4.6166998,34.859021,5.8745775,0.000693342
NC_INTER_C13_24647,8.0002,0,0,0,8.0002,205.18477,,"[Minus], [# Lnc isoforms: 27], [# of exons: 1], [Gene type: lncRNA]","chr13:97,413,944-97,418,528",,"lnc_inter_chr13_24647, ",,lnc_inter_chr13_24647,0.15243343,-6.5602408,3.6584698,0.52559911,0.11066977,0.25009061,-3.9985508,10.451311,3.3231383,0.35081206,0.14357031,-6.9652282,22.548732,3.5558013,0.21372681,0.1932782,-5.1738892,205.18477,26.393498,0.044008618
NC_INTER_C10_9281,8.0002,0,0,0,8.0002,22.764288,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr10:114,690,127-114,693,537",,"lnc_inter_chr10_9281, ",,lnc_inter_chr10_9281,0.16999436,-5.8825482,0.049740721,0,1,0.24651131,-4.0566091,0.82172853,0.16655013,0.85431377,0.22275464,-4.4892443,1.6546196,0.3990539,0.95983578,0.16337996,-6.1207016,22.764288,2.6418939,0.009059061
NC_INTER_C11_9995,8.0002,0,0,0,8.0002,23.032907,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr11:94,572,914-94,574,127",,"lnc_inter_chr11_9995, ",,lnc_inter_chr11_9995,1,1,0,0,1,0.050232787,-19.9073169,0.66189917,0,1,0.052810316,-18.9356943,0.79338289,0,1,0.017429302,-57.3746446,23.032907,0.17950531,0.019097994
NC_INTER_C14_11847,8.0002,0,0,0,8.0002,15.717187,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr14:19,184,226-19,186,238",,"lnc_inter_chr14_11847, ",,lnc_inter_chr14_11847,0.34832998,-2.8708411,0.17478257,0.050973476,1,0.076074252,-13.145052,1.1769401,0.080843487,0.18759797,0.091404434,-10.9403884,1.1949808,0.1066824,0.46436432,0.047974947,-20.8442125,15.717187,0.50947928,1.32E-06
NC_INTER_C7_44067,8.0002,0,0,0,8.0002,3.5706152,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr7:27,075,416-27,080,609",,"lnc_inter_chr7_44067, ",,lnc_inter_chr7_44067,1,1,0,0,1,0.85786762,-1.165681,0.081479107,0.062608981,1,0.053875813,-18.5612049,0.19439154,0,1,0.025192168,-39.6948763,3.5706152,0.062461076,0.000474692
NC_INTER_C7_44074,8.0002,0,0,0,8.0002,2.2623672,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr7:27,137,187-27,140,844",,"lnc_inter_chr7_44074, ",,lnc_inter_chr7_44074,0.034327291,-29.1313408,0.30970168,0,0.85535421,0.018263642,-54.753593,0.82953093,0,0.068447333,0.071239174,-14.0372207,0.81523761,0.044746611,0.15055732,0.01458127,-68.581133,2.2623672,0,0.017434709
NC_INTER_C1_292,8.0002,0,0,0,8.0002,11.227154,,"[Minus], [# Lnc isoforms: 53], [# of exons: 6], [Gene type: lncRNA]","chr1:71,937,681-71,985,206",AK144102 XR_004936166 XR_373491 XR_373492,"Gm28818, predicted gene 28818; lnc_inter_chr1_292, ",,Gm28818 lnc_inter_chr1_292,0.51709794,-1.9338696,1.0255938,0.49326582,1,0.62825785,-1.5917031,1.3211337,0.84638858,1,0.58007588,-1.7239124,2.5230754,1.559861,1,0.3664865,-2.7286135,11.227154,3.0911954,0.021053747
NC_INTER_C17_13857,8.0002,0,0,0,8.0002,4.4775233,,"[Minus], [# Lnc isoforms: 5], [# of exons: 5], [Gene type: lncRNA]","chr17:33,087,906-33,102,666",NR_033585,"Cyp4f41-ps, cytochrome P450, family 4, subfamily f, polypeptide 41 pseudogene; lnc_inter_chr17_13857, ",,Cyp4f41-ps lnc_inter_chr17_13857,0.73105397,-1.3678881,0.11405136,0.07763602,1,0.42505353,-2.3526448,0.42367858,0.19787081,1,0.28115172,-3.5567985,0.64148483,0.18788717,0.76195776,0.1972974,-5.0684905,4.4775233,0.64999672,0.043758671
NC_INTER_C11_9778,8.0002,0,0,0,8.0002,8.0238011,,"[Minus], [# Lnc isoforms: 7], [# of exons: 3], [Gene type: lncRNA]","chr11:61,037,142-61,049,773",NM_001331114,"Aldh3a2, aldehyde dehydrogenase family 3, subfamily A2, aldehyde dehydrogenase family 3 member A2|alcohol dehydrogenase family 3, subfamily A2|aldehyde dehydrogenase 3|aldehyde dehydrogenase 4, liver microsomal (class 3) regulator|fatty aldehyde dehydrogenase variant form; lnc_inter_chr11_9778,9779,9780, ","response to reactive oxygen species (GO:0000302); 3-chloroallyl aldehyde dehydrogenase activity (GO:0004028); aldehyde dehydrogenase (NAD) activity (GO:0004029); nucleus (GO:0005634); mitochondrion (GO:0005739); mitochondrial inner membrane (GO:0005743); peroxisome (GO:0005777); endoplasmic reticulum (GO:0005783); cytosol (GO:0005829); cellular aldehyde metabolic process (GO:0006081); lipid metabolic process (GO:0006629); fatty acid metabolic process (GO:0006631); sesquiterpenoid metabolic process (GO:0006714); central nervous system development (GO:0007417); peripheral nervous system development (GO:0007422); epidermis development (GO:0008544); membrane (GO:0016020); integral component of membrane (GO:0016021); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor (GO:0016620); phytol metabolic process (GO:0033306); extrinsic component of endoplasmic reticulum membrane (GO:0042406); protein homodimerization activity (GO:0042803); intracellular membrane-bounded organelle (GO:0043231); glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity (GO:0043878); formaldehyde metabolic process (GO:0046292); hexadecanal metabolic process (GO:0046458); long-chain-alcohol oxidase activity (GO:0046577); long-chain-aldehyde dehydrogenase activity (GO:0050061); medium-chain-aldehyde dehydrogenase activity (GO:0052814)",Aldh3a2 lnc_inter_chr11_9778,0.11070047,-9.0333855,0.10309515,0.008119597,1,0.2016126,-4.9600075,0.52954168,0.10489714,0.62815834,0.1399915,-7.1432908,0.76270284,0.10382535,0.16231821,0.20082442,-4.979474,8.0238011,1.3167057,0.021053747
NC_INTER_C6_5626,8.0002,0,0,0,8.0002,2.9084884,,"[Minus], [# Lnc isoforms: 8], [# of exons: 5], [Gene type: lncRNA]","chr6:127,268,080-127,291,792",,"lnc_inter_chr6_5626,5627, ",,lnc_inter_chr6_5626,0.55075685,-1.8156833,0.02556032,0.014221166,1,0.13678304,-7.310848,0.091479087,0.011338678,0.61803451,0.1072651,-9.3226966,0.078081071,0.006901078,0.88575246,0.10659041,-9.3817067,2.9084884,0.22684537,8.73E-07
VEPH1,8.0002,0,0,0,8.0002,0.81215832,,"[Minus], [# of exons: 14], [Gene type: NM]","chr3:65,857,480-66,100,759",NM_145820,"Veph1, ventricular zone expressed PH domain-containing 1, ventricular zone-expressed PH domain-containing protein 1|protein melted homolog, Predicted to have phosphatidylinositol-5-phosphate binding activity. Predicted to be involved in negative regulation of SMAD protein signal transduction and negative regulation of transforming growth factor beta receptor signaling pathway. Predicted to localize to plasma membrane. Is expressed in central nervous system; eye; and metanephros. Orthologous to human VEPH1 (ventricular zone expressed PH domain containing 1).",plasma membrane (GO:0005886); regulation of signal transduction (GO:0009966); phosphatidylinositol-5-phosphate binding (GO:0010314); membrane (GO:0016020); negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512); negative regulation of SMAD protein signal transduction (GO:0060392),Veph1,1.0457071,1.0457071,0.009321378,0.009976648,1,0.49334861,-2.0269643,0.035920436,0.017530847,1,0.38738432,-2.5814158,0.05643275,0.024363072,1,0.35049427,-2.8531137,0.81215832,0.20829513,0.041467903
PLTP,8.0002,0,0,0,8.0002,51.51784,,"[Minus], [# of exons: 16], [Gene type: NM]","chr2:164,665,018-164,683,208",NM_011125,"Pltp, phospholipid transfer protein, phospholipid transfer protein|lipid transfer protein II, Exhibits lipid transfer activity. Involved in flagellated sperm motility and vitamin E biosynthetic process. Localizes to extracellular space. Is expressed in dental placode; humerus cartilage condensation; oral epithelium; and tooth epithelium. Used to study dry eye syndrome. Orthologous to human PLTP (phospholipid transfer protein).",extracellular region (GO:0005576); extracellular space (GO:0005615); nucleus (GO:0005634); lipid metabolic process (GO:0006629); lipid transport (GO:0006869); high-density lipoprotein particle binding (GO:0008035); lipid binding (GO:0008289); phosphatidylethanolamine binding (GO:0008429); phosphatidylcholine transporter activity (GO:0008525); phosphatidylinositol transporter activity (GO:0008526); vitamin E biosynthetic process (GO:0010189); positive regulation of cholesterol efflux (GO:0010875); phospholipid transport (GO:0015914); diacylglycerol binding (GO:0019992); low-density lipoprotein particle binding (GO:0030169); flagellated sperm motility (GO:0030317); phosphatidylcholine binding (GO:0031210); very-low-density lipoprotein particle binding (GO:0034189); high-density lipoprotein particle (GO:0034364); high-density lipoprotein particle remodeling (GO:0034375); ceramide transport (GO:0035627); glycolipid transport (GO:0046836); phosphatidic acid binding (GO:0070300); ceramide binding (GO:0097001); intermembrane phospholipid transfer activity (GO:0120014); intermembrane ceramide transfer activity (GO:0120017); intermembrane phosphotidylcholine transfer activity (GO:0120019); intermembrane cholesterol transfer activity (GO:0120020); phosphatidylglycerol binding (GO:1901611); phosphatidylethanolamine transporter activity (GO:1904121); phosphatidic acid transporter activity (GO:1990050),Pltp,1.0083376,1.0083376,12.869497,12.346992,1,0.51468169,-1.9429485,44.210717,25.369271,0.25118016,0.48705159,-2.0531706,43.930593,22.832374,0.33179283,0.34405901,-2.9064782,51.51784,12.352366,0.046268233
PHEX,8.0002,0,0,0,8.0002,0.26619087,,"[Minus], [# of exons: 22], [Gene type: NM]","chrX:153,596,618-153,853,218",NM_011077,"Phex, phosphate regulating endopeptidase homolog, X-linked, phosphate-regulating neutral endopeptidase PHEX|Metalloendopeptidase homolog PEX (Phosphate regulating neutral endopeptidase) (X-linked hypophosphatemia protein) (HYP) (Vitamin D-resistant hypophosphatemic rickets protein)|X-linked hypophosphatemia protein|X-linked phosphate regulating endopeptidase|phosphate regulating gene with homologies to endopeptidases on the X chromosome (hypophosphatemia, vitamin D resistant rickets)|phosphate regulating neutral endopeptidase|vitamin D-resistant hypophosphatemic rickets protein, Predicted to have metalloendopeptidase activity. Involved in bone mineralization; odontogenesis; and organophosphate metabolic process. Localizes to Golgi apparatus; endoplasmic reticulum; and perinuclear region of cytoplasm. Is expressed in several structures, including chondrocranium; epidermis; limb; liver; and tooth. Used to study X-linked dominant hypophosphatemic rickets and otitis media. Human ortholog(s) of this gene implicated in X-linked dominant hypophosphatemic rickets. Orthologous to human PHEX (phosphate regulating endopeptidase homolog X-linked).",metalloendopeptidase activity (GO:0004222); endoplasmic reticulum (GO:0005783); Golgi apparatus (GO:0005794); plasma membrane (GO:0005886); proteolysis (GO:0006508); peptidase activity (GO:0008233); metallopeptidase activity (GO:0008237); membrane (GO:0016020); integral component of membrane (GO:0016021); protein processing (GO:0016485); hydrolase activity (GO:0016787); organophosphate metabolic process (GO:0019637); bone mineralization (GO:0030282); biomineral tissue development (GO:0031214); odontogenesis (GO:0042476); metal ion binding (GO:0046872); perinuclear region of cytoplasm (GO:0048471),Phex,0.14117718,-7.0832977,0.004083286,0.000399683,1,0.41661158,-2.4003173,0.004114586,0.001690142,1,0.21615284,-4.626356,0.009292838,0.001913153,1,0.1687341,-5.9264843,0.26619087,0.029660897,0.031390261
SGSM1,8.0002,0,0,0,8.0002,3.9900639,,"[Minus], [# of exons: 26], [Gene type: NM]","chr5:113,672,240-113,739,806",NM_001162965 NM_001254731 NM_001309526 NM_001309528 NM_172718,"Sgsm1, small G protein signaling modulator 1, small G protein signaling modulator 1|RUN and TBC1 domain containing 2|RUN and TBC1 domain-containing protein 2|nurr1-interacting protein, Exhibits small GTPase binding activity. Involved in positive regulation of transcription by RNA polymerase II. Localizes to cytoplasmic vesicle membrane. Is expressed in several structures, including brain. Orthologous to human SGSM1 (small G protein signaling modulator 1).",GTPase activator activity (GO:0005096); protein binding (GO:0005515); cytoplasm (GO:0005737); Golgi apparatus (GO:0005794); cytosol (GO:0005829); intracellular protein transport (GO:0006886); membrane (GO:0016020); cytoplasmic vesicle membrane (GO:0030659); small GTPase binding (GO:0031267); cytoplasmic vesicle (GO:0031410); positive regulation of transcription by RNA polymerase II (GO:0045944); activation of GTPase activity (GO:0090630),Sgsm1,0.49716156,-2.0114186,0.50570539,0.23947931,1,0.32423327,-3.0841993,0.92915008,0.34132988,0.058199587,0.39112798,-2.5567079,0.57900779,0.2416726,0.23587979,0.29360668,-3.4059171,3.9900639,0.81399509,0.022312856
GM11541,8.0002,0,0,0,8.0002,4.7399432,,"[Minus], [# of exons: 2], [Gene type: NM]","chr11:94,555,812-94,565,813",NM_001007584,"Gm11541, predicted gene 11541, uncharacterized protein LOC432589",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Gm11541,0.051853151,-19.2852312,0.080155436,0,1,0.1708843,-5.8519126,0.15146396,0.021673062,1,0.023913744,-41.8169567,0.2226418,0,0.68715804,0.08753533,-11.4239588,4.7399432,0.27505815,0.040519671
GJB4,8.0002,0,0,0,8.0002,14.026753,,"[Minus], [# of exons: 2], [Gene type: NM]","chr4:127,028,330-127,031,325",NM_008127,"Gjb4, gap junction protein, beta 4, gap junction beta-4 protein|connexin b|connexin-30.3|gap junction membrane channel protein beta 4, Exhibits gap junction channel activity. Involved in several processes, including gap junction-mediated intercellular transport; olfactory behavior; and sensory perception of smell. Localizes to connexin complex and integral component of plasma membrane. Is expressed in early conceptus and testis. Human ortholog(s) of this gene implicated in erythrokeratodermia variabilis and erythrokeratodermia variabilis et progressiva 2. Orthologous to human GJB4 (gap junction protein beta 4).",gap junction channel activity (GO:0005243); protein binding (GO:0005515); nucleoplasm (GO:0005654); nucleolus (GO:0005730); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); gap junction (GO:0005921); connexin complex (GO:0005922); cell communication (GO:0007154); cell-cell signaling (GO:0007267); sensory perception of smell (GO:0007608); membrane (GO:0016020); integral component of membrane (GO:0016021); cell junction (GO:0030054); olfactory behavior (GO:0042048); gap junction-mediated intercellular transport (GO:1990349),Gjb4,0.035278116,-28.3461851,1.7227794,0.039174234,1,0.094660933,-10.5640201,4.6826463,0.60459316,0.68552932,0.10857016,-9.2106342,6.2784738,0.74489573,0.7960077,0.003568157,-280.2567379,14.026753,0,0.044070405
4930594M17RIK,8.0002,0,0,0,8.0002,1.1267327,,"[Minus], [# of exons: 2], [Gene type: lincRNA]","chr18:81,422,943-81,432,805",AK016392,"4930594M17Rik, RIKEN cDNA 4930594M17 gene, uncharacterized protein LOC75937",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),4930594M17Rik,1,1,0,0,1,0.088265748,-11.3294231,0.063067575,0,1,1,1,0,0,1,0.076436768,-13.0827091,1.1267327,0.054968598,0.0373301
GM44707,8.0002,0,0,0,8.0002,6.3881414,,"[Minus], [# of exons: 2], [Gene type: lincRNA]","chr7:51,111,456-51,112,783",,"Gm44707, ",,Gm44707,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0.015590808,-64.1403595,6.3881414,0,0.049155261
GM47770,8.0002,0,0,0,8.0002,3.8178056,,"[Minus], [# of exons: 2], [Gene type: lincRNA]","chr10:17,242,419-17,246,720",,"Gm47770, ",,Gm47770,1.0605466,1.0605466,0.019718189,0.0238453,1,0.20230282,-4.9430848,0.33377483,0.075636873,1,0.14871587,-6.7242321,0.34370684,0.038123348,1,0.030290566,-33.0135793,3.8178056,0.050625423,0.002647321
NC_INTER_CX_15244,8.0002,0,0,0,8.0002,7.2183598,,"[Plus], [# Lnc isoforms: 10], [# of exons: 1], [Gene type: lncRNA]","chrX:9,364,108-9,374,686",,"lnc_inter_chrX_15244, ",,lnc_inter_chrX_15244,0.28688309,-3.4857405,0.008409107,0,1,0.16778721,-5.9599298,0.16098819,0.028085504,1,0.083232286,-12.0145684,0.22229642,0.015469688,1,0.15617584,-6.4030388,7.2183598,0.78685331,0.000523226
NC_INTER_C13_24552,8.0002,0,0,0,8.0002,99.689741,,"[Plus], [# Lnc isoforms: 12], [# of exons: 1], [Gene type: lncRNA]","chr13:87,770,773-87,772,593",,"lnc_inter_chr13_24552, ",,lnc_inter_chr13_24552,0.3484563,-2.8698003,5.0513286,1.639674,1,0.6010766,-1.6636815,5.4786496,3.5231767,1,0.62389736,-1.6028278,11.793112,7.872098,1,0.32387662,-3.0875955,99.689741,23.692984,0.017912805
NC_INTER_C16_28698,8.0002,0,0,0,8.0002,24.762841,,"[Plus], [# Lnc isoforms: 12], [# of exons: 1], [Gene type: lncRNA]","chr16:86,196,507-86,201,717",,"lnc_inter_chr16_28698, ",,lnc_inter_chr16_28698,0.23155845,-4.318564,0.21977156,0.042779259,1,0.40254855,-2.4841724,2.568479,1.2186243,1,0.31890672,-3.1357132,3.3336455,1.1567612,0.20882771,0.26693927,-3.7461704,24.762841,4.7615815,0.003815406
NC_INTER_C2_1451,8.0002,0,0,0,8.0002,4.8923812,,"[Plus], [# Lnc isoforms: 17], [# of exons: 5], [Gene type: lncRNA]","chr2:70,761,136-70,777,894",,"lnc_inter_chr2_1451, ",,lnc_inter_chr2_1451,0.21575427,-4.6349025,0.068788739,0.01241865,1,0.21710604,-4.6060442,0.26021986,0.05459866,0.76035167,0.050115833,-19.953774,0.60950108,0.029294371,0.18937709,0.11134063,-8.9814473,4.8923812,0.39005613,0.005823227
NC_AS_C9_7843,8.0002,0,0,0,8.0002,6.5460493,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr9:40,131,258-40,139,886",,"lnc_as_chr9_7843, ",,lnc_as_chr9_7843,0.12419454,-8.051884,0.030928906,0,1,0.31877286,-3.1370299,0.39431238,0.12565287,1,0.32464383,-3.0802988,0.18498939,0.062847922,1,0.19612296,-5.0988421,6.5460493,0.94859101,0.001482659
NC_INTER_C1_15604,8.0002,0,0,0,8.0002,124.20044,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr1:7,308,221-7,308,515",,"lnc_inter_chr1_15604, ",,lnc_inter_chr1_15604,1,1,0,0,1,0.068941244,-14.5051053,2.6071285,0,1,0.37838319,-2.6428236,4.1419841,1.6697791,1,0.14543376,-6.8759826,124.20044,15.058802,0.006944144
NC_INTER_C10_18326,8.0002,0,0,0,8.0002,20.208983,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr10:33,610,942-33,612,108",,"lnc_inter_chr10_18326, ",,lnc_inter_chr10_18326,1,1,0,0,1,0.15038007,-6.6498172,0.25730401,0,1,0.064803073,-15.431367,0.68442903,0,1,0.004784311,-209.0165335,20.208983,0,0.00031429
NC_INTER_C11_20411,8.0002,0,0,0,8.0002,9.7069674,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:57,797,555-57,798,969",,"lnc_inter_chr11_20411, ",,lnc_inter_chr11_20411,0.17375986,-5.7550691,0.12581546,0,1,0.047742496,-20.9457001,0.7309781,0,1,4.1142394,4.1142394,0,0.15179985,1,0.034875254,-28.6736265,9.7069674,0.15398865,0.001670364
NC_INTER_C11_20695,8.0002,0,0,0,8.0002,189.2826,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:70,848,474-70,848,872",,"lnc_inter_chr11_20695, ",,lnc_inter_chr11_20695,4.2847927,4.2847927,0,0.29479103,1,1.324216,1.324216,2.9883328,3.9986487,1,0.14093658,-7.0953898,9.8480343,1.2334549,0.29581869,0.3002468,-3.3305933,189.2826,44.822145,0.027170163
NC_INTER_C14_12193,8.0002,0,0,0,8.0002,60.296694,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr14:76,233,905-76,239,302",,"lnc_inter_chr14_12193, ",,lnc_inter_chr14_12193,0.36139974,-2.7670191,0.97010253,0.32268394,1,0.35703732,-2.8008276,3.4225235,1.2096202,0.23793612,0.35683585,-2.802409,3.4431858,1.3095923,1,0.18603519,-5.3753272,60.296694,8.2939817,0.006607957
NC_INTER_C15_26842,8.0002,0,0,0,8.0002,14.601106,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr15:60,786,966-60,788,180",,"lnc_inter_chr15_26842, ",,lnc_inter_chr15_26842,1,1,0,0,1,0.14927984,-6.6988281,0.23830894,0,1,0.29479357,-3.3922043,0.082892283,0,1,0.007345451,-136.1386846,14.601106,0,5.79E-05
NC_INTER_C2_34674,8.0002,0,0,0,8.0002,7.5671222,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr2:153,431,677-153,433,177",,"lnc_inter_chr2_34674, ",,lnc_inter_chr2_34674,4.3254049,4.3254049,0,0.078217887,1,0.043719185,-22.8732535,0.80753064,0,1,0.16568584,-6.0355187,0.18341932,0,1,0.04022594,-24.8595807,7.5671222,0.21624025,0.023642609
NC_INTER_C4_37970,8.0002,0,0,0,8.0002,41.954129,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr4:60,174,844-60,175,299",,"lnc_inter_chr4_37970, ",,lnc_inter_chr4_37970,0.28634998,-3.49223,0.19549788,0,1,0.50129543,-1.9948317,0.58819318,0.29545355,1,0.75752495,-1.3200885,2.0716799,1.7982237,1,0.073498339,-13.6057497,41.954129,2.0185756,0.014059928
NC_INTER_C6_41681,8.0002,0,0,0,8.0002,4.2652897,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr6:5,428,151-5,431,129",,"lnc_inter_chr6_41681, ",,lnc_inter_chr6_41681,6.8224427,6.8224427,0,0.073836623,1,0.24905131,-4.0152368,0.60104435,0.12667524,1,0.21335683,-4.6869838,0.54192096,0.11011989,1,0.059513558,-16.8028939,4.2652897,0.14623233,0.034840087
NC_INTER_CX_15240,8.0002,0,0,0,8.0002,4.5200609,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrX:9,325,108-9,333,758",,"lnc_inter_chrX_15240, ",,lnc_inter_chrX_15240,0.17381602,-5.7532098,0.020566828,0,1,0.021836196,-45.7955225,0.24201216,0,0.12606939,0.1275381,-7.840794,0.19843686,0.018917729,1,0.20648104,-4.8430597,4.5200609,0.71320314,0.035214218
NC_INTER_CX_15243,8.0002,0,0,0,8.0002,25.322917,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrX:9,359,746-9,363,525",,"lnc_inter_chrX_15243, ",,lnc_inter_chrX_15243,1,1,0,0,1,0.41553808,-2.4065183,0.1999964,0.071146529,1,0.014716467,-67.951093,0.98494254,0,0.063911626,0.11980928,-8.3465987,25.322917,2.3065885,0.001674464
NC_INTER_CX_15246,8.0002,0,0,0,8.0002,54.756325,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrX:9,378,393-9,379,790",,"lnc_inter_chrX_15246, ",,lnc_inter_chrX_15246,8.1797508,8.1797508,0,0.16796969,1,0.083051544,-12.0407153,0.4297017,0,1,0.082060237,-12.1861701,0.3866066,0,1,0.11847714,-8.4404471,54.756325,4.6546641,0.000235328
NC_INTER_CX_15247,8.0002,0,0,0,8.0002,55.092236,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrX:9,381,147-9,382,118",,"lnc_inter_chrX_15247, ",,lnc_inter_chrX_15247,1,1,0,0,1,0.052757322,-18.9547151,0.8599505,0,1,0.043788013,-22.8373001,1.1400036,0,1,0.09105702,-10.9821296,55.092236,3.8305238,6.18E-06
NC_INTER_C1_290,8.0002,0,0,0,8.0002,2.8814262,,"[Plus], [# Lnc isoforms: 20], [# of exons: 2], [Gene type: lncRNA]","chr1:71,860,185-71,888,434",,"lnc_inter_chr1_290, ",,lnc_inter_chr1_290,0.2889712,-3.4605525,0.09979784,0.023563501,1,0.13955317,-7.1657275,0.22538611,0.034310783,0.068632466,0.25460656,-3.9276286,0.30809453,0.077122568,0.8307964,0.1837975,-5.4407704,2.8814262,0.37130863,0.002485522
NC_INTER_C13_11440,8.0002,0,0,0,8.0002,2.3126596,,"[Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr13:60,602,667-60,608,140",,"lnc_inter_chr13_11440, ",,lnc_inter_chr13_11440,8.1699373,8.1699373,0,0.042874778,1,0.033773107,-29.6093573,0.26425634,0,0.42078322,0.091718159,-10.9029664,0.46490969,0.029899206,0.507053,0.11985101,-8.3436929,2.3126596,0.19809988,0.046480255
NC_INTER_C15_12594,8.0002,0,0,0,8.0002,18.093035,,"[Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr15:60,755,166-60,756,367",AK015045 AV258845 XR_001781666,"4930402D18Rik, RIKEN cDNA 4930402D18 gene; lnc_inter_chr15_12594, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),4930402D18Rik lnc_inter_chr15_12594,1,1,0,0,1,0.080714201,-12.3893935,0.48177695,0,1,0.036827798,-27.153402,1.0977307,0,1,0.00578755,-172.7846866,18.093035,0,4.84E-06
NC_INTER_C15_26844,8.0002,0,0,0,8.0002,7.564966,,"[Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr15:60,800,452-60,804,492",,"lnc_inter_chr15_26844, ",,lnc_inter_chr15_26844,0.24133775,-4.1435706,0.044167927,0,1,0.044871185,-22.2860173,0.23722198,0,1,0.03381987,-29.5684168,0.37189675,0,1,0.028217028,-35.439594,7.564966,0.10779205,2.05E-05
NC_INTER_C19_14771,8.0002,0,0,0,8.0002,5.7408876,,"[Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr19:7,926,292-7,928,521",,"lnc_inter_chr19_14771, ",,lnc_inter_chr19_14771,1,1,0,0,1,1,1,0,0,1,0.29519511,-3.38759,0.045146358,0,1,0.009330106,-107.1799221,5.7408876,0,0.001573916
NC_INTER_C7_44061,8.0002,0,0,0,8.0002,7.6064161,,"[Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr7:27,035,268-27,037,942",,"lnc_inter_chr7_44061, ",,lnc_inter_chr7_44061,0.09359515,-10.6843143,0.13151179,0,1,0.73502318,-1.3605013,0.27453523,0.19135013,1,1.1831416,1.1831416,0.12671165,0.20291026,1,0.023981311,-41.6991375,7.6064161,0.081428551,6.55E-05
NC_INTER_C4_3641,8.0002,0,0,0,8.0002,4.1979522,,"[Plus], [# Lnc isoforms: 39], [# of exons: 12], [Gene type: lncRNA]","chr4:125,627,051-125,676,986",,"lnc_inter_chr4_3641, ",,lnc_inter_chr4_3641,0.21061938,-4.7479012,0.26594814,0.048501828,0.53989225,0.28593105,-3.4973466,0.30823514,0.087590272,1,0.24019642,-4.1632594,0.23580407,0.058820128,0.14857173,0.16990768,-5.8855492,4.1979522,0.54586178,0.001694477
NC_INTER_C15_12563,8.0002,0,0,0,8.0002,4.8158312,,"[Plus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr15:59,004,090-59,012,171",,"lnc_inter_chr15_12563, ",,lnc_inter_chr15_12563,1,1,0,0,1,0.10179197,-9.8239578,0.052327766,0,1,0.059606421,-16.776716,0.096310498,0,1,0.045522445,-21.9671855,4.8158312,0.1406004,0.008610217
NC_INTER_C15_12564,8.0002,0,0,0,8.0002,4.8667886,,"[Plus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr15:59,013,120-59,020,699",,"lnc_inter_chr15_12564, ",,lnc_inter_chr15_12564,0.10314094,-9.6954709,0.05882417,0,1,0.22606667,-4.4234738,0.095378961,0.014299531,1,6.3912519,6.3912519,0,0.043269171,1,0.073965683,-13.5197832,4.8667886,0.26057277,0.021506075
NC_INTER_C14_26126,8.0002,0,0,0,8.0002,5.1735905,,"[Plus], [# Lnc isoforms: 3], [# of exons: 2], [Gene type: lncRNA]","chr14:103,901,968-103,905,354",AK079958 XR_003951019 XR_003951025 XR_003951028 XR_004938589 XR_004938590 XR_004938591 XR_004938592,"Gm34907, predicted gene, 34907; lnc_inter_chr14_26126, ",,Gm34907 lnc_inter_chr14_26126,0.24029243,-4.1615959,0.18160333,0.03465057,1,0.042956491,-23.2793691,0.35449681,0,1,0.46846618,-2.1346258,0.41117574,0.23850364,1,0.066078529,-15.1335089,5.1735905,0.22096989,0.001573916
NC_AS_C11_21353,8.0002,0,0,0,8.0002,91.276074,,"[Plus], [# Lnc isoforms: 3], [# of exons: 3], [Gene type: lncRNA]","chr11:106,442,080-106,450,818",,"lnc_as_chr11_21353, ",,lnc_as_chr11_21353,0.54528609,-1.8338997,1.6795837,0.85615356,1,0.45348227,-2.2051579,5.648767,2.573774,0.38184045,0.43491177,-2.2993169,8.4414409,3.9146249,0.17270411,0.34443486,-2.9033066,91.276074,23.789337,0.008863955
NC_INTER_C15_27363,8.0002,0,0,0,8.0002,1.8742309,,"[Plus], [# Lnc isoforms: 3], [# of exons: 3], [Gene type: lncRNA]","chr15:88,021,363-88,027,337",,"lnc_inter_chr15_27363, ",,lnc_inter_chr15_27363,0.28640784,-3.4915246,0.014889778,0,1,0.5275792,-1.89545,0.050220367,0.027227502,1,0.83887258,-1.1920761,0.056716932,0.063376885,1,0.072786232,-13.7388621,1.8742309,0.072895864,0.034882892
NC_INTER_CX_49474,8.0002,0,0,0,8.0002,3.8399146,,"[Plus], [# Lnc isoforms: 43], [# of exons: 1], [Gene type: lncRNA]","chrX:9,402,837-9,419,768",,"lnc_inter_chrX_49474, ",,lnc_inter_chrX_49474,1.9349665,1.9349665,0.005009033,0.013164015,1,0.64040963,-1.5615006,0.092677288,0.06877734,1,0.1178994,-8.4818074,0.25651523,0.028995043,0.55155834,0.21539555,-4.6426215,3.8399146,0.59797898,0.031390261
NC_INTER_C4_38002,8.0002,0,0,0,8.0002,62.190713,,"[Plus], [# Lnc isoforms: 5], [# of exons: 2], [Gene type: lncRNA]","chr4:61,266,682-61,270,230",,"lnc_inter_chr4_38002, ",,lnc_inter_chr4_38002,0.50398218,-1.9841971,0.22609072,0.086718124,1,0.1149158,-8.7020233,1.552542,0.20535747,0.25105936,0.26453153,-3.7802678,2.6989721,0.7642586,0.89407223,0.087788575,-11.3910039,62.190713,3.8364826,0.000168809
NC_INTER_C9_8183,8.0002,0,0,0,8.0002,21.875622,,"[Plus], [# Lnc isoforms: 6], [# of exons: 1], [Gene type: lncRNA]","chr9:89,201,219-89,210,132",,"lnc_inter_chr9_8183,8184,8185,8186,8187, ",,lnc_inter_chr9_8183,0.2404965,-4.1580646,0.020020019,0,1,0.3211906,-3.1134162,0.32939619,0.093885188,1,0.34794306,-2.8740334,0.37472344,0.12859069,1,0.36099106,-2.7701517,21.875622,6.1620989,0.041878856
NC_AS_C1_746,8.0002,0,0,0,8.0002,1.5457353,,"[Plus], [# Lnc isoforms: 7], [# of exons: 10], [Gene type: lncRNA]","chr1:163,934,733-164,020,736",NR_040562,"2810442N19Rik, RIKEN cDNA 2810442N19 gene; lnc_as_chr1_746, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),2810442N19Rik lnc_as_chr1_746,0.27936965,-3.5794869,0.017469414,0.003784038,1,0.26321682,-3.7991493,0.1132477,0.030431019,0.07372343,0.37169843,-2.690353,0.12197764,0.045441027,0.78243157,0.29963982,-3.3373401,1.5457353,0.34741313,0.040519671
NC_INTER_C2_1936,8.0002,0,0,0,8.0002,24.893885,,"[Plus], [# Lnc isoforms: 7], [# of exons: 1], [Gene type: lncRNA]","chr2:160,072,222-160,078,686",,"lnc_inter_chr2_1936, ",,lnc_inter_chr2_1936,0.23131061,-4.3231913,0.17465513,0.032195505,1,0.2097222,-4.7682123,1.7311959,0.3552555,0.23711884,0.18455949,-5.4183071,2.3009369,0.45439095,0.077750242,0.10883008,-9.1886362,24.893885,2.0683602,0.000334966
NC_INTER_C14_11911,8.0002,0,0,0,8.0002,6.4509241,,"[Plus], [# Lnc isoforms: 84], [# of exons: 15], [Gene type: lncRNA]","chr14:29,462,822-29,572,589",NR_168471,"Gm35164, predicted gene, 35164; lnc_inter_chr14_11911, ",,Gm35164 lnc_inter_chr14_11911,0.52918145,-1.889711,0.31776105,0.14548847,1,0.49031692,-2.0394972,0.43822774,0.23304019,0.2319695,0.39705621,-2.5185351,0.56976956,0.24250333,0.52877096,0.33089647,-3.0220933,6.4509241,1.5755138,0.049071222
NC_INTER_C12_10421,8.0002,0,0,0,8.0002,2.8789958,,"[Plus], [# Lnc isoforms: 88], [# of exons: 25], [Gene type: lncRNA]","chr12:25,813,911-25,915,096",XR_003950180 XR_004937752 XR_381342 XR_872584,"Gm17746Gm47705, ; Gm36287, predicted gene, 36287; lnc_inter_chr12_10421, ",,Gm17746Gm47705 Gm36287 lnc_inter_chr12_10421,0.47652081,-2.0985442,0.1193064,0.054524613,1,0.45969145,-2.1753722,0.20677816,0.098675092,0.40151939,0.43293375,-2.3098222,0.21078803,0.099696698,1,0.26405273,-3.7871224,2.8789958,0.55064248,0.000508381
ADCY10,8.0002,0,0,0,8.0002,1.3014466,,"[Plus], [# of exons: 35], [Gene type: NM]","chr1:167,415,314-167,506,904",NM_001357427 NM_173029,"Adcy10, adenylate cyclase 10, adenylate cyclase type 10|germ cell soluble adenylyl cyclase|testicular soluble adenylyl cyclase, Predicted to have several functions, including ATPase binding activity; bicarbonate binding activity; and manganese ion binding activity. Predicted to be involved in several processes, including cAMP biosynthetic process; epithelial cilium movement involved in extracellular fluid movement; and positive regulation of apoptotic process. Localizes to apical plasma membrane. Predicted to colocalize with microtubule cytoskeleton and motile cilium. Is expressed in several structures, including gonad; heart; hemolymphoid system gland; liver; and lung. Orthologous to human ADCY10 (adenylate cyclase 10).",nucleotide binding (GO:0000166); magnesium ion binding (GO:0000287); epithelial cilium movement (GO:0003351); adenylate cyclase activity (GO:0004016); protein binding (GO:0005515); ATP binding (GO:0005524); nucleus (GO:0005634); cytoplasm (GO:0005737); mitochondrion (GO:0005739); cytosol (GO:0005829); cytoskeleton (GO:0005856); plasma membrane (GO:0005886); cAMP biosynthetic process (GO:0006171); spermatogenesis (GO:0007283); cyclic nucleotide biosynthetic process (GO:0009190); microtubule cytoskeleton (GO:0015630); membrane (GO:0016020); apical plasma membrane (GO:0016324); lyase activity (GO:0016829); manganese ion binding (GO:0030145); axon (GO:0030424); dendrite (GO:0030425); growth cone (GO:0030426); motile cilium (GO:0031514); intracellular signal transduction (GO:0035556); cell projection (GO:0042995); neuronal cell body (GO:0043025); positive regulation of apoptotic process (GO:0043065); apical part of cell (GO:0045177); basal part of cell (GO:0045178); metal ion binding (GO:0046872); perinuclear region of cytoplasm (GO:0048471); ATPase binding (GO:0051117); cellular response to inorganic substance (GO:0071241); bicarbonate binding (GO:0071890),Adcy10,0.45025411,-2.2209681,0.008656097,0.003553211,1,0.38933712,-2.5684682,0.062876959,0.022747057,1,0.23879061,-4.1877694,0.096976849,0.02490063,0.70892891,0.33462751,-2.9883975,1.3014466,0.32457554,0.046268233
PDZK1IP1,8.0002,0,0,0,8.0002,11.90014,,"[Plus], [# of exons: 4], [Gene type: NM]","chr4:114,761,313-114,766,499",NM_001164557 NM_001164558 NM_026018,"Pdzk1ip1, PDZK1 interacting protein 1, PDZK1-interacting protein 1|17 kDa membrane-associated protein|membrane-associated protein 17 (Map17), Predicted to localize to integral component of membrane. Is expressed in several structures, including central nervous system; dorsal aorta; metanephros; naris; and retina. Orthologous to human PDZK1IP1 (PDZK1 interacting protein 1).",molecular_function (GO:0003674); biological_process (GO:0008150); membrane (GO:0016020); integral component of membrane (GO:0016021),Pdzk1ip1,0.31450605,-3.179589,9.1343462,2.4923106,0.58077201,0.41122701,-2.4317469,10.869909,5.0773144,0.70673129,0.45012373,-2.2216114,11.90014,5.7919404,1,0.2232267,-4.4797509,10.365881,1.664579,0.01615937
G6PC,8.0002,0,0,0,8.0002,395.26717,,"[Plus], [# of exons: 5], [Gene type: NM]","chr11:101,229,030-101,239,217",NM_008061,"G6pc, glucose-6-phosphatase, catalytic, glucose-6-phosphatase catalytic subunit 1|Glc-6-Pase-alpha, Exhibits glucose-6-phosphatase activity and phosphotransferase activity, alcohol group as acceptor. Involved in several processes, including cholesterol homeostasis; glucose-6-phosphate transport; and glycogen catabolic process. Localizes to endoplasmic reticulum. Is expressed in liver; metanephros; and small intestine. Used to study glycogen storage disease I. Human ortholog(s) of this gene implicated in hepatocellular carcinoma and type 2 diabetes mellitus. Orthologous to human G6PC1 (glucose-6-phosphatase catalytic subunit 1).","glucose-6-phosphatase activity (GO:0004346); endoplasmic reticulum (GO:0005783); endoplasmic reticulum membrane (GO:0005789); glycogen metabolic process (GO:0005977); glycogen catabolic process (GO:0005980); gluconeogenesis (GO:0006094); triglyceride metabolic process (GO:0006641); phosphate-containing compound metabolic process (GO:0006796); steroid metabolic process (GO:0008202); regulation of gene expression (GO:0010468); glucose-6-phosphate transport (GO:0015760); membrane (GO:0016020); integral component of membrane (GO:0016021); phosphotransferase activity, alcohol group as acceptor (GO:0016773); hydrolase activity (GO:0016787); multicellular organism growth (GO:0035264); phosphate ion binding (GO:0042301); glucose homeostasis (GO:0042593); cholesterol homeostasis (GO:0042632); intracellular membrane-bounded organelle (GO:0043231); urate metabolic process (GO:0046415); phosphorylated carbohydrate dephosphorylation (GO:0046838); glucose 6-phosphate metabolic process (GO:0051156); lipid homeostasis (GO:0055088)",G6pc,0.54557026,-1.8329445,115.38928,61.156378,1,0.39765495,-2.514743,237.57729,98.025961,0.095323455,0.4687024,-2.13355,279.3977,132.04047,1,0.23084699,-4.3318738,395.26717,73.365919,0.017591599
IFNLR1,8.0002,0,0,0,8.0002,2.6727013,,"[Plus], [# of exons: 7], [Gene type: NM]","chr4:135,242,372-135,264,095",NM_174851,"Ifnlr1, interferon lambda receptor 1, interferon lambda receptor 1|IFN-lambda R1|IL-28 receptor subunit alpha|IL-28R-alpha|IL-28RA|class II cytokine receptor 12|cytokine receptor class-II member 12|cytokine receptor family 2 member 12|interleukin 28 receptor alpha|interleukin-28 receptor subunit alpha, Predicted to have cytokine receptor activity. Involved in defense response to virus and mucosal immune response. Predicted to localize to interleukin-28 receptor complex. Is expressed in alimentary system; epidermis; lower urinary tract; and sensory organ. Orthologous to human IFNLR1 (interferon lambda receptor 1).",mucosal immune response (GO:0002385); cytokine receptor activity (GO:0004896); plasma membrane (GO:0005886); membrane (GO:0016020); integral component of membrane (GO:0016021); cytokine-mediated signaling pathway (GO:0019221); interleukin-28 receptor complex (GO:0032002); regulation of defense response to virus by host (GO:0050691); defense response to virus (GO:0051607); positive regulation of cellular respiration (GO:1901857),Ifnlr1,0.90868688,-1.1004891,0.055992093,0.05062061,1,0.29735316,-3.3630044,0.32984836,0.10450355,0.16848747,0.35320042,-2.8312537,0.27049799,0.10739658,1,0.21664697,-4.6158043,2.6727013,0.4153723,0.044526549
PMVK,8.0002,0,0,0,8.0002,96.874833,,"[Plus], [# of exons: 7], [Gene type: NM]","chr3:89,258,463-89,272,931",NM_001310640 NM_026784 NM_027348,"Pmvk, phosphomevalonate kinase, Exhibits phosphomevalonate kinase activity. Predicted to be involved in cholesterol biosynthetic process and isopentenyl diphosphate biosynthetic process, mevalonate pathway. Predicted to localize to cytosol. Is expressed in early conceptus. Human ortholog(s) of this gene implicated in porokeratosis. Orthologous to human PMVK (phosphomevalonate kinase).","nucleotide binding (GO:0000166); phosphomevalonate kinase activity (GO:0004631); ATP binding (GO:0005524); cytoplasm (GO:0005737); cytosol (GO:0005829); lipid metabolic process (GO:0006629); steroid biosynthetic process (GO:0006694); cholesterol biosynthetic process (GO:0006695); steroid metabolic process (GO:0008202); cholesterol metabolic process (GO:0008203); isoprenoid biosynthetic process (GO:0008299); sterol biosynthetic process (GO:0016126); kinase activity (GO:0016301); phosphorylation (GO:0016310); transferase activity (GO:0016740); isopentenyl diphosphate biosynthetic process, mevalonate pathway (GO:0019287)",Pmvk,1.084695,1.084695,34.24274,31.084963,1,0.57128396,-1.750443,38.347294,25.226931,1,0.51604246,-1.9378251,38.666037,21.187849,1,0.34034003,-2.938238,96.874833,23.337272,0.034777911
NC_AS_C19_14772,8.0002,0,0,0,8.0002,1.4742592,,"[~1%  IN BLACKLIST], [Plus], [# Lnc isoforms: 50], [# of exons: 35], [Gene type: lncRNA]","chr19:7,940,357-8,420,426",,"lnc_as_chr19_14772, ",,lnc_as_chr19_14772,0.33907909,-2.9491645,0.026849527,0.008513436,0.53740104,0.42168778,-2.3714228,0.087463628,0.036062044,0.35854947,0.42868186,-2.3327322,0.19678602,0.091513282,0.67608404,0.35502496,-2.8167034,1.4742592,0.38885286,0.01819642
ZFP933,8.0002,0,0,0,8.0002,24.68737,,"[~19%  IN BLACKLIST], [Minus], [# of exons: 4], [Gene type: NM]","chr4:147,197,095-147,222,527",NM_001355730 NM_198619,"Zfp933, zinc finger protein 933, uncharacterized protein LOC242747|zinc finger-like protein, Predicted to have DNA-binding transcription factor activity and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Is expressed in forelimb bud. Orthologous to human ZNF101 (zinc finger protein 101).",RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); DNA binding transcription factor activity (GO:0003700); regulation of transcription by RNA polymerase II (GO:0006357),Zfp933,0.71684856,-1.3949948,0.48657984,0.32977128,1,0.3751141,-2.6658556,1.4528259,0.62131912,0.20874797,0.32832906,-3.0457249,3.4451277,1.2326847,0.32601613,0.15639907,-6.3938999,24.68737,2.7101239,1.94E-06
NC_INTER_C7_43869,8.0002,0,0,0,8.0002,11.878768,,"[~3% MAX. MULTIPLE IN BLACKLIST], [Plus], [# Lnc isoforms: 33], [# of exons: 11], [Gene type: lncRNA]","chr7:14,431,458-14,485,617",,"lnc_inter_chr7_43869, ",,lnc_inter_chr7_43869,0.11884185,-8.414544,0.042579419,0.004059999,1,0.04950789,-20.1988005,0.33073655,0.019496432,0.052561127,0.029226331,-34.2157214,0.81847904,0.025119438,0.10406386,0.010028264,-99.7181581,11.878768,0.075625292,1.15E-05
NC_INTER_C11_21411,8.0001,0,0,0,8.0001,37027.316,,"[100%  IN BLACKLIST], [Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:108,872,952-108,873,432",,"lnc_inter_chr11_21411, ",,lnc_inter_chr11_21411,2.0382856,2.0382856,10974.031,17910.037,1,1.0757262,1.0757262,10728.669,13162.342,1,0.62712499,-1.5945785,8443.0302,5650.6969,1,8.128487,8.128487,6429.5096,37027.316,3.05E-07
NC_INTRA_C16_13383,8.0001,0,0,0,8.0001,37249.291,,"[100%  IN BLACKLIST], [Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr16:57,391,224-57,391,795",,"lnc_intra-as_chr16_13383, ",,lnc_intra-as_chr16_13383,1.9207822,1.9207822,7360.3624,11631.123,1,1.3802175,1.3802175,6852.7706,10733.357,1,0.67421406,-1.4832085,5889.9212,4232.5516,1,13.547426,13.5474259,3942.8082,37249.291,8.53E-07
NC_INTRA_C2_1052,8.0001,0,0,0,8.0001,40.699273,,"[100%  IN BLACKLIST], [Minus], [# Lnc isoforms: 1], [# of exons: 2], [Gene type: lncRNA]","chr2:5,244,786-5,244,789 chr2:5,300,098-5,300,422",,"lnc_intra_chr2_1052, ",,lnc_intra_chr2_1052,1.8170632,1.8170632,4.0835612,6.2953166,1,1.2787829,1.2787829,4.4632159,6.5206061,1,0.68212313,-1.466011,4.4577873,3.2407315,1,18.663553,18.6635526,3.1129064,40.699273,6.77E-06
NC_INTRA_C11_9610,8.0001,0,0,0,8.0001,2.3983524,,"[100%  IN BLACKLIST], [Minus], [# Lnc isoforms: 3], [# of exons: 2], [Gene type: lncRNA]","chr11:33,654,764-33,655,100 chr11:33,855,698-33,855,713",,"lnc_intra_chr11_9610, ",,lnc_intra_chr11_9610,1.7996085,1.7996085,0.16351847,0.22110804,1,1.3952741,1.3952741,0.19196856,0.30187327,1,0.73347842,-1.3633666,0.16262016,0.12630823,1,15.267014,15.2670144,0.22981625,2.3983524,5.24E-05
NC_INTRA_C16_27786,8.0001,0,0,0,8.0001,47.003923,,"[100%  IN BLACKLIST], [Minus], [# Lnc isoforms: 7], [# of exons: 1], [Gene type: lncRNA]","chr16:11,144,022-11,144,558",NM_145931,"lnc_intra_chr16_27786, ; Zc3h7a, zinc finger CCCH type containing 7 A, zinc finger CCCH domain-containing protein 7A|zinc finger CCCH type domain containing 7, Predicted to have miRNA binding activity. Predicted to be involved in production of miRNAs involved in gene silencing by miRNA. Is expressed in Meckel's cartilage; embryo mesenchyme; and skeleton. Orthologous to human ZC3H7A (zinc finger CCCH-type containing 7A).",cellular_component (GO:0005575); posttranscriptional regulation of gene expression (GO:0010608); production of miRNAs involved in gene silencing by miRNA (GO:0035196); miRNA binding (GO:0035198),lnc_intra_chr16_27786 Zc3h7a,1.9381023,1.9381023,5.4099146,8.8732968,1,2.1087326,2.1087326,5.2068362,11.14002,1,0.71194915,-1.4045947,2.7531682,2.1383,1,8.2417782,8.2417782,8.006382,47.003923,0.018382386
AY036118,8.0001,0,0,0,8.0001,49.490453,,"[100%  IN BLACKLIST], [Minus], [# of exons: 1], [Gene type: lincRNA]","chr17:39,984,058-39,984,980",NM_133243,"AY036118, cDNA sequence AY036118, ETS-related transcription factor ERF, Involved in hemopoiesis and positive regulation of cell population proliferation. Is expressed in lung and testis.",positive regulation of cell proliferation (GO:0008284); hemopoiesis (GO:0030097),AY036118,1.4062421,1.4062421,25.572453,29.339645,1,2.7546218,2.7546218,8.7130992,23.872268,1,0.86589721,-1.1548715,5.6091207,5.3165226,1,9.3748119,9.3748119,6.8104131,49.490453,0.001377555
NC_INTER_C3_35283,8.0001,0,0,0,8.0001,92242.595,,"[100%  IN BLACKLIST], [Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr3:5,860,337-5,860,775",,"lnc_inter_chr3_35283, ",,lnc_inter_chr3_35283,2.0530326,2.0530326,12524.444,20432.984,1,1.2119048,1.2119048,12925.68,17964.504,1,0.61223892,-1.6333493,10393.406,6770.9322,1,12.166147,12.1661468,10790.829,92242.595,6.93E-06
NC_INTER_C7_44340,8.0001,0,0,0,8.0001,39.015003,,"[100%  IN BLACKLIST], [Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr7:38,984,662-38,985,299",,"lnc_inter_chr7_44340, ",,lnc_inter_chr7_44340,0.15691424,-6.3729078,0.41976446,0,1,2.8914376,2.8914376,0.9083424,2.9749799,1,0.66609405,-1.5012895,1.826744,1.4456285,1,5.2233365,5.2233365,8.9718578,39.015003,0.048569784
NC_INTER_C6_42157,8.0001,0,0,0,8.0001,734.7911,,"[100%  IN BLACKLIST], [Plus], [# Lnc isoforms: 1], [# of exons: 2], [Gene type: lncRNA]","chr6:44,742,928-44,743,250",,"lnc_inter_chr6_42157, ",,lnc_inter_chr6_42157,1.5797261,1.5797261,51.523102,66.138614,1,1.1615898,1.1615898,55.158681,71.8006,1,0.91036917,-1.0984555,43.14331,42.295784,1,13.053227,13.0532271,78.446044,734.7911,0.000251684
NC_INTER_C15_27355,8.0001,0,0,0,8.0001,7374.4735,,"[100%  IN BLACKLIST], [Plus], [# Lnc isoforms: 6], [# of exons: 2], [Gene type: lncRNA]","chr15:86,025,205-86,025,693",,"lnc_inter_chr15_27355, ",,lnc_inter_chr15_27355,2.0821178,2.0821178,1024.6857,1730.0886,1,1.4270661,1.4270661,951.88069,1533.3806,1,0.60073287,-1.6646334,967.25642,617.86964,1,14.208925,14.2089255,745.99068,7374.4735,6.12E-07
NC_INTRA_C13_23748,8.0001,0,0,0,8.0001,9.8078955,,"[Minus], [# Lnc isoforms: 11], [# of exons: 1], [Gene type: lncRNA]","chr13:34,342,114-34,354,605",,"lnc_intra_chr13_23748, ",,lnc_intra_chr13_23748,1,1,0,0,1,1.8560128,1.8560128,0.093502333,0.21702743,1,0.034055814,-29.3635618,0.1210977,0,0.72373822,5.223379,5.223379,2.6797414,9.8078955,0.010889713
NC_INTER_C14_11820,8.0001,0,0,0,8.0001,15.880549,,"[Minus], [# Lnc isoforms: 153], [# of exons: 26], [Gene type: lncRNA]","chr14:12,043,053-12,190,907",,"lnc_inter_chr14_11820,11821,11822,11823,11824,11825,11826,11827, ",,lnc_inter_chr14_11820,2.0894366,2.0894366,0.17374905,0.38135014,1,3.3777835,3.3777835,0.27886049,0.95306883,0.55055612,2.5540775,2.5540775,0.25729948,0.72852511,1,6.2879571,6.2879571,3.3950202,15.880549,0.01819642
NC_INTER_C14_12241,8.0001,0,0,0,8.0001,20.438264,,"[Minus], [# Lnc isoforms: 16], [# of exons: 1], [Gene type: lncRNA]","chr14:100,631,229-100,641,375",,"lnc_inter_chr14_12241,12242, ",,lnc_inter_chr14_12241,0.94865092,-1.0541285,0.079009907,0.064151109,1,2.1842851,2.1842851,0.19815106,0.42916189,1,0.54040277,-1.8504716,0.15103396,0.08070689,1,7.293962,7.293962,3.9021447,20.438264,0.018382386
NC_INTRA_C18_30820,8.0001,0,0,0,8.0001,18.661913,,"[Minus], [# Lnc isoforms: 19], [# of exons: 1], [Gene type: lncRNA]","chr18:16,881,281-16,891,915",,"lnc_intra_chr18_30820, ",,lnc_intra_chr18_30820,0.81105659,-1.2329596,0.023925502,0.020959182,1,1.5579122,1.5579122,0.24581082,0.46088542,1,1.314153,1.314153,0.083607759,0.12796444,1,5.5099309,5.5099309,4.6649497,18.661913,0.029077214
NC_AS_C2_33975,8.0001,0,0,0,8.0001,11.053471,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr2:103,291,033-103,293,317",,"lnc_as_chr2_33975, ",,lnc_as_chr2_33975,0.58524042,-1.7086995,0.42547537,0.19901012,1,0.55055179,-1.8163595,1.003501,0.56766385,1,0.87821394,-1.1386747,0.73115368,0.68990761,1,8.9268697,8.9268697,1.6048104,11.053471,0.009059061
NC_AS_C9_8435,8.0001,0,0,0,8.0001,2.3370156,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr9:123,684,650-123,688,483",,"lnc_as_chr9_8435, ",,lnc_as_chr9_8435,3.4569577,3.4569577,0.023206766,0.091828982,1,8.6127704,8.6127704,0,0.11258018,1,0.29061963,-3.4409238,0.026253908,0,1,17.005426,17.0054265,0.16905023,2.3370156,0.041983429
NC_INTER_C13_11665,8.0001,0,0,0,8.0001,9.1355368,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr13:104,304,956-104,309,541",,"lnc_inter_chr13_11665, ",,lnc_inter_chr13_11665,2.5751542,2.5751542,0.038917868,0.070978969,1,7.0449317,7.0449317,0.067826873,0.54764522,0.62815834,7.9960748,7.9960748,0.09000948,0.89043655,0.51225651,8.0590049,8.0590049,1.3898505,9.1355368,0.001377555
NC_INTER_C13_24762,8.0001,0,0,0,8.0001,14.835123,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr13:104,319,732-104,321,395",,"lnc_inter_chr13_24762, ",,lnc_inter_chr13_24762,1,1,0,0,1,3.5142939,3.5142939,0,0.097809438,1,3.8379228,3.8379228,0,0.098399492,1,12.939683,12.939683,1.4172783,14.835123,0.000168229
NC_INTER_C13_24764,8.0001,0,0,0,8.0001,25.255614,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr13:104,328,136-104,328,642",,"lnc_inter_chr13_24764, ",,lnc_inter_chr13_24764,1,1,0,0,1,6.0406858,6.0406858,0,0.58713135,1,1,1,0,0,1,7.4459921,7.4459921,4.0674561,25.255614,0.029458696
NC_INTER_C14_26022,8.0001,0,0,0,8.0001,47.52007,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr14:85,522,240-85,522,447",,"lnc_inter_chr14_26022, ",,lnc_inter_chr14_26022,1,1,0,0,1,1,1,0,0,1,1.2235867,1.2235867,0.48614121,1.0369323,1,16.577716,16.5777157,3.1302875,47.52007,0.0437964
NC_INTER_C15_12779,8.0001,0,0,0,8.0001,131.8867,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr15:82,536,737-82,537,540",,"lnc_inter_chr15_12779, ",,lnc_inter_chr15_12779,1.9918335,1.9918335,0.98281906,1.748833,1,2.3769734,2.3769734,3.4625344,9.7790563,1,1.1972513,1.1972513,0.84390274,1.287045,1,6.0053221,6.0053221,30.73461,131.8867,0.038400732
NC_INTER_C16_13338,8.0001,0,0,0,8.0001,10.806086,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr16:45,885,461-45,887,404",,"lnc_inter_chr16_13338, ",,lnc_inter_chr16_13338,1,1,0,0,1,0.56118646,-1.7819389,0.38333332,0.19526989,1,1.2235247,1.2235247,0.051791678,0.11047092,1,9.274945,9.274945,1.6782337,10.806086,0.03755672
NC_INTER_C3_2446,8.0001,0,0,0,8.0001,13.199335,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr3:79,088,927-79,089,558",,"lnc_inter_chr3_2446, ",,lnc_inter_chr3_2446,1,1,0,0,1,0.26723884,-3.7419711,0.24642331,0,1,1,1,0,0,1,26.939368,26.9393678,0.47353576,13.199335,0.045332259
NC_INTER_C3_35342,8.0001,0,0,0,8.0001,8.0820589,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr3:14,695,379-14,697,804",,"lnc_inter_chr3_35342, ",,lnc_inter_chr3_35342,1,1,0,0,1,0.26709575,-3.7439757,0.064120869,0,1,1.1297923,1.1297923,0.17018287,0.22360902,1,8.4404521,8.4404521,1.2006761,8.0820589,0.005313132
NC_INTER_C3_35348,8.0001,0,0,0,8.0001,16.885422,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr3:14,719,223-14,721,076",,"lnc_inter_chr3_35348, ",,lnc_inter_chr3_35348,1,1,0,0,1,2.2283402,2.2283402,0.083914251,0.17546057,1,2.2297897,2.2297897,0.35126238,0.96639187,1,7.8083182,7.8083182,2.7318191,16.885422,0.000730765
NC_INTER_C4_3178,8.0001,0,0,0,8.0001,401.11912,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr4:43,505,657-43,505,931",NR_001460,"lnc_inter_chr4_3178, ; Rmrp, RNA component of mitochondrial RNAase P, RNA component of mitochondrial RNAase P, 1|RNase MRP",in utero embryonic development (GO:0001701); molecular_function (GO:0003674); cellular_component (GO:0005575),lnc_inter_chr4_3178 Rmrp,1.4485713,1.4485713,13.778584,16.522694,1,0.64283217,-1.555616,29.661137,21.507559,1,1.0804479,1.0804479,12.986667,15.453835,1,5.0219231,5.0219231,114.17299,401.11912,0.023738342
NC_INTER_C4_3187,8.0001,0,0,0,8.0001,3.1326298,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr4:44,190,968-44,195,278",,"lnc_inter_chr4_3187, ",,lnc_inter_chr4_3187,1,1,0,0,1,0.92498213,-1.081102,0.036077287,0.025145277,1,0.80917752,-1.2358228,0.095752545,0.087768758,1,11.112431,11.1124314,0.35345991,3.1326298,0.016103114
NC_INTER_C4_38509,8.0001,0,0,0,8.0001,29.854365,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr4:107,818,729-107,819,386",,"lnc_inter_chr4_38509, ",,lnc_inter_chr4_38509,78.028641,78.0286405,0,4.1732066,0.05636326,19.842202,19.8422015,0.2036742,5.6324945,0.084928161,71.146056,71.1460561,0,6.5049445,0.16147262,60.311871,60.3118713,0.42289276,29.854365,0.000218693
NC_INTER_C5_4776,8.0001,0,0,0,8.0001,13.628679,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr5:148,710,446-148,712,849",,"lnc_inter_chr5_4776, ",,lnc_inter_chr5_4776,1.1167589,1.1167589,0.1799113,0.22203509,1,0.62471095,-1.6007403,1.9649684,1.2607185,1,1.712136,1.712136,0.85662452,1.4534726,1,8.9507367,8.9507367,1.99655,13.628679,0.0373301
NC_INTER_C7_43894,8.0001,0,0,0,8.0001,26.405462,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr7:15,673,624-15,674,651",,"lnc_inter_chr7_43894, ",,lnc_inter_chr7_43894,1,1,0,0,1,27.496492,27.496492,0,1.21365,1,43.88084,43.8808402,0,2.6183369,0.9360342,76.045597,76.0455969,0.36039822,26.405462,1.17E-05
NC_INTER_C8_7506,8.0001,0,0,0,8.0001,9.9013625,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr8:118,221,251-118,222,091",,"lnc_inter_chr8_7506, ",,lnc_inter_chr8_7506,1,1,0,0,1,0.9275641,-1.0780926,0.55533253,0.48269596,1,1.2238576,1.2238576,0.11979908,0.25552975,1,96.393976,96.3939759,0,9.9013625,0.02349111
NC_INTER_CY_15553,8.0001,0,0,0,8.0001,15.996266,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:588,597-590,357",,"lnc_inter_chrY_15553, ",,lnc_inter_chrY_15553,1,1,0,0,1,18.565248,18.5652482,0,0.53713669,1,18.673301,18.6733009,0,0.61582012,1,284.70376,284.7037613,0,15.996266,6.28E-08
NC_INTER_CY_50508,8.0001,0,0,0,8.0001,8.1572257,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,792,944-2,794,806",,"lnc_inter_chrY_50508, ",,lnc_inter_chrY_50508,4.6874162,4.6874162,0.045546686,0.25204475,1,8.4490819,8.4490819,0,0.18860562,1,2.669824,2.669824,0.073879962,0.26364934,1,45.905429,45.9054287,0.19878033,8.1572257,0.000118809
NC_INTER_CY_50515,8.0001,0,0,0,8.0001,53.759731,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,851,150-2,851,494",,"lnc_inter_chrY_50515, ",,lnc_inter_chrY_50515,4.2897054,4.2897054,0,0.34106637,1,6.0423958,6.0423958,0,0.94568079,1,0.29087744,-3.4378741,0.29253265,0,1,196.6959,196.6958961,0,53.759731,2.99E-06
NC_INTER_CY_50516,8.0001,0,0,0,8.0001,22.267395,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,851,547-2,852,399",,"lnc_inter_chrY_50516, ",,lnc_inter_chrY_50516,1,1,0,0,1,6.0423916,6.0423916,0,0.38182417,1,3.8366031,3.8366031,0,0.1920638,1,200.46686,200.4668601,0,22.267395,1.53E-06
NC_INTER_CY_50520,8.0001,0,0,0,8.0001,18.994464,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,857,804-2,859,081",,"lnc_inter_chrY_50520, ",,lnc_inter_chrY_50520,0.15694534,-6.3716449,0.20938916,0,1,6.0406232,6.0406232,0,0.23264562,1,2.0175991,2.0175991,0.078802843,0.2562856,1,271.39632,271.3963177,0,18.994464,2.84E-06
NC_INTER_CY_50546,8.0001,0,0,0,8.0001,11.381065,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,891,068-2,891,728",,"lnc_inter_chrY_50546, ",,lnc_inter_chrY_50546,1,1,0,0,1,1,1,0,0,1,3.8366727,3.8366727,0,0.2479369,1,81.299028,81.2990277,0,11.381065,0.005414893
NC_INTER_CY_50551,8.0001,0,0,0,8.0001,16.536966,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,898,167-2,899,001",,"lnc_inter_chrY_50551, ",,lnc_inter_chrY_50551,4.2892799,4.2892799,0,0.14067965,1,1,1,0,0,1,9.3735013,9.3735013,0,0.58862718,1,24.233025,24.2330247,0.6914168,16.536966,0.001753331
NC_INTRA_C6_5291,8.0001,0,0,0,8.0001,8.1394621,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr6:83,398,284-83,402,417",,"lnc_intra_chr6_5291, ",,lnc_intra_chr6_5291,1.9397041,1.9397041,0.021522268,0.053202387,1,0.63248951,-1.5810539,0.23706645,0.18311977,1,1.1519819,1.1519819,0.033284415,0.051934428,1,7.8637585,7.8637585,1.5086691,8.1394621,0.044822418
NC_INTRA_C6_5443,8.0001,0,0,0,8.0001,9.298421,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr6:99,456,797-99,462,217",,"lnc_intra_chr6_5443, ",,lnc_intra_chr6_5443,6.4446693,6.4446693,0,0.038397001,1,1.623546,1.623546,0.25415101,0.43410018,1,0.076004298,-13.1571507,0.16134608,0,1,10.091718,10.091718,1.2686029,9.298421,0.010248141
NC_INTRA_C5_40435,8.0001,0,0,0,8.0001,12.10302,,"[Minus], [# Lnc isoforms: 1], [# of exons: 2], [Gene type: lncRNA]","chr5:90,766,613-90,768,540 chr5:90,768,870-90,770,569",,"lnc_intra_chr5_40435, ",,lnc_intra_chr5_40435,0.59398464,-1.6835452,0.067590991,0.026681777,1,0.87393125,-1.1442548,0.53654586,0.48511948,1,1.7529938,1.7529938,0.12042251,0.28703498,1,8.6908655,8.6908655,1.8530774,12.10302,0.035214218
NC_AS_C10_9023,8.0001,0,0,0,8.0001,1.8733277,,"[Minus], [# Lnc isoforms: 1], [# of exons: 4], [Gene type: lncRNA]","chr10:76,008,616-76,024,971",NR_045354,"4930483K19Rik, RIKEN cDNA 4930483K19 gene; lnc_as_chr10_9023, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),4930483K19Rik lnc_as_chr10_9023,0.84697396,-1.1806738,0.059385532,0.045530819,1,2.663154,2.663154,0.069431309,0.20973761,1,4.2043262,4.2043262,0.055998143,0.31530829,0.38784705,5.7381562,5.7381562,0.42400743,1.8733277,0.001573916
NC_INTER_C12_10462,8.0001,0,0,0,8.0001,2.6978823,,"[Minus], [# Lnc isoforms: 20], [# of exons: 15], [Gene type: lncRNA]","chr12:28,741,376-28,769,143",,"lnc_inter_chr12_10462, ",,lnc_inter_chr12_10462,8.1114768,8.1114768,0.009629775,0.068510747,0.84722081,3.5534524,3.5534524,0.043237892,0.1568729,0.65610291,5.163346,5.163346,0.035736706,0.1839061,0.33472275,17.594101,17.5941013,0.19337012,2.6978823,2.64E-06
NC_AS_C15_27603,8.0001,0,0,0,8.0001,5.071452,,"[Minus], [# Lnc isoforms: 20], [# of exons: 1], [Gene type: lncRNA]","chr15:101,927,673-101,933,411",,"lnc_as_chr15_27603, ",,lnc_as_chr15_27603,2.048688,2.048688,0.19738219,0.37861919,1,0.88564662,-1.1291185,0.55830187,0.53207037,1,0.49711062,-2.0116247,0.42889398,0.2088055,1,5.0740293,5.0740293,1.369894,5.071452,0.029878557
NC_INTER_C14_12246,8.0001,0,0,0,8.0001,19.1317,,"[Minus], [# Lnc isoforms: 20], [# of exons: 1], [Gene type: lncRNA]","chr14:100,654,797-100,659,205",,"lnc_inter_chr14_12246,12247, ",,lnc_inter_chr14_12246,0.3488592,-2.8664859,0.076958194,0.023945805,1,1.5921825,1.5921825,0.20181496,0.33743808,1,0.15028646,-6.6539596,0.39229409,0.048694417,1,9.3355469,9.3355469,2.7020037,19.1317,0.003341224
NC_INTER_CY_50486,8.0001,0,0,0,8.0001,2.1665178,,"[Minus], [# Lnc isoforms: 21], [# of exons: 1], [Gene type: lncRNA]","chrY:590,427-595,084",,"lnc_inter_chrY_50486, ",,lnc_inter_chrY_50486,3.7064157,3.7064157,0,0.022022468,1,10.97791,10.9779097,0,0.11033729,1,11.954652,11.9546519,0,0.14076528,1,113.68582,113.6858239,0,2.1665178,0.00082983
NC_INTER_C3_36122,8.0001,0,0,0,8.0001,5.1978,,"[Minus], [# Lnc isoforms: 25], [# of exons: 1], [Gene type: lncRNA]","chr3:79,046,825-79,052,086",,"lnc_inter_chr3_36122, ",,lnc_inter_chr3_36122,0.23934562,-4.1780585,0.033917207,0,1,2.0396451,2.0396451,0.10586104,0.30917524,1,9.3727315,9.3727315,0,0.09331212,1,12.884522,12.8845218,0.51674899,5.1978,0.010300261
NC_AS_C2_1965,8.0001,0,0,0,8.0001,21.865828,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr2:163,311,851-163,318,146",,"lnc_as_chr2_1965, ",,lnc_as_chr2_1965,1.0753342,1.0753342,0.027602774,0.032584157,1,2.1335087,2.1335087,0.58355744,1.3949879,1,1.1001193,1.1001193,0.29948033,0.40454813,1,3.1223409,3.1223409,9.5107417,21.865828,0.021686174
NC_INTER_C1_17118,8.0001,0,0,0,8.0001,23.636524,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr1:152,978,279-152,979,890",,"lnc_inter_chr1_17118, ",,lnc_inter_chr1_17118,0.86612485,-1.154568,0.59483812,0.5204444,1,1.5387219,1.5387219,1.1936332,1.966423,1,1.4985515,1.4985515,1.498381,2.3625396,1,8.0377184,8.0377184,3.9048664,23.636524,0.016185759
NC_INTER_CY_50530,8.0001,0,0,0,8.0001,16.758267,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chrY:2,869,547-2,870,606",,"lnc_inter_chrY_50530, ",,lnc_inter_chrY_50530,1,1,0,0,1,13.606399,13.6063986,0,0.63675859,1,0.24740342,-4.0419813,0.24358341,0,1,55.174212,55.1742117,0.349508,16.758267,7.02E-05
NC_INTRA_C19_32696,8.0001,0,0,0,8.0001,4.7749633,,"[Minus], [# Lnc isoforms: 2], [# of exons: 2], [Gene type: lncRNA]","chr19:58,345,236-58,358,722 chr19:58,358,909-58,358,930",NM_001285457,"Gfra1, glial cell line derived neurotrophic factor family receptor alpha 1, GDNF family receptor alpha-1|GDNF receptor alpha 1 (GFRa-1)|GDNF receptor alpha 1c|GDNF receptor alpha 1d|GDNF receptor alpha 1e|GDNFR-alpha-1|GFR alpha-1|TGF-beta-related neurotrophic factor receptor 1; lnc_intra_chr19_32696, ",neurotrophin receptor activity (GO:0005030); integrin binding (GO:0005178); extracellular space (GO:0005615); endosome (GO:0005768); Golgi apparatus (GO:0005794); plasma membrane (GO:0005886); transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169); nervous system development (GO:0007399); anatomical structure morphogenesis (GO:0009653); external side of plasma membrane (GO:0009897); membrane (GO:0016020); cell migration (GO:0016477); extrinsic component of membrane (GO:0019898); neuron differentiation (GO:0030182); axon (GO:0030424); neuron projection development (GO:0031175); anchored component of membrane (GO:0031225); signaling receptor activity (GO:0038023); neuronal cell body (GO:0043025); receptor complex (GO:0043235); positive regulation of peptidyl-tyrosine phosphorylation (GO:0050731); plasma membrane protein complex (GO:0098797),Gfra1 lnc_intra_chr19_32696,1.1378272,1.1378272,0.019486972,0.023765048,1,3.0898628,3.0898628,0.033263442,0.12241311,1,0.51200381,-1.9531105,0.03767414,0.011949639,1,6.5083091,6.5083091,1.0370643,4.7749633,0.033050451
NC_INTER_C8_7109,8.0001,0,0,0,8.0001,9.5739611,,"[Minus], [# Lnc isoforms: 36], [# of exons: 1], [Gene type: lncRNA]","chr8:70,576,532-70,582,196",,"lnc_inter_chr8_7109,7110, ",,lnc_inter_chr8_7109,0.62646294,-1.5962636,0.030677871,0.018107104,1,0.9748604,-1.0257879,0.14364285,0.16230674,1,9.6589669,9.6589669,0,0.095736559,1,4.3794856,4.3794856,3.021398,9.5739611,0.011630365
NC_INTER_C16_13185,8.0001,0,0,0,8.0001,2.1769933,,"[Minus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr16:25,939,667-25,945,815",,"lnc_inter_chr16_13185, ",,lnc_inter_chr16_13185,6.8213527,6.8213527,0,0.035765365,1,18.748691,18.7486911,0,0.1760163,1,38.749546,38.7495464,0,0.37936169,0.21854024,7.6668681,7.6668681,0.3913998,2.1769933,0.039936375
NC_INTER_C2_34471,8.0001,0,0,0,8.0001,4.1641654,,"[Minus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr2:136,696,050-136,697,564",,"lnc_inter_chr2_34471, ",,lnc_inter_chr2_34471,0.23929694,-4.1789085,0.11785893,0,1,0.16031021,-6.2379057,0.20540701,0,1,6.3882473,6.3882473,0,0.21660307,1,19.483574,19.4835736,0.18351423,4.1641654,0.049155261
NC_INTER_CY_50485,8.0001,0,0,0,8.0001,9.592808,,"[Minus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chrY:583,514-586,230",,"lnc_inter_chrY_50485, ",,lnc_inter_chrY_50485,1,1,0,0,1,18.828801,18.8288007,0,0.37764976,1,13.498466,13.4984663,0,0.29733922,1,269.4988,269.4988029,0,9.592808,4.88E-09
NC_INTRA_C6_5434,8.0001,0,0,0,8.0001,4.2099056,,"[Minus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr6:99,396,712-99,404,654",,"lnc_intra_chr6_5434,5435, ",,lnc_intra_chr6_5434,0.17004721,-5.8807197,0.021356819,0,1,2.0481261,2.0481261,0.037775934,0.095295142,1,0.29107437,-3.4355481,0.012670767,0,1,4.6936161,4.6936161,1.194868,4.2099056,0.035140478
NC_INTRA_C5_4468,8.0001,0,0,0,8.0001,0.28825389,,"[Minus], [# Lnc isoforms: 3], [# of exons: 6], [Gene type: lncRNA]","chr5:105,257,401-105,257,760 chr5:105,265,684-105,266,050 chr5:105,266,074-105,266,250 chr5:105,288,500-105,288,553 chr5:105,289,088-105,293,460",NM_001039231,"lnc_intra_chr5_4468, ; Zfp951, zinc finger protein 951, kruppel-related zinc finger protein-like, Predicted to have DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Orthologous to human ZNF101 (zinc finger protein 101).","RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); RNA polymerase II transcription factor activity, sequence-specific DNA binding (GO:0000981); regulation of transcription by RNA polymerase II (GO:0006357)",lnc_intra_chr5_4468 Zfp951,6.4446851,6.4446851,0,0.005771423,1,13.425968,13.4259677,0,0.019543625,1,0.98239159,-1.017924,0.007153688,0.004538073,1,13.360789,13.3607888,0.026837436,0.28825389,0.040519671
NC_INTER_CX_15445,8.0001,0,0,0,8.0001,0.23517618,,"[Minus], [# Lnc isoforms: 4], [# of exons: 6], [Gene type: lncRNA]","chrX:122,169,485-122,478,940",,"lnc_inter_chrX_15445, ",,lnc_inter_chrX_15445,1,1,0,0,1,41.379147,41.379147,0,0.006887458,0.13791619,11.146513,11.1465133,0.000325189,0.007373089,0.77982306,69.899305,69.8993053,0.004255545,0.23517618,5.75E-18
NC_INTER_C7_43873,8.0001,0,0,0,8.0001,10.12402,,"[Minus], [# Lnc isoforms: 6], [# of exons: 1], [Gene type: lncRNA]","chr7:14,993,371-14,995,019",,"lnc_inter_chr7_43873, ",,lnc_inter_chr7_43873,3.2948612,3.2948612,0.15689769,0.63310013,1,5.5151475,5.5151475,0.44545341,2.8750164,0.27019219,14.76758,14.7675797,0,0.49707662,1,17.029437,17.0294369,0.79908953,10.12402,0.00320041
C8A,8.0001,0,0,0,8.0001,114.34398,,"[Minus], [# of exons: 11], [Gene type: NM]","chr4:104,488,285-104,549,003",NM_001290645 NM_001316667 NM_146148,"C8a, complement component 8, alpha polypeptide, complement component C8 alpha chain|complement component 8 alpha subunit, Predicted to have complement binding activity. Predicted to be involved in complement activation. Predicted to localize to extracellular space and membrane attack complex. Is expressed in liver lobe. Human ortholog(s) of this gene implicated in type I complement component 8 deficiency. Orthologous to human C8A (complement C8 alpha chain).","complement binding (GO:0001848); immune system process (GO:0002376); extracellular region (GO:0005576); membrane attack complex (GO:0005579); extracellular space (GO:0005615); plasma membrane (GO:0005886); immune response (GO:0006955); complement activation (GO:0006956); complement activation, alternative pathway (GO:0006957); complement activation, classical pathway (GO:0006958); membrane (GO:0016020); integral component of membrane (GO:0016021); cytolysis (GO:0019835); protein-containing complex binding (GO:0044877); innate immune response (GO:0045087)",C8a,1.2341571,1.2341571,51.586415,63.33414,1,1.5612411,1.5612411,36.475265,58.848284,0.9919516,1.8145005,1.8145005,59.744465,114.34398,0.55050705,2.4358509,2.4358509,39.831599,74.411759,0.004511541
GCK,8.0001,0,0,0,8.0001,63.125619,,"[Minus], [# of exons: 11], [Gene type: NM]","chr11:5,800,824-5,850,084",NM_001287386 NM_010292,"Gck, glucokinase, hexokinase-4|HK IV|hexokinase type IV|hexokinase-D, Exhibits glucokinase activity. Involved in several processes, including carbohydrate phosphorylation; cellular glucose homeostasis; and regulation of ion transport. Localizes to cytosol; mitochondrion; and nucleus. Predicted to colocalize with actin filament. Is expressed in several structures, including alimentary system; brain; genitourinary system; musculoskeletal system; and sensory organ. Used to study hyperinsulinemic hypoglycemia; maturity-onset diabetes of the young type 2; and type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in artery disease (multiple); familial hyperinsulinemic hypoglycemia 3; and glucose metabolism disease (multiple). Orthologous to human GCK (glucokinase).","nucleotide binding (GO:0000166); magnesium ion binding (GO:0000287); cellular glucose homeostasis (GO:0001678); catalytic activity (GO:0003824); glucokinase activity (GO:0004340); hexokinase activity (GO:0004396); protein binding (GO:0005515); ATP binding (GO:0005524); glucose binding (GO:0005536); nucleus (GO:0005634); nucleoplasm (GO:0005654); cytoplasm (GO:0005737); mitochondrion (GO:0005739); cytosol (GO:0005829); actin filament (GO:0005884); cell cortex (GO:0005938); carbohydrate metabolic process (GO:0005975); glycogen biosynthetic process (GO:0005978); fructose 6-phosphate metabolic process (GO:0006002); fructose 2,6-bisphosphate metabolic process (GO:0006003); glucose metabolic process (GO:0006006); mannose metabolic process (GO:0006013); glycolytic process (GO:0006096); NADP metabolic process (GO:0006739); positive regulation of cytosolic calcium ion concentration (GO:0007204); metabolic process (GO:0008152); fructokinase activity (GO:0008865); kinase activity (GO:0016301); phosphorylation (GO:0016310); transferase activity (GO:0016740); phosphotransferase activity, alcohol group as acceptor (GO:0016773); mannokinase activity (GO:0019158); protein phosphatase binding (GO:0019903); second-messenger-mediated signaling (GO:0019932); secretory granule (GO:0030141); positive regulation of insulin secretion (GO:0032024); negative regulation of epinephrine secretion (GO:0032811); cellular response to insulin stimulus (GO:0032869); cellular response to glucose starvation (GO:0042149); positive regulation of phosphorylation (GO:0042327); glucose homeostasis (GO:0042593); regulation of potassium ion transport (GO:0043266); ADP binding (GO:0043531); cellular response to leptin stimulus (GO:0044320); basal cortex (GO:0045180); negative regulation of gluconeogenesis (GO:0045721); positive regulation of glycogen biosynthetic process (GO:0045725); positive regulation of glycolytic process (GO:0045821); carbohydrate phosphorylation (GO:0046835); regulation of insulin secretion (GO:0050796); glucose 6-phosphate metabolic process (GO:0051156); detection of glucose (GO:0051594); lipid homeostasis (GO:0055088); calcium ion import (GO:0070509)",Gck,1.5806607,1.5806607,13.78178,20.50584,1,1.513568,1.513568,20.048622,33.27526,1,1.3918555,1.3918555,15.466526,22.718435,1,3.2248471,3.2248471,25.357641,63.125619,0.005313132
CES1F,8.0001,0,0,0,8.0001,256.5319,,"[Minus], [# of exons: 14], [Gene type: NM]","chr8:95,780,135-95,803,635",NM_144930,"Ces1f, carboxylesterase 1F, carboxylesterase 1F|carboxylic ester hydrolase|liver carboxylesterase B-1|triacylglycerol hydrolase 2, Predicted to have sterol esterase activity and triglyceride lipase activity. Involved in short-chain fatty acid catabolic process. Localizes to cytosol and lipid droplet. Orthologous to human CES1 (carboxylesterase 1).",cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); lipid droplet (GO:0005811); cytosol (GO:0005829); lipid catabolic process (GO:0016042); hydrolase activity (GO:0016787); short-chain fatty acid catabolic process (GO:0019626); intracellular membrane-bounded organelle (GO:0043231); carboxylic ester hydrolase activity (GO:0052689); methyl indole-3-acetate esterase activity (GO:0080030),Ces1f,1.2704534,1.2704534,76.740248,97.287965,1,1.5375936,1.5375936,80.359534,133.99976,1,1.7495538,1.7495538,105.48079,195.44611,1,2.4390383,2.4390383,135.56852,256.5319,0.022312856
GM20199,8.0001,0,0,0,8.0001,8.6122401,,"[Minus], [# of exons: 1], [Gene type: NR]","chr9:59,325,552-59,329,548",NR_045640,"Gm20199, predicted gene, 20199",,Gm20199,1,1,0,0,1,18.588324,18.5883242,0,0.26428754,1,6.088349,6.088349,0.025182991,0.30960798,1,6.0326013,6.0326013,1.9292666,8.6122401,0.029458696
MIR6970,8.0001,0,0,0,8.0001,100.26168,,"[Minus], [# of exons: 1], [Gene type: NR]","chr17:34,982,046-34,982,112",NR_105936,"Mir6970, microRNA 6970, microRNA mir-6970",,Mir6970,1.1149274,1.1149274,10.405313,12.791223,1,0.84957035,-1.1770656,66.388826,59.002417,1,1.4061698,1.4061698,17.678771,24.632805,1,20.433465,20.4334653,4.2097052,100.26168,0.039936375
DHX9,8.0001,0,0,0,8.0001,9.1549044,,"[Minus], [# of exons: 28], [Gene type: NM]","chr1:155,302,888-155,334,790",NM_007842,"Dhx9, DEAH (Asp-Glu-Ala-His) box polypeptide 9, ATP-dependent RNA helicase A|D-E-A-D (aspartate-glutamate-alanine-aspartate) box polypeptide 9|DEAD (aspartate-glutamate-alanine-aspartate) box polypeptide 9|DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 9|DEAH box protein 9|RNA helicase A|leukophysin|nuclear DNA helicase II, Exhibits regulatory region RNA binding activity. Involved in several processes, including positive regulation of interleukin-18 production; pyroptosis; and regulation of defense response. Localizes to nucleolus. Is expressed in several structures, including alimentary system; central nervous system; lung; sensory organ; and vibrissa. Orthologous to human DHX9 (DExH-box helicase 9).","nucleotide binding (GO:0000166); alternative mRNA splicing, via spliceosome (GO:0000380); RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); RNA polymerase II core binding (GO:0000993); regulatory region RNA binding (GO:0001069); immune system process (GO:0002376); nucleic acid binding (GO:0003676); DNA binding (GO:0003677); DNA helicase activity (GO:0003678); DNA replication origin binding (GO:0003688); double-stranded DNA binding (GO:0003690); single-stranded DNA binding (GO:0003697); transcription cofactor activity (GO:0003712); transcription coactivator activity (GO:0003713); RNA binding (GO:0003723); RNA helicase activity (GO:0003724); double-stranded RNA binding (GO:0003725); single-stranded RNA binding (GO:0003727); mRNA binding (GO:0003729); helicase activity (GO:0004386); protein binding (GO:0005515); ATP binding (GO:0005524); intracellular (GO:0005622); nucleus (GO:0005634); nucleoplasm (GO:0005654); perichromatin fibrils (GO:0005726); nucleolus (GO:0005730); cytoplasm (GO:0005737); centrosome (GO:0005813); polysome (GO:0005844); cytoskeleton (GO:0005856); DNA-templated transcription, termination (GO:0006353); regulation of transcription by RNA polymerase II (GO:0006357); mRNA processing (GO:0006397); regulation of translation (GO:0006417); inflammatory response (GO:0006954); circadian rhythm (GO:0007623); RNA splicing (GO:0008380); RNA secondary structure unwinding (GO:0010501); actin cytoskeleton (GO:0015629); RISC complex (GO:0016442); nuclear body (GO:0016604); hydrolase activity (GO:0016787); targeting of mRNA for destruction involved in RNA interference (GO:0030423); gene silencing by RNA (GO:0031047); chromatin DNA binding (GO:0031490); DNA duplex unwinding (GO:0032508); positive regulation of interferon-alpha production (GO:0032727); positive regulation of interferon-beta production (GO:0032728); positive regulation of interleukin-18 production (GO:0032741); positive regulation of interleukin-6 production (GO:0032755); positive regulation of tumor necrosis factor production (GO:0032760); protein-containing complex (GO:0032991); 3'-5' DNA/RNA helicase activity (GO:0033679); 3'-5' RNA helicase activity (GO:0034458); cellular response to heat (GO:0034605); cellular protein-containing complex assembly (GO:0034622); siRNA binding (GO:0035197); RNA stem-loop binding (GO:0035613); cytoplasmic ribonucleoprotein granule (GO:0036464); DNA-templated viral transcription (GO:0039695); polysomal ribosome (GO:0042788); 3'-5' DNA helicase activity (GO:0043138); G-quadruplex DNA unwinding (GO:0044806); innate immune response (GO:0045087); positive regulation of innate immune response (GO:0045089); triplex DNA binding (GO:0045142); positive regulation of DNA repair (GO:0045739); positive regulation of DNA replication (GO:0045740); positive regulation of transcription by RNA polymerase II (GO:0045944); positive regulation of RNA export from nucleus (GO:0046833); metal ion binding (GO:0046872); nucleoside-triphosphate diphosphatase activity (GO:0047429); positive regulation of fibroblast proliferation (GO:0048146); rhythmic process (GO:0048511); positive regulation of viral transcription (GO:0050434); regulation of mRNA processing (GO:0050684); regulation of defense response to virus by host (GO:0050691); positive regulation of inflammatory response (GO:0050729); mRNA transport (GO:0051028); positive regulation of NF-kappaB transcription factor activity (GO:0051092); positive regulation of response to cytokine stimulus (GO:0060760); RNA polymerase II sequence-specific DNA binding transcription factor binding (GO:0061629); importin-alpha family protein binding (GO:0061676); RNA polymerase binding (GO:0070063); pyroptosis (GO:0070269); RISC-loading complex (GO:0070578); small RNA loading onto RISC (GO:0070922); CRD-mediated mRNA stabilization (GO:0070934); CRD-mediated mRNA stability complex (GO:0070937); cellular response to tumor necrosis factor (GO:0071356); cellular response to exogenous dsRNA (GO:0071360); nuclear stress granule (GO:0097165); protein localization to cytoplasmic stress granule (GO:1903608); positive regulation of viral translation (GO:1904973); RISC complex binding (GO:1905172); polysome binding (GO:1905538); positive regulation of polysome binding (GO:1905698); single-stranded DNA-dependent ATP-dependent 3'-5' DNA helicase activity (GO:1990518); sequence-specific mRNA binding (GO:1990825); promoter-specific chromatin binding (GO:1990841); ribonucleoprotein complex (GO:1990904); positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity (GO:2000373); positive regulation of gene silencing by miRNA (GO:2000637); regulation of cytoplasmic translation (GO:2000765); positive regulation of cytoplasmic translation (GO:2000767)",Dhx9,1.043024,1.043024,2.8723396,2.976766,1,1.279216,1.279216,2.114403,2.7433549,1,1.6362392,1.6362392,4.9101316,8.3021903,1,2.9431968,2.9431968,4.1039148,9.1549044,0.009059061
PLEKHF1,8.0001,0,0,0,8.0001,19.988708,,"[Minus], [# of exons: 2], [Gene type: NM]","chr7:39,005,673-39,013,013",NM_024413,"Plekhf1, pleckstrin homology domain containing, family F (with FYVE domain) member 1, pleckstrin homology domain-containing family F member 1|PH domain-containing family F member 1|lysosome-associated apoptosis-inducing protein containing PH and FYVE domains, Predicted to have phosphatidylinositol-3-phosphate binding activity; phosphatidylinositol-4-phosphate binding activity; and phosphatidylinositol-5-phosphate binding activity. Involved in positive regulation of intrinsic apoptotic signaling pathway. Localizes to lysosome. Predicted to colocalize with endosome. Orthologous to human PLEKHF1 (pleckstrin homology and FYVE domain containing 1).",nucleus (GO:0005634); cytoplasm (GO:0005737); lysosome (GO:0005764); endosome (GO:0005768); apoptotic process (GO:0006915); endosome organization (GO:0007032); phosphatidylinositol-5-phosphate binding (GO:0010314); positive regulation of autophagy (GO:0010508); vesicle organization (GO:0016050); phosphatidylinositol-3-phosphate binding (GO:0032266); phosphatidylinositol binding (GO:0035091); metal ion binding (GO:0046872); regulation of mitochondrial membrane permeability (GO:0046902); phosphatidylinositol-4-phosphate binding (GO:0070273); protein localization to plasma membrane (GO:0072659); positive regulation of intrinsic apoptotic signaling pathway (GO:2001244),Plekhf1,2.0837591,2.0837591,7.2640581,15.103676,1,2.0231095,2.0231095,9.2624541,19.988708,0.52933469,2.1615026,2.1615026,5.669102,12.996732,0.67860125,3.0355889,3.0355889,6.639385,15.165816,0.019891237
HES6,8.0001,0,0,0,8.0001,325.60673,,"[Minus], [# of exons: 5], [Gene type: NM]","chr1:93,308,060-93,310,615",NM_001360899 NM_001360900 NM_019479,"Hes6, hairy and enhancer of split 6, transcription cofactor HES-6, Exhibits DNA-binding transcription repressor activity, RNA polymerase II-specific; RNA polymerase II transcription regulatory region sequence-specific DNA binding activity; and RNA polymerase II-specific DNA-binding transcription factor binding activity. Involved in cell differentiation; nervous system development; and regulation of transcription, DNA-templated. Localizes to transcription regulator complex. Is expressed in several structures, including alimentary system; central nervous system; embryo mesenchyme; genitourinary system; and sensory organ. Orthologous to human HES6 (hes family bHLH transcription factor 6).","negative regulation of transcription by RNA polymerase II (GO:0000122); RNA polymerase II regulatory region sequence-specific DNA binding (GO:0000977); RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); RNA polymerase II transcription factor activity, sequence-specific DNA binding (GO:0000981); transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0001227); DNA binding (GO:0003677); DNA binding transcription factor activity (GO:0003700); nucleus (GO:0005634); transcription factor complex (GO:0005667); regulation of transcription, DNA-templated (GO:0006355); regulation of transcription by RNA polymerase II (GO:0006357); multicellular organism development (GO:0007275); nervous system development (GO:0007399); transcription factor binding (GO:0008134); anterior/posterior pattern specification (GO:0009952); cell differentiation (GO:0030154); protein homodimerization activity (GO:0042803); negative regulation of DNA binding transcription factor activity (GO:0043433); protein heterodimerization activity (GO:0046982); protein dimerization activity (GO:0046983); regulation of neurogenesis (GO:0050767); RNA polymerase II sequence-specific DNA binding transcription factor binding (GO:0061629); sequence-specific double-stranded DNA binding (GO:1990837)",Hes6,2.1660682,2.1660682,138.41016,255.1186,1,1.5332701,1.5332701,181.29741,302.98218,1,1.519774,1.519774,111.45106,179.14532,1,2.3440636,2.3440636,186.94437,325.60673,0.022312856
SLC35E3,8.0001,0,0,0,8.0001,11.295428,,"[Minus], [# of exons: 5], [Gene type: NM]","chr10:117,170,734-117,183,414",NM_029875,"Slc35e3, solute carrier family 35, member E3, solute carrier family 35 member E3, Predicted to have antiporter activity and nucleotide-sugar transmembrane transporter activity. Predicted to localize to Golgi apparatus. Is expressed in limb mesenchyme; respiratory system; sensory organ; skeleton; and stomach. Orthologous to human SLC35E3 (solute carrier family 35 member E3).",nucleotide-sugar transmembrane transporter activity (GO:0005338); Golgi apparatus (GO:0005794); antiporter activity (GO:0015297); membrane (GO:0016020); integral component of membrane (GO:0016021),Slc35e3,2.3421059,2.3421059,2.8978623,6.8795152,1,1.9153323,1.9153323,3.9178518,7.7108763,0.325437,2.3986882,2.3986882,4.571147,11.295428,0.34284172,2.8438166,2.8438166,4.0311552,8.6477318,0.038581976
UGT2B5,8.0001,0,0,0,8.0001,510.23916,,"[Minus], [# of exons: 6], [Gene type: NM]","chr5:87,553,972-87,569,365",NM_009467,"Ugt2b5, UDP glucuronosyltransferase 2 family, polypeptide B5, UDP-glucuronosyltransferase 2B17|UDP-glucuronosyltransferase 2 family, member 5|UDP-glucuronosyltransferase 2B5, Predicted to have glucuronosyltransferase activity. Predicted to be involved in steroid metabolic process. Localizes to mitochondrial inner membrane. Human ortholog(s) of this gene implicated in osteoporosis. Orthologous to human UGT2B15 (UDP glucuronosyltransferase family 2 member B15) and UGT2B17 (UDP glucuronosyltransferase family 2 member B17).","nuclear outer membrane (GO:0005640); mitochondrial inner membrane (GO:0005743); endoplasmic reticulum (GO:0005783); lipid metabolic process (GO:0006629); UDP-glycosyltransferase activity (GO:0008194); steroid metabolic process (GO:0008202); glucuronosyltransferase activity (GO:0015020); membrane (GO:0016020); integral component of membrane (GO:0016021); transferase activity (GO:0016740); transferase activity, transferring glycosyl groups (GO:0016757); intracellular membrane-bounded organelle (GO:0043231)",Ugt2b5,1.7779564,1.7779564,150.30249,238.7709,1,1.9407806,1.9407806,112.84433,224.96752,0.17863434,2.1495539,2.1495539,225.87227,510.23916,0.22766067,2.6527634,2.6527634,113.78764,238.63688,0.006002085
BMP7,8.0001,0,0,0,8.0001,0.82763548,,"[Minus], [# of exons: 7], [Gene type: NM]","chr2:172,693,513-172,765,822",NM_007557,"Bmp7, bone morphogenetic protein 7, bone morphogenetic protein 7|osteogenic protein 1, Predicted to have BMP receptor binding activity; cytokine activity; and heparin binding activity. Involved in several processes, including animal organ development; embryonic morphogenesis; and regulation of morphogenesis of a branching structure. Localizes to extracellular space. Is expressed in several structures, including alimentary system; embryo ectoderm; embryo mesenchyme; genitourinary system; and sensory organ. Used to study osteoarthritis. Human ortholog(s) of this gene implicated in prostate cancer. Orthologous to human BMP7 (bone morphogenetic protein 7).","ossification (GO:0001503); eye development (GO:0001654); ureteric bud development (GO:0001657); mesoderm formation (GO:0001707); kidney development (GO:0001822); endocardial cushion formation (GO:0003272); pericardium morphogenesis (GO:0003344); cytokine activity (GO:0005125); protein binding (GO:0005515); extracellular region (GO:0005576); extracellular space (GO:0005615); multicellular organism development (GO:0007275); pattern specification process (GO:0007389); axon guidance (GO:0007411); salivary gland morphogenesis (GO:0007435); growth factor activity (GO:0008083); heparin binding (GO:0008201); negative regulation of cell proliferation (GO:0008285); embryonic pattern specification (GO:0009880); animal organ morphogenesis (GO:0009887); positive regulation of gene expression (GO:0010628); positive regulation of epithelial to mesenchymal transition (GO:0010718); positive regulation of peptidyl-threonine phosphorylation (GO:0010800); positive regulation of pathway-restricted SMAD protein phosphorylation (GO:0010862); positive regulation of cell death (GO:0010942); neural fold elevation formation (GO:0021502); cell differentiation (GO:0030154); embryonic limb morphogenesis (GO:0030326); positive regulation of bone mineralization (GO:0030501); BMP signaling pathway (GO:0030509); epithelial cell differentiation (GO:0030855); hindbrain development (GO:0030902); vesicle (GO:0031982); positive regulation of heterotypic cell-cell adhesion (GO:0034116); protein localization to nucleus (GO:0034504); tube morphogenesis (GO:0035239); regulation of phosphorylation (GO:0042325); negative regulation of phosphorylation (GO:0042326); odontogenesis of dentin-containing tooth (GO:0042475); positive regulation of apoptotic process (GO:0043065); steroid hormone mediated signaling pathway (GO:0043401); negative regulation of MAP kinase activity (GO:0043407); positive regulation of cell differentiation (GO:0045597); negative regulation of neuron differentiation (GO:0045665); positive regulation of neuron differentiation (GO:0045666); positive regulation of osteoblast differentiation (GO:0045669); negative regulation of Notch signaling pathway (GO:0045746); negative regulation of cell cycle (GO:0045786); negative regulation of mitotic nuclear division (GO:0045839); negative regulation of transcription, DNA-templated (GO:0045892); positive regulation of transcription, DNA-templated (GO:0045893); positive regulation of transcription by RNA polymerase II (GO:0045944); cell development (GO:0048468); camera-type eye morphogenesis (GO:0048593); embryonic camera-type eye morphogenesis (GO:0048596); anatomical structure formation involved in morphogenesis (GO:0048646); cardiac muscle tissue development (GO:0048738); branching morphogenesis of an epithelial tube (GO:0048754); mesenchymal cell differentiation (GO:0048762); neuron projection morphogenesis (GO:0048812); negative regulation of neurogenesis (GO:0050768); cartilage development (GO:0051216); pharyngeal system development (GO:0060037); embryonic skeletal joint morphogenesis (GO:0060272); regulation of pathway-restricted SMAD protein phosphorylation (GO:0060393); SMAD protein signal transduction (GO:0060395); cardiac septum morphogenesis (GO:0060411); branching involved in salivary gland morphogenesis (GO:0060445); mesenchyme development (GO:0060485); negative regulation of cell death (GO:0060548); negative regulation of prostatic bud formation (GO:0060686); regulation of branching involved in prostate gland morphogenesis (GO:0060687); chorio-allantoic fusion (GO:0060710); heart trabecula morphogenesis (GO:0061384); collagen-containing extracellular matrix (GO:0062023); monocyte aggregation (GO:0070487); BMP receptor binding (GO:0070700); cellular response to BMP stimulus (GO:0071773); negative regulation of mesenchymal cell apoptotic process involved in nephron morphogenesis (GO:0072040); negative regulation of glomerular mesangial cell proliferation (GO:0072125); metanephric mesenchyme morphogenesis (GO:0072133); nephrogenic mesenchyme morphogenesis (GO:0072134); metanephric mesenchymal cell proliferation involved in metanephros development (GO:0072136); positive regulation of brown fat cell differentiation (GO:0090336); positive regulation of dendrite development (GO:1900006); positive regulation of hyaluranon cable assembly (GO:1900106); allantois development (GO:1905069); positive regulation of cardiac neural crest cell migration involved in outflow tract morphogenesis (GO:1905312)",Bmp7,2.6018539,2.6018539,0.067027457,0.1870457,1,2.0065287,2.0065287,0.095998383,0.19809702,1,1.7108216,1.7108216,0.085815933,0.16953351,1,4.218172,4.218172,0.25170459,0.82763548,0.03484179
CRYM,8.0001,0,0,0,8.0001,4.240393,,"[Minus], [# of exons: 8], [Gene type: NM]","chr7:127,329,894-127,345,503",NM_016669,"Crym, crystallin, mu, ketimine reductase mu-crystallin|NADP-regulated thyroid-hormone-binding protein|mu-crystallin homolog|thiomorpholine-carboxylate dehydrogenase, Exhibits hormone binding activity. Involved in thyroid hormone metabolic process. Localizes to mitochondrion and nucleus. Is expressed in several structures, including brain; genitourinary system; respiratory system; sensory organ; and tooth. Human ortholog(s) of this gene implicated in autosomal dominant nonsyndromic deafness 40. Orthologous to human CRYM (crystallin mu).",negative regulation of transcription by RNA polymerase II (GO:0000122); transcription corepressor activity (GO:0003714); nucleus (GO:0005634); cytoplasm (GO:0005737); mitochondrion (GO:0005739); cytosol (GO:0005829); mitochondrial transport (GO:0006839); sensory perception of sound (GO:0007605); oxidoreductase activity (GO:0016491); thyroid hormone metabolic process (GO:0042403); hormone binding (GO:0042562); protein homodimerization activity (GO:0042803); thiomorpholine-carboxylate dehydrogenase activity (GO:0047127); NADP binding (GO:0050661); thyroid hormone binding (GO:0070324); thyroid hormone transport (GO:0070327),Crym,2.2220932,2.2220932,1.9497806,4.1288542,1,2.6231294,2.6231294,1.4133505,4.240393,0.49587956,3.3348549,3.3348549,0.99474238,3.7769356,0.46898896,4.6703075,4.6703075,1.0512424,3.4318865,0.018867704
SULT2A8,8.0001,0,0,0,8.0001,346.92492,,"[Minus], [# of exons: 8], [Gene type: NM]","chr7:14,996,035-15,031,936",NM_001199306 NM_175250,"Sult2a8, sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 8, sulfotransferase-like protein 1, Predicted to have sulfotransferase activity. Predicted to be involved in sulfation. Predicted to localize to cytoplasm. Is expressed in liver and olfactory epithelium. Human ortholog(s) of this gene implicated in prostate cancer. Orthologous to human SULT2A1 (sulfotransferase family 2A member 1).",cytoplasm (GO:0005737); sulfotransferase activity (GO:0008146); sulfation (GO:0051923),Sult2a8,0.80337188,-1.2447536,38.882175,28.709873,1,1.6090466,1.6090466,22.109141,36.83747,1,1.8063344,1.8063344,72.301073,139.69755,1,2.2305952,2.2305952,212.07703,346.92492,0.035214218
SLC15A4,8.0001,0,0,0,8.0001,24.53512,,"[Minus], [# of exons: 8], [Gene type: NM]","chr5:128,076,036-128,097,762",NM_133895,"Slc15a4, solute carrier family 15, member 4, solute carrier family 15 member 4|peptide transporter 4|peptide-histidine transporter 4|peptide/histidine transporter 1, Exhibits L-histidine transmembrane transporter activity and peptide:proton symporter activity. Involved in several processes, including organic substance transport; positive regulation of pattern recognition receptor signaling pathway; and regulation of isotype switching to IgG isotypes. Localizes to early endosome membrane; integral component of endosome membrane; and integral component of lysosomal membrane. Is expressed in embryo. Orthologous to human SLC15A4 (solute carrier family 15 member 4).",immune system process (GO:0002376); L-histidine transmembrane transporter activity (GO:0005290); lysosome (GO:0005764); lysosomal membrane (GO:0005765); endosome (GO:0005768); oligopeptide transport (GO:0006857); endosome membrane (GO:0010008); protein transport (GO:0015031); symporter activity (GO:0015293); peptide:proton symporter activity (GO:0015333); peptidoglycan transmembrane transporter activity (GO:0015647); histidine transport (GO:0015817); peptide transport (GO:0015833); peptidoglycan transport (GO:0015835); membrane (GO:0016020); integral component of membrane (GO:0016021); transmembrane transporter activity (GO:0022857); integral component of endosome membrane (GO:0031303); early endosome membrane (GO:0031901); mast cell homeostasis (GO:0033023); positive regulation of toll-like receptor 7 signaling pathway (GO:0034157); positive regulation of toll-like receptor 8 signaling pathway (GO:0034161); positive regulation of toll-like receptor 9 signaling pathway (GO:0034165); endolysosome membrane (GO:0036020); innate immune response (GO:0045087); positive regulation of innate immune response (GO:0045089); regulation of isotype switching to IgG isotypes (GO:0048302); transmembrane transport (GO:0055085); regulation of nucleotide-binding oligomerization domain containing signaling pathway (GO:0070424); positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway (GO:0070430); positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway (GO:0070434); dipeptide transmembrane transporter activity (GO:0071916); L-histidine transmembrane export from vacuole (GO:0089708); dipeptide import across plasma membrane (GO:0140206); integral component of lysosomal membrane (GO:1905103),Slc15a4,1.6706593,1.6706593,7.4921045,12.244885,1,1.380157,1.380157,12.899277,18.639902,1,1.4479661,1.4479661,9.5836611,14.753409,1,3.0436471,3.0436471,10.977803,24.53512,0.03755672
ARSA,8.0001,0,0,0,8.0001,75.491962,,"[Minus], [# of exons: 9], [Gene type: NM]","chr15:89,302,907-89,307,855",NM_009713,"Arsa, arylsulfatase A, arylsulfatase A|cerebroside-sulfatase, Predicted to have arylsulfatase activity and calcium ion binding activity. Involved in binding activity of sperm to zona pellucida. Localizes to integral component of membrane and plasma membrane. Is expressed in brain and genitourinary system. Used to study metachromatic leukodystrophy. Human ortholog(s) of this gene implicated in metachromatic leukodystrophy. Orthologous to human ARSA (arylsulfatase A).",acrosomal vesicle (GO:0001669); catalytic activity (GO:0003824); arylsulfatase activity (GO:0004065); cerebroside-sulfatase activity (GO:0004098); calcium ion binding (GO:0005509); extracellular space (GO:0005615); cytoplasm (GO:0005737); lysosome (GO:0005764); endosome (GO:0005768); endoplasmic reticulum (GO:0005783); plasma membrane (GO:0005886); autophagy (GO:0006914); binding of sperm to zona pellucida (GO:0007339); central nervous system development (GO:0007417); response to nutrient (GO:0007584); sulfuric ester hydrolase activity (GO:0008484); response to pH (GO:0009268); integral component of membrane (GO:0016021); hydrolase activity (GO:0016787); extrinsic component of external side of plasma membrane (GO:0031232); response to estrogen (GO:0043627); response to ethanol (GO:0045471); metal ion binding (GO:0046872); response to methylmercury (GO:0051597),Arsa,2.9335243,2.9335243,17.350614,51.376654,1,1.5924016,1.5924016,44.676187,75.491962,1,1.7315517,1.7315517,38.791992,70.182555,1,2.9696179,2.9696179,25.724991,59.026229,0.016618383
CYP2C23,8.0001,0,0,0,8.0001,26.18437,,"[Minus], [# of exons: 9], [Gene type: NM]","chr19:44,079,512-44,103,737",NM_001001446 NM_001167905,"Cyp2c23, cytochrome P450, family 2, subfamily c, polypeptide 23, cytochrome P450 2C44|Mutant line 386|arachidonic acid epoxygenase|cytochrome P450, 2c44|cytochrome P450, family 2, subfamily c, polypeptide 44, Predicted to have heme binding activity and monooxygenase activity. Predicted to be involved in exogenous drug catabolic process; icosanoid metabolic process; and xenobiotic metabolic process. Predicted to localize to endoplasmic reticulum membrane. Orthologous to human CYP2C23P (cytochrome P450 family 2 subfamily C member 23, pseudogene).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); endoplasmic reticulum membrane (GO:0005789); organic acid metabolic process (GO:0006082); lipid metabolic process (GO:0006629); fatty acid metabolic process (GO:0006631); xenobiotic metabolic process (GO:0006805); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); arachidonic acid 14,15-epoxygenase activity (GO:0008404); arachidonic acid 11,12-epoxygenase activity (GO:0008405); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); icosanoid biosynthetic process (GO:0046456); metal ion binding (GO:0046872)",Cyp2c23,2.6145058,2.6145058,6.3838166,17.862642,1,3.6423077,3.6423077,3.5246691,14.448912,0.19814363,5.407227,5.407227,4.388023,26.18437,0.051234727,4.3140349,4.3140349,6.6260737,20.91127,0.018039418
NC_INTER_C4_39163,8.0001,0,0,0,8.0001,4.2781082,,"[Plus], [# Lnc isoforms: 10], [# of exons: 2], [Gene type: lncRNA]","chr4:138,883,101-138,894,765",,"lnc_inter_chr4_39163, ",,lnc_inter_chr4_39163,1.4752918,1.4752918,0.29182809,0.41574519,1,1.3045636,1.3045636,0.49708387,0.73482703,1,1.4749215,1.4749215,0.31833721,0.54066337,1,4.2974698,4.2974698,1.3852029,4.2781082,0.027592362
NC_AS_C15_12818,8.0001,0,0,0,8.0001,41.231041,,"[Plus], [# Lnc isoforms: 11], [# of exons: 1], [Gene type: lncRNA]","chr15:85,652,073-85,660,217",,"lnc_as_chr15_12818, ",,lnc_as_chr15_12818,2.6699323,2.6699323,0.15036879,0.45029523,1,1.7663564,1.7663564,1.4708512,2.7406788,1,1.7586115,1.7586115,1.4537604,2.7266526,1,4.2644601,4.2644601,12.688218,41.231041,3.97E-05
NC_INTER_C11_21651,8.0001,0,0,0,8.0001,5.2425039,,"[Plus], [# Lnc isoforms: 11], [# of exons: 1], [Gene type: lncRNA]","chr11:120,362,867-120,366,291",,"lnc_inter_chr11_21651, ",,lnc_inter_chr11_21651,7.1128092,7.1128092,0.051957671,0.46660528,0.53989225,2.3092557,2.3092557,0.7538093,1.8160087,1,0.91632784,-1.0913125,0.41109216,0.34643307,1,5.5091943,5.5091943,1.1455219,5.2425039,0.034850842
NC_INTER_C8_6984,8.0001,0,0,0,8.0001,2.7469483,,"[Plus], [# Lnc isoforms: 11], [# of exons: 1], [Gene type: lncRNA]","chr8:48,008,330-48,015,705",,"lnc_inter_chr8_6984, ",,lnc_inter_chr8_6984,1,1,0,0,1,20.960972,20.9609718,0,0.16172134,1,3.4123367,3.4123367,0.018652812,0.088887311,1,7.8960811,7.8960811,0.48834308,2.7469483,0.015560825
NC_INTER_C13_11769,8.0001,0,0,0,8.0001,2.219765,,"[Plus], [# Lnc isoforms: 11], [# of exons: 2], [Gene type: lncRNA]","chr13:112,976,504-112,993,686",,"lnc_inter_chr13_11769,11770,11771, ",,lnc_inter_chr13_11769,2.5751497,2.5751497,0.010385195,0.018940669,1,5.7442735,5.7442735,0.017461091,0.11976017,1,3.6499793,3.6499793,0.053894667,0.23169413,1,4.6844574,4.6844574,0.60325249,2.219765,0.003774011
NC_INTER_C8_7540,8.0001,0,0,0,8.0001,5.2524325,,"[Plus], [# Lnc isoforms: 12], [# of exons: 5], [Gene type: lncRNA]","chr8:122,772,140-122,792,555",,"lnc_inter_chr8_7540,7541,7542,7543,7544,7545,7546,7547, ",,lnc_inter_chr8_7540,1,1,0,0,1,6.0547369,6.0547369,0.007079273,0.069048881,1,4.116392,4.116392,0,0.010514082,1,5.5311782,5.5311782,1.4164759,5.2524325,0.037239323
NC_INTRA_C1_16454,8.0001,0,0,0,8.0001,18.613645,,"[Plus], [# Lnc isoforms: 13], [# of exons: 25], [Gene type: lncRNA]","chr1:89,993,443-89,993,458 chr1:89,996,279-89,996,416 chr1:89,998,883-89,998,913 chr1:90,004,375-90,004,696 chr1:90,005,063-90,005,291 chr1:90,005,456-90,005,700 chr1:90,015,281-90,017,979 chr1:90,018,117-90,018,355 chr1:90,024,313-90,024,372 chr1:90,024,903-90,025,655 chr1:90,026,849-90,026,900 chr1:90,027,984-90,029,703 chr1:90,030,496-90,030,678 chr1:90,034,172-90,034,251 chr1:90,036,116-90,036,510 chr1:90,036,901-90,037,022 chr1:90,037,144-90,037,386 chr1:90,037,743-90,037,821 chr1:90,041,726-90,041,749 chr1:90,042,089-90,042,107 chr1:90,048,648-90,048,733 chr1:90,049,958-90,050,175 chr1:90,055,151-90,055,363 chr1:90,059,601-90,059,620 chr1:90,061,527-90,061,625",,"lnc_intra_chr1_16454, ",,lnc_intra_chr1_16454,0.93820468,-1.0658655,0.042309494,0.036422978,1,2.0913091,2.0913091,0.29367457,0.65933565,0.28961558,0.66647279,-1.5004363,0.31022021,0.23251748,1,3.4237195,3.4237195,7.3800628,18.613645,0.001253962
NC_INTER_CX_15297,8.0001,0,0,0,8.0001,13.75685,,"[Plus], [# Lnc isoforms: 16], [# of exons: 11], [Gene type: lncRNA]","chrX:34,073,989-34,137,925",,"lnc_inter_chrX_15297, ",,lnc_inter_chrX_15297,4.2873817,4.2873817,0.00955276,0.04310483,1,3.431977,3.431977,0.098682837,0.34310512,1,4.6740407,4.6740407,0.057537803,0.29723252,0.20537206,6.0847625,6.0847625,2.6647842,13.75685,0.03469736
NC_AS_C15_12817,8.0001,0,0,0,8.0001,184.38859,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr15:85,637,875-85,645,221",,"lnc_as_chr15_12817, ",,lnc_as_chr15_12817,1.7445383,1.7445383,0.47618414,0.83319509,1,3.3947227,3.3947227,2.0829367,7.5011671,0.072768794,1.7033756,1.7033756,2.4763499,4.5939123,1,3.0245711,3.0245711,76.272478,184.38859,0.023241813
NC_AS_C8_7331,8.0001,0,0,0,8.0001,0.97364019,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr8:95,780,407-95,803,569",,"lnc_as_chr8_7331, ",,lnc_as_chr8_7331,0.32105177,-3.1147625,0.23172614,0.068219411,1,2.0534024,2.0534024,0.12692805,0.27244816,1,1.0051173,1.0051173,0.21989993,0.24079049,1,5.0020471,5.0020471,0.24743074,0.97364019,0.04400875
NC_INTER_C11_21358,8.0001,0,0,0,8.0001,348.87837,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:106,492,662-106,492,985",,"lnc_inter_chr11_21358, ",,lnc_inter_chr11_21358,7.5846807,7.5846807,1.9198861,10.864341,0.27655709,3.2239611,3.2239611,76.513175,273.66428,1,5.4468318,5.4468318,66.535985,348.87837,1,7.8244739,7.8244739,15.882308,102.79248,0.045936972
NC_INTER_C15_12819,8.0001,0,0,0,8.0001,13.924636,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr15:85,660,542-85,662,236",,"lnc_inter_chr15_12819, ",,lnc_inter_chr15_12819,1,1,0,0,1,2.186653,2.186653,0.078992886,0.27139643,1,10.036429,10.0364293,0,0.35021163,1,6.210421,6.210421,3.1937745,13.924636,0.015393736
NC_INTER_C16_28214,8.0001,0,0,0,8.0001,26.280416,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr16:31,584,046-31,584,795",,"lnc_inter_chr16_28214, ",,lnc_inter_chr16_28214,1,1,0,0,1,10.987283,10.9872832,0,0.7961915,1,6.635334,6.635334,0,0.43739236,1,11.929852,11.9298523,2.556077,26.280416,0.01326476
NC_INTER_C18_14228,8.0001,0,0,0,8.0001,9.4409465,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr18:4,941,804-4,952,893",,"lnc_inter_chr18_14228, ",,lnc_inter_chr18_14228,4.2504303,4.2504303,0.008021601,0.048115278,1,1.098677,1.098677,0.23968178,0.29313733,1,2.0585681,2.0585681,0.068004814,0.12725405,1,4.6658201,4.6658201,2.8126945,9.4409465,0.013210828
NC_INTER_C18_14230,8.0001,0,0,0,8.0001,14.183608,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr18:4,966,346-4,967,639",,"lnc_inter_chr18_14230, ",,lnc_inter_chr18_14230,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,8.0499736,8.0499736,2.3791425,14.183608,0.049266087
NC_INTER_C18_14238,8.0001,0,0,0,8.0001,9.7984466,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr18:4,995,155-4,998,301",,"lnc_inter_chr18_14238, ",,lnc_inter_chr18_14238,1,1,0,0,1,3.5142277,3.5142277,0,0.051702828,1,1,1,0,0,1,12.33872,12.3387196,1.0794637,9.7984466,0.007419358
NC_INTER_C18_14242,8.0001,0,0,0,8.0001,16.487691,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr18:5,006,080-5,007,326",,"lnc_inter_chr18_14242, ",,lnc_inter_chr18_14242,1,1,0,0,1,0.89953796,-1.1116818,0.23218865,0.26108683,1,1,1,0,0,1,6.3250807,6.3250807,3.5190084,16.487691,0.037951488
NC_INTER_C19_32372,8.0001,0,0,0,8.0001,24.80825,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr19:39,313,586-39,314,416",NR_033614,"Cyp2c53-ps, cytochrome P450, family 2, subfamily c, polypeptide 53, pseudogene, cytochrome P450, family 2, subfamily c, polypeptide 29 pseudogene|cytochrome P450, family 2, subfamily c, polypeptide 53-ps; lnc_inter_chr19_32372, ",,Cyp2c53-ps lnc_inter_chr19_32372,1.1448384,1.1448384,0.21434104,0.26492225,1,3.5040007,3.5040007,0.17412454,0.84644948,1,1.5388039,1.5388039,0.4320314,0.59186173,1,11.079293,11.0792927,2.8132507,24.80825,0.004511541
NC_INTER_C2_33115,8.0001,0,0,0,8.0001,13.414733,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr2:27,618,938-27,623,285",,"lnc_inter_chr2_33115, ",,lnc_inter_chr2_33115,2.2306263,2.2306263,0.23983363,0.58464259,1,1.1747947,1.1747947,0.46581299,0.56659722,1,0.33191251,-3.0128421,0.39720437,0.12474163,1,4.2981695,4.2981695,4.2196578,13.414733,0.049689457
NC_INTER_C2_33254,8.0001,0,0,0,8.0001,7.368408,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr2:34,018,948-34,020,354",,"lnc_inter_chr2_33254, ",,lnc_inter_chr2_33254,3.7295443,3.7295443,0,0.075073336,1,7.4264354,7.4264354,0.11059254,1.0393825,1,11.570566,11.5705659,0.071572711,1.7313862,0.70892891,17.95243,17.9524305,0.46086025,7.368408,0.00745748
NC_INTER_C3_36463,8.0001,0,0,0,8.0001,164.73475,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr3:95,728,837-95,729,143",,"lnc_inter_chr3_36463, ",,lnc_inter_chr3_36463,15.716585,15.7165854,0,1.8016764,1,8.1307439,8.1307439,1.4177465,12.263593,0.29018527,5.184303,5.184303,0.44955715,3.3752836,1,139.87889,139.8788924,1.2095718,164.73475,0.000437986
NC_INTER_C5_40084,8.0001,0,0,0,8.0001,50.808857,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr5:53,760,115-53,760,443",,"lnc_inter_chr5_40084, ",,lnc_inter_chr5_40084,6.260762,6.260762,0,0.62535753,1,17.995038,17.9950375,0,2.4783962,1,27.410889,27.4108888,0,5.0797357,1,12.260709,12.2607094,5.3608428,50.808857,0.018414373
NC_INTER_C5_4407,8.0001,0,0,0,8.0001,2.891836,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr5:94,129,863-94,131,917",,"lnc_inter_chr5_4407, ",,lnc_inter_chr5_4407,6.4447457,6.4447457,0,0.10132023,1,23.480023,23.4800229,0,0.65985977,1,44.379708,44.3797083,0,1.3393316,0.29581869,62.712132,62.7121321,0,2.891836,0.026516506
NC_INTER_C8_7538,8.0001,0,0,0,8.0001,6.8633091,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr8:122,754,647-122,763,274",,"lnc_inter_chr8_7538, ",,lnc_inter_chr8_7538,6.2625031,6.2625031,0,0.023776199,1,18.719587,18.7195866,0,0.12870916,1,0.18640297,-5.3647213,0.023329369,0,1,3.771343,3.771343,2.5392216,6.8633091,0.038400732
NC_INTER_CY_15558,8.0001,0,0,0,8.0001,8.4125242,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,869,547-2,870,427",,"lnc_inter_chrY_15558, ",,lnc_inter_chrY_15558,4.2891949,4.2891949,0,0.13332594,1,3.5461489,3.5461489,0,0.15276292,1,3.8366474,3.8366474,0,0.18595268,1,74.610851,74.6108508,0,8.4125242,0.026025367
NC_INTER_CY_50522,8.0001,0,0,0,8.0001,2.3335321,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,859,533-2,862,616",,"lnc_inter_chrY_50522, ",,lnc_inter_chrY_50522,2.9178071,2.9178071,0.028852265,0.11034926,1,0.14001231,-7.1422294,0.086807622,0,1,6.2331017,6.2331017,0.032640685,0.37154346,1,75.906224,75.906224,0,2.3335321,0.015724959
NC_INTER_CY_50539,8.0001,0,0,0,8.0001,7.3980396,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,884,343-2,886,457",,"lnc_inter_chrY_50539, ",,lnc_inter_chrY_50539,1,1,0,0,1,1.6443369,1.6443369,0.13685291,0.26874253,1,0.53309448,-1.8758401,0.27295301,0.17909816,1,164.38909,164.3890854,0,7.3980396,2.58E-06
NC_INTRA_C14_25319,8.0001,0,0,0,8.0001,137.25383,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr14:35,511,295-35,512,226",,"lnc_intra_chr14_25319, ",,lnc_intra_chr14_25319,1,1,0,0,1,7.0641091,7.0641091,0.65628645,4.4662985,0.29018527,1.3959059,1.3959059,2.0249502,3.3715344,1,8.4720519,8.4720519,19.382413,137.25383,0.007142156
NC_INTRA_C4_38599,8.0001,0,0,0,8.0001,95.411244,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr4:115,275,586-115,275,957",,"lnc_intra_chr4_38599, ",,lnc_intra_chr4_38599,0.57866776,-1.7281073,3.6924341,2.2276497,1,1.4842555,1.4842555,9.2206155,13.421081,1,8.0660036,8.0660036,1.7613859,12.055374,0.90137871,11.215014,11.2150144,11.400309,95.411244,0.00939012
NC_INTRA_C11_21655,8.0001,0,0,0,8.0001,47.71223,,"[Plus], [# Lnc isoforms: 1], [# of exons: 2], [Gene type: lncRNA]","chr11:120,393,813-120,394,385 chr11:120,394,467-120,394,488",,"lnc_intra_chr11_21655, ",,lnc_intra_chr11_21655,1.0672914,1.0672914,0.12564138,0.15637498,1,0.646923,-1.545779,3.347567,2.4059688,1,1.0406262,1.0406262,1.5937158,1.4555414,1,8.2468574,8.2468574,7.7617283,47.71223,0.005790573
NC_INTRA_C2_34193,8.0001,0,0,0,8.0001,1.6240452,,"[Plus], [# Lnc isoforms: 1], [# of exons: 2], [Gene type: lncRNA]","chr2:122,070,474-122,070,732 chr2:122,083,419-122,083,473",,"lnc_intra_chr2_34193, ",,lnc_intra_chr2_34193,19.050396,19.0503962,0,0.05545849,1,2.0180278,2.0180278,0.10345793,0.21466904,1,3.5117999,3.5117999,0.048751061,0.18734668,1,14.759105,14.7591049,0.14728069,1.6240452,0.024068985
NC_INTRA_C4_38445,8.0001,0,0,0,8.0001,41.779186,,"[Plus], [# Lnc isoforms: 1], [# of exons: 2], [Gene type: lncRNA]","chr4:104,832,658-104,832,983 chr4:104,833,540-104,833,591",,"lnc_intra_chr4_38445, ",,lnc_intra_chr4_38445,0.28635551,-3.4921626,0.095339264,0,1,5.4895068,5.4895068,0.15490178,1.3039438,1,0.51116954,-1.9562981,0.32357309,0.17538945,1,11.345563,11.3455631,5.2940946,41.779186,0.007419358
NC_INTER_C8_6981,8.0001,0,0,0,8.0001,3.4958945,,"[Plus], [# Lnc isoforms: 23], [# of exons: 1], [Gene type: lncRNA]","chr8:47,970,407-47,984,919",,"lnc_inter_chr8_6981, ",,lnc_inter_chr8_6981,12.812838,12.8128378,0,0.030510295,1,2.2279425,2.2279425,0.059033289,0.14357695,1,8.8345245,8.8345245,0.006934346,0.12688813,1,11.990183,11.9901833,0.3894168,3.4958945,0.000110593
NC_INTER_C10_8733,8.0001,0,0,0,8.0001,3.804166,,"[Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr10:18,090,691-18,092,744",,"lnc_inter_chr10_8733, ",,lnc_inter_chr10_8733,3.7299851,3.7299851,0,0.051414082,1,0.068390765,-14.6218573,0.36813754,0,1,1,1,0,0,1,25.439623,25.4396231,0.18028688,3.804166,0.037721516
NC_INTER_C18_30832,8.0001,0,0,0,8.0001,7.1453764,,"[Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr18:20,401,055-20,403,432",,"lnc_inter_chr18_30832, ",,lnc_inter_chr18_30832,0.28547496,-3.5029342,0.035678557,0,1,2.9133665,2.9133665,0.065415695,0.25088239,1,1,1,0,0,1,17.098007,17.0980066,0.51519189,7.1453764,0.000788827
NC_INTER_C3_37077,8.0001,0,0,0,8.0001,628.74406,,"[Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr3:138,043,547-138,043,909",NR_033581,"Adh6-ps1, alcohol dehydrogenase 6 (class V), pseudogene 1; lnc_inter_chr3_37077, ",,Adh6-ps1 lnc_inter_chr3_37077,4.3199186,4.3199186,0,0.32410726,1,13.520137,13.5201368,1.6575496,22.068407,0.08030342,7.4517625,7.4517625,4.5937829,34.074744,0.10673533,10.912932,10.9129316,66.092145,628.74406,0.03753141
NC_INTER_C4_3471,8.0001,0,0,0,8.0001,11.998969,,"[Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr4:103,173,192-103,175,759",,"lnc_inter_chr4_3471, ",,lnc_inter_chr4_3471,3.7033105,3.7033105,0,0.039952721,1,13.712359,13.7123594,0,0.25169521,1,15.435246,15.4352462,0,0.33860476,1,38.428523,38.4285234,0.32470652,11.998969,7.55E-07
NC_INTER_C3_37079,8.0001,0,0,0,8.0001,281.61301,,"[Plus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr3:138,045,077-138,045,695",NR_033581,"Adh6-ps1, alcohol dehydrogenase 6 (class V), pseudogene 1; lnc_inter_chr3_37079, ",,Adh6-ps1 lnc_inter_chr3_37079,8.2009342,8.2009342,0,0.37969848,1,4.6070875,4.6070875,4.3756433,20.732253,1,7.2815985,7.2815985,3.3977712,27.850101,0.19169959,8.5468048,8.5468048,40.321078,281.61301,0.018382386
NC_INTRA_C18_30761,8.0001,0,0,0,8.0001,10.245778,,"[Plus], [# Lnc isoforms: 3], [# of exons: 4], [Gene type: lncRNA]","chr18:12,865,541-12,866,102 chr18:12,872,737-12,873,314 chr18:12,873,320-12,874,832 chr18:12,887,998-12,888,100",NR_035471,"lnc_intra_chr18_30761, ; Mir1948, microRNA 1948, microRNA mir-1948",cellular response to amino acid stimulus (GO:0071230),lnc_intra_chr18_30761 Mir1948,1.3920218,1.3920218,0.015612301,0.018972348,1,9.6564467,9.6564467,0.024687927,0.32761497,0.34102563,4.5569324,4.5569324,0.008921604,0.067632999,1,27.653378,27.6533778,0.51240362,10.245778,7.20E-06
NC_INTER_C7_45724,8.0001,0,0,0,8.0001,5.6015693,,"[Plus], [# Lnc isoforms: 46], [# of exons: 1], [Gene type: lncRNA]","chr7:151,329,355-151,338,022",,"lnc_inter_chr7_45724, ",,lnc_inter_chr7_45724,3.7047417,3.7047417,0,0.011833233,1,3.5467579,3.5467579,0,0.015510715,1,1,1,0,0,1,9.7275645,9.7275645,0.78268597,5.6015693,0.022695024
NC_INTER_C16_13421,8.0001,0,0,0,8.0001,1.9991402,,"[Plus], [# Lnc isoforms: 4], [# of exons: 1], [Gene type: lncRNA]","chr16:70,570,110-70,584,775",,"lnc_inter_chr16_13421,13422,13423, ",,lnc_inter_chr16_13421,0.28644233,-3.4911042,0.006065567,0,1,3.2040619,3.2040619,0.028104416,0.11059382,1,6.2737239,6.2737239,0.016242463,0.15481489,0.91749212,6.1035814,6.1035814,0.43634133,1.9991402,0.015296721
NC_INTER_C9_49223,8.0001,0,0,0,8.0001,1.1903308,,"[Plus], [# Lnc isoforms: 6], [# of exons: 6], [Gene type: lncRNA]","chr9:112,687,420-112,756,315",,"lnc_inter_chr9_49223, ",,lnc_inter_chr9_49223,11.862269,11.8622695,0.001291117,0.022888444,0.88026372,6.6875048,6.6875048,0.008394714,0.060953229,0.56597249,5.5882675,5.5882675,0.02160464,0.12138288,0.14300379,10.795763,10.7957628,0.14109178,1.1903308,0.001215896
NC_INTER_C19_15004,8.0001,0,0,0,8.0001,10.678676,,"[Plus], [# Lnc isoforms: 7], [# of exons: 1], [Gene type: lncRNA]","chr19:39,356,430-39,361,422",,"lnc_inter_chr19_15004, ",,lnc_inter_chr19_15004,6.2368426,6.2368426,0.016988768,0.15508672,1,3.6744884,3.6744884,0.14920205,0.58026612,1,1.5425676,1.5425676,0.4802275,0.73993386,1,6.225375,6.225375,2.1849511,10.678676,0.000144504
NC_INTER_C6_5846,8.0001,0,0,0,8.0001,1.5208899,,"[Plus], [# Lnc isoforms: 7], [# of exons: 2], [Gene type: lncRNA]","chr6:147,592,450-147,603,561",,"lnc_inter_chr6_5846,5847,5848,5849, ",,lnc_inter_chr6_5846,9.0774707,9.0774707,0,0.027960614,1,2.7247488,2.7247488,0.039045128,0.13896717,1,0.86189355,-1.1602361,0.027170704,0.029514629,1,11.752121,11.7521207,0.16400083,1.5208899,0.039424705
NC_AS_C7_5884,8.0001,0,0,0,8.0001,4.4776997,,"[Plus], [# Lnc isoforms: 9], [# of exons: 2], [Gene type: lncRNA]","chr7:4,115,479-4,124,434",,"lnc_as_chr7_5884,5885,5886, ",,lnc_as_chr7_5884,5.0972922,5.0972922,0.019926122,0.073663472,1,3.9187315,3.9187315,0.1788395,0.73747855,0.2253256,3.226811,3.226811,0.21607096,0.79651553,0.84246564,3.5602486,3.5602486,1.6558981,4.4776997,0.018320297
IL1RAP,8.0001,0,0,0,8.0001,18.256412,,"[Plus], [# of exons: 12], [Gene type: NM,NR]","chr16:26,581,791-26,714,086 chr16:26,714,786-26,725,233",NM_001159317 NM_001159318 NM_008364 NM_134103 NR_152416,"Il1rap, interleukin 1 receptor accessory protein, interleukin-1 receptor accessory protein|IL-1 receptor accessory protein|interleukin-33 receptot beta chain","interleukin-33 receptor activity (GO:0002114); immune system process (GO:0002376); interleukin-1 receptor activity (GO:0004908); interleukin-1 receptor binding (GO:0005149); protein binding (GO:0005515); extracellular region (GO:0005576); cytoplasm (GO:0005737); plasma membrane (GO:0005886); inflammatory response (GO:0006954); signal transduction (GO:0007165); membrane (GO:0016020); integral component of membrane (GO:0016021); hydrolase activity (GO:0016787); cytokine-mediated signaling pathway (GO:0019221); interleukin-2 production (GO:0032623); positive regulation of interleukin-13 production (GO:0032736); positive regulation of interleukin-4 production (GO:0032753); positive regulation of interleukin-5 production (GO:0032754); positive regulation of interleukin-6 production (GO:0032755); protein-containing complex (GO:0032991); interleukin-33-mediated signaling pathway (GO:0038172); innate immune response (GO:0045087); NAD(P)+ nucleosidase activity (GO:0050135); positive regulation of NF-kappaB transcription factor activity (GO:0051092); positive regulation of synapse assembly (GO:0051965); NAD+ nucleotidase, cyclic ADP-ribose generating (GO:0061809); glutamatergic synapse (GO:0098978); regulation of postsynaptic density assembly (GO:0099151); trans-synaptic signaling by trans-synaptic complex (GO:0099545); synaptic membrane adhesion (GO:0099560); positive regulation of dendrite development (GO:1900006); regulation of presynapse assembly (GO:1905606); protein tyrosine kinase binding (GO:1990782)",Il1rap,1.4515538,1.4515538,1.4454986,1.9803122,1,2.0221642,2.0221642,1.2230177,2.5026078,0.28961558,2.05721,2.05721,2.8114338,6.1197795,0.66003444,2.5331007,2.5331007,9.4843367,18.256412,0.012017963
DCUN1D4,8.0001,0,0,0,8.0001,4.6532127,,"[Plus], [# of exons: 14], [Gene type: NM,NR]","chr5:73,872,294-73,952,033",NM_001190733 NM_001190734 NM_178896 NR_153313,"Dcun1d4, DCN1, defective in cullin neddylation 1, domain containing 4 (S. cerevisiae), DCN1-like protein 4|DCUN1 domain-containing protein 4|defective in cullin neddylation protein 1-like protein 4, Predicted to have cullin family protein binding activity; ubiquitin conjugating enzyme binding activity; and ubiquitin-like protein binding activity. Predicted to be involved in positive regulation of protein neddylation; positive regulation of ubiquitin-protein transferase activity; and protein neddylation. Predicted to localize to nucleus and ubiquitin ligase complex. Is expressed in early conceptus; genitourinary system; nervous system; and neural retina. Orthologous to human DCUN1D4 (defective in cullin neddylation 1 domain containing 4).",ubiquitin ligase complex (GO:0000151); nucleus (GO:0005634); ubiquitin conjugating enzyme binding (GO:0031624); ubiquitin-like protein binding (GO:0032182); protein neddylation (GO:0045116); positive regulation of ubiquitin-protein transferase activity (GO:0051443); cullin family protein binding (GO:0097602); positive regulation of protein neddylation (GO:2000436),Dcun1d4,1.1524112,1.1524112,1.1788252,1.3159097,1,1.59458,1.59458,0.88659706,1.4454924,1,1.7266027,1.7266027,1.5803906,2.8450174,1,2.9709574,2.9709574,2.1498968,4.6532127,0.020655305
FAM160B1,8.0001,0,0,0,8.0001,19.882798,,"[Plus], [# of exons: 17], [Gene type: NM]","chr19:57,435,499-57,464,084",NM_145505,"Fam160b1, family with sequence similarity 160, member B1, protein FAM160B1, Orthologous to human FAM160B1 (family with sequence similarity 160 member B1).",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Fam160b1,1.5166408,1.5166408,3.5572885,5.4524936,1,1.5002358,1.5002358,5.9304486,9.3507943,1,2.0919276,2.0919276,6.327358,13.824242,0.3336801,3.0432907,3.0432907,8.4421243,19.882798,0.002617679
GSE1,8.0001,0,0,0,8.0001,11.453161,,"[Plus], [# of exons: 18], [Gene type: NM]","chr8:123,012,766-123,062,595 chr8:123,062,655-123,105,283",NM_001145896 NM_001145897 NM_198671,"Gse1, genetic suppressor element 1, coiled-coil protein, genetic suppressor element 1, Orthologous to human GSE1 (Gse1 coiled-coil protein).",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Gse1,1.7185525,1.7185525,0.50259875,0.89019273,1,1.3526102,1.3526102,1.016237,1.4774216,1,1.6207211,1.6207211,0.68782693,1.154745,1,3.0845472,3.0845472,5.2293619,11.453161,0.038400732
MIR5125,8.0001,0,0,0,8.0001,1270.2601,,"[Plus], [# of exons: 1], [Gene type: NR]","chr17:23,960,258-23,960,336",NR_039586,"Mir5125, microRNA 5125, microRNA mir-5125",,Mir5125,0.53357831,-1.8741392,7.8765837,4.2106801,1,1.2396259,1.2396259,99.575524,140.83584,1,1.1913869,1.1913869,75.980307,91.360771,1,3.5667193,3.5667193,473.09794,1270.2601,0.039142265
MIR6236,8.0001,0,0,0,8.0001,6090.029,,"[Plus], [# of exons: 1], [Gene type: NR]","chr9:110,183,791-110,183,913",NR_105744,"Mir6236, microRNA 6236, microRNA mir-6236",,Mir6236,1.9184793,1.9184793,1018.2563,1549.8975,1,1.4885341,1.4885341,914.12691,1549.0448,1,0.60081193,-1.6644144,958.0569,616.39533,1,7.9268942,7.9268942,1059.0577,6090.029,7.80E-07
TNS2,8.0001,0,0,0,8.0001,109.20516,,"[Plus], [# of exons: 29], [Gene type: NM]","chr15:101,933,365-101,946,832",NM_001355636 NM_153533,"Tns2, tensin 2, tensin-2|C1 domain-containing phosphatase and tensin homolog|C1 domain-containing phosphatase and tensin-like protein|tensin-like C1 domain-containing phosphatase, Predicted to have several functions, including identical protein binding activity; protein kinase binding activity; and protein tyrosine phosphatase activity. Involved in several processes, including collagen metabolic process; multicellular organismal homeostasis; and response to muscle activity. Predicted to localize to focal adhesion. Is expressed in genitourinary system; hand mesenchyme; hindlimb digit mesenchyme; sensory organ; and skeleton. Used to study Pierson syndrome. Orthologous to human TNS2 (tensin 2).",kidney development (GO:0001822); phosphoprotein phosphatase activity (GO:0004721); protein tyrosine phosphatase activity (GO:0004725); signaling receptor binding (GO:0005102); plasma membrane (GO:0005886); focal adhesion (GO:0005925); negative regulation of cell proliferation (GO:0008285); response to muscle activity (GO:0014850); membrane (GO:0016020); hydrolase activity (GO:0016787); cellular homeostasis (GO:0019725); kinase binding (GO:0019900); protein kinase binding (GO:0019901); cell junction (GO:0030054); collagen metabolic process (GO:0032963); multicellular organism growth (GO:0035264); peptidyl-tyrosine dephosphorylation (GO:0035335); intracellular signal transduction (GO:0035556); identical protein binding (GO:0042802); negative regulation of insulin receptor signaling pathway (GO:0046627); metal ion binding (GO:0046872); multicellular organismal homeostasis (GO:0048871),Tns2,2.5212547,2.5212547,8.2440267,21.158171,1,1.3791106,1.3791106,22.565553,34.043644,1,1.3273918,1.3273918,17.138281,24.035465,1,2.5257857,2.5257857,55.702584,109.20516,0.03596146
OLFR872,8.0001,0,0,0,8.0001,2.6978042,,"[Plus], [# of exons: 2], [Gene type: NM]","chr9:20,041,606-20,065,357",NM_146560,"Olfr872, olfactory receptor 872, olfactory receptor 872|GA_x6K02T2PVTD-13999915-14000844|olfactory receptor MOR145-3, Predicted to have olfactory receptor activity. Predicted to be involved in G protein-coupled receptor signaling pathway and sensory perception of smell. Predicted to localize to integral component of membrane. Orthologous to human OR7E24 (olfactory receptor family 7 subfamily E member 24).",olfactory receptor activity (GO:0004984); G-protein coupled receptor signaling pathway (GO:0007186); sensory perception of smell (GO:0007608); integral component of membrane (GO:0016021),Olfr872,3.7292227,3.7292227,0,0.004444154,1,11.045322,11.045322,0.006546803,0.10244449,1,11.385318,11.3853176,0.005791945,0.098687407,0.79152182,13.144731,13.1447312,0.27766808,2.6978042,0.001694477
ACVR1B,8.0001,0,0,0,8.0001,4.1208307,,"[Plus], [# of exons: 9], [Gene type: NM]","chr15:101,004,503-101,024,299 chr15:101,024,363-101,044,115",NM_007395,"Acvr1b, activin A receptor, type 1B, activin receptor type-1B|activin receptor type IB|activin receptor-like kinase 4|serine/threonine-protein kinase receptor R2, Exhibits activin binding activity and protein serine/threonine kinase activity. Is predicted to contribute to activin-activated receptor activity and growth factor binding activity. Involved in several processes, including activin receptor signaling pathway; hair follicle development; and regulation of gene expression. Predicted to localize to activin receptor complex; cell surface; and cytosol. Is expressed in several structures, including alimentary system; central nervous system; egg cylinder; respiratory system; and sensory organ. Human ortholog(s) of this gene implicated in pancreatic cancer. Orthologous to human ACVR1B (activin A receptor type 1B).","G1/S transition of mitotic cell cycle (GO:0000082); nucleotide binding (GO:0000166); in utero embryonic development (GO:0001701); hair follicle development (GO:0001942); protein kinase activity (GO:0004672); protein serine/threonine kinase activity (GO:0004674); transmembrane receptor protein serine/threonine kinase activity (GO:0004675); protein binding (GO:0005515); ATP binding (GO:0005524); cytosol (GO:0005829); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); regulation of transcription, DNA-templated (GO:0006355); protein phosphorylation (GO:0006468); signal transduction (GO:0007165); cell surface receptor signaling pathway (GO:0007166); transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0007178); nervous system development (GO:0007399); mesoderm development (GO:0007498); embryo development (GO:0009790); regulation of signal transduction (GO:0009966); cell surface (GO:0009986); positive regulation of gene expression (GO:0010628); negative regulation of gene expression (GO:0010629); positive regulation of pathway-restricted SMAD protein phosphorylation (GO:0010862); membrane (GO:0016020); integral component of membrane (GO:0016021); kinase activity (GO:0016301); phosphorylation (GO:0016310); activin receptor activity, type I (GO:0016361); transferase activity (GO:0016740); activin-activated receptor activity (GO:0017002); peptidyl-threonine phosphorylation (GO:0018107); growth factor binding (GO:0019838); negative regulation of cell growth (GO:0030308); activin receptor signaling pathway (GO:0032924); positive regulation of activin receptor signaling pathway (GO:0032927); inhibin binding (GO:0034711); nodal signaling pathway (GO:0038092); receptor complex (GO:0043235); positive regulation of erythrocyte differentiation (GO:0045648); positive regulation of transcription by RNA polymerase II (GO:0045944); SMAD binding (GO:0046332); protein autophosphorylation (GO:0046777); metal ion binding (GO:0046872); activin receptor complex (GO:0048179); activin binding (GO:0048185); cellular response to growth factor stimulus (GO:0071363); extrinsic apoptotic signaling pathway (GO:0097191); positive regulation of trophoblast cell migration (GO:1901165)",Acvr1b,1.1054566,1.1054566,1.370205,1.5522357,1,1.1377027,1.1377027,1.9087107,2.2958789,1,1.7038539,1.7038539,1.1377089,1.9890649,1,2.901902,2.901902,1.950366,4.1208307,0.049155261
PEAK1,8.0001,0,0,0,8.0001,36.481819,,"[~1%  IN BLACKLIST], [Minus], [# of exons: 7], [Gene type: NM]","chr9:56,048,936-56,265,857",NM_172924,"Peak1, pseudopodium-enriched atypical kinase 1, inactive tyrosine-protein kinase PEAK1|NKF3 kinase family member|sugen kinase 269|tyrosine-protein kinase SgK269, Predicted to have identical protein binding activity and non-membrane spanning protein tyrosine kinase activity. Predicted to be involved in several processes, including focal adhesion assembly; regulation of focal adhesion assembly; and substrate adhesion-dependent cell spreading. Localizes to actin cytoskeleton and focal adhesion. Orthologous to human PEAK1 (pseudopodium enriched atypical kinase 1).",protein kinase activity (GO:0004672); non-membrane spanning protein tyrosine kinase activity (GO:0004715); ATP binding (GO:0005524); cytoplasm (GO:0005737); cytoskeleton (GO:0005856); focal adhesion (GO:0005925); protein phosphorylation (GO:0006468); actin cytoskeleton (GO:0015629); cell migration (GO:0016477); cell junction (GO:0030054); substrate adhesion-dependent cell spreading (GO:0034446); identical protein binding (GO:0042802); protein autophosphorylation (GO:0046777); focal adhesion assembly (GO:0048041); regulation of focal adhesion assembly (GO:0051893),Peak1,1.668358,1.668358,2.380417,3.3611116,1,1.2508884,1.2508884,2.8002675,3.8806722,1,0.70413901,-1.4201741,2.5051487,1.8795343,1,3.3538116,3.3538116,15.06009,36.481819,0.001416525
NC_INTER_CY_15556,8.0001,0,0,0,8.0001,7.9956904,,"[~12%  IN BLACKLIST], [Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chrY:2,867,689-2,869,476",,"lnc_inter_chrY_15556, ",,lnc_inter_chrY_15556,3.706421,3.706421,0,0.057391513,1,6.042387,6.042387,0,0.18204487,1,1.8881364,1.8881364,0.076980688,0.18332785,1,44.487492,44.4874922,0.16720821,7.9956904,0.000768825
NC_INTER_C6_4822,8.0001,0,0,0,8.0001,534.45417,,"[~12% MAX. MULTIPLE IN BLACKLIST], [Plus], [# Lnc isoforms: 13], [# of exons: 7], [Gene type: lncRNA]","chr6:3,131,102-3,152,501",,"lnc_inter_chr6_4822, ",,lnc_inter_chr6_4822,1.2866387,1.2866387,209.0713,227.17753,1,1.3562847,1.3562847,109.33665,160.2045,1,0.83594926,-1.1962449,54.57029,48.707861,1,12.668436,12.6684359,58.3482,534.45417,9.22E-08
NC_INTER_C4_38027,8.0001,0,0,0,8.0001,9.228718,,"[~14%  IN BLACKLIST], [Plus], [# Lnc isoforms: 15], [# of exons: 1], [Gene type: lncRNA]","chr4:61,779,901-61,788,750",,"Gm12910, ; lnc_inter_chr4_38027, ",,Gm12910 lnc_inter_chr4_38027,1,1,0,0,1,7.4518139,7.4518139,0.015121929,0.17348813,1,2.5004164,2.5004164,0.029150733,0.055514209,1,20.851637,20.8516374,0.59916919,9.228718,0.030038663
LARS2,8.0001,0,0,0,8.0001,279.80699,,"[~2%  IN BLACKLIST], [Plus], [# of exons: 22], [Gene type: NM]","chr9:123,276,045-123,371,793",NM_001348167 NM_001348168 NM_153168,"Lars2, leucyl-tRNA synthetase, mitochondrial, probable leucine--tRNA ligase, mitochondrial, Predicted to have leucine-tRNA ligase activity. Predicted to be involved in leucyl-tRNA aminoacylation and mitochondrial translation. Localizes to mitochondrion. Is expressed in pancreas epithelium. Human ortholog(s) of this gene implicated in Perrault syndrome. Orthologous to human LARS2 (leucyl-tRNA synthetase 2, mitochondrial).",nucleotide binding (GO:0000166); aminoacyl-tRNA editing activity (GO:0002161); aminoacyl-tRNA ligase activity (GO:0004812); leucine-tRNA ligase activity (GO:0004823); ATP binding (GO:0005524); mitochondrion (GO:0005739); translation (GO:0006412); tRNA aminoacylation for protein translation (GO:0006418); leucyl-tRNA aminoacylation (GO:0006429); ligase activity (GO:0016874); mitochondrial translation (GO:0032543),Lars2,1.7997659,1.7997659,23.336592,35.281337,1,1.4413648,1.4413648,26.766009,43.546867,1,0.67356114,-1.4846462,22.662622,16.210685,1,7.9061533,7.9061533,49.440131,279.80699,3.43E-07
IL31RA,8.0001,0,0,0,8.0001,24.648378,,"[~3%  IN BLACKLIST], [Minus], [# of exons: 17], [Gene type: NM]","chr13:113,313,015-113,370,870",NM_139299,"Il31ra, interleukin 31 receptor A, interleukin-31 receptor subunit alpha|IL-31 receptor subunit alpha|IL-31R subunit alpha|IL-31R-alpha|IL-31RA|class I cytokine receptor|cytokine receptor NR10|gp130-like monocyte receptor|gp130-like receptor|interleukin 31RA|interleukin-31 receptor subunit alpha short peptide|mGLM-R|novel cytokine receptor 10|zcytoR17, Exhibits cytokine binding activity. Involved in several processes, including T-helper 2 cell cytokine production; acute inflammatory response to antigenic stimulus; and glandular epithelial cell differentiation. Localizes to external side of plasma membrane. Is expressed in brain; peripheral nervous system; reproductive system; and stomach. Human ortholog(s) of this gene implicated in primary cutaneous amyloidosis. Orthologous to human IL31RA (interleukin 31 receptor A).",glandular epithelial cell differentiation (GO:0002067); immune system process (GO:0002376); acute inflammatory response to antigenic stimulus (GO:0002438); cytokine receptor activity (GO:0004896); plasma membrane (GO:0005886); positive regulation of cell proliferation (GO:0008284); external side of plasma membrane (GO:0009897); membrane (GO:0016020); integral component of membrane (GO:0016021); cytokine-mediated signaling pathway (GO:0019221); cytokine binding (GO:0019955); cell junction (GO:0030054); T-helper 2 cell cytokine production (GO:0035745); cell projection (GO:0042995); receptor complex (GO:0043235); synapse (GO:0045202); granulocyte colony-stimulating factor binding (GO:0051916); defense response to other organism (GO:0098542),Il31ra,2.0366448,2.0366448,1.2449759,2.0177337,1,1.3935365,1.3935365,1.3456226,2.2150319,1,0.73175862,-1.3665709,1.523209,1.1958211,1,9.7286102,9.7286102,3.6310445,24.648378,0.001181173
NC_AS_C2_1119,8.0001,0,0,0,8.0001,56.326972,,"[~4%  IN BLACKLIST], [Minus], [# Lnc isoforms: 9], [# of exons: 3], [Gene type: lncRNA]","chr2:22,599,554-22,632,207",,"lnc_as_chr2_1119, ",,lnc_as_chr2_1119,1.8340952,1.8340952,7.8623892,11.538642,1,1.1452805,1.1452805,6.4791595,8.7032741,1,0.64334848,-1.5543675,7.7778848,5.3350634,1,11.428249,11.4282491,7.1552178,56.326972,0.000523226
GM19951,8.0001,0,0,0,8.0001,943.90778,,"[~41%  IN BLACKLIST], [Plus], [# of exons: 2], [Gene type: lincRNA]","chr12:100,881,303-100,885,431",NR_166738,"Gm19951, predicted gene, 19951",,Gm19951,2.4525706,2.4525706,86.333946,160.61211,1,1.4929803,1.4929803,81.11905,137.57713,1,0.70062835,-1.4272902,79.816809,59.466529,1,14.802076,14.8020765,92.358943,943.90778,6.18E-06
NC_INTER_CY_15555,8.0001,0,0,0,8.0001,3.6106676,,"[~53%  IN BLACKLIST], [Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chrY:2,786,718-2,789,456",,"lnc_inter_chrY_15555, ",,lnc_inter_chrY_15555,16.700936,16.7009365,0,0.17140516,1,2.2470912,2.2470912,0.20722573,0.50360306,1,4.295055,4.295055,0.14701422,0.9154757,1,106.38698,106.3869796,0,3.6106676,0.000625057
NC_INTER_CY_15554,8.0001,0,0,0,8.0001,6.3080195,,"[~53%  IN BLACKLIST], [Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chrY:2,786,720-2,789,577",,"lnc_inter_chrY_15554, ",,lnc_inter_chrY_15554,0.2868726,-3.4858679,0.031134593,0,1,0.52451129,-1.9065366,0.2379346,0.13279993,1,3.040039,3.040039,0.090288706,0.22910515,1,54.162133,54.1621333,0.12955162,6.3080195,0.000117681
NC_INTER_C13_23226,8.0001,0,0,0,8.0001,17.769367,,"[~6%  IN BLACKLIST], [Plus], [# Lnc isoforms: 4], [# of exons: 1], [Gene type: lncRNA]","chr13:4,255,969-4,258,436",,"lnc_inter_chr13_23226, ",,lnc_inter_chr13_23226,4.1142251,4.1142251,0.03605656,0.21150247,1,3.0391521,3.0391521,0.90150013,2.7737222,0.68133342,4.4088795,4.4088795,1.3757671,6.8330481,0.49514487,8.1767698,8.1767698,2.7242228,17.769367,0.002645826
NC_INTER_CY_50534,8.0001,0,0,0,8.0001,6.9801869,,"[~72%  IN BLACKLIST], [Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,875,820-2,877,349",,"lnc_inter_chrY_50534, ",,lnc_inter_chrY_50534,1.144872,1.144872,0.11635256,0.14380998,1,0.88849044,-1.1255045,0.094521494,0.070880409,1,2.7784456,2.7784456,0.089970235,0.35442884,1,111.50449,111.5044885,0,6.9801869,0.000235328
NC_INTRA_C5_41495,8.0001,0,0,0,8.0001,5403.8861,,"[~84%  IN BLACKLIST], [Plus], [# Lnc isoforms: 26], [# of exons: 1], [Gene type: lncRNA]","chr5:147,071,607-147,074,099",,"lnc_intra_chr5_41495, ",,lnc_intra_chr5_41495,1.9789593,1.9789593,872.32739,1353.6186,1,1.0867599,1.0867599,692.42399,867.67919,1,0.67838998,-1.4740784,677.32452,487.8798,1,9.2410338,9.2410338,834.11038,5403.8861,0.00015462
NC_INTER_C16_28282,8.0001,0,0,0,8.0001,779.79604,,"[~89%  IN BLACKLIST], [Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr16:35,981,583-35,982,844",AK144265 XR_001781900 XR_003951858 XR_876052,"Gm15564, predicted gene 15564; lnc_inter_chr16_28282, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Gm15564 lnc_inter_chr16_28282,1.6790063,1.6790063,58.86993,76.531904,1,1.3574252,1.3574252,65.852926,102.40067,1,0.83951134,-1.1911691,50.799904,45.082568,1,7.8865437,7.8865437,141.18076,779.79604,0.000261624
ABCD2,7.222,1.2,2.02,4.002,0,10.021848,,"[Minus], [# of exons: 10], [Gene type: NM]","chr15:90,976,302-91,022,438",NM_001358967 NM_011994,"Abcd2, ATP-binding cassette, sub-family D (ALD), member 2, ATP-binding cassette sub-family D member 2|adrenoleukodystrophy related|adrenoleukodystrophy-related protein, Predicted to have several functions, including ATP binding activity; long-chain fatty acid transporter activity; and protein homodimerization activity. Involved in several processes, including fatty acid catabolic process; negative regulation of cytokine production involved in inflammatory response; and positive regulation of fatty acid metabolic process. Localizes to mitochondrion. Is expressed in several structures, including alimentary system; hemolymphoid system; limb; nervous system; and sensory organ. Orthologous to human ABCD2 (ATP binding cassette subfamily D member 2).","very long-chain fatty acid metabolic process (GO:0000038); nucleotide binding (GO:0000166); long-chain fatty acid transporter activity (GO:0005324); protein binding (GO:0005515); ATP binding (GO:0005524); mitochondrion (GO:0005739); peroxisome (GO:0005777); peroxisomal membrane (GO:0005778); fatty acid beta-oxidation (GO:0006635); peroxisome organization (GO:0007031); response to bacterium (GO:0009617); peroxisomal long-chain fatty acid import (GO:0015910); membrane (GO:0016020); integral component of membrane (GO:0016021); ATPase activity (GO:0016887); positive regulation of fatty acid beta-oxidation (GO:0032000); ATPase activity, coupled to transmembrane movement of substances (GO:0042626); very long-chain fatty acid catabolic process (GO:0042760); protein homodimerization activity (GO:0042803); myelin maintenance (GO:0043217); transmembrane transport (GO:0055085); negative regulation of cytokine production involved in inflammatory response (GO:1900016); negative regulation of reactive oxygen species biosynthetic process (GO:1903427); neuron projection maintenance (GO:1990535); positive regulation of unsaturated fatty acid biosynthetic process (GO:2001280)",Abcd2,0.17339117,-5.7673063,2.8554207,0.4947446,0.000720647,0.29975493,-3.3360586,1.9935653,0.60248962,0.005627405,0.29081533,-3.4386083,4.0865834,1.2702058,0.011140081,0.34966197,-2.859905,10.021848,2.6723453,0.33989296
FMO6,7.222,1.2,2.02,4.002,0,0.46172754,,"[Minus], [# of exons: 8], [Gene type: NM]","chr1:164,846,682-164,867,356",NM_001178038,"Fmo6, flavin containing monooxygenase 6, Predicted to have monooxygenase activity. Is expressed in olfactory epithelium. Orthologous to human FMO6P (flavin containing dimethylaniline monoxygenase 6, pseudogene).","monooxygenase activity (GO:0004497); N,N-dimethylaniline monooxygenase activity (GO:0004499); cellular_component (GO:0005575)",Fmo6,0.004224152,-236.7338962,0.46172754,0,3.93E-10,0.047018723,-21.2681231,0.19675526,0.005242147,0.033391053,0.014340548,-69.732341,0.20578998,0,0.020691761,0.45686043,-2.1888523,0.15183868,0.044425457,1
DIPK1C,7.222,1.2,2.02,4.002,0,1.115051,,"[Plus], [# of exons: 5], [Gene type: NM]","chr18:84,889,536-84,909,828",NM_173770,"Dipk1c, divergent protein kinase domain 1C, divergent protein kinase domain 1C|family with sequence similarity 69, member C|protein FAM69C, Predicted to localize to endoplasmic reticulum and integral component of membrane. Is expressed in forelimb bud; lip; sensory organ; and ventricular layer. Orthologous to human DIPK1C (divergent protein kinase domain 1C).",molecular_function (GO:0003674); cellular_component (GO:0005575); endoplasmic reticulum (GO:0005783); biological_process (GO:0008150); membrane (GO:0016020); integral component of membrane (GO:0016021),Dipk1c,0.025651445,-38.984158,0.28760004,0.005201711,0.005371317,0.010159054,-98.4343619,0.241304,0,0.025980478,0.010254522,-97.5179581,0.25542261,0,0.0296844,0.1908246,-5.2404144,1.115051,0.13207629,0.77648938
ACNAT2,7.222,1.2,2.02,4.002,0,38.285681,,"[~5%  IN BLACKLIST], [Minus], [# of exons: 6], [Gene type: NM]","chr4:49,392,712-49,421,023",NM_001356289 NM_145368,"Acnat2, acyl-coenzyme A amino acid N-acyltransferase 2, acyl-coenzyme A amino acid N-acyltransferase 2|acyl-CoA:amino acid N-acyltransferase 2, Predicted to have acyl-CoA hydrolase activity. Predicted to be involved in acyl-CoA metabolic process and fatty acid metabolic process. Predicted to localize to peroxisome.","peroxisome (GO:0005777); lipid metabolic process (GO:0006629); fatty acid metabolic process (GO:0006631); acyl-CoA metabolic process (GO:0006637); transferase activity (GO:0016740); transferase activity, transferring acyl groups (GO:0016746); thiolester hydrolase activity (GO:0016790); acyl-CoA hydrolase activity (GO:0047617)",Acnat2,0.21597532,-4.6301587,28.782508,5.6972841,3.05E-05,0.31033314,-3.2223436,20.672048,6.6011784,1.09E-05,0.28678389,-3.4869462,23.575725,7.1270936,0.00067272,0.38848693,-2.5740892,38.285681,11.456081,0.13267793
NC_INTER_C18_30760,7.111,1.1,2.01,4.001,0,9.2211549,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr18:12,800,789-12,801,885",,"lnc_inter_chr18_30760, ",,lnc_inter_chr18_30760,15.34781,15.34781,0.23969981,4.4993226,0.000275946,9.1296471,9.1296471,0.91375437,9.0522723,3.80E-05,11.346577,11.3465769,0.40096549,6.7192352,0.006987917,6.5013717,6.5013717,1.9611733,9.2211549,0.36906301
ASNS,7.111,1.1,2.01,4.001,0,3.5200511,,"[Minus], [# of exons: 12], [Gene type: NM]","chr6:7,625,165-7,643,209",NM_012055,"Asns, asparagine synthetase, asparagine synthetase [glutamine-hydrolyzing]|glutamine-dependent asparagine synthetase, Predicted to have asparagine synthase (glutamine-hydrolyzing) activity and identical protein binding activity. Predicted to be involved in several processes, including asparagine biosynthetic process; cellular response to glucose starvation; and positive regulation of mitotic cell cycle. Predicted to localize to cytosol. Is expressed in several structures, including alimentary system; eye; genitourinary system; nervous system; and respiratory system. Orthologous to human ASNS (asparagine synthetase (glutamine-hydrolyzing)).",nucleotide binding (GO:0000166); asparagine synthase (glutamine-hydrolyzing) activity (GO:0004066); ATP binding (GO:0005524); cytosol (GO:0005829); asparagine biosynthetic process (GO:0006529); glutamine metabolic process (GO:0006541); cellular amino acid biosynthetic process (GO:0008652); ligase activity (GO:0016874); cellular response to glucose starvation (GO:0042149); identical protein binding (GO:0042802); negative regulation of apoptotic process (GO:0043066); positive regulation of mitotic cell cycle (GO:0045931),Asns,7.5658242,7.5658242,0.38067991,2.2262912,0.022240907,7.2544332,7.2544332,0.41368496,3.1682745,0.030320325,9.8151828,9.8151828,0.35689363,3.5200511,0.006051236,4.6767311,4.6767311,0.40710021,1.31725,0.25905593
NAT8,7.111,1.1,2.01,4.001,0,12.633838,,"[Minus], [# of exons: 4], [Gene type: NM]","chr6:85,780,381-85,782,595 chr6:85,785,543-85,785,621 chr6:85,786,457-85,786,851",NM_001362060 NM_023455,"Nat8, N-acetyltransferase 8 (GCN5-related), N-acetyltransferase 8|N-acetyltransferase 8 (GCN5-related, putative)|acetyltransferase 2|camello-like 4|camello-like protein 4|cysteinyl-conjugate N-acetyltransferase|probable N-acetyltransferase CML4, Predicted to have cysteine-S-conjugate N-acetyltransferase activity and lysine N-acetyltransferase activity, acting on acetyl phosphate as donor. Involved in gastrulation with mouth forming second. Predicted to localize to several cellular components, including Golgi apparatus; endoplasmic reticulum membrane; and endoplasmic reticulum-Golgi intermediate compartment membrane. Orthologous to several human genes including NAT8 (N-acetyltransferase 8 (putative)).","gastrulation with mouth forming second (GO:0001702); lysine N-acetyltransferase activity, acting on acetyl phosphate as donor (GO:0004468); late recombination nodule (GO:0005715); endoplasmic reticulum (GO:0005783); endoplasmic reticulum membrane (GO:0005789); endoplasmic reticulum-Golgi intermediate compartment (GO:0005793); Golgi apparatus (GO:0005794); glutathione metabolic process (GO:0006749); negative regulation of cell adhesion (GO:0007162); N-acetyltransferase activity (GO:0008080); positive regulation of gene expression (GO:0010628); membrane (GO:0016020); integral component of membrane (GO:0016021); transferase activity (GO:0016740); transferase activity, transferring acyl groups (GO:0016746); peptidyl-lysine N6-acetylation (GO:0018003); endoplasmic reticulum-Golgi intermediate compartment membrane (GO:0033116); negative regulation of apoptotic process (GO:0043066); cysteine-S-conjugate N-acetyltransferase activity (GO:0047198); amyloid-beta metabolic process (GO:0050435)",Nat8,5.0432895,5.0432895,1.915045,8.3940933,0.013572877,3.4805074,3.4805074,3.1121641,12.633838,0.014647243,3.5112108,3.5112108,2.6727343,10.209515,0.007812421,2.2426537,2.2426537,5.6732614,9.3115398,0.78301697
MUP5,7.111,1.1,2.01,4.001,0,20.82978,,"[Minus], [# of exons: 7], [Gene type: NM]","chr4:61,492,353-61,496,214",NM_008649,"Mup5, major urinary protein 5, major urinary protein 5|MUP 5|Mup V|major urinary protein 18, Predicted to have odorant binding activity. Predicted to be involved in behavior. Predicted to localize to extracellular space. Is expressed in nervous system and nose.",odorant binding (GO:0005549); pheromone binding (GO:0005550); extracellular region (GO:0005576); extracellular space (GO:0005615); behavior (GO:0007610); biological_process (GO:0008150); small molecule binding (GO:0036094),Mup5,7.5311781,7.5311781,2.0080374,11.724009,0.019187141,7.4835259,7.4835259,1.8145049,14.411297,7.10E-13,3.8303497,3.8303497,5.006292,20.82978,0.000234501,3.1743746,3.1743746,1.8291518,4.7837629,0.67244045
MUP8,7.111,1.1,2.01,4.001,0,51.417115,,"[Minus], [# of exons: 7], [Gene type: NM]","chr4:60,231,493-60,231,744 chr4:60,232,147-60,235,412",NM_001347131,"Mup8, major urinary protein 8, major urinary protein 8|major urinary protein (Mup) gene family member|major urinary protein 5",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Mup8,37.283304,37.2833045,1.8410281,51.417115,0.005456325,19.771032,19.7710316,1.8084885,42.799775,0.000319273,13.730929,13.7309293,2.6507139,35.409931,0.002193267,6.1238087,6.1238087,1.5653469,6.8624761,0.15533536
FITM1,7.111,1.1,2.01,4.001,0,95.572922,,"[Plus], [# of exons: 2], [Gene type: NM]","chr14:56,194,511-56,195,789",NM_026808,"Fitm1, fat storage-inducing transmembrane protein 1, fat storage-inducing transmembrane protein 1|fat-inducing protein 1|fat-inducing transcript 1, Exhibits diacylglycerol binding activity and triglyceride binding activity. Involved in lipid droplet formation and positive regulation of sequestering of triglyceride. Localizes to integral component of endoplasmic reticulum membrane. Is expressed in genitourinary system; gut; liver; lung; and musculature. Orthologous to human FITM1 (fat storage inducing transmembrane protein 1).",endoplasmic reticulum (GO:0005783); endoplasmic reticulum membrane (GO:0005789); lipid metabolic process (GO:0006629); phospholipid biosynthetic process (GO:0008654); positive regulation of sequestering of triglyceride (GO:0010890); membrane (GO:0016020); integral component of membrane (GO:0016021); triglyceride binding (GO:0017129); lipid storage (GO:0019915); diacylglycerol binding (GO:0019992); integral component of endoplasmic reticulum membrane (GO:0030176); lipid particle organization (GO:0034389); lipid droplet formation (GO:0140042),Fitm1,4.0585113,4.0585113,25.961843,95.572922,0.00920881,4.3475195,4.3475195,11.970561,59.341367,0.000813035,5.9266528,5.9266528,7.0962083,44.814256,0.000801974,3.9469832,3.9469832,9.7306191,29.367638,0.18146302
MTNR1A,7.111,1.1,2.01,4.001,0,3.2640942,,"[Plus], [# of exons: 2], [Gene type: NM]","chr8:46,154,461-46,173,860",NM_008639,"Mtnr1a, melatonin receptor 1A, melatonin receptor type 1A|Mel1a receptor|mel-1A-R, Predicted to have hormone binding activity; melatonin receptor activity; and organic cyclic compound binding activity. Predicted to be involved in adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; circadian rhythm; and negative regulation of insulin secretion. Predicted to localize to integral component of plasma membrane; neuronal cell body; and receptor complex. Is expressed in several structures, including adrenal gland; brain; gonad; intestine; and liver and biliary system. Orthologous to human MTNR1A (melatonin receptor 1A).",G-protein coupled receptor activity (GO:0004930); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); signal transduction (GO:0007165); G-protein coupled receptor signaling pathway (GO:0007186); adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway (GO:0007193); circadian rhythm (GO:0007623); melatonin receptor activity (GO:0008502); membrane (GO:0016020); integral component of membrane (GO:0016021); hormone binding (GO:0042562); neuronal cell body (GO:0043025); receptor complex (GO:0043235); negative regulation of insulin secretion (GO:0046676); organic cyclic compound binding (GO:0097159),Mtnr1a,5.4788159,5.4788159,0.11311856,0.52337971,0.036675488,6.8812605,6.8812605,0.099691364,0.72383253,3.80E-05,8.2074516,8.2074516,0.066220126,0.62038538,0.010697536,3.9754296,3.9754296,0.97630356,3.2640942,0.079656902
NC_INTER_C6_42054,6.022,0,2.02,4.002,0,20.628064,,"[Minus], [# Lnc isoforms: 15], [# of exons: 1], [Gene type: lncRNA]","chr6:37,820,025-37,820,803",,"lnc_inter_chr6_42054, ",,lnc_inter_chr6_42054,0.096776781,-10.3330571,10.123457,0.926613,0.11841055,0.14399748,-6.944566,14.009727,2.2241907,2.80E-05,0.06676579,-14.9777303,10.374657,0.69740622,0.000594994,0.090588074,-11.0389807,20.628064,1.363661,0.22433203
NC_INTER_C13_11437,6.022,0,2.02,4.002,0,7.2070404,,"[Minus], [# Lnc isoforms: 35], [# of exons: 4], [Gene type: lncRNA]","chr13:60,569,089-60,582,351",,"Gm48500, ; lnc_inter_chr13_11437, ",,Gm48500 lnc_inter_chr13_11437,0.33632299,-2.9733323,0.25553571,0.081140406,1,0.18820446,-5.3133705,1.498423,0.27299038,0.007291214,0.17611561,-5.6780885,2.0441278,0.37638198,0.000510713,0.25733486,-3.8859873,7.2070404,1.3065646,0.071813113
SLC13A3,6.022,0,2.02,4.002,0,5.7495704,,"[Minus], [# of exons: 13], [Gene type: NM]","chr2:165,230,795-165,298,697",NM_054055,"Slc13a3, solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3, solute carrier family 13 member 3|Na(+)/dicarboxylate cotransporter 3|mNaDC3|sodium-dependent high-affinity dicarboxylate transporter 2, Exhibits high-affinity sodium:dicarboxylate symporter activity and succinate transmembrane transporter activity. Involved in succinate transmembrane transport. Localizes to membrane. Is expressed in central nervous system; esophagus; genitourinary system; liver; and retina. Orthologous to human SLC13A3 (solute carrier family 13 member 3).",dicarboxylic acid transmembrane transporter activity (GO:0005310); organic acid:sodium symporter activity (GO:0005343); plasma membrane (GO:0005886); ion transport (GO:0006811); sodium ion transport (GO:0006814); dicarboxylic acid transport (GO:0006835); citrate transmembrane transporter activity (GO:0015137); alpha-ketoglutarate transmembrane transporter activity (GO:0015139); succinate transmembrane transporter activity (GO:0015141); L-aspartate transmembrane transporter activity (GO:0015183); symporter activity (GO:0015293); high-affinity sodium:dicarboxylate symporter activity (GO:0015362); succinate transport (GO:0015744); citrate transport (GO:0015746); aspartate transmembrane transport (GO:0015810); membrane (GO:0016020); integral component of membrane (GO:0016021); basolateral plasma membrane (GO:0016323); sodium:dicarboxylate symporter activity (GO:0017153); transmembrane transporter activity (GO:0022857); glutathione transmembrane transporter activity (GO:0034634); glutathione transmembrane transport (GO:0034775); transmembrane transport (GO:0055085); succinate transmembrane transport (GO:0071422); anion transmembrane transport (GO:0098656),Slc13a3,0.92131753,-1.0854021,4.037854,3.5830417,1,0.39971868,-2.5017595,5.5011297,2.4417057,0.009466795,0.3502281,-2.855282,5.7495704,2.1343009,0.011685336,0.628034,-1.5922705,4.832157,2.2397166,1
MSMP,6.022,0,2.02,4.002,0,30.352438,,"[Minus], [# of exons: 3], [Gene type: NM]","chr4:43,596,088-43,597,366",NM_001099314,"Msmp, microseminoprotein, prostate associated, prostate-associated microseminoprotein|PC3-secreted microprotein homolog|Vmicroseminoprotein, prostate associated, Predicted to have CCR2 chemokine receptor binding activity. Predicted to be involved in lymphocyte chemotaxis and monocyte chemotaxis. Predicted to localize to cytoplasm and extracellular space. Orthologous to human MSMP (microseminoprotein, prostate associated).",monocyte chemotaxis (GO:0002548); cytokine activity (GO:0005125); extracellular region (GO:0005576); extracellular space (GO:0005615); cytoplasm (GO:0005737); chemotaxis (GO:0006935); inflammatory response (GO:0006954); CCR2 chemokine receptor binding (GO:0031727); lymphocyte chemotaxis (GO:0048247),Msmp,0.050370123,-19.8530386,2.360826,0.080249323,0.39068722,0.05367118,-18.6319736,30.352438,1.8388851,0.002948895,0.075252994,-13.2885079,22.736272,1.8244564,0.018248222,0.047213996,-21.1801604,2.205302,0,1
HTRA4,6.022,0,2.02,4.002,0,1.06768,,"[Minus], [# of exons: 9], [Gene type: NM]","chr8:26,135,400-26,149,434",NM_001081187,"Htra4, HtrA serine peptidase 4, serine protease HTRA4|high-temperature requirement factor A4, Predicted to have endopeptidase activity and identical protein binding activity. Predicted to be involved in proteolysis. Predicted to localize to extracellular region. Is expressed in several structures, including genitourinary system; gut; hemolymphoid system gland; lung; and muscle tissue. Orthologous to human HTRA4 (HtrA serine peptidase 4).",endopeptidase activity (GO:0004175); serine-type endopeptidase activity (GO:0004252); insulin-like growth factor binding (GO:0005520); cellular_component (GO:0005575); extracellular region (GO:0005576); proteolysis (GO:0006508); peptidase activity (GO:0008233); serine-type peptidase activity (GO:0008236); hydrolase activity (GO:0016787); identical protein binding (GO:0042802),Htra4,0.48055004,-2.0809487,0.87827899,0.40453706,1,0.21733107,-4.6012749,0.96277543,0.23515522,0.00629613,0.22378328,-4.4686092,1.06768,0.24075405,0.017185963,0.40614601,-2.4621687,0.60125897,0.17290126,1
NC_AS_C2_34310,6.022,0,2.02,4.002,0,1.0432339,,"[Plus], [# Lnc isoforms: 17], [# of exons: 4], [Gene type: lncRNA]","chr2:127,348,023-127,357,203",,"lnc_as_chr2_34310, ",,lnc_as_chr2_34310,0.1074307,-9.3083259,0.24516185,0.022670125,0.98885969,0.14402286,-6.9433422,0.71137659,0.11196811,0.025980478,0.12081133,-8.2773692,0.90810932,0.11265332,0.011589497,0.50686475,-1.9729129,1.0432339,0.3742302,1
NC_INTER_CX_50183,6.022,0,2.02,4.002,0,16.581598,,"[Plus], [# Lnc isoforms: 18], [# of exons: 2], [Gene type: lncRNA]","chrX:112,941,453-112,950,872",,"lnc_inter_chrX_50183, ",,lnc_inter_chrX_50183,0.81597293,-1.2255309,0.074841399,0.045439772,1,0.21916836,-4.5627024,0.69091375,0.16368065,0.024649495,0.23873248,-4.1887891,4.1940657,1.069774,0.001055738,0.35295588,-2.8332153,16.581598,4.4973181,0.051057112
NC_INTER_C13_24673,6.022,0,2.02,4.002,0,27.161379,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr13:98,622,757-98,623,085",,"lnc_inter_chr13_24673, ",,lnc_inter_chr13_24673,0.026103224,-38.3094448,4.2380357,0,0.52379831,0.013841428,-72.2468818,11.025024,0,0.019089446,0.041355716,-24.1804541,15.228977,0.49990403,0.041524425,0.053451238,-18.7086406,27.161379,0.98890356,0.21543251
NC_INTER_C2_34673,6.022,0,2.02,4.002,0,5.1565359,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr2:153,426,931-153,428,813",,"lnc_inter_chr2_34673, ",,lnc_inter_chr2_34673,0.042523692,-23.5163024,0.45531449,0,1,0.024558105,-40.7197547,4.0285441,0.057585625,3.60E-06,0.041947563,-23.8392873,2.8332071,0.11405154,0.0024339,0.082658024,-12.0980391,5.1565359,0.31327972,0.071210413
NC_INTER_C14_25944,6.022,0,2.02,4.002,0,113.38483,,"[Plus], [# Lnc isoforms: 25], [# of exons: 1], [Gene type: lncRNA]","chr14:76,204,912-76,214,128",,"lnc_inter_chr14_25944, ",,lnc_inter_chr14_25944,0.21349404,-4.6839716,0.24623499,0.046440669,1,0.11156932,-8.9630373,5.2926043,0.57543883,0.013385655,0.1539685,-6.4948351,5.0817368,0.80903986,0.045774958,0.1162145,-8.6047784,113.38483,9.5911377,0.056356149
PRLR,6.022,0,2.02,4.002,0,145.29563,,"[Plus], [# of exons: 13], [Gene type: NM]","chr15:10,106,993-10,278,935",NM_001253781 NM_001253782 NM_011169,"Prlr, prolactin receptor, prolactin receptor|PRL-R|prolactin receptor related sequence 1, Exhibits prolactin receptor activity. Is predicted to contribute to oncostatin-M receptor activity. Involved in several processes, including gland development; positive regulation of cold-induced thermogenesis; and receptor signaling pathway via JAK-STAT. Predicted to localize to external side of plasma membrane and receptor complex. Is expressed in several structures, including alimentary system; central nervous system; genitourinary system; hemolymphoid system gland; and limb segment. Used to study familial medullary thyroid carcinoma. Human ortholog(s) of this gene implicated in hyperprolactinemia. Orthologous to human PRLR (prolactin receptor).",cytokine receptor activity (GO:0004896); leukemia inhibitory factor receptor activity (GO:0004923); oncostatin-M receptor activity (GO:0004924); prolactin receptor activity (GO:0004925); ciliary neurotrophic factor receptor binding (GO:0005127); protein binding (GO:0005515); activation of transmembrane receptor protein tyrosine kinase activity (GO:0007171); JAK-STAT cascade (GO:0007259); lactation (GO:0007595); positive regulation of cell proliferation (GO:0008284); response to bacterium (GO:0009617); external side of plasma membrane (GO:0009897); cell surface (GO:0009986); membrane (GO:0016020); integral component of membrane (GO:0016021); peptide hormone binding (GO:0017046); cytokine-mediated signaling pathway (GO:0019221); protein kinase binding (GO:0019901); cytokine binding (GO:0019955); regulation of cell adhesion (GO:0030155); regulation of epithelial cell differentiation (GO:0030856); prolactin signaling pathway (GO:0038161); activation of Janus kinase activity (GO:0042976); negative regulation of apoptotic process (GO:0043066); receptor complex (GO:0043235); metal ion binding (GO:0046872); mammary gland epithelial cell differentiation (GO:0060644); prostate gland growth (GO:0060736); mammary gland alveolus development (GO:0060749); mammary gland epithelium development (GO:0061180),Prlr,0.3871773,-2.582796,6.7419492,2.5979675,0.22120328,0.40203833,-2.487325,7.815931,3.3245632,0.008905311,0.34711544,-2.880886,15.964142,5.9238994,0.001604681,0.40926972,-2.4433765,145.29563,47.039727,0.072654793
SLC16A5,6.022,0,2.02,4.002,0,25.430793,,"[Plus], [# of exons: 5], [Gene type: NM]","chr11:115,323,787-115,335,712",NM_001080934 NM_001359606 NM_001359608 NM_001359609,"Slc16a5, solute carrier family 16 (monocarboxylic acid transporters), member 5, monocarboxylate transporter 6|monocarboxylate transporter 5|solute carrier family 16 member 5, Predicted to have monocarboxylic acid transmembrane transporter activity. Predicted to be involved in monocarboxylic acid transport. Predicted to localize to integral component of plasma membrane. Orthologous to human SLC16A5 (solute carrier family 16 member 5).",plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); monocarboxylic acid transmembrane transporter activity (GO:0008028); symporter activity (GO:0015293); monocarboxylic acid transport (GO:0015718); membrane (GO:0016020); integral component of membrane (GO:0016021); transmembrane transporter activity (GO:0022857); transmembrane transport (GO:0055085),Slc16a5,0.1667348,-5.9975483,16.960281,2.9933407,0.10337812,0.2018119,-4.9551092,22.905118,4.9111866,0.000499761,0.22667296,-4.4116422,14.140366,3.4471124,0.004780229,0.39342733,-2.5417655,25.430793,7.4442064,1
WNT4,6.022,0,2.02,4.002,0,6.3842663,,"[Plus], [# of exons: 5], [Gene type: NM]","chr4:136,833,550-136,855,416",NM_009523,"Wnt4, wingless-type MMTV integration site family, member 4, protein Wnt-4|signal molecule|wingless-related MMTV integration site 4, Exhibits frizzled binding activity and transcription corepressor activity. Involved in several processes, including Wnt signaling pathway; animal organ development; and positive regulation of cellular component organization. Localizes to cell surface; extracellular matrix; and extracellular space. Is expressed in several structures, including alimentary system; central nervous system; genitourinary system; limb; and sensory organ. Human ortholog(s) of this gene implicated in Mullerian aplasia and hyperandrogenism. Orthologous to human WNT4 (Wnt family member 4).","metanephros development (GO:0001656); branching involved in ureteric bud morphogenesis (GO:0001658); mesonephros development (GO:0001823); embryonic epithelial tube formation (GO:0001838); transcription corepressor activity (GO:0003714); signaling receptor binding (GO:0005102); frizzled binding (GO:0005109); cytokine activity (GO:0005125); protein binding (GO:0005515); extracellular region (GO:0005576); extracellular space (GO:0005615); cytoplasm (GO:0005737); endoplasmic reticulum lumen (GO:0005788); Golgi apparatus (GO:0005794); signal transduction (GO:0007165); cell-cell signaling (GO:0007267); multicellular organism development (GO:0007275); gamete generation (GO:0007276); sex differentiation (GO:0007548); male gonad development (GO:0008584); female gonad development (GO:0008585); cellular response to starvation (GO:0009267); cell surface (GO:0009986); negative regulation of gene expression (GO:0010629); negative regulation of steroid biosynthetic process (GO:0010894); Wnt signaling pathway (GO:0016055); regulation of cell-cell adhesion (GO:0022407); cell differentiation (GO:0030154); neuron differentiation (GO:0030182); female sex determination (GO:0030237); negative regulation of cell migration (GO:0030336); positive regulation of bone mineralization (GO:0030501); extracellular matrix (GO:0031012); positive regulation of aldosterone biosynthetic process (GO:0032349); positive regulation of collagen biosynthetic process (GO:0032967); T cell differentiation in thymus (GO:0033077); immature T cell proliferation in thymus (GO:0033080); tube morphogenesis (GO:0035239); non-canonical Wnt signaling pathway (GO:0035567); non-canonical Wnt signaling pathway via MAPK cascade (GO:0038030); negative regulation of fibroblast growth factor receptor signaling pathway (GO:0040037); hormone metabolic process (GO:0042445); positive regulation of GTPase activity (GO:0043547); cell fate commitment (GO:0045165); negative regulation of cell differentiation (GO:0045596); positive regulation of osteoblast differentiation (GO:0045669); positive regulation of meiotic nuclear division (GO:0045836); negative regulation of transcription, DNA-templated (GO:0045892); positive regulation of transcription, DNA-templated (GO:0045893); receptor ligand activity (GO:0048018); oocyte development (GO:0048599); branching morphogenesis of an epithelial tube (GO:0048754); anatomical structure development (GO:0048856); smooth muscle cell differentiation (GO:0051145); positive regulation of stress fiber assembly (GO:0051496); positive regulation of focal adhesion assembly (GO:0051894); canonical Wnt signaling pathway (GO:0060070); somatotropin secreting cell differentiation (GO:0060126); thyroid-stimulating hormone-secreting cell differentiation (GO:0060129); mesenchymal to epithelial transition (GO:0060231); tertiary branching involved in mammary gland duct morphogenesis (GO:0060748); kidney morphogenesis (GO:0060993); negative regulation of wound healing (GO:0061045); positive regulation of dermatome development (GO:0061184); paramesonephric duct development (GO:0061205); negative regulation of testicular blood vessel morphogenesis (GO:0061369); nephron development (GO:0072006); renal vesicle formation (GO:0072033); renal vesicle induction (GO:0072034); metanephric mesenchymal cell differentiation (GO:0072162); mesonephric tubule development (GO:0072164); metanephric tubule formation (GO:0072174); metanephric nephron development (GO:0072210); metanephric nephron morphogenesis (GO:0072273); negative regulation of male gonad development (GO:2000019); positive regulation of cortisol biosynthetic process (GO:2000066); negative regulation of androgen biosynthetic process (GO:2000180); negative regulation of testosterone biosynthetic process (GO:2000225); negative regulation of apoptotic signaling pathway (GO:2001234)",Wnt4,0.41373014,-2.4170345,0.82965191,0.31536938,1,0.45802247,-2.183299,4.7821051,2.2765357,0.047190533,0.3514435,-2.8454076,6.0396114,2.2559483,0.036564596,0.5728025,-1.7458024,6.3842663,2.733854,0.93047024
CHIC1,6.022,0,2.02,4.002,0,14.541248,,"[Plus], [# of exons: 6], [Gene type: NM]","chrX:100,551,815-100,591,457",NM_009767,"Chic1, cysteine-rich hydrophobic domain 1, cysteine-rich hydrophobic domain-containing protein 1|brain X-linked protein, Predicted to localize to cytoplasmic vesicle and plasma membrane. Is expressed in several structures, including central nervous system; metanephros; and retina. Orthologous to human CHIC1 (cysteine rich hydrophobic domain 1).",molecular_function (GO:0003674); plasma membrane (GO:0005886); membrane (GO:0016020); cytoplasmic vesicle (GO:0031410),Chic1,0.30914307,-3.2347483,1.1182955,0.34349668,0.15967213,0.38645242,-2.5876407,1.6489919,0.67268434,0.013901885,0.33666618,-2.9703013,3.3525694,1.2080163,0.014975192,0.44671077,-2.2385849,14.541248,4.9981821,0.17046211
UBC,6.022,0,2.02,4.002,0,403.71202,,"[~27%  IN BLACKLIST], [Minus], [# of exons: 2], [Gene type: NM]","chr5:125,866,335-125,870,387",NM_019639,"Ubc, ubiquitin C, polyubiquitin-C|polyubiquitin C, Predicted to have protease binding activity; protein tag; and ubiquitin protein ligase binding activity. Predicted to be involved in modification-dependent protein catabolic process and protein ubiquitination. Localizes to myelin sheath. Is expressed in inner ear; oocyte; telencephalon; and trunk unsegmented mesenchyme. Orthologous to human UBC (ubiquitin C).",protease binding (GO:0002020); protein binding (GO:0005515); nucleus (GO:0005634); nucleoplasm (GO:0005654); cytoplasm (GO:0005737); cytosol (GO:0005829); protein ubiquitination (GO:0016567); modification-dependent protein catabolic process (GO:0019941); protein tag (GO:0031386); ubiquitin protein ligase binding (GO:0031625); myelin sheath (GO:0043209),Ubc,0.30399041,-3.2895774,297.79868,71.733893,0.55926494,0.29764608,-3.3596949,403.71202,119.21959,3.98E-05,0.2916311,-3.4289895,388.48442,119.52082,0.000625344,0.53887614,-1.855714,363.93093,153.25717,0.57568011
NC_INTER_C1_931,6.011,0,2.01,4.001,0,11.387527,,"[Minus], [# Lnc isoforms: 10], [# of exons: 1], [Gene type: lncRNA]","chr1:182,909,526-182,911,796",,"lnc_inter_chr1_931, ",,lnc_inter_chr1_931,2.1421043,2.1421043,0.5832527,1.1571126,1,7.3430134,7.3430134,1.2186022,8.0695442,0.019679275,8.8299002,8.8299002,0.6958116,6.4571104,0.006857299,5.3374375,5.3374375,2.7597957,11.387527,0.071452593
NC_INTER_C6_5864,6.011,0,2.01,4.001,0,17.636832,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr6:149,163,400-149,164,755",AK005642,"1700003I16Rik, RIKEN cDNA 1700003I16 gene, uncharacterized protein LOC76699; lnc_inter_chr6_5864, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),1700003I16Rik lnc_inter_chr6_5864,59.879029,59.8790286,0,1.4111735,0.32421647,16.29314,16.2931403,0.96802954,15.720281,0.02393546,29.120216,29.1202161,0.26463916,7.9763095,0.004261148,11.530803,11.5308031,1.5962623,17.636832,0.36836841
UGDH,6.011,0,2.01,4.001,0,128.68921,,"[Minus], [# of exons: 12], [Gene type: NM]","chr5:65,804,461-65,827,081",NM_009466,"Ugdh, UDP-glucose dehydrogenase, UDP-glucose 6-dehydrogenase|UDP-Glc dehydrogenase|UDP-GlcDH, Exhibits UDP-glucose 6-dehydrogenase activity. Involved in chondroitin sulfate biosynthetic process; gastrulation with mouth forming second; and heparan sulfate proteoglycan biosynthetic process. Predicted to localize to cytosol and nucleoplasm. Is expressed in several structures, including alimentary system; brain; integumental system; respiratory system; and sensory organ. Human ortholog(s) of this gene implicated in early infantile epileptic encephalopathy. Orthologous to human UGDH (UDP-glucose 6-dehydrogenase).","gastrulation with mouth forming second (GO:0001702); catalytic activity (GO:0003824); UDP-glucose 6-dehydrogenase activity (GO:0003979); nucleus (GO:0005634); nucleoplasm (GO:0005654); cytosol (GO:0005829); carbohydrate metabolic process (GO:0005975); glycosaminoglycan biosynthetic process (GO:0006024); UDP-glucuronate biosynthetic process (GO:0006065); metabolic process (GO:0008152); heparan sulfate proteoglycan biosynthetic process (GO:0015012); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor (GO:0016616); chondroitin sulfate biosynthetic process (GO:0030206); protein hexamerization (GO:0034214); identical protein binding (GO:0042802); neuron development (GO:0048666); NAD binding (GO:0051287)",Ugdh,1.8563875,1.8563875,16.133662,28.481496,1,2.422921,2.422921,12.474119,31.88126,0.005381893,2.7542636,2.7542636,21.539031,62.153147,0.001993279,2.108824,2.108824,80.022176,128.68921,0.3435528
ENPP3,6.011,0,2.01,4.001,0,16.013831,,"[Minus], [# of exons: 25], [Gene type: NM]","chr10:24,493,620-24,556,001",NM_134005,"Enpp3, ectonucleotide pyrophosphatase/phosphodiesterase 3, ectonucleotide pyrophosphatase/phosphodiesterase family member 3|E-NPP 3|PD-Ibeta|phosphodiesterase I beta|phosphodiesterase I/nucleotide pyrophosphatase 3, Exhibits nucleoside-triphosphate diphosphatase activity. Involved in several processes, including basophil activation involved in immune response; negative regulation of mast cell activation involved in immune response; and negative regulation of mast cell proliferation. Localizes to external side of plasma membrane. Orthologous to human ENPP3 (ectonucleotide pyrophosphatase/phosphodiesterase 3).",basophil activation involved in immune response (GO:0002276); nucleic acid binding (GO:0003676); catalytic activity (GO:0003824); phosphodiesterase I activity (GO:0004528); nucleotide diphosphatase activity (GO:0004551); calcium ion binding (GO:0005509); extracellular region (GO:0005576); plasma membrane (GO:0005886); pyrimidine nucleotide metabolic process (GO:0006220); phosphate-containing compound metabolic process (GO:0006796); metabolic process (GO:0008152); zinc ion binding (GO:0008270); nucleoside triphosphate catabolic process (GO:0009143); external side of plasma membrane (GO:0009897); membrane (GO:0016020); integral component of membrane (GO:0016021); hydrolase activity (GO:0016787); negative regulation of mast cell activation involved in immune response (GO:0033007); NADH pyrophosphatase activity (GO:0035529); dTTP diphosphatase activity (GO:0036218); ATP metabolic process (GO:0046034); metal ion binding (GO:0046872); nucleoside-triphosphate diphosphatase activity (GO:0047429); perinuclear region of cytoplasm (GO:0048471); negative regulation of inflammatory response (GO:0050728); negative regulation of mast cell proliferation (GO:0070667),Enpp3,2.2020152,2.2020152,2.0054955,4.309537,0.68201181,2.1624183,2.1624183,1.7712444,3.9542235,0.019255462,2.6097265,2.6097265,2.4754888,6.8040114,0.016125475,1.9768266,1.9768266,10.879384,16.013831,0.41977228
NC_INTER_C14_25214,6.011,0,2.01,4.001,0,25.909319,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr14:28,386,037-28,389,898",,"lnc_inter_chr14_25214, ",,lnc_inter_chr14_25214,3.3633645,3.3633645,0.02303847,0.10857756,1,5.9105417,5.9105417,0.35399872,2.2217279,0.014647243,8.5308536,8.5308536,0.75763003,7.4807633,0.00019086,3.9217515,3.9217515,8.0910884,25.909319,0.22938357
NC_INTRA_C4_37977,6.011,0,2.01,4.001,0,1.6221692,,"[~1%  IN BLACKLIST], [Minus], [# Lnc isoforms: 13], [# of exons: 11], [Gene type: lncRNA]","chr4:60,432,935-60,432,978 chr4:60,434,368-60,434,414 chr4:60,434,825-60,510,884 chr4:60,511,543-60,511,626 chr4:60,514,833-60,591,132 chr4:60,591,818-60,591,871 chr4:60,595,028-60,671,337 chr4:60,672,079-60,672,161 chr4:60,673,146-60,673,759 chr4:60,674,794-60,675,073",,"lnc_intra_chr4_37977, ",,lnc_intra_chr4_37977,1.6929419,1.6929419,0.37193368,0.55918579,1,4.068432,4.068432,0.18653075,0.85650464,0.000557464,4.1289354,4.1289354,0.37512667,1.5948464,0.00745274,2.9944264,2.9944264,0.70915717,1.6221692,0.060936262
NC_INTER_C7_5922,6.011,0,2.01,4.001,0,0.37874448,,"[~1% MAX. MULTIPLE IN BLACKLIST], [Minus], [# Lnc isoforms: 2], [# of exons: 2], [Gene type: lncRNA]","chr7:15,550,326-15,672,489",,"lnc_inter_chr7_5922, ",,lnc_inter_chr7_5922,2.8235516,2.8235516,0.002154878,0.005256075,1,14.232118,14.2321179,0.004824075,0.075570722,9.73E-05,72.421129,72.4211295,0.001647491,0.21162764,2.07E-08,1.8213844,1.8213844,0.29967986,0.37874448,1
NC_AS_C11_21516,5.202,1.2,0,4.002,0,7.5994413,,"[Minus], [# Lnc isoforms: 17], [# of exons: 9], [Gene type: lncRNA]","chr11:115,319,782-115,335,122",XR_001780362 XR_001780363 XR_389152 XR_389153 XR_880314,"Gm11695, predicted gene 11695; lnc_as_chr11_21516, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Gm11695 lnc_as_chr11_21516,0.083124304,-12.0301759,2.9673753,0.24572064,4.37E-05,0.42038525,-2.3787704,2.1805093,0.90278746,0.66191112,0.18920619,-5.2852394,2.0848848,0.42092609,0.011589497,0.47063882,-2.1247716,7.5994413,2.8172017,0.77291564
NC_INTER_CX_49493,5.202,1.2,0,4.002,0,15.910025,,"[Minus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chrX:11,860,019-11,865,216",,"lnc_inter_chrX_49493, ",,lnc_inter_chrX_49493,0.11261433,-8.8798645,1.7831183,0.17265817,0.043905837,0.32589378,-3.0684844,4.0290305,1.3526431,0.068220718,0.17214648,-5.8090063,3.9906267,0.72279496,0.000609614,0.38571592,-2.5925816,15.910025,4.6279747,0.28941529
HSD3B1,5.202,1.2,0,4.002,0,2.6702133,,"[Minus], [# of exons: 5], [Gene type: NM]","chr3:98,656,117-98,663,717",NM_001304800 NM_008293,"Hsd3b1, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1, 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1|3-beta-hydroxy-5-ene steroid dehydrogenase|3-beta-hydroxy-Delta(5)-steroid dehydrogenase|3-beta-hydroxysteroid 3-dehydrogenase|delta-5-3-ketosteroid isomerase|dihydrotestosterone oxidoreductase|steroid Delta-isomerase, Predicted to have 3-beta-hydroxy-delta5-steroid dehydrogenase activity and steroid delta-isomerase activity. Predicted to be involved in cellular hormone metabolic process; hippocampus development; and response to corticosterone. Localizes to mitochondrion. Is expressed in several structures, including endocrine gland; genitourinary system; liver; nervous system; and respiratory system. Human ortholog(s) of this gene implicated in hypertension and hypospadias. Orthologous to human HSD3B1 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1) and HSD3B2 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2).","3-keto sterol reductase activity (GO:0000253); catalytic activity (GO:0003824); 3-beta-hydroxy-delta5-steroid dehydrogenase activity (GO:0003854); steroid delta-isomerase activity (GO:0004769); nucleolus (GO:0005730); cytoplasm (GO:0005737); mitochondrion (GO:0005739); endoplasmic reticulum (GO:0005783); lipid metabolic process (GO:0006629); steroid biosynthetic process (GO:0006694); androgen biosynthetic process (GO:0006702); metabolic process (GO:0008152); steroid metabolic process (GO:0008202); C21-steroid hormone metabolic process (GO:0008207); membrane (GO:0016020); integral component of membrane (GO:0016021); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor (GO:0016616); isomerase activity (GO:0016853); hippocampus development (GO:0021766); intracellular membrane-bounded organelle (GO:0043231); intercellular bridge (GO:0045171); 5alpha-androstane-3beta,17beta-diol dehydrogenase activity (GO:0047024); response to corticosterone (GO:0051412); cholesterol dehydrogenase activity (GO:0102294)",Hsd3b1,0.087874954,-11.3798068,2.6702133,0.22255735,0.00063501,0.17539854,-5.7013018,2.2434328,0.42713933,0.088894904,0.11204844,-8.9247116,2.47656,0.26530496,0.046126223,0.1757948,-5.6884505,1.7560031,0.23332584,0.44682925
NIPAL1,5.202,1.2,0,4.002,0,12.056612,,"[Plus], [# of exons: 6], [Gene type: NM]","chr5:73,039,035-73,062,317",NM_001081205,"Nipal1, NIPA-like domain containing 1, magnesium transporter NIPA3|NIPA-like protein 1|non-imprinted in Prader-Willi/Angelman syndrome region protein 3 homolog, Predicted to have magnesium ion transmembrane transporter activity. Involved in magnesium ion transport. Predicted to localize to membrane. Orthologous to human NIPAL1 (NIPA like domain containing 1).",molecular_function (GO:0003674); ion transport (GO:0006811); magnesium ion transmembrane transporter activity (GO:0015095); magnesium ion transport (GO:0015693); membrane (GO:0016020); integral component of membrane (GO:0016021),Nipal1,0.14536446,-6.8792605,4.0672391,0.55446806,7.05E-05,0.24797501,-4.0326645,4.2216663,1.1709828,0.11372068,0.21100889,-4.7391369,9.3836856,2.170696,0.008699305,0.32556917,-3.0715439,12.056612,2.8091509,0.78500458
NC_INTER_C17_13843,4.002,0,0,4.002,0,144.05169,,"[Minus], [# Lnc isoforms: 10], [# of exons: 1], [Gene type: lncRNA]","chr17:32,042,133-32,046,203",,"lnc_inter_chr17_13843, ",,lnc_inter_chr17_13843,0.19128371,-5.2278368,144.05169,26.646064,0.052556997,0.30703052,-3.2570052,55.930838,17.693159,0.052865409,0.2679707,-3.7317513,40.716936,11.157343,0.015095522,0.36196369,-2.7627081,36.767797,10.848694,0.51416772
NC_INTER_C4_3138,4.002,0,0,4.002,0,29.445127,,"[Minus], [# Lnc isoforms: 17], [# of exons: 1], [Gene type: lncRNA]","chr4:34,736,106-34,747,951",,"lnc_inter_chr4_3138, ",,lnc_inter_chr4_3138,1.0560769,1.0560769,0.097501319,0.080671893,1,0.42926372,-2.3295703,2.0459924,0.95099527,0.65967192,0.27390492,-3.6509019,3.4925542,1.0425946,0.046318402,0.45207557,-2.2120195,29.445127,10.895702,0.64839041
NC_INTER_C4_37289,4.002,0,0,4.002,0,13.334349,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr4:4,817,198-4,817,560",,"lnc_inter_chr4_37289, ",,lnc_inter_chr4_37289,0.21431309,-4.6660706,2.2174178,0.28331114,1,0.3243354,-3.0832281,10.617945,4.2648578,1,0.041928252,-23.8502668,13.334349,0.45295172,0.042700645,0.33167971,-3.0149568,10.927463,2.5371599,1
NC_INTER_C5_4335,4.002,0,0,4.002,0,41.861037,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr5:87,774,192-87,779,869",,"lnc_inter_chr5_4335, ",,lnc_inter_chr5_4335,0.21367936,-4.6799092,0.14057183,0.018593114,1,0.31975337,-3.1274104,1.8508038,0.64245142,0.62815834,0.21291221,-4.6967714,2.4641722,0.52642591,0.045836964,0.32601157,-3.0673758,41.861037,11.480517,0.43447255
NC_INTER_C9_47672,4.002,0,0,4.002,0,4.9092724,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr9:3,187,772-3,189,547",,"lnc_inter_chr9_47672, ",,lnc_inter_chr9_47672,0.055681441,-17.9593054,0.34145708,0,1,0.77102289,-1.2969783,0.43800875,0.32006857,1,0.046937308,-21.305014,2.6939932,0.12092676,0.004988649,0.34454428,-2.9023846,4.9092724,1.1817672,1
NC_INTER_C5_4008,4.002,0,0,4.002,0,6.8099524,,"[Minus], [# Lnc isoforms: 1], [# of exons: 2], [Gene type: lncRNA]","chr5:22,063,262-22,079,506",,"lnc_inter_chr5_4008, ",,lnc_inter_chr5_4008,0.53544541,-1.867604,0.21669396,0.099803245,1,0.49902719,-2.0038988,0.33523006,0.16659549,1,0.17603735,-5.6806126,0.73311374,0.13114197,0.025189075,0.32420433,-3.0844745,6.8099524,1.6784523,0.0999831
NC_INTER_C5_39581,4.002,0,0,4.002,0,28.591817,,"[Minus], [# Lnc isoforms: 5], [# of exons: 1], [Gene type: lncRNA]","chr5:9,034,896-9,042,756",,"lnc_inter_chr5_39581, ",,lnc_inter_chr5_39581,0.58107255,-1.7209555,0.23760638,0.11192698,1,0.25583937,-3.9087026,2.5346687,0.70035546,0.20765965,0.21138831,-4.7306306,7.7491729,1.7509426,0.018500621,0.25571747,-3.9105658,28.591817,5.1980658,0.20641198
NC_INTER_C6_42997,4.002,0,0,4.002,0,133.19407,,"[Minus], [# Lnc isoforms: 6], [# of exons: 1], [Gene type: lncRNA]","chr6:101,092,348-101,093,179",,"lnc_inter_chr6_42997, ",,lnc_inter_chr6_42997,3.8835762,3.8835762,0.21408311,0.93499786,1,0.72418833,-1.3808563,6.4650155,4.7248553,1,0.13535939,-7.38774,17.982042,2.6718944,0.017365518,0.75222627,-1.3293872,133.19407,81.477791,1
NC_INTER_C2_34512,4.002,0,0,4.002,0,140.62971,,"[Minus], [# Lnc isoforms: 8], [# of exons: 1], [Gene type: lncRNA]","chr2:144,947,643-144,949,453",,"lnc_inter_chr2_34512, ",,lnc_inter_chr2_34512,0.20677261,-4.8362305,2.3891377,0.4730379,1,0.26386806,-3.7897729,16.81231,4.0985977,1,0.069858382,-14.3146745,41.810534,3.2205807,0.048673833,0.20163385,-4.9594848,140.62971,24.338732,0.84290536
NC_AS_C19_14976,4.002,0,0,4.002,0,20.173249,,"[Minus], [# Lnc isoforms: 9], [# of exons: 7], [Gene type: lncRNA]","chr19:36,636,689-36,658,418",,"lnc_as_chr19_14976, ",,lnc_as_chr19_14976,0.76403234,-1.3088451,0.48894459,0.34794465,1,0.34063967,-2.9356534,1.9864912,0.64286749,0.12676529,0.3145427,-3.1792186,4.3040447,1.4115661,0.008883073,0.40209029,-2.4870036,20.173249,6.7986694,0.64971305
TTLL10,4.002,0,0,4.002,0,3.2715057,,"[Minus], [# of exons: 14], [Gene type: NM]","chr4:155,408,944-155,424,926",NM_001368641 NM_029264,"Ttll10, tubulin tyrosine ligase-like family, member 10, protein polyglycylase TTLL10|tubulin tyrosine ligase-like family, member 5|tubulin--tyrosine ligase-like protein 10, Exhibits protein-glycine ligase activity, elongating. Involved in protein phosphopantetheinylation and protein polyglycylation. Localizes to axoneme and microtubule cytoskeleton. Is expressed in white fat. Orthologous to human TTLL10 (tubulin tyrosine ligase like 10).","nucleotide binding (GO:0000166); ATP binding (GO:0005524); cytoplasm (GO:0005737); cytoskeleton (GO:0005856); microtubule (GO:0005874); cilium (GO:0005929); axoneme (GO:0005930); cellular protein modification process (GO:0006464); microtubule cytoskeleton (GO:0015630); ligase activity (GO:0016874); protein polyglycylation (GO:0018094); cell projection (GO:0042995); protein-glycine ligase activity (GO:0070735); protein-glycine ligase activity, elongating (GO:0070737)",Ttll10,0.65953805,-1.5162127,0.038441592,0.026043267,1,0.46398237,-2.1552543,0.22626755,0.1203525,1,0.13444088,-7.4382139,0.47582795,0.064686977,0.046126223,0.32562796,-3.0709893,3.2715057,0.71551461,0.63679151
TGM1,4.002,0,0,4.002,0,27.839147,,"[Minus], [# of exons: 16], [Gene type: NM]","chr14:56,318,846-56,332,329",NM_001161714 NM_001161715 NM_019984,"Tgm1, transglutaminase 1, K polypeptide, protein-glutamine gamma-glutamyltransferase K|K polypeptide|TG(K)|TGK|TGase K|TGase-1|epidermal TGase|protein-glutamine-gamma-glutamyltransferase|transglutaminase K|transglutaminase type 1|transglutaminase-1, Predicted to have identical protein binding activity and protein-glutamine gamma-glutamyltransferase activity. Involved in animal organ morphogenesis. Localizes to adherens junction. Is expressed in epidermis; epidermis stratum granulosum; epidermis stratum spinosum; external naris epithelium; and stomach. Used to study autosomal recessive congenital ichthyosis 1. Human ortholog(s) of this gene implicated in autosomal recessive congenital ichthyosis 1. Orthologous to human TGM1 (transglutaminase 1).","protein-glutamine gamma-glutamyltransferase activity (GO:0003810); adherens junction (GO:0005912); animal organ morphogenesis (GO:0009887); positive regulation of keratinocyte proliferation (GO:0010838); membrane (GO:0016020); transferase activity (GO:0016740); transferase activity, transferring acyl groups (GO:0016746); peptide cross-linking (GO:0018149); protein metabolic process (GO:0019538); keratinocyte differentiation (GO:0030216); intrinsic component of membrane (GO:0031224); keratinization (GO:0031424); identical protein binding (GO:0042802); positive regulation of cell cycle (GO:0045787); metal ion binding (GO:0046872)",Tgm1,0.48308696,-2.0700207,17.049427,7.7713343,1,0.45256169,-2.2096435,19.364622,9.1177371,0.19814363,0.35398721,-2.8249608,18.621638,7.02494,0.041638719,0.53409009,-1.8723433,27.839147,10.73319,0.77670782
NC_INTER_C3_2369,4.002,0,0,4.002,0,2.2081559,,"[Plus], [# Lnc isoforms: 10], [# of exons: 15], [Gene type: lncRNA]","chr3:58,496,405-58,636,010",NR_045167,"4930593A02Rik, RIKEN cDNA 4930593A02 gene; lnc_inter_chr3_2369, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),4930593A02Rik lnc_inter_chr3_2369,0.9785972,-1.0218709,0.022183077,0.018670557,1,0.64537748,-1.5494808,0.12262095,0.085206556,1,0.18049691,-5.5402612,0.13968918,0.026534639,0.021119715,0.48450405,-2.0639663,2.2081559,0.79502294,0.40366576
NC_INTER_C1_15978,4.002,0,0,4.002,0,72.825718,,"[Plus], [# Lnc isoforms: 14], [# of exons: 1], [Gene type: lncRNA]","chr1:45,791,128-45,793,279",,"lnc_inter_chr1_15978, ",,lnc_inter_chr1_15978,0.070832547,-14.1178037,0.93789651,0.047679514,0.36157931,0.25693135,-3.8920903,4.8265386,1.4234717,0.92184898,0.054864097,-18.2268562,12.9397,0.76213624,0.032539285,0.19942335,-5.0144578,72.825718,10.10606,0.4463071
NC_INTER_C1_15761,4.002,0,0,4.002,0,9.887213,,"[Plus], [# Lnc isoforms: 15], [# of exons: 1], [Gene type: lncRNA]","chr1:23,307,843-23,310,308",,"lnc_inter_chr1_15761, ",,lnc_inter_chr1_15761,0.02134111,-46.8579192,0.70658752,0,0.26761535,0.17856888,-5.6000799,2.7580469,0.51372566,1,0.029688283,-33.6833221,4.9820079,0.13276946,0.003655885,0.9492589,-1.0534534,9.887213,6.359579,1
NC_INTER_C15_12956,4.002,0,0,4.002,0,21.563308,,"[Plus], [# Lnc isoforms: 16], [# of exons: 1], [Gene type: lncRNA]","chr15:103,089,007-103,091,068",,"lnc_inter_chr15_12956, ",,lnc_inter_chr15_12956,0.27021349,-3.7007774,2.1544688,0.51775868,1,0.16027406,-6.2393127,6.982401,1.2687058,0.20901386,0.052376041,-19.0926991,6.3202403,0.34281929,0.015955582,0.12614108,-7.9276313,21.563308,1.7838164,0.14340718
NC_AS_C7_6192,4.002,0,0,4.002,0,10.00178,,"[Plus], [# Lnc isoforms: 17], [# of exons: 8], [Gene type: lncRNA]","chr7:56,097,717-56,125,011",,"lnc_as_chr7_6192, ",,lnc_as_chr7_6192,0.27959202,-3.57664,0.76424618,0.20114761,0.25671601,0.31890549,-3.1357253,0.96449946,0.3553648,0.11334706,0.29637468,-3.3741074,1.5908716,0.48638733,0.035808319,0.24823525,-4.0284367,10.00178,1.7684835,0.13503125
NC_INTER_C8_7675,4.002,0,0,4.002,0,29.279137,,"[Plus], [# Lnc isoforms: 18], [# of exons: 2], [Gene type: lncRNA]","chr8:129,183,884-129,195,470",,"lnc_inter_chr8_7675, ",,lnc_inter_chr8_7675,0.48799793,-2.049189,0.41423374,0.18444602,1,0.41987024,-2.3816882,3.7674777,1.6912436,0.061016641,0.26679067,-3.7482571,3.6211953,1.0467526,0.026478208,0.43032099,-2.3238467,29.279137,9.4473544,0.14294696
NC_INTER_C17_30189,4.002,0,0,4.002,0,31.097331,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr17:71,189,007-71,190,117",,"lnc_inter_chr17_30189, ",,lnc_inter_chr17_30189,3.7024888,3.7024888,0,0.092395166,1,0.90404719,-1.1061369,0.40072087,0.33985485,1,0.11498157,-8.6970463,5.2363333,0.59028266,0.042725019,0.58536384,-1.7083392,31.097331,13.772364,1
NC_INTER_C13_11028,4.002,0,0,4.002,0,24.201017,,"[Plus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr13:8,901,873-8,909,098",,"lnc_inter_chr13_11028, ",,lnc_inter_chr13_11028,0.088468809,-11.3034188,0.061058744,0,1,0.10980284,-9.1072328,1.2346889,0.15275802,0.14191259,0.004667544,-214.245439,1.6072924,0,0.011921997,0.1090076,-9.1736722,24.201017,1.5993687,0.095619104
NC_INTER_C13_24247,4.002,0,0,4.002,0,67.059824,,"[Plus], [# Lnc isoforms: 5], [# of exons: 1], [Gene type: lncRNA]","chr13:60,599,278-60,601,065",,"lnc_inter_chr13_24247, ",,lnc_inter_chr13_24247,0.27499043,-3.6364902,49.245896,10.861256,0.57050659,0.26053158,-3.8383063,36.983079,9.4249763,0.20317359,0.18553722,-5.3897542,49.201457,9.6838659,0.008970745,0.26259338,-3.8081691,67.059824,12.878509,0.072654793
NC_INTER_C14_25943,4.002,0,0,4.002,0,22.608748,,"[Plus], [# Lnc isoforms: 5], [# of exons: 1], [Gene type: lncRNA]","chr14:76,198,823-76,200,960",,"lnc_inter_chr14_25943, ",,lnc_inter_chr14_25943,0.9228763,-1.0835688,0.2879945,0.21269964,1,0.20893182,-4.7862503,3.3818976,0.69298809,0.10882827,0.12834232,-7.7916623,9.2349803,1.1724764,0.038532724,0.19812829,-5.0472348,22.608748,3.2177255,0.27013036
UBE2U,4.002,0,0,4.002,0,3.2863053,,"[Plus], [# of exons: 10], [Gene type: NM]","chr4:100,151,472-100,222,750",NM_001033773,"Ube2u, ubiquitin-conjugating enzyme E2U (putative), ubiquitin-conjugating enzyme E2 U, Predicted to have ubiquitin conjugating enzyme activity. Predicted to be involved in protein K11-linked ubiquitination and protein K48-linked ubiquitination. Predicted to localize to nucleus. Orthologous to human UBE2U (ubiquitin conjugating enzyme E2 U).",protein polyubiquitination (GO:0000209); nucleus (GO:0005634); ubiquitin conjugating enzyme activity (GO:0061631); protein K48-linked ubiquitination (GO:0070936); protein K11-linked ubiquitination (GO:0070979),Ube2u,0.22043682,-4.5364472,0.46180339,0.10666905,0.62519132,0.29079293,-3.4388731,0.25130751,0.076013957,0.86646609,0.2383586,-4.1953594,0.65124217,0.16067898,0.013278211,0.2248147,-4.4481078,3.2863053,0.61391713,0.30759912
NC_INTER_C16_28608,4.001,0,0,4.001,0,10.608938,,"[Minus], [# Lnc isoforms: 15], [# of exons: 1], [Gene type: lncRNA]","chr16:76,137,444-76,139,466",,"lnc_inter_chr16_28608, ",,lnc_inter_chr16_28608,2.2743446,2.2743446,2.1123706,5.0547055,1,2.480794,2.480794,2.0779091,5.2846512,0.82884954,6.0972943,6.0972943,1.7311556,10.608938,0.002803283,1.9869444,1.9869444,4.0865875,5.9071399,1
NC_INTER_C7_43837,4.001,0,0,4.001,0,30.101299,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr7:12,073,604-12,073,885",,"lnc_inter_chr7_43837, ",,lnc_inter_chr7_43837,13.734953,13.7349528,0,1.8248867,1,62.882133,62.8821332,0,12.285262,0.14923067,136.93618,136.9361844,0,30.101299,0.001075242,43.162252,43.1622521,0,12.975217,0.48444438
NC_INTER_C1_196,4.001,0,0,4.001,0,2.5195249,,"[Minus], [# Lnc isoforms: 45], [# of exons: 3], [Gene type: lncRNA]","chr1:51,559,342-51,570,100",NR_151621,"Gm17767, predicted gene, 17767; lnc_inter_chr1_196, ",,Gm17767 lnc_inter_chr1_196,2.5413988,2.5413988,0.064606605,0.18638229,1,3.4734953,3.4734953,0.13943878,0.52587213,0.76383571,8.5596447,8.5596447,0.062990696,0.75606786,0.002034403,4.0003713,4.0003713,0.82910353,2.5195249,0.15948001
NC_INTER_CX_50217,4.001,0,0,4.001,0,9.902109,,"[Minus], [# Lnc isoforms: 5], [# of exons: 1], [Gene type: lncRNA]","chrX:122,680,258-122,680,989",,"lnc_inter_chrX_50217, ",,lnc_inter_chrX_50217,2.5673638,2.5673638,0.12168472,0.42089727,1,41.043553,41.0435526,0,3.0344813,0.086116129,117.54459,117.5445878,0,9.902109,0.000161588,3.2887098,3.2887098,1.6465809,4.1591086,1
NC_INTER_C10_17892,4.001,0,0,4.001,0,35.506795,,"[Minus], [# Lnc isoforms: 6], [# of exons: 1], [Gene type: lncRNA]","chr10:4,628,269-4,628,825",,"lnc_inter_chr10_17892, ",,lnc_inter_chr10_17892,17.307637,17.3076374,0.47995432,10.652057,0.24477689,20.86252,20.8625201,0.83899158,15.445965,0.50021048,18.654391,18.6543909,1.5326469,35.506795,0.035773529,4.6994089,4.6994089,7.9954114,34.611605,1
NC_INTER_C10_19433,4.001,0,0,4.001,0,4.6056028,,"[Minus], [# Lnc isoforms: 6], [# of exons: 1], [Gene type: lncRNA]","chr10:116,919,466-116,923,052",,"lnc_inter_chr10_19433, ",,lnc_inter_chr10_19433,6.8499464,6.8499464,0,0.0621528,1,2.4668261,2.4668261,0.42144797,0.97155113,1,11.504196,11.5041965,0.10478533,1.6600199,0.012826727,5.4558007,5.4558007,0.95548661,4.6056028,0.55291903
NC_INTER_C3_2733,4.001,0,0,4.001,0,1.7097218,,"[Minus], [# Lnc isoforms: 6], [# of exons: 3], [Gene type: lncRNA]","chr3:112,605,584-112,608,934",,"lnc_inter_chr3_2733, ",,lnc_inter_chr3_2733,29.0469,29.0469004,0,0.34569843,1,35.594965,35.5949653,0,0.50022922,0.38383036,92.526518,92.5265179,0,1.7097218,0.002391195,3.8821466,3.8821466,0,0.096823991,1
NC_INTER_C9_49368,4.001,0,0,4.001,0,29.642061,,"[Minus], [# Lnc isoforms: 7], [# of exons: 1], [Gene type: lncRNA]","chr9:122,753,681-122,756,958",,"lnc_inter_chr9_49368, ",,lnc_inter_chr9_49368,2.0591015,2.0591015,0.3481435,0.63884825,1,1.670715,1.670715,4.7316937,8.373801,1,3.3465675,3.3465675,4.4637838,15.478795,0.003589536,2.2901247,2.2901247,16.360055,29.642061,0.41997084
NC_AS_C16_13337,4.001,0,0,4.001,0,3.3960704,,"[Plus], [# Lnc isoforms: 192], [# of exons: 5], [Gene type: lncRNA]","chr16:45,880,853-45,968,776",NR_152226,"Gm15638, predicted gene 15638; Gm15640, ; lnc_as_chr16_13337,13349, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Gm15638 Gm15640 lnc_as_chr16_13337,1.4132628,1.4132628,0.29803345,0.36765733,1,2.046124,2.046124,0.32245251,0.71367687,0.12676529,2.7461709,2.7461709,0.45307514,1.334432,0.046847314,1.5877945,1.5877945,2.8434481,3.3960704,1
NC_INTER_C12_10522,4.001,0,0,4.001,0,1.960102,,"[Plus], [# Lnc isoforms: 19], [# of exons: 1], [Gene type: lncRNA]","chr12:35,832,893-35,838,717",,"lnc_inter_chr12_10522, ",,lnc_inter_chr12_10522,0.24111497,-4.1473991,0.030638466,0,1,1.6100501,1.6100501,0.20044934,0.3529445,1,54.77372,54.7737204,0,0.56944659,0.040566383,2.9561324,2.9561324,0.94857113,1.960102,0.93489313
NC_INTER_C1_17425,4.001,0,0,4.001,0,16.551985,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr1:173,418,443-173,418,919",,"lnc_inter_chr1_17425, ",,lnc_inter_chr1_17425,1.404518,1.404518,8.5479932,12.084317,1,2.835323,2.835323,5.3098655,16.233129,1,5.5925755,5.5925755,2.5435666,16.551985,0.047796174,5.8413674,5.8413674,1.3612805,6.1876558,1
NC_INTER_C17_29138,4.001,0,0,4.001,0,18.126039,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr17:12,267,689-12,268,050",,"lnc_inter_chr17_29138, ",,lnc_inter_chr17_29138,3.7025941,3.7025941,0,0.28409594,1,2.5313658,2.5313658,2.4324375,7.8817757,1,30.367598,30.3675979,0.38106507,18.126039,0.010697536,36.273493,36.2734927,0,8.5534639,0.83525682
NC_INTER_C2_33955,4.001,0,0,4.001,0,42.105296,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr2:100,959,048-100,959,317",,"lnc_inter_chr2_33955, ",,lnc_inter_chr2_33955,0.96409183,-1.0372456,0.66333987,0.39239074,1,4.9217257,4.9217257,4.2980926,23.22898,0.55055612,51.383424,51.3834243,0.9589399,42.105296,5.90E-07,9.2601941,9.2601941,0,2.824685,1
NC_AS_C2_33533,4.001,0,0,4.001,0,1.9956833,,"[Plus], [# Lnc isoforms: 1], [# of exons: 2], [Gene type: lncRNA]","chr2:62,756,109-62,759,075",,"lnc_as_chr2_33533, ",,lnc_as_chr2_33533,3.3443676,3.3443676,0.028593368,0.14033159,1,28.599943,28.5999431,0,0.51027724,0.56597249,67.317002,67.3170023,0,1.4034955,0.016164489,16.904579,16.9045787,0.093675167,1.9956833,0.28395982
NC_INTER_C7_43925,4.001,0,0,4.001,0,7.3818088,,"[Plus], [# Lnc isoforms: 1], [# of exons: 2], [Gene type: lncRNA]","chr7:17,553,950-17,554,852",,"lnc_inter_chr7_43925, ",,lnc_inter_chr7_43925,12.238712,12.2387125,0,0.47449801,1,4.1070237,4.1070237,0.86193518,3.3891234,1,7.1050763,7.1050763,0.75127927,7.3818088,0.043246428,20.065206,20.0652055,0,1.7950819,1
NC_INTER_C7_6109,4.001,0,0,4.001,0,3.8575444,,"[Plus], [# Lnc isoforms: 4], [# of exons: 1], [Gene type: lncRNA]","chr7:46,847,094-46,848,513",,"lnc_inter_chr7_6109, ",,lnc_inter_chr7_6109,3.7292751,3.7292751,0,0.07438556,1,9.9389414,9.9389414,0.10184874,1.3521925,0.51084583,88.677709,88.6777093,0,3.8575444,0.000459049,1.2999123,1.2999123,3.4696778,3.5702842,1
GM17017,4.001,0,0,4.001,0,1.2065807,,"[~59%  IN BLACKLIST], [Minus], [# of exons: 2], [Gene type: antisense]","chr1:87,537,797-87,547,160",,"Gm17017, ",,Gm17017,0.6286903,-1.5906083,0.62784222,0.40166395,1,1.850866,1.850866,0.37879425,0.7297118,1,6.1173417,6.1173417,0.20019015,1.2065807,0.02074504,1.1174638,1.1174638,0.91075842,0.68397199,1
NC_AS_C5_40917,3.22,1.2,2.02,0,0,7.5138153,,"[Minus], [# Lnc isoforms: 23], [# of exons: 3], [Gene type: lncRNA]","chr5:116,365,729-116,372,171",,"lnc_as_chr5_40917, ",,lnc_as_chr5_40917,0.20045378,-4.9886812,7.5138153,1.3839378,0.000267957,0.30147327,-3.3170436,3.5465601,1.0689539,0.014003327,0.51131862,-1.9557277,3.4517183,1.8535889,1,0.48721284,-2.0524911,3.3255177,1.2056752,1
NC_INTER_C17_13948,3.22,1.2,2.02,0,0,1.256982,,"[Minus], [# Lnc isoforms: 4], [# of exons: 3], [Gene type: lncRNA]","chr17:46,185,568-46,191,629",,"lnc_inter_chr17_13948, ",,lnc_inter_chr17_13948,0.021409693,-46.707815,1.256982,0.019357669,0.000275946,0.018527486,-53.9738621,0.42050065,0,0.02393546,0.12206255,-8.192521,0.49913592,0.070828244,0.79099183,0.13300367,-7.5185897,0.64128722,0.035924756,1
CYP2C68,3.22,1.2,2.02,0,0,34.94944,,"[Minus], [# of exons: 9], [Gene type: NM]","chr19:39,763,326-39,763,743 chr19:39,773,751-39,773,892 chr19:39,777,819-39,778,006 chr19:39,786,902-39,787,043 chr19:39,808,774-39,808,950 chr19:39,810,067-39,810,227 chr19:39,813,543-39,813,692 chr19:39,813,866-39,814,028 chr19:39,815,364-39,815,591",NM_001039555,"Cyp2c68, cytochrome P450, family 2, subfamily c, polypeptide 68, cytochrome P450, family 2, subfamily c, polypeptide 68|cytochrome P450 2C40 family, Predicted to have heme binding activity and monooxygenase activity. Predicted to be involved in epoxygenase P450 pathway; exogenous drug catabolic process; and xenobiotic metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in several diseases, including eosinophilic esophagitis; glucose metabolism disease (multiple); multiple myeloma; sickle cell anemia; and warfarin resistance. Orthologous to human CYP2C19 (cytochrome P450 family 2 subfamily C member 19) and CYP2C9 (cytochrome P450 family 2 subfamily C member 9).","cytoplasm (GO:0005737); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231)",Cyp2c68,0.31684412,-3.1561261,32.2239,9.5281272,0.021214431,0.36693902,-2.7252485,19.113972,7.3183897,0.000156163,0.40301052,-2.4813248,34.94944,14.786674,0.086297779,0.42557302,-2.349773,11.078647,3.716684,0.64071465
NC_INTER_C3_2937,3.22,1.2,2.02,0,0,1.4796433,,"[Plus], [# Lnc isoforms: 14], [# of exons: 4], [Gene type: lncRNA]","chr3:137,923,913-137,940,476",,"lnc_inter_chr3_2937, ",,lnc_inter_chr3_2937,0.11480515,-8.7104106,0.44120869,0.044416658,0.013379567,0.055520242,-18.011449,0.32042082,0.016232732,0.000317116,0.27332419,-3.658659,0.48586025,0.13771532,0.47344277,0.19705168,-5.0748109,1.4796433,0.19237677,0.095619104
ITGA6,3.22,1.2,2.02,0,0,3.4208286,,"[Plus], [# of exons: 26], [Gene type: NM]","chr2:71,624,996-71,696,484",NM_001277970 NM_008397,"Itga6, integrin alpha 6, integrin alpha-6|CD49 antigen-like family member F, Exhibits integrin binding activity. Involved in several processes, including brown fat cell differentiation; cell adhesion mediated by integrin; and filopodium assembly. Localizes to several cellular components, including basolateral plasma membrane; external side of plasma membrane; and hemidesmosome. Is expressed in several structures, including alimentary system; genitourinary system; heart; nervous system; and sensory organ. Used to study junctional epidermolysis bullosa Herlitz type. Human ortholog(s) of this gene implicated in junctional epidermolysis bullosa and junctional epidermolysis bullosa with pyloric atresia. Orthologous to human ITGA6 (integrin subunit alpha 6).",integrin binding (GO:0005178); protein binding (GO:0005515); basement membrane (GO:0005604); plasma membrane (GO:0005886); adherens junction (GO:0005912); cell adhesion (GO:0007155); cell-matrix adhesion (GO:0007160); integrin-mediated signaling pathway (GO:0007229); integrin complex (GO:0008305); external side of plasma membrane (GO:0009897); basal plasma membrane (GO:0009925); cell surface (GO:0009986); positive regulation of cell-substrate adhesion (GO:0010811); positive regulation of neuron projection development (GO:0010976); membrane (GO:0016020); integral component of membrane (GO:0016021); basolateral plasma membrane (GO:0016323); positive regulation of cell-cell adhesion (GO:0022409); hemidesmosome (GO:0030056); filopodium (GO:0030175); positive regulation of cell migration (GO:0030335); cell-substrate adhesion (GO:0031589); cellular response to extracellular stimulus (GO:0031668); insulin-like growth factor I binding (GO:0031994); cell adhesion mediated by integrin (GO:0033627); integrin alpha6-beta4 complex (GO:0034676); nail development (GO:0035878); neuregulin binding (GO:0038132); positive regulation of phosphorylation (GO:0042327); odontogenesis of dentin-containing tooth (GO:0042475); positive regulation of apoptotic process (GO:0043065); laminin binding (GO:0043236); positive regulation of GTPase activity (GO:0043547); skin morphogenesis (GO:0043589); protein-containing complex binding (GO:0044877); basal part of cell (GO:0045178); positive regulation of transcription by RNA polymerase II (GO:0045944); filopodium assembly (GO:0046847); metal ion binding (GO:0046872); brown fat cell differentiation (GO:0050873); leukocyte migration (GO:0050900); cell-cell adhesion (GO:0098609); negative regulation of extrinsic apoptotic signaling pathway (GO:2001237),Itga6,0.13074167,-7.6486707,0.82147569,0.095479451,3.86E-06,0.39756031,-2.5153417,1.1199436,0.43837205,0.04704849,0.51379048,-1.9463186,1.8050723,0.95349258,1,0.67099761,-1.4903183,3.4208286,1.7984059,1
CYP2A4,3.22,1.2,2.02,0,0,126.16656,,"[Plus], [# of exons: 9], [Gene type: NM]","chr7:27,092,211-27,100,107",NM_009997,"Cyp2a4, cytochrome P450, family 2, subfamily a, polypeptide 4, cytochrome P450 2A4|CYPIIA4|cytochrome P450, 2a4|cytochrome P450-15-alpha|cytochrome P450-IIA3.1|testosterone 15-alpha-hydroxylase|testosterone 15alpha-hydroxylase, Predicted to have enzyme binding activity; heme binding activity; and monooxygenase activity. Involved in response to stilbenoid. Predicted to localize to cytoplasmic microtubule and intracellular membrane-bounded organelle. Is expressed in liver; lung; metanephros; nervous system; and nose. Human ortholog(s) of this gene implicated in nicotine dependence and warfarin resistance. Orthologous to several human genes including CYP2A13 (cytochrome P450 family 2 subfamily A member 13) and CYP2A6 (cytochrome P450 family 2 subfamily A member 6).","cytoplasm (GO:0005737); cytoplasmic microtubule (GO:0005881); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); coumarin 7-hydroxylase activity (GO:0008389); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); coumarin metabolic process (GO:0009804); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); epoxygenase P450 pathway (GO:0019373); enzyme binding (GO:0019899); heme binding (GO:0020037); response to stilbenoid (GO:0035634); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231)",Cyp2a4,0.062198762,-16.0774904,88.683834,5.9214269,0.000155339,0.10333375,-9.6773805,105.79373,12.702686,0.00331693,0.12939413,-7.7283257,126.16656,17.650982,0.087595763,0.26554516,-3.7658377,61.017991,12.311451,0.95136301
SH2D4A,3.22,1.2,2.02,0,0,5.588167,,"[Plus], [# of exons: 9], [Gene type: NM]","chr8:70,800,427-70,871,603",NM_028182,"Sh2d4a, SH2 domain containing 4A, SH2 domain-containing protein 4A, Predicted to have phosphatase binding activity. Predicted to be involved in negative regulation of phosphatase activity. Localizes to cytoplasm. Is expressed in medulla oblongata floor plate; metencephalon floor plate; and spinal cord floor plate. Orthologous to human SH2D4A (SH2 domain containing 4A).",cytoplasm (GO:0005737); cytosol (GO:0005829); negative regulation of phosphatase activity (GO:0010923); phosphatase binding (GO:0019902),Sh2d4a,0.27134087,-3.6854013,0.66845001,0.17269011,0.011896918,0.40763489,-2.4531757,0.65848112,0.27956019,0.011755723,0.34919571,-2.8637236,0.94427619,0.35658894,0.085475037,0.3828595,-2.6119242,5.588167,1.5633364,0.31780971
WDR86,3.11,1.1,2.01,0,0,2.8440662,,"[Minus], [# of exons: 6], [Gene type: NM]","chr5:24,218,087-24,236,498",NM_001081441,"Wdr86, WD repeat domain 86, WD repeat-containing protein 86, Is expressed in testis. Orthologous to human WDR86 (WD repeat domain 86).",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Wdr86,15.112908,15.1129078,0.046288789,0.82188526,9.38E-06,2.7284075,2.7284075,0.61755397,1.8913317,0.038367034,3.2001425,3.2001425,0.31829781,1.0364537,0.11613272,2.2295906,2.2295906,1.7219463,2.8440662,0.60502071
NC_INTER_C10_18388,3.11,1.1,2.01,0,0,25.495495,,"[Plus], [# Lnc isoforms: 28], [# of exons: 1], [Gene type: lncRNA]","chr10:41,162,488-41,164,116",,"lnc_inter_chr10_18388, ",,lnc_inter_chr10_18388,24.922786,24.9227861,0.9142415,25.495495,0.049634875,15.930136,15.9301364,0.89495354,13.774603,0.012885226,39.855809,39.855809,0.3438873,15.671569,0.078649861,43.60831,43.6083096,0,2.6902921,0.33547371
SSTR2,3.11,1.1,2.01,0,0,1.5023648,,"[Plus], [# of exons: 2], [Gene type: NM]","chr11:113,480,641-113,487,332",NM_001042606 NM_009217,"Sstr2, somatostatin receptor 2, somatostatin receptor type 2, Exhibits somatostatin receptor activity. Involved in adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway and neuropeptide signaling pathway. Localizes to plasma membrane. Is expressed in several structures, including central nervous system; eye; intestine; liver and biliary system; and reproductive system. Orthologous to human SSTR2 (somatostatin receptor 2).",G-protein coupled receptor activity (GO:0004930); somatostatin receptor activity (GO:0004994); cytoplasm (GO:0005737); cytosol (GO:0005829); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); regulation of muscle contraction (GO:0006937); signal transduction (GO:0007165); G-protein coupled receptor signaling pathway (GO:0007186); adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway (GO:0007193); neuropeptide signaling pathway (GO:0007218); membrane (GO:0016020); integral component of membrane (GO:0016021); PDZ domain binding (GO:0030165); peristalsis (GO:0030432); peptide binding (GO:0042277); neuropeptide binding (GO:0042923); neuron projection (GO:0043005); cellular response to glucocorticoid stimulus (GO:0071385); cellular response to estradiol stimulus (GO:0071392),Sstr2,22.798364,22.7983645,0.025349852,0.78525034,0.000792651,6.0573634,6.0573634,0.22259347,1.3576903,0.002889375,6.9155808,6.9155808,0.2114161,1.5023648,0.14649934,1.6663878,1.6663878,0.49800269,0.58026443,1
LEFTY1,3.11,1.1,2.01,0,0,1.2064356,,"[Plus], [# of exons: 4], [Gene type: NM]","chr1:182,865,153-182,868,532",NM_010094,"Lefty1, left right determination factor 1, left-right determination factor 1|TGF-beta-4|left-right determination, factor B|protein lefty-1|stimulated by retinoic acid gene 3 protein|transforming growth factor beta-4, Exhibits nodal binding activity. Involved in several processes, including negative regulation of nodal receptor complex assembly; negative regulation of nodal signaling pathway; and response to retinoic acid. Localizes to extracellular region. Is expressed in several structures, including blastocyst; embryo mesoderm; extraembryonic visceral endoderm; neural ectoderm; and primitive streak. Orthologous to human LEFTY1 (left-right determination factor 1) and LEFTY2 (left-right determination factor 2).",negative regulation of transcription by RNA polymerase II (GO:0000122); heart morphogenesis (GO:0003007); cytokine activity (GO:0005125); transforming growth factor beta receptor binding (GO:0005160); extracellular region (GO:0005576); extracellular space (GO:0005615); multicellular organism development (GO:0007275); determination of left/right symmetry (GO:0007368); growth factor activity (GO:0008083); negative regulation of cell proliferation (GO:0008285); anterior/posterior axis specification (GO:0009948); positive regulation of pathway-restricted SMAD protein phosphorylation (GO:0010862); BMP signaling pathway (GO:0030509); response to retinoic acid (GO:0032526); nodal binding (GO:0038100); cell migration involved in gastrulation (GO:0042074); SMAD protein signal transduction (GO:0060395); negative regulation of nodal signaling pathway (GO:1900108); negative regulation of nodal receptor complex assembly (GO:1900124),Lefty1,67.388867,67.3888673,0,0.75833166,0.011438537,19.292712,19.2927121,0.042771046,1.2064356,0.014678244,11.482326,11.4823257,0.076340584,0.73895961,0.60708724,18.225917,18.225917,0,0.50940668,1
NC_INTER_C17_29934,2.02,0,2.02,0,0,9.5343295,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr17:47,190,543-47,191,290",,"lnc_inter_chr17_29934, ",,lnc_inter_chr17_29934,0.1425607,-7.0145557,7.1590149,0.9811015,0.2324301,0.078487135,-12.7409416,8.1073888,0.47012538,0.040629431,0.53764027,-1.8599797,5.6986822,3.3435139,1,0.061667308,-16.2160476,9.5343295,0.355063,0.46109543
NC_INTER_C9_48147,2.02,0,2.02,0,0,12.043513,,"[Minus], [# Lnc isoforms: 35], [# of exons: 1], [Gene type: lncRNA]","chr9:42,054,806-42,059,266",,"lnc_inter_chr9_48147, ",,lnc_inter_chr9_48147,0.20495092,-4.879217,0.5351397,0.096634907,1,0.19727793,-5.0689908,3.2476852,0.76428929,0.029178987,0.2335706,-4.2813607,3.0741579,0.75749153,0.47344277,0.47253971,-2.1162243,12.043513,3.9401805,1
NC_INTER_C6_5690,2.02,0,2.02,0,0,1.7483622,,"[Minus], [# Lnc isoforms: 8], [# of exons: 1], [Gene type: lncRNA]","chr6:136,410,054-136,413,050",,"lnc_inter_chr6_5690,5691, ",,lnc_inter_chr6_5690,0.38736877,-2.5815194,1.4776826,0.52240508,1,0.15432203,-6.4799563,1.7483622,0.26994616,0.014649189,0.64003514,-1.5624142,0.97409055,0.54674045,1,0.17215709,-5.8086482,1.5016384,0.17705745,1
ASB2,2.02,0,2.02,0,0,2.3484524,,"[Minus], [# of exons: 10], [Gene type: NM]","chr12:104,559,352-104,594,211",NM_001374764 NM_023049,"Asb2, ankyrin repeat and SOCS box-containing 2, ankyrin repeat and SOCS box protein 2|ASB-2|ankyrin repeat and SOCS box-containing protein 2|ankyrin repeat-containing SOCS box protein 2, Contributes to ubiquitin protein ligase activity. Involved in cellular protein metabolic process; myoblast differentiation; and skeletal muscle cell differentiation. Localizes to Cul5-RING ubiquitin ligase complex. Is expressed in several structures, including embryo mesenchyme; genitourinary system; gut; heart; and musculature. Orthologous to human ASB2 (ankyrin repeat and SOCS box containing 2).",ubiquitin ligase complex (GO:0000151); protein polyubiquitination (GO:0000209); ubiquitin-dependent protein catabolic process (GO:0006511); protein ubiquitination (GO:0016567); Cul5-RING ubiquitin ligase complex (GO:0031466); intracellular signal transduction (GO:0035556); skeletal muscle cell differentiation (GO:0035914); myoblast differentiation (GO:0045445); ubiquitin protein ligase activity (GO:0061630),Asb2,0.81619165,-1.2252024,0.9961494,0.8040311,1,0.43884478,-2.27871,1.7435772,0.80210433,0.03601772,0.49946448,-2.0021444,0.97702605,0.52453783,0.90137871,0.81979875,-1.2198116,2.3484524,1.48817,1
SLC22A7,2.02,0,2.02,0,0,164.37776,,"[Minus], [# of exons: 10], [Gene type: NM]","chr17:46,569,134-46,575,426",NM_144856,"Slc22a7, solute carrier family 22 (organic anion transporter), member 7, solute carrier family 22 member 7|mOAT2|organic anion transporter 2, Exhibits organic anion transmembrane transporter activity. Involved in response to stilbenoid. Predicted to localize to basolateral plasma membrane. Is expressed in metanephros. Orthologous to human SLC22A7 (solute carrier family 22 member 7).",plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); ion transport (GO:0006811); organic anion transmembrane transporter activity (GO:0008514); organic anion transport (GO:0015711); membrane (GO:0016020); integral component of membrane (GO:0016021); basolateral plasma membrane (GO:0016323); transmembrane transporter activity (GO:0022857); response to stilbenoid (GO:0035634); transmembrane transport (GO:0055085),Slc22a7,0.77191668,-1.2954766,97.873822,74.638473,1,0.3905751,-2.5603271,155.81058,70.086804,0.036209423,0.38062937,-2.6272276,164.04368,67.432872,0.17546191,0.44252925,-2.2597376,164.37776,54.813241,0.29261579
FMO1,2.02,0,2.02,0,0,67.224701,,"[Minus], [# of exons: 11], [Gene type: NM]","chr1:164,759,692-164,796,741",NM_001330291 NM_001330318 NM_010231,"Fmo1, flavin containing monooxygenase 1, dimethylaniline monooxygenase [N-oxide-forming] 1|dimethylaniline oxidase 1|hepatic flavin-containing monooxygenase 1, Exhibits monooxygenase activity. Involved in drug metabolic process. Predicted to localize to intracellular membrane-bounded organelle. Is expressed in brain; cortical renal tubule; late tubule; and testis. Orthologous to human FMO1 (flavin containing dimethylaniline monoxygenase 1).","monooxygenase activity (GO:0004497); N,N-dimethylaniline monooxygenase activity (GO:0004499); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); toxin metabolic process (GO:0009404); membrane (GO:0016020); integral component of membrane (GO:0016021); oxidoreductase activity (GO:0016491); drug metabolic process (GO:0017144); intracellular membrane-bounded organelle (GO:0043231); flavin adenine dinucleotide binding (GO:0050660); NADP binding (GO:0050661); NADPH oxidation (GO:0070995)",Fmo1,0.30496841,-3.2790282,38.091742,11.887805,0.065356072,0.42014329,-2.3801404,27.321443,12.005549,0.016211248,0.50140485,-1.9943963,46.330053,24.476809,0.74564941,0.49557536,-2.0178566,67.224701,25.751308,0.18579786
SLC39A5,2.02,0,2.02,0,0,6.0124651,,"[Minus], [# of exons: 12], [Gene type: NM]","chr10:127,832,987-127,838,280",NM_001136237 NM_028051 NM_028092,"Slc39a5, solute carrier family 39 (metal ion transporter), member 5, zinc transporter ZIP5|ZIP-5|solute carrier family 39 member 5|zrt- and Irt-like protein 5, Predicted to have zinc ion transmembrane transporter activity. Involved in cellular response to zinc ion starvation and positive regulation of mRNA splicing, via spliceosome. Localizes to basolateral plasma membrane. Is expressed in several structures, including branchial arch; genitourinary system; gut; hemolymphoid system gland; and liver and biliary system. Human ortholog(s) of this gene implicated in myopia. Orthologous to human SLC39A5 (solute carrier family 39 member 5).","eye development (GO:0001654); zinc ion transmembrane transporter activity (GO:0005385); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); ion transport (GO:0006811); zinc ion transport (GO:0006829); cellular zinc ion homeostasis (GO:0006882); membrane (GO:0016020); integral component of membrane (GO:0016021); basolateral plasma membrane (GO:0016323); metal ion transport (GO:0030001); BMP signaling pathway (GO:0030509); cellular response to zinc ion starvation (GO:0034224); metal ion transmembrane transporter activity (GO:0046873); positive regulation of mRNA splicing, via spliceosome (GO:0048026); transmembrane transport (GO:0055085); zinc ion import across plasma membrane (GO:0071578)",Slc39a5,0.3671019,-2.7240393,3.5376892,1.2266722,1,0.23249534,-4.3011616,6.0124651,1.4144187,1.31E-05,0.22798729,-4.3862094,5.8570621,1.4000978,0.052338912,0.22480166,-4.4483657,5.9971766,1.0431577,0.29802561
LRATD2,2.02,0,2.02,0,0,17.768892,,"[Minus], [# of exons: 2], [Gene type: NM]","chr15:60,650,551-60,656,635",NM_001162926,"Lratd2, LRAT domain containing 1, protein LRATD2|family with sequence similarity 84, member B, Predicted to localize to cytoplasm and plasma membrane. Is expressed in alimentary system; brain; metanephros; and vibrissa. Orthologous to human LRATD2 (LRAT domain containing 2).",molecular_function (GO:0003674); cytoplasm (GO:0005737); plasma membrane (GO:0005886); biological_process (GO:0008150),Lratd2,0.258305,-3.8713924,17.768892,4.3308025,0.07319554,0.34333183,-2.9126341,12.601159,4.3732856,0.011548635,0.51968175,-1.9242546,15.442518,8.4375305,1,0.60503695,-1.6527916,7.0862506,3.2748911,1
NAT8F3,2.02,0,2.02,0,0,5.2284337,,"[Minus], [# of exons: 3], [Gene type: NM]","chr6:85,710,625-85,715,738",NM_001037842,"Nat8f3, N-acetyltransferase 8 (GCN5-related) family member 3, N-acetyltransferase family 8 member 3|N-acetyltransferase CML3|camello-like 3|camello-like protein 3|probable N-acetyltransferase CML3, Exhibits H4 histone acetyltransferase activity. Involved in histone acetylation. Localizes to nuclear membrane. Orthologous to human NAT8 (N-acetyltransferase 8 (putative)).",gastrulation with mouth forming second (GO:0001702); axis elongation (GO:0003401); extracellular space (GO:0005615); nucleus (GO:0005634); endoplasmic reticulum (GO:0005783); Golgi apparatus (GO:0005794); negative regulation of cell adhesion (GO:0007162); N-acetyltransferase activity (GO:0008080); H4 histone acetyltransferase activity (GO:0010485); integral component of membrane (GO:0016021); histone acetylation (GO:0016573); nuclear membrane (GO:0031965),Nat8f3,0.19772774,-5.0574594,3.3427362,0.45374431,1,0.19827465,-5.043509,3.1124896,0.64919627,0.007799636,0.29791915,-3.3566154,3.7482022,1.1763713,0.17329816,0.20620338,-4.8495811,5.2284337,0.84048403,0.06870958
GZMB,2.02,0,2.02,0,0,7.8688828,,"[Minus], [# of exons: 5], [Gene type: NM]","chr14:56,877,673-56,881,171",NM_013542,"Gzmb, granzyme B, granzyme B(G,H)|cytotoxic cell protease 1|fragmentin-2, Exhibits serine-type peptidase activity. Involved in T cell mediated cytotoxicity and granzyme-mediated programmed cell death signaling pathway. Localizes to cytolytic granule. Is expressed in extraembryonic component; placenta; and thymus primordium. Orthologous to several human genes including GZMB (granzyme B).",T cell mediated cytotoxicity (GO:0001913); serine-type endopeptidase activity (GO:0004252); protein binding (GO:0005515); extracellular region (GO:0005576); cytoplasm (GO:0005737); cytosol (GO:0005829); proteolysis (GO:0006508); apoptotic process (GO:0006915); peptidase activity (GO:0008233); serine-type peptidase activity (GO:0008236); hydrolase activity (GO:0016787); cytolysis (GO:0019835); intracellular membrane-bounded organelle (GO:0043231); cytolytic granule (GO:0044194),Gzmb,0.2622952,-3.8124983,0.77604194,0.18356144,1,0.27100548,-3.6899623,4.8404876,1.2588015,0.046599383,0.45198539,-2.2124609,7.8688828,3.6918275,1,0.22247758,-4.494835,0.89768098,0.12449397,1
GSTT3,2.02,0,2.02,0,0,61.948298,,"[Minus], [# of exons: 6], [Gene type: NM]","chr10:75,236,862-75,244,167",NM_001346523 NM_133994,"Gstt3, glutathione S-transferase, theta 3, glutathione S-transferase theta-3, Exhibits glutathione transferase activity. Involved in glutathione metabolic process. Predicted to localize to cytoplasm. Is expressed in several structures, including alimentary system; epidermis; metatarsal bone; olfactory epithelium; and urinary system.",glutathione transferase activity (GO:0004364); cytoplasm (GO:0005737); glutathione metabolic process (GO:0006749); transferase activity (GO:0016740),Gstt3,0.40765249,-2.4530698,61.948298,24.630314,0.3024247,0.3972907,-2.5170486,49.355068,21.038588,0.004942619,0.52250558,-1.9138551,30.062253,16.248302,1,0.52992183,-1.8870708,34.851093,14.601206,0.84118885
DCT,2.02,0,2.02,0,0,5.9814719,,"[Minus], [# of exons: 8], [Gene type: NM]","chr14:118,412,012-118,451,468",NM_010024,"Dct, dopachrome tautomerase, L-dopachrome tautomerase|DOPAchrome conversion factor|DOPAchrome isomerase|DOPAchrome oxidoreductase|L-dopachrome Delta-isomerase|SLATY locus protein|tyrosinase-related protein 2, Exhibits dopachrome isomerase activity. Involved in several processes, including developmental pigmentation; generation of neurons; and melanin biosynthetic process from tyrosine. Localizes to cytosol and melanosome. Is expressed in several structures, including embryo ectoderm; embryo mesenchyme; integumental system; sensory organ; and skeleton. Orthologous to human DCT (dopachrome tautomerase).",positive regulation of neuroblast proliferation (GO:0002052); dopachrome isomerase activity (GO:0004167); cytoplasm (GO:0005737); cytosol (GO:0005829); plasma membrane (GO:0005886); melanin biosynthetic process from tyrosine (GO:0006583); response to blue light (GO:0009637); membrane (GO:0016020); integral component of membrane (GO:0016021); oxidoreductase activity (GO:0016491); isomerase activity (GO:0016853); ventricular zone neuroblast division (GO:0021847); melanin biosynthetic process (GO:0042438); melanosome (GO:0042470); intracellular membrane-bounded organelle (GO:0043231); pigmentation (GO:0043473); metal ion binding (GO:0046872); developmental pigmentation (GO:0048066); cell development (GO:0048468),Dct,0.26735821,-3.7403003,5.9814719,1.4010227,0.050779353,0.23131726,-4.3230669,4.862777,1.2077301,7.77E-07,0.27707844,-3.6090863,3.5603605,1.0565794,0.099927479,0.33499257,-2.9851408,2.1192646,0.53112083,0.687233
CYP2C54,2.02,0,2.02,0,0,49.195887,,"[Minus], [# of exons: 9], [Gene type: NM]","chr19:40,112,430-40,112,908 chr19:40,114,682-40,114,823 chr19:40,120,566-40,120,753 chr19:40,121,994-40,122,135 chr19:40,144,658-40,144,834 chr19:40,145,936-40,146,096 chr19:40,146,545-40,146,694 chr19:40,146,857-40,147,019 chr19:40,148,134-40,148,303",NM_206537,"Cyp2c54, cytochrome P450, family 2, subfamily c, polypeptide 54, cytochrome P450 2C54|CYPIIC54, Exhibits arachidonic acid epoxygenase activity and linoleic acid epoxygenase activity. Involved in arachidonic acid metabolic process and linoleic acid metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in several diseases, including eosinophilic esophagitis; glucose metabolism disease (multiple); multiple myeloma; sickle cell anemia; and warfarin resistance. Orthologous to human CYP2C19 (cytochrome P450 family 2 subfamily C member 19) and CYP2C9 (cytochrome P450 family 2 subfamily C member 9).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); arachidonic acid metabolic process (GO:0019369); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); linoleic acid metabolic process (GO:0043651); metal ion binding (GO:0046872); aromatase activity (GO:0070330); linoleic acid epoxygenase activity (GO:0071614)",Cyp2c54,0.30008092,-3.3324344,49.195887,14.818187,0.067997916,0.33286332,-3.0042361,26.457202,9.7670521,0.000176118,0.47372062,-2.1109489,30.050074,15.008688,1,0.45238883,-2.2104878,10.764374,3.8018849,0.70507161
ZBP1,2.02,0,2.02,0,0,12.454474,,"[Minus], [# of exons: 9], [Gene type: NM]","chr2:173,032,113-173,044,423",NM_001139519 NM_021394,"Zbp1, Z-DNA binding protein 1, Z-DNA-binding protein 1|DNA-dependent activator of IFN-regulatory factors|tumor stroma and activated macrophage protein DLM-1, Exhibits double-stranded RNA binding activity and left-handed Z-DNA binding activity. Involved in several processes, including positive regulation of defense response; positive regulation of programmed cell death; and regulation of interleukin-1-mediated signaling pathway. Localizes to cytoplasm and nucleus. Is expressed in eye and heart. Orthologous to human ZBP1 (Z-DNA binding protein 1).",activation of innate immune response (GO:0002218); immune system process (GO:0002376); DNA binding (GO:0003677); left-handed Z-DNA binding (GO:0003692); RNA binding (GO:0003723); double-stranded RNA binding (GO:0003725); protein binding (GO:0005515); nucleus (GO:0005634); cytoplasm (GO:0005737); cytosol (GO:0005829); apoptotic process (GO:0006915); programmed cell death (GO:0012501); viral process (GO:0016032); identical protein binding (GO:0042802); positive regulation of apoptotic process (GO:0043065); innate immune response (GO:0045087); regulation of inflammatory response (GO:0050727); positive regulation of inflammatory response (GO:0050729); defense response to virus (GO:0051607); positive regulation of type I interferon-mediated signaling pathway (GO:0060340); positive regulation of necroptotic process (GO:0060545); pyroptosis (GO:0070269); regulation of interleukin-1-mediated signaling pathway (GO:2000659),Zbp1,0.35382237,-2.826277,10.047767,3.3588432,0.22756954,0.32649172,-3.0628648,10.289492,3.4361619,0.000375071,0.39102074,-2.5574091,9.3252922,3.8390188,0.3237892,0.33921856,-2.9479519,12.454474,3.1246548,0.20437355
NC_INTER_C2_2084,2.02,0,2.02,0,0,5.2847603,,"[Plus], [# Lnc isoforms: 14], [# of exons: 4], [Gene type: lncRNA]","chr2:178,225,464-178,230,962",,"lnc_inter_chr2_2084,2085, ",,lnc_inter_chr2_2084,0.009751979,-102.5432868,0.79276557,0,0.63218153,0.002314619,-432.0366404,3.2409848,0,0.043431423,0.00537913,-185.9036747,1.8303243,0,0.20832347,0.032725899,-30.5568385,5.2847603,0.079206964,0.34213572
NC_INTER_C11_20753,2.02,0,2.02,0,0,40.238121,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:75,268,291-75,268,905",,"lnc_inter_chr11_20753, ",,lnc_inter_chr11_20753,0.28100698,-3.5586304,19.866876,5.3035135,0.30260005,0.18083323,-5.5299572,16.270115,3.0404502,0.000845876,0.18679758,-5.3533884,15.854125,3.1026167,0.1125409,0.19097212,-5.2363665,40.238121,6.0387661,0.062055017
NC_INTER_C14_12191,2.02,0,2.02,0,0,562.29737,,"[Plus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr14:76,201,118-76,204,672",,"lnc_inter_chr14_12191, ",,lnc_inter_chr14_12191,0.32870204,-3.0422689,2.145482,0.59658183,1,0.17637561,-5.6697182,23.662987,4.0940918,0.018247916,0.12430388,-8.0448011,42.064584,5.4246262,0.077596102,0.1402392,-7.1306741,562.29737,58.840801,0.079692513
NC_INTRA_C1_16024,2.02,0,2.02,0,0,12.241878,,"[Plus], [# Lnc isoforms: 3], [# of exons: 2], [Gene type: lncRNA]","chr1:52,943,123-52,944,643 chr1:52,950,388-52,951,395",,"lnc_intra_chr1_16024, ",,lnc_intra_chr1_16024,3.7074252,3.7074252,0,0.012398288,1,0.042201769,-23.6956892,0.77264375,0.03591495,0.03402958,0.079510496,-12.5769559,0.98847156,0.07924854,0.75525702,0.34709867,-2.8810252,12.241878,3.2906997,0.20002268
LAD1,2.02,0,2.02,0,0,4.0902663,,"[Plus], [# of exons: 10], [Gene type: NM]","chr1:137,715,175-137,729,918",NM_133664,"Lad1, ladinin, ladinin-1|linear IgA disease antigen homolog, Predicted to have structural molecule activity. Predicted to localize to actin cytoskeleton. Is expressed in alimentary system; central nervous system; ganglia; renal cortex; and sensory organ. Orthologous to human LAD1 (ladinin 1).",structural molecule activity (GO:0005198); extracellular region (GO:0005576); basement membrane (GO:0005604); actin cytoskeleton (GO:0015629),Lad1,0.58878909,-1.698401,3.1495164,1.7822826,1,0.41206961,-2.4267744,4.0902663,1.8238708,0.024406895,0.5323623,-1.87842,2.706374,1.5112313,1,0.97012495,-1.0307951,2.9771208,2.2115745,1
KITL,2.02,0,2.02,0,0,1.7805817,,"[Plus], [# of exons: 10], [Gene type: NM]","chr10:99,478,455-99,563,049",NM_001347156 NM_013598,"Kitl, kit ligand, kit ligand|C-kit ligand|Steel factor|cloud gray|grizzle-belly|hematopoietic growth factor KL|mast cell growth factor|stem cell factor, Exhibits cytokine activity and stem cell factor receptor binding activity. Involved in several processes, including positive regulation of cell differentiation; positive regulation of cell population proliferation; and positive regulation of protein phosphorylation. Localizes to extracellular space; integral component of membrane; and plasma membrane. Is expressed in several structures, including alimentary system; central nervous system; genitourinary system; integumental system; and sensory organ. Human ortholog(s) of this gene implicated in autosomal dominant nonsyndromic deafness 69 and familial progressive hyperpigmentation with or without hypopigmentation. Orthologous to human KITLG (KIT ligand).",ovarian follicle development (GO:0001541); neural crest cell migration (GO:0001755); positive regulation of leukocyte migration (GO:0002687); positive regulation of myeloid leukocyte differentiation (GO:0002763); cytokine activity (GO:0005125); stem cell factor receptor binding (GO:0005173); protein binding (GO:0005515); extracellular region (GO:0005576); extracellular space (GO:0005615); cytoplasm (GO:0005737); cytoskeleton (GO:0005856); plasma membrane (GO:0005886); cell adhesion (GO:0007155); germ cell development (GO:0007281); growth factor activity (GO:0008083); positive regulation of cell proliferation (GO:0008284); membrane (GO:0016020); integral component of membrane (GO:0016021); lamellipodium (GO:0030027); filopodium (GO:0030175); negative regulation of mast cell apoptotic process (GO:0033026); embryonic hemopoiesis (GO:0035162); ectopic germ cell programmed cell death (GO:0035234); cell projection (GO:0042995); negative regulation of apoptotic process (GO:0043066); positive regulation of MAP kinase activity (GO:0043406); positive regulation of melanocyte differentiation (GO:0045636); positive regulation of Ras protein signal transduction (GO:0046579); positive regulation of peptidyl-tyrosine phosphorylation (GO:0050731); positive regulation of mast cell proliferation (GO:0070668); extrinsic apoptotic signaling pathway in absence of ligand (GO:0097192); positive regulation of hematopoietic stem cell proliferation (GO:1902035),Kitl,0.219776,-4.5500874,0.063551357,0.011819552,0.73330011,0.2770153,-3.6099089,0.24655448,0.071742039,0.017773189,0.48781655,-2.0499509,0.64946075,0.32553291,1,0.48576777,-2.0585969,1.7805817,0.61410894,1
PKP3,2.02,0,2.02,0,0,6.549456,,"[Plus], [# of exons: 14], [Gene type: NM]","chr7:148,264,128-148,276,409",NM_001162924 NM_019762,"Pkp3, plakophilin 3, plakophilin-3, Predicted to have alpha-catenin binding activity; cadherin binding activity; and enzyme binding activity. Predicted to be involved in several processes, including desmosome assembly; negative regulation of mRNA catabolic process; and protein localization to plasma membrane. Localizes to desmosome. Is expressed in skin. Orthologous to human PKP3 (plakophilin 3).",desmosome assembly (GO:0002159); protein binding (GO:0005515); nucleus (GO:0005634); nucleoplasm (GO:0005654); cytoplasm (GO:0005737); plasma membrane (GO:0005886); adherens junction (GO:0005912); spot adherens junction (GO:0005914); cell-cell junction assembly (GO:0007043); cell adhesion (GO:0007155); positive regulation of gene expression (GO:0010628); enzyme binding (GO:0019899); cell junction (GO:0030054); desmosome (GO:0030057); alpha-catenin binding (GO:0045294); cadherin binding (GO:0045296); cell adhesion molecule binding (GO:0050839); protein localization to plasma membrane (GO:0072659); cell-cell adhesion (GO:0098609); negative regulation of mRNA catabolic process (GO:1902373); messenger ribonucleoprotein complex (GO:1990124),Pkp3,0.61680165,-1.6212667,2.624704,1.5891403,1,0.33595372,-2.9766005,3.9841486,1.4165191,0.003926388,0.45207473,-2.2120237,3.1246394,1.5349991,0.67948942,0.5632639,-1.7753668,6.549456,2.6289519,1
LRTM1,2.02,0,2.02,0,0,46.926692,,"[Plus], [# of exons: 3], [Gene type: NM]","chr14:29,831,394-29,846,828",NM_176920,"Lrtm1, leucine-rich repeats and transmembrane domains 1, leucine-rich repeat and transmembrane domain-containing protein 1, Predicted to have Roundabout binding activity and heparin binding activity. Involved in positive regulation of synapse assembly. Predicted to localize to integral component of membrane. Is expressed in head. Orthologous to human LRTM1 (leucine rich repeats and transmembrane domains 1).",axon guidance (GO:0007411); heparin binding (GO:0008201); membrane (GO:0016020); integral component of membrane (GO:0016021); Roundabout binding (GO:0048495); negative chemotaxis (GO:0050919); positive regulation of synapse assembly (GO:0051965),Lrtm1,0.23380724,-4.2770275,12.218314,2.7389769,0.16859996,0.25990756,-3.8475218,11.256619,3.4738102,0.00629613,0.24091863,-4.1507791,15.088584,3.9968789,0.11613272,0.33033538,-3.0272265,46.926692,10.732921,0.1517036
NC_INTER_C13_24603,2.02,0,2.02,0,0,17.637522,,"[~25%  IN BLACKLIST], [Plus], [# Lnc isoforms: 6], [# of exons: 1], [Gene type: lncRNA]","chr13:93,968,744-93,974,810",,"lnc_inter_chr13_24603, ",,lnc_inter_chr13_24603,0.019706302,-50.7451871,0.33590472,0,0.80721568,0.002750543,-363.5645317,8.7647932,0.022161452,0.013918698,0.00477131,-209.5860326,7.0836689,0.027030749,0.1039525,0.028587492,-34.9803331,17.637522,0.2845012,0.089231737
ITIH5,2.02,0,2.02,0,0,1.5383513,,"[~3%  IN BLACKLIST], [Plus], [# of exons: 14], [Gene type: NM]","chr2:10,075,170-10,178,156",NM_172471,"Itih5, inter-alpha (globulin) inhibitor H5, inter-alpha-trypsin inhibitor heavy chain H5|ITI heavy chain H5|ITI-HC5|inter-alpha trypsin inhibitor heavy chain precursor 5|inter-alpha-inhibitor heavy chain 5, Predicted to have serine-type endopeptidase inhibitor activity. Predicted to be involved in hyaluronan metabolic process and negative regulation of peptidase activity. Localizes to collagen-containing extracellular matrix. Is expressed in several structures, including foregut; genitourinary system; limb segment; meninges; and sensory organ. Orthologous to human ITIH5 (inter-alpha-trypsin inhibitor heavy chain 5).",molecular_function (GO:0003674); serine-type endopeptidase inhibitor activity (GO:0004867); extracellular region (GO:0005576); biological_process (GO:0008150); negative regulation of peptidase activity (GO:0010466); hyaluronan metabolic process (GO:0030212); peptidase inhibitor activity (GO:0030414); collagen-containing extracellular matrix (GO:0062023),Itih5,0.30174644,-3.3140408,0.42796519,0.13044785,0.19151967,0.39084135,-2.5585829,0.38067202,0.15196329,0.020636059,0.4824215,-2.0728761,0.77075564,0.39560246,0.38530364,0.54572951,-1.8324096,1.5383513,0.62490406,0.89032838
NC_INTER_C3_2156,2.01,0,2.01,0,0,13.274095,,"[Minus], [# Lnc isoforms: 13], [# of exons: 1], [Gene type: lncRNA]","chr3:14,722,035-14,725,755",,"lnc_inter_chr3_2156, ",,lnc_inter_chr3_2156,3.4440594,3.4440594,0.047967319,0.11902296,1,4.4370741,4.4370741,0.39461132,1.839455,0.040719963,6.553603,6.553603,0.19209332,1.6785866,0.26675369,4.874387,4.874387,3.1450379,13.274095,0.14340718
NC_INTER_C1_274,2.01,0,2.01,0,0,2.7042186,,"[Minus], [# Lnc isoforms: 14], [# of exons: 10], [Gene type: lncRNA]","chr1:64,726,434-64,737,233",NR_038009,"2810408I11Rik, RIKEN cDNA 2810408I11 gene; lnc_inter_chr1_274, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),2810408I11Rik lnc_inter_chr1_274,1.1320152,1.1320152,0.52547459,0.50142835,1,6.1522084,6.1522084,0.080370513,0.54029399,0.033391053,1.9304699,1.9304699,0.39473704,0.85645119,1,2.5443999,2.5443999,1.4181904,2.7042186,0.84313657
NC_INTER_C13_11221,2.01,0,2.01,0,0,14.156293,,"[Minus], [# Lnc isoforms: 175], [# of exons: 17], [Gene type: lncRNA]","chr13:37,703,447-37,763,401",NM_183203 XR_873251 XR_873252,"AI463229, expressed sequence AI463229; CT009713.1, ; Gm40915, predicted gene, 40915; lnc_inter_chr13_11221,11222,11223,11224,11225,11227, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),AI463229 CT009713.1 Gm40915 lnc_inter_chr13_11221,2.0607745,2.0607745,0.64888792,1.2084916,1,2.3725414,2.3725414,0.72113731,1.715046,0.035113483,2.088782,2.088782,2.4573697,5.4970728,0.67909384,2.2197866,2.2197866,8.1165858,14.156293,0.28745779
NC_INTER_C10_18890,2.01,0,2.01,0,0,19.323688,,"[Minus], [# Lnc isoforms: 21], [# of exons: 2], [Gene type: lncRNA]","chr10:78,874,643-78,880,742",,"Gm47015, ; lnc_inter_chr10_18890, ",,Gm47015 lnc_inter_chr10_18890,2.4835138,2.4835138,0.17247331,0.39127946,1,4.0242414,4.0242414,2.9894904,13.026206,0.016861022,4.0877737,4.0877737,2.6943358,11.803909,0.057103149,3.2766473,3.2766473,7.7456228,19.323688,0.18678959
NC_INTER_C9_49383,2.01,0,2.01,0,0,369.74258,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr9:123,215,685-123,216,105",,"lnc_inter_chr9_49383, ",,lnc_inter_chr9_49383,1.570814,1.570814,128.04665,175.17787,1,2.3653884,2.3653884,63.213344,153.43437,0.036209423,2.7756102,2.7756102,126.26712,369.74258,0.51607149,1.8781484,1.8781484,109.02175,164.60701,1
NC_INTER_C2_1232,2.01,0,2.01,0,0,8.6962013,,"[Minus], [# Lnc isoforms: 2], [# of exons: 4], [Gene type: lncRNA]","chr2:34,917,566-34,924,259",,"lnc_inter_chr2_1232, ",,lnc_inter_chr2_1232,1.8361957,1.8361957,5.1821859,8.6962013,1,2.6961369,2.6961369,1.8161937,5.1818576,0.018588831,1.9057557,1.9057557,2.7993548,5.863835,1,2.2823361,2.2823361,2.8239895,4.7511729,0.60860023
NC_AS_C10_19571,2.01,0,2.01,0,0,2.414528,,"[Minus], [# Lnc isoforms: 60], [# of exons: 3], [Gene type: lncRNA]","chr10:122,962,519-122,973,358",,"lnc_as_chr10_19571, ",,lnc_as_chr10_19571,5.1342949,5.1342949,0.073243165,0.38087877,1,30.513858,30.5138582,0.02767935,0.86673537,0.039509394,19.902783,19.9027826,0.031259983,0.87231277,0.42134758,7.7130309,7.7130309,0.38151818,2.414528,0.86789031
NC_INTRA_C2_34452,2.01,0,2.01,0,0,155.81667,,"[Minus], [# Lnc isoforms: 6], [# of exons: 2], [Gene type: lncRNA]","chr2:134,369,863-134,371,985 chr2:134,372,061-134,373,425",,"lnc_intra_chr2_34452, ",,lnc_intra_chr2_34452,5.3259406,5.3259406,0.12020866,0.73007134,0.58165397,2.6034655,2.6034655,2.1293313,5.7583211,0.033391053,1.166528,1.166528,4.1060765,5.308253,1,1.9400716,1.9400716,105.40959,155.81667,0.87229258
SLC15A5,2.01,0,2.01,0,0,0.71752742,,"[Minus], [# of exons: 9], [Gene type: NM]","chr6:137,932,111-138,028,437",NM_177787,"Slc15a5, solute carrier family 15, member 5, solute carrier family 15 member 5, Predicted to have symporter activity. Predicted to be involved in protein transport and transmembrane transport. Predicted to localize to integral component of membrane. Orthologous to human SLC15A5 (solute carrier family 15 member 5).",protein transport (GO:0015031); symporter activity (GO:0015293); peptide transport (GO:0015833); membrane (GO:0016020); integral component of membrane (GO:0016021); transmembrane transporter activity (GO:0022857); transmembrane transport (GO:0055085),Slc15a5,2.8366371,2.8366371,0.07451319,0.18570156,1,4.4398081,4.4398081,0.041312207,0.1977564,0.028888629,3.2280205,3.2280205,0.072396049,0.22463544,1,2.393793,2.393793,0.4328525,0.71752742,0.98012422
NC_INTER_C10_18389,2.01,0,2.01,0,0,6.6723176,,"[Plus], [# Lnc isoforms: 12], [# of exons: 1], [Gene type: lncRNA]","chr10:41,164,237-41,165,335",,"lnc_inter_chr10_18389, ",,lnc_inter_chr10_18389,4.0053716,4.0053716,0.93441017,4.3833405,1,9.0014896,9.0014896,0.54671518,5.2683924,0.001576833,2.9426309,2.9426309,1.9796805,6.6723176,1,3.6282863,3.6282863,1.3492633,4.1268398,1
NC_INTER_C5_41044,2.01,0,2.01,0,0,15.075024,,"[Plus], [# Lnc isoforms: 13], [# of exons: 1], [Gene type: lncRNA]","chr5:122,645,968-122,650,151",,"lnc_inter_chr5_41044, ",,lnc_inter_chr5_41044,4.8401268,4.8401268,0.70319868,3.6647136,0.41741691,4.1909856,4.1909856,0.93622388,4.046506,0.01313085,2.4772537,2.4772537,2.4659804,6.5950021,0.57557671,1.4140343,1.4140343,13.608769,15.075024,1
NC_INTER_C11_9522,2.01,0,2.01,0,0,63.874723,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr11:19,620,623-19,621,013",,"lnc_inter_chr11_9522, ",,lnc_inter_chr11_9522,4.248612,4.248612,14.271929,63.874723,0.24045479,3.9625681,3.9625681,10.771825,43.561558,0.032981216,5.3440057,5.3440057,7.0043641,34.779475,0.2683999,1.2235847,1.2235847,6.0755077,5.8771905,1
NC_INTER_C18_31469,2.01,0,2.01,0,0,13.75448,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr18:70,974,408-70,975,347",,"lnc_inter_chr18_31469, ",,lnc_inter_chr18_31469,1,1,0,0,1,45.966862,45.9668621,0,2.5630803,0.03402958,5.5737447,5.5737447,0.54667167,3.8935069,1,2.3299698,2.3299698,6.9383604,13.75448,1
NC_INTER_C10_18562,2.01,0,2.01,0,0,43.545233,,"[Plus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr10:58,764,898-58,765,215",,"lnc_inter_chr10_18562, ",,lnc_inter_chr10_18562,6.1302342,6.1302342,1.9692959,9.3200825,1,7.5214979,7.5214979,2.8738775,23.626553,0.002921748,7.330135,7.330135,6.2384751,43.545233,0.35221387,5.3895201,5.3895201,7.9543389,36.681265,0.5071533
NUGGC,2.01,0,2.01,0,0,1.0406141,,"[Plus], [# of exons: 19], [Gene type: NM]","chr14:66,224,104-66,267,280",NM_001195674,"Nuggc, nuclear GTPase, germinal center associated, nuclear GTPase SLIP-GC|speckled-like pattern in the germinal center, Predicted to have GTPase activity. Involved in cellular response to DNA damage stimulus and somatic hypermutation of immunoglobulin genes. Localizes to nucleus. Orthologous to human NUGGC (nuclear GTPase, germinal center associated).",nucleotide binding (GO:0000166); GTPase activity (GO:0003924); GTP binding (GO:0005525); nucleus (GO:0005634); cellular response to DNA damage stimulus (GO:0006974); somatic hypermutation of immunoglobulin genes (GO:0016446); hydrolase activity (GO:0016787); regulation of nuclear cell cycle DNA replication (GO:0033262); negative regulation of apoptotic process (GO:0043066); cellular response to lipopolysaccharide (GO:0071222),Nuggc,2.8386769,2.8386769,0.16108501,0.3967363,0.9461153,5.306815,5.306815,0.090927659,0.52938162,5.44E-05,3.8373364,3.8373364,0.23198209,0.89432637,0.15055732,3.3631777,3.3631777,0.42714962,1.0406141,0.14636162
CAPN8,2.01,0,2.01,0,0,1.0012536,,"[Plus], [# of exons: 22], [Gene type: NM]","chr1:184,495,138-184,562,483",NM_001145806 NM_130890,"Capn8, calpain 8, calpain-8|new calpain 2|stomach-specific M-type calpain|stomach-specific calpain (nCL-2), Exhibits calcium-dependent cysteine-type endopeptidase activity and identical protein binding activity. Involved in calcium-dependent self proteolysis. Predicted to localize to cytoplasm. Is expressed in gut; liver; and male reproductive gland or organ. Orthologous to human CAPN8 (calpain 8).",calcium-dependent cysteine-type endopeptidase activity (GO:0004198); calcium ion binding (GO:0005509); cytoplasm (GO:0005737); Golgi apparatus (GO:0005794); proteolysis (GO:0006508); digestion (GO:0007586); peptidase activity (GO:0008233); cysteine-type peptidase activity (GO:0008234); hydrolase activity (GO:0016787); identical protein binding (GO:0042802); metal ion binding (GO:0046872); calcium-dependent self proteolysis (GO:1990092),Capn8,5.9277882,5.9277882,0.088945592,0.44523238,0.37719557,6.3806894,6.3806894,0.063874912,0.43623248,0.027835625,6.6196799,6.6196799,0.082762281,0.53287782,0.16147262,2.7260198,2.7260198,0.55419282,1.0012536,0.86605619
BHLHA15,2.01,0,2.01,0,0,1.0254021,,"[Plus], [# of exons: 2], [Gene type: NM]","chr5:144,951,155-144,955,310",NM_010800,"Bhlha15, basic helix-loop-helix family, member a15, class A basic helix-loop-helix protein 15|basic helix-loop-helix domain containing, class B, 8|muscle, intestine and stomach expression 1, Exhibits DNA-binding transcription activator activity, RNA polymerase II-specific; RNA polymerase II transcription regulatory region sequence-specific DNA binding activity; and identical protein binding activity. Involved in several processes, including cellular response to glucose starvation; intracellular distribution of mitochondria; and negative regulation of myotube differentiation. Localizes to nucleus. Is expressed in alimentary system; early conceptus; genitourinary system; and limb mesenchyme. Orthologous to human BHLHA15 (basic helix-loop-helix family member a15).","RNA polymerase II regulatory region sequence-specific DNA binding (GO:0000977); RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); RNA polymerase II transcription factor activity, sequence-specific DNA binding (GO:0000981); transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0001228); DNA binding (GO:0003677); nucleus (GO:0005634); regulation of transcription, DNA-templated (GO:0006355); regulation of transcription by RNA polymerase II (GO:0006357); mitochondrial calcium ion transmembrane transport (GO:0006851); Golgi organization (GO:0007030); G-protein coupled receptor signaling pathway (GO:0007186); cell-cell signaling (GO:0007267); negative regulation of myotube differentiation (GO:0010832); calcium-mediated signaling (GO:0019722); neuron differentiation (GO:0030182); endoplasmic reticulum unfolded protein response (GO:0030968); cellular response to glucose starvation (GO:0042149); glucose homeostasis (GO:0042593); identical protein binding (GO:0042802); positive regulation of transcription by RNA polymerase II (GO:0045944); protein dimerization activity (GO:0046983); intracellular distribution of mitochondria (GO:0048312); cell maturation (GO:0048469); sequence-specific double-stranded DNA binding (GO:1990837)",Bhlha15,2.1322053,2.1322053,0.35310031,0.6428776,1,12.330706,12.3307062,0.07220613,1.0254021,0.04286361,4.2214094,4.2214094,0.15420473,0.91609664,0.79872538,4.2268534,4.2268534,0.15594934,0.49449909,1
PROCA1,2.01,0,2.01,0,0,6.806084,,"[Plus], [# of exons: 5], [Gene type: NM]","chr11:78,006,894-78,019,265",NM_001045516 NM_001368876,"Proca1, protein interacting with cyclin A1, protein PROCA1, Predicted to have cyclin binding activity. Orthologous to human PROCA1 (protein interacting with cyclin A1).",cellular_component (GO:0005575); biological_process (GO:0008150); cyclin binding (GO:0030332),Proca1,2.394377,2.394377,0.86382919,1.7722993,1,3.6402542,3.6402542,0.42551387,1.6603987,0.007535052,2.6218546,2.6218546,0.63746966,1.7435058,0.28074874,2.0762947,2.0762947,4.48185,6.806084,0.78301697
NC_INTER_C5_4115,15.2222,1.2,2.02,4.002,8.0002,21.316716,,"[Minus], [# Lnc isoforms: 12], [# of exons: 1], [Gene type: lncRNA]","chr5:33,787,359-33,802,388",,"lnc_inter_chr5_4115, ",,lnc_inter_chr5_4115,0.022857427,-43.7494555,1.4325522,0.028677336,1.67E-11,0.043129276,-23.186107,2.2009066,0.086257135,3.32E-16,0.030598803,-32.6810165,2.3135986,0.068744889,1.56E-14,0.03544551,-28.2123177,21.316716,0.53438316,8.77E-09
NC_INTER_C3_2915,15.2222,1.2,2.02,4.002,8.0002,8.4810505,,"[Minus], [# Lnc isoforms: 13], [# of exons: 7], [Gene type: lncRNA]","chr3:133,451,906-133,496,105",NR_166483 XR_376100,"Gm30484, predicted gene, 30484; Gm6135, prediticted gene 6135; lnc_inter_chr3_2915, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Gm30484 Gm6135 lnc_inter_chr3_2915,0.065889165,-15.1770021,8.4810505,0.54682259,2.51E-09,0.12667367,-7.8943001,4.8552838,0.61185019,1.03E-05,0.11495973,-8.6986985,5.0176114,0.59969616,2.85E-05,0.13616489,-7.344037,1.9180207,0.21256103,0.001694477
NC_INTER_C5_41475,15.2222,1.2,2.02,4.002,8.0002,82.464255,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr5:146,196,477-146,196,799",,"lnc_inter_chr5_41475, ",,lnc_inter_chr5_41475,0.008523997,-117.3158616,59.787123,0.36436904,1.06E-06,0.020127219,-49.683962,24.821604,0.41748872,0.000327394,0.002186436,-457.365247,82.464255,0,5.14E-08,0.007049118,-141.8617172,52.755045,0,0.0005421
NC_INTRA_C5_4726,15.2222,1.2,2.02,4.002,8.0002,3.9908804,,"[Minus], [# Lnc isoforms: 38], [# of exons: 52], [Gene type: lncRNA]","chr5:146,226,308-146,226,683 chr5:146,227,188-146,227,208 chr5:146,229,177-146,229,231 chr5:146,230,593-146,319,532 chr5:146,323,914-146,324,392 chr5:146,335,032-146,336,839 chr5:146,339,071-146,339,906 chr5:146,339,930-146,339,963 chr5:146,340,359-146,340,499 chr5:146,340,650-146,340,820 chr5:146,341,713-146,341,912 chr5:146,344,231-146,344,351 chr5:146,345,600-146,505,623 chr5:146,508,580-146,508,705 chr5:146,510,490-146,510,513 chr5:146,510,584-146,510,730 chr5:146,525,333-146,525,839 chr5:146,526,032-146,526,088 chr5:146,526,261-146,526,274 chr5:146,531,713-146,585,558 chr5:146,588,483-146,588,574 chr5:146,588,653-146,588,893 chr5:146,600,955-146,600,990 chr5:146,611,428-146,611,489 chr5:146,611,898-146,612,002 chr5:146,612,433-146,612,450 chr5:146,617,451-146,666,182 chr5:146,667,435-146,667,609 chr5:146,668,573-146,668,646 chr5:146,669,166-146,669,283 chr5:146,670,753-146,670,818",,"lnc_intra_chr5_4726, ",,lnc_intra_chr5_4726,0.16512618,-6.0559748,0.94610739,0.13275079,0.012826292,0.15777672,-6.3380706,1.2511072,0.2110936,1.21E-06,0.16421727,-6.0894935,2.8015832,0.47942567,0.00027957,0.074229206,-13.4717863,3.9908804,0.23470459,3.60E-13
NC_AS_C7_6007,15.2222,1.2,2.02,4.002,8.0002,10.221358,,"[Minus], [# Lnc isoforms: 3], [# of exons: 4], [Gene type: lncRNA]","chr7:27,089,230-27,099,814",MT019822 MT019823 MT019824 MT019825 XR_881902,"Gm42375, predicted gene, 42375; lnc_as_chr7_6007, ",,Gm42375 lnc_as_chr7_6007,0.10922908,-9.155071,0.98368189,0.09916309,0.003649415,0.10282666,-9.7251042,2.8897228,0.31488427,4.24E-07,0.085081071,-11.7534957,3.0118084,0.27650838,7.06E-08,0.065517652,-15.2630623,10.221358,0.50516694,8.73E-07
NC_AS_C7_5999,15.2222,1.2,2.02,4.002,8.0002,3.2018042,,"[Minus], [# Lnc isoforms: 46], [# of exons: 25], [Gene type: lncRNA]","chr7:26,693,288-26,995,060",,"lnc_as_chr7_5999, ",,lnc_as_chr7_5999,0.098124669,-10.1911172,0.050897695,0.004585449,1.90E-05,0.041155216,-24.2982567,0.23421769,0.009037731,3.00E-23,0.040233632,-24.8548281,0.26527403,0.011321426,6.35E-15,0.033222681,-30.0999185,3.2018042,0.07844216,9.98E-25
H2-T9,15.2222,1.2,2.02,4.002,8.0002,141.04851,,"[Minus], [# of exons: 10], [Gene type: NM]","chr17:36,175,354-36,175,721 chr17:36,175,930-36,175,999 chr17:36,176,122-36,176,168 chr17:36,176,287-36,176,319 chr17:36,177,170-36,177,274 chr17:36,177,423-36,177,698 chr17:36,178,394-36,178,630 chr17:36,178,813-36,179,073 chr17:36,179,287-36,179,405 chr17:36,179,515-36,179,637",NM_010399,"H2-T9, histocompatibility 2, T region locus 9, Is expressed in several structures, including genitourinary system; gut; lung; musculoskeletal system; and thymus.",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),H2-T9,0.209049,-4.7835674,141.04851,29.228498,0.010796226,0.25602692,-3.9058393,122.23913,31.45459,0.000597476,0.26635722,-3.7543567,101.67859,28.00958,0.021082894,0.18215409,-5.4898575,56.629572,8.4696072,0.025595659
SLC22A26,15.2222,1.2,2.02,4.002,8.0002,25.57808,,"[Minus], [# of exons: 10], [Gene type: NM]","chr19:7,856,471-7,877,157",NM_146232,"Slc22a26, solute carrier family 22 (organic cation transporter), member 26, solute carrier family 22 member 9, Predicted to be involved in organic anion transport. Is expressed in liver and metanephros. Orthologous to human SLC22A25 (solute carrier family 22 member 25) and SLC22A9 (solute carrier family 22 member 9).",organic anion transport (GO:0015711),Slc22a26,0.009118339,-109.6690986,25.57808,0.21316257,4.81E-25,0.01977171,-50.5773152,12.633786,0.26371582,1.40E-42,0.013212229,-75.6874537,23.146533,0.32139773,4.81E-26,0.012770442,-78.3058253,15.941379,0.14272751,1.33E-22
SLC22A27,15.2222,1.2,2.02,4.002,8.0002,5.17603,,"[Minus], [# of exons: 11], [Gene type: NM]","chr19:7,938,879-7,980,618 chr19:7,984,183-7,984,351 chr19:7,984,441-7,984,595 chr19:8,000,348-8,000,451 chr19:8,000,859-8,001,301 chr19:8,040,452-8,040,517",NM_001361980 NM_134256,"Slc22a27, solute carrier family 22, member 27, solute carrier family 22 member 27|mOAT6 related protein|organic anion transporter 6|organic anion transporter 9, Predicted to have transmembrane transporter activity. Predicted to be involved in organic anion transport. Predicted to localize to integral component of membrane and plasma membrane. Is expressed in several structures, including genitourinary system; heart; liver; and lung. Orthologous to several human genes including SLC22A25 (solute carrier family 22 member 25) and SLC22A9 (solute carrier family 22 member 9).",plasma membrane (GO:0005886); organic anion transport (GO:0015711); membrane (GO:0016020); integral component of membrane (GO:0016021); transmembrane transporter activity (GO:0022857); transmembrane transport (GO:0055085),Slc22a27,0.035470511,-28.1924331,1.0596142,0.035562791,1.02E-11,0.045336143,-22.0574564,0.75454218,0.034878299,8.34E-25,0.042108075,-23.7484138,1.9365596,0.085368565,9.88E-22,0.038460737,-26.0005419,5.17603,0.15212884,3.26E-23
CYP3A41A,15.2222,1.2,2.02,4.002,8.0002,96.995011,,"[Minus], [# of exons: 13], [Gene type: NM]","chr5:146,505,624-146,506,177 chr5:146,509,713-146,509,875 chr5:146,511,302-146,511,528 chr5:146,513,704-146,513,864 chr5:146,516,367-146,516,436 chr5:146,517,326-146,517,453 chr5:146,520,033-146,520,181 chr5:146,520,453-146,520,541 chr5:146,520,621-146,520,734 chr5:146,525,090-146,525,189 chr5:146,527,046-146,527,098 chr5:146,529,501-146,529,594 chr5:146,531,555-146,531,712",NM_017396,"Cyp3a41a, cytochrome P450, family 3, subfamily a, polypeptide 41A, cytochrome P450 3A41|cytochrome P450, family 3, subfamily a, polypeptide 41|cytochrome P450, steroid inducible 3a41|steroid inducible, Predicted to have demethylase activity; retinoic acid 4-hydroxylase activity; and steroid hydroxylase activity. Involved in regulation of gene expression and response to bacterium. Predicted to localize to endoplasmic reticulum membrane. Human ortholog(s) of this gene implicated in B-lymphoblastic leukemia/lymphoma; acute lymphoblastic leukemia; chronic myeloid leukemia; essential hypertension; and familial Mediterranean fever. Orthologous to several human genes including CYP3A4 (cytochrome P450 family 3 subfamily A member 4) and CYP3A5 (cytochrome P450 family 3 subfamily A member 5).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); endoplasmic reticulum (GO:0005783); endoplasmic reticulum membrane (GO:0005789); steroid metabolic process (GO:0008202); steroid hydroxylase activity (GO:0008395); retinoic acid 4-hydroxylase activity (GO:0008401); response to bacterium (GO:0009617); regulation of gene expression (GO:0010468); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); heme binding (GO:0020037); demethylase activity (GO:0032451); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); testosterone 6-beta-hydroxylase activity (GO:0050649); aromatase activity (GO:0070330); oxidative demethylation (GO:0070989); estrogen 16-alpha-hydroxylase activity (GO:0101020)",Cyp3a41a,0.007193879,-139.0070577,96.995011,0.66372561,6.43E-24,0.014550413,-68.7265725,40.592601,0.63929617,4.58E-48,0.010841212,-92.2406099,82.195468,0.91276895,2.72E-28,0.00649748,-153.9058263,22.25265,0.10726574,5.06E-23
CYP3A41B,15.2222,1.2,2.02,4.002,8.0002,67.891063,,"[Minus], [# of exons: 13], [Gene type: NM]","chr5:146,319,533-146,320,086 chr5:146,323,616-146,323,778 chr5:146,325,206-146,325,432 chr5:146,327,576-146,327,736 chr5:146,330,240-146,330,309 chr5:146,331,200-146,331,327 chr5:146,333,912-146,334,060 chr5:146,334,332-146,334,420 chr5:146,334,500-146,334,613 chr5:146,338,965-146,339,064 chr5:146,340,921-146,340,973 chr5:146,343,384-146,343,477 chr5:146,345,438-146,345,599",NM_001105159,"Cyp3a41b, cytochrome P450, family 3, subfamily a, polypeptide 41B, cytochrome P450 3A41, Predicted to have demethylase activity; retinoic acid 4-hydroxylase activity; and steroid hydroxylase activity. Involved in response to bacterium. Predicted to localize to endoplasmic reticulum membrane.","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cellular_component (GO:0005575); endoplasmic reticulum (GO:0005783); endoplasmic reticulum membrane (GO:0005789); retinoic acid 4-hydroxylase activity (GO:0008401); response to bacterium (GO:0009617); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); heme binding (GO:0020037); demethylase activity (GO:0032451); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); testosterone 6-beta-hydroxylase activity (GO:0050649); aromatase activity (GO:0070330); estrogen 16-alpha-hydroxylase activity (GO:0101020)",Cyp3a41b,0.003215223,-311.0204625,61.011352,0.17119468,3.79E-27,0.008169445,-122.4073325,31.91641,0.28815161,4.69E-47,0.004559084,-219.3422952,67.891063,0.31935144,7.49E-32,0.000217476,-4598.211653,20.848706,0,8.67E-29
CYP3A44,15.2222,1.2,2.02,4.002,8.0002,51.963165,,"[Minus], [# of exons: 13], [Gene type: NM]","chr5:146,585,559-146,586,016 chr5:146,589,497-146,589,659 chr5:146,591,099-146,591,325 chr5:146,599,937-146,600,097 chr5:146,602,226-146,602,295 chr5:146,603,191-146,603,318 chr5:146,605,895-146,606,043 chr5:146,606,311-146,606,399 chr5:146,606,479-146,606,592 chr5:146,610,897-146,610,996 chr5:146,612,852-146,612,904 chr5:146,615,240-146,615,333 chr5:146,617,295-146,617,450",NM_177380,"Cyp3a44, cytochrome P450, family 3, subfamily a, polypeptide 44, cytochrome P450, family 3, subfamily a, polypeptide 44|cytochrome P450, 3a44, Predicted to have demethylase activity; retinoic acid 4-hydroxylase activity; and steroid hydroxylase activity. Predicted to be involved in oxidative demethylation and steroid metabolic process. Predicted to localize to endoplasmic reticulum membrane. Human ortholog(s) of this gene implicated in B-lymphoblastic leukemia/lymphoma; acute lymphoblastic leukemia; chronic myeloid leukemia; essential hypertension; and familial Mediterranean fever. Orthologous to several human genes including CYP3A4 (cytochrome P450 family 3 subfamily A member 4) and CYP3A5 (cytochrome P450 family 3 subfamily A member 5).",cellular_component (GO:0005575); endoplasmic reticulum membrane (GO:0005789); steroid metabolic process (GO:0008202); steroid hydroxylase activity (GO:0008395); retinoic acid 4-hydroxylase activity (GO:0008401); oxidoreductase activity (GO:0016491); demethylase activity (GO:0032451); intracellular membrane-bounded organelle (GO:0043231); testosterone 6-beta-hydroxylase activity (GO:0050649); aromatase activity (GO:0070330); oxidative demethylation (GO:0070989); estrogen 16-alpha-hydroxylase activity (GO:0101020),Cyp3a44,0.038501908,-25.9727389,51.963165,1.9161578,4.95E-07,0.072482724,-13.796391,23.568266,1.813847,1.52E-09,0.084670617,-11.8104726,47.040998,4.0062003,9.94E-06,0.030109552,-33.2120513,13.70806,0.32814623,2.83E-07
SYBU,15.2222,1.2,2.02,4.002,8.0002,8.9447773,,"[Minus], [# of exons: 13], [Gene type: NM]","chr15:44,503,402-44,619,609",NM_001032727 NM_001285840 NM_001285841 NM_001285842 NM_001285843 NM_001285844 NM_001358582 NM_001358583 NM_001358584 NM_176998 NM_178765,"Sybu, syntabulin (syntaxin-interacting), syntabulin|Golgi-localized syntaphilin-related protein|Golsyn/Syntabulin|syntaxin-1-binding protein, Predicted to have microtubule binding activity. Predicted to be involved in several processes, including axonal transport; positive regulation of insulin secretion involved in cellular response to glucose stimulus; and regulation of synaptic activity. Predicted to localize to several cellular components, including cytoplasmic microtubule; dense body; and vesicle. Is expressed in alimentary system; central nervous system; dorsal root ganglion; and sensory organ. Orthologous to human SYBU (syntabulin).",Golgi apparatus (GO:0005794); microtubule (GO:0005874); cytoplasmic microtubule (GO:0005881); microtubule binding (GO:0008017); membrane (GO:0016020); integral component of membrane (GO:0016021); syntaxin-1 binding (GO:0017075); kinesin binding (GO:0019894); axonal transport of mitochondrion (GO:0019896); vesicle (GO:0031982); positive regulation of insulin secretion involved in cellular response to glucose stimulus (GO:0035774); intracellular membrane-bounded organelle (GO:0043231); regulation of synaptic activity (GO:0060025); synapse maturation (GO:0060074); regulation of insulin secretion involved in cellular response to glucose stimulus (GO:0061178); dense body (GO:0097433); anterograde neuronal dense core vesicle transport (GO:1990048),Sybu,0.14358039,-6.9647395,0.16503585,0.021471729,0.000275946,0.059831237,-16.7136775,0.49201877,0.028171638,2.23E-12,0.072033666,-13.8823977,0.59142105,0.045137474,5.54E-07,0.08124461,-12.3085088,8.9447773,0.56437708,7.81E-11
MARCO,15.2222,1.2,2.02,4.002,8.0002,10.557405,,"[Minus], [# of exons: 17], [Gene type: NM]","chr1:122,371,115-122,401,601",NM_010766,"Marco, macrophage receptor with collagenous structure, macrophage receptor MARCO, Predicted to have G protein-coupled receptor binding activity; amyloid-beta binding activity; and cargo receptor activity. Involved in apoptotic cell clearance and endocytosis. Predicted to localize to cytoplasm and plasma membrane. Is expressed in spleen. Orthologous to human MARCO (macrophage receptor with collagenous structure).","amyloid-beta binding (GO:0001540); G-protein coupled receptor binding (GO:0001664); positive regulation of protein phosphorylation (GO:0001934); immune system process (GO:0002376); scavenger receptor activity (GO:0005044); collagen trimer (GO:0005581); intracellular (GO:0005622); cytoplasm (GO:0005737); plasma membrane (GO:0005886); endocytosis (GO:0006897); receptor-mediated endocytosis (GO:0006898); phagocytosis, engulfment (GO:0006911); adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway (GO:0007193); membrane (GO:0016020); integral component of membrane (GO:0016021); cargo receptor activity (GO:0038024); apoptotic cell clearance (GO:0043277); innate immune response (GO:0045087); positive regulation of ERK1 and ERK2 cascade (GO:0070374); amyloid-beta clearance (GO:0097242)",Marco,0.23757754,-4.2091521,3.5366354,0.74940308,0.00920881,0.22788405,-4.3881966,7.0195491,1.6434714,1.30E-06,0.21549145,-4.6405554,10.557405,2.3993015,0.000167263,0.25922579,-3.8576408,3.3656411,0.65667591,0.018039418
CUX2,15.2222,1.2,2.02,4.002,8.0002,20.115184,,"[Minus], [# of exons: 24], [Gene type: NM]","chr5:122,310,225-122,499,860",NM_001312908 NM_007804,"Cux2, cut-like homeobox 2, homeobox protein cut-like 2|homeobox protein Cux-2, Exhibits DNA-binding transcription repressor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Involved in several processes, including positive regulation of nervous system development; regulation of gene expression; and short-term memory. Localizes to nucleus. Is expressed in several structures, including 1st branchial arch; central nervous system; genitourinary system; limb; and sensory organ. Human ortholog(s) of this gene implicated in early infantile epileptic encephalopathy. Orthologous to human CUX2 (cut like homeobox 2).","negative regulation of transcription by RNA polymerase II (GO:0000122); RNA polymerase II regulatory region sequence-specific DNA binding (GO:0000977); RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); RNA polymerase II transcription factor activity, sequence-specific DNA binding (GO:0000981); transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0001227); DNA binding (GO:0003677); nucleus (GO:0005634); regulation of transcription, DNA-templated (GO:0006355); regulation of transcription by RNA polymerase II (GO:0006357); short-term memory (GO:0007614); positive regulation of gene expression (GO:0010628); sequence-specific DNA binding (GO:0043565); negative regulation of transcription, DNA-templated (GO:0045892); positive regulation of dendrite morphogenesis (GO:0050775); cognition (GO:0050890); positive regulation of synapse assembly (GO:0051965); positive regulation of dendritic spine morphogenesis (GO:0061003); cellular response to organic substance (GO:0071310); sequence-specific double-stranded DNA binding (GO:1990837); positive regulation of excitatory postsynaptic potential (GO:2000463)",Cux2,0.044936615,-22.2535675,0.3356454,0.013683832,9.38E-06,0.063524885,-15.7418624,1.0939649,0.079806625,4.35E-10,0.051308017,-19.4901316,0.74169984,0.04131421,2.18E-10,0.1000176,-9.9982407,20.115184,1.4813647,2.59E-05
PROM2,15.2222,1.2,2.02,4.002,8.0002,7.0176154,,"[Minus], [# of exons: 24], [Gene type: NM]","chr2:127,352,689-127,367,153",NM_138750 NM_178047,"Prom2, prominin 2, prominin-2|PROM-2|mPROML2|prominin-like protein 2|prominin-related protein, Predicted to have cholesterol binding activity. Predicted to be involved in several processes, including negative regulation of endocytosis; positive regulation of protein phosphorylation; and regulation of GTPase activity. Localizes to cell surface; plasma membrane; and prominosome. Predicted to colocalize with membrane raft. Is expressed in several structures, including alimentary system; brain; genitourinary system; lung; and naris epithelium. Orthologous to human PROM2 (prominin 2).",positive regulation of protein phosphorylation (GO:0001934); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); microvillus (GO:0005902); cilium (GO:0005929); cell surface (GO:0009986); cholesterol binding (GO:0015485); membrane (GO:0016020); integral component of membrane (GO:0016021); apical plasma membrane (GO:0016324); positive regulation of cell projection organization (GO:0031346); cytoplasmic vesicle (GO:0031410); cell projection (GO:0042995); regulation of GTPase activity (GO:0043087); microspike (GO:0044393); membrane raft (GO:0045121); negative regulation of pinocytosis (GO:0048550); prominosome (GO:0071914); negative regulation of caveolin-mediated endocytosis (GO:2001287),Prom2,0.074326772,-13.4541023,3.0905446,0.22371435,0.01653345,0.051100597,-19.5692431,4.8286523,0.28062687,6.08E-07,0.11270492,-8.872727,3.8540479,0.47176996,3.59E-06,0.06806195,-14.6924971,7.0176154,0.31278574,5.37E-06
PROM1,15.2222,1.2,2.02,4.002,8.0002,2.1391454,,"[Minus], [# of exons: 29], [Gene type: NM]","chr5:44,384,861-44,492,975",NM_001163577 NM_001163578 NM_001163581 NM_001163582 NM_001163583 NM_001163584 NM_001163585 NM_008935,"Prom1, prominin 1, prominin-1|antigen AC133 homolog|prominin-like 1|prominin-like protein 1, Predicted to have actinin binding activity; cadherin binding activity; and cholesterol binding activity. Involved in camera-type eye photoreceptor cell differentiation and retina layer formation. Localizes to several cellular components, including brush border; photoreceptor outer segment; and prominosome. Is expressed in several structures, including epithelium; eye; future hindbrain; genitourinary system; and nervous system. Used to study retinitis pigmentosa 41. Human ortholog(s) of this gene implicated in cone-rod dystrophy 12 and retinitis pigmentosa 41. Orthologous to human PROM1 (prominin 1).",photoreceptor outer segment (GO:0001750); extracellular space (GO:0005615); endoplasmic reticulum (GO:0005783); endoplasmic reticulum-Golgi intermediate compartment (GO:0005793); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); microvillus (GO:0005902); brush border (GO:0005903); cilium (GO:0005929); cell surface (GO:0009986); retina layer formation (GO:0010842); cholesterol binding (GO:0015485); membrane (GO:0016020); integral component of membrane (GO:0016021); apical plasma membrane (GO:0016324); stereocilium (GO:0032420); photoreceptor outer segment membrane (GO:0042622); actinin binding (GO:0042805); cell projection (GO:0042995); cadherin binding (GO:0045296); photoreceptor cell maintenance (GO:0045494); retina morphogenesis in camera-type eye (GO:0060042); camera-type eye photoreceptor cell differentiation (GO:0060219); extracellular exosome (GO:0070062); prominosome (GO:0071914); glomerular visceral epithelial cell differentiation (GO:0072112); glomerular parietal epithelial cell differentiation (GO:0072139); positive regulation of nephron tubule epithelial cell differentiation (GO:2000768),Prom1,0.062063999,-16.1124004,0.62822951,0.037642512,1.71E-05,0.13606529,-7.3494132,0.8651772,0.11039648,2.14E-06,0.15952238,-6.2687129,1.3046882,0.21604957,0.00013173,0.12301629,-8.1290049,2.1391454,0.20257329,0.00075369
NAT8F7,15.2222,1.2,2.02,4.002,8.0002,52.896208,,"[Minus], [# of exons: 2], [Gene type: NM]","chr6:85,656,701-85,658,555",NM_001253910,"Nat8f7, N-acetyltransferase 8 (GCN5-related) family member 7, N-acetyltransferase family 8 member 7|Camello-like protein 3|N-acetyltransferase CML3|N-acetyltransferase family 8 member 3|camello-like 3-like, Exhibits H4 histone acetyltransferase activity. Involved in histone acetylation. Localizes to nuclear membrane. Orthologous to human NAT8 (N-acetyltransferase 8 (putative)).",nucleus (GO:0005634); N-acetyltransferase activity (GO:0008080); H4 histone acetyltransferase activity (GO:0010485); histone acetylation (GO:0016573); nuclear membrane (GO:0031965),Nat8f7,0.11667144,-8.5710779,52.896208,5.459919,7.61E-06,0.21042816,-4.7522157,47.012764,10.878551,8.71E-05,0.24353373,-4.1062074,42.296145,10.63621,0.000288789,0.27104791,-3.6893847,41.683016,8.5230058,0.024542897
SULT3A2,15.2222,1.2,2.02,4.002,8.0002,20.062257,,"[Minus], [# of exons: 6], [Gene type: NM]","chr10:33,486,230-33,501,921",NM_001101452,"Sult3a2, sulfotransferase family 3A, member 2, uncharacterized protein LOC215895, Predicted to have sulfotransferase activity. Predicted to be involved in sulfation. Predicted to localize to cytoplasm.",cytoplasm (GO:0005737); sulfotransferase activity (GO:0008146); sulfation (GO:0051923),Sult3a2,0.013299701,-75.1896597,5.3249703,0.06725683,3.55E-09,0.033039249,-30.2670318,3.0763959,0.11014275,7.83E-08,0.007017797,-142.494868,6.8931631,0.044986949,2.86E-16,0.0117642,-85.0036573,20.062257,0.2100309,5.13E-09
SULT2A1,15.2222,1.2,2.02,4.002,8.0002,14.703602,,"[Minus], [# of exons: 6], [Gene type: NM]","chr7:14,381,595-14,383,624 chr7:14,386,731-14,386,908 chr7:14,389,379-14,389,473 chr7:14,417,926-14,418,052 chr7:14,421,310-14,421,518 chr7:14,422,570-14,422,759",NM_001111296,"Sult2a1, sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 1, sulfotransferase 2A1|ST|bile salt sulfotransferase 1|hydroxysteroid sulfotransferase|sulfotransferase, DHEA preferring|sulfotransferase, hydroxysteroid preferring 1, Exhibits alcohol sulfotransferase activity and steroid sulfotransferase activity. Involved in steroid metabolic process and sulfation. Predicted to localize to cytosol. Is expressed in alimentary system and heart. Human ortholog(s) of this gene implicated in prostate cancer. Orthologous to human SULT2A1 (sulfotransferase family 2A member 1).",alcohol sulfotransferase activity (GO:0004027); cytoplasm (GO:0005737); cytosol (GO:0005829); lipid metabolic process (GO:0006629); sulfotransferase activity (GO:0008146); steroid metabolic process (GO:0008202); transferase activity (GO:0016740); bile-salt sulfotransferase activity (GO:0047704); steroid sulfotransferase activity (GO:0050294); 3'-phosphoadenosine 5'-phosphosulfate binding (GO:0050656); sulfation (GO:0051923),Sult2a1,0.007621425,-131.2090575,14.703602,0.096717511,7.43E-14,0.022095756,-45.257559,5.9553855,0.15154297,1.12E-17,0.007059263,-141.6578514,9.7473338,0.072576266,1.48E-22,0.020832236,-48.002528,6.7949535,0.097191865,3.04E-13
SULT2A3,15.2222,1.2,2.02,4.002,8.0002,0.46578162,,"[Minus], [# of exons: 6], [Gene type: NM]","chr7:14,652,904-14,653,016 chr7:14,655,202-14,708,397",NM_001101586,"Sult2a3, sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 3, sulfotransferase family 2A member 1 family member, Predicted to have 3'-phosphoadenosine 5'-phosphosulfate binding activity and sulfotransferase activity. Predicted to be involved in sulfation. Predicted to localize to cytosol. Human ortholog(s) of this gene implicated in prostate cancer. Orthologous to human SULT2A1 (sulfotransferase family 2A member 1).",alcohol sulfotransferase activity (GO:0004027); cytoplasm (GO:0005737); cytosol (GO:0005829); sulfotransferase activity (GO:0008146); transferase activity (GO:0016740); bile-salt sulfotransferase activity (GO:0047704); steroid sulfotransferase activity (GO:0050294); 3'-phosphoadenosine 5'-phosphosulfate binding (GO:0050656); sulfation (GO:0051923),Sult2a3,0.006431029,-155.4961226,0.4376891,0.001902098,3.34E-09,0.061072626,-16.3739479,0.18610727,0.010703894,0.000118887,0.013140833,-76.0986752,0.30490321,0.002948811,5.83E-11,0.064402874,-15.5272575,0.46578162,0.018472101,0.003341224
SULT2A4,15.2222,1.2,2.02,4.002,8.0002,0.93578678,,"[Minus], [# of exons: 6], [Gene type: NM]","chr7:14,495,026-14,495,247 chr7:14,500,487-14,500,664 chr7:14,517,022-14,517,116 chr7:14,570,197-14,570,323 chr7:14,573,546-14,573,754 chr7:14,574,805-14,574,937",NM_001101534,"Sult2a4, sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 4, sulfotransferase family member-like, Predicted to have 3'-phosphoadenosine 5'-phosphosulfate binding activity and sulfotransferase activity. Predicted to be involved in sulfation. Predicted to localize to cytosol.",alcohol sulfotransferase activity (GO:0004027); cytoplasm (GO:0005737); cytosol (GO:0005829); sulfotransferase activity (GO:0008146); transferase activity (GO:0016740); bile-salt sulfotransferase activity (GO:0047704); steroid sulfotransferase activity (GO:0050294); 3'-phosphoadenosine 5'-phosphosulfate binding (GO:0050656); sulfation (GO:0051923),Sult2a4,0.005106912,-195.8130523,0.93578678,0.003925177,1.93E-13,0.020541978,-48.6808033,0.46969018,0.009115423,5.25E-18,0.008206245,-121.858411,0.85187694,0.006785697,4.52E-21,0.010837894,-92.2688524,0.54810828,0.00405902,5.83E-11
SULT2A6,15.2222,1.2,2.02,4.002,8.0002,3.1015904,,"[Minus], [# of exons: 6], [Gene type: NM]","chr7:14,807,752-14,840,219",NM_001081325,"Sult2a6, sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 6, sulfotransferase family 2A member 1 family member, Predicted to have 3'-phosphoadenosine 5'-phosphosulfate binding activity and sulfotransferase activity. Predicted to be involved in sulfation. Predicted to localize to cytosol. Human ortholog(s) of this gene implicated in prostate cancer. Orthologous to human SULT2A1 (sulfotransferase family 2A member 1).",alcohol sulfotransferase activity (GO:0004027); cytoplasm (GO:0005737); cytosol (GO:0005829); sulfotransferase activity (GO:0008146); transferase activity (GO:0016740); bile-salt sulfotransferase activity (GO:0047704); steroid sulfotransferase activity (GO:0050294); 3'-phosphoadenosine 5'-phosphosulfate binding (GO:0050656); sulfation (GO:0051923),Sult2a6,0.009461517,-105.6912976,3.1015904,0.026002424,3.52E-14,0.023894651,-41.8503709,1.4461252,0.035793664,8.12E-18,0.004202262,-237.9670735,2.866516,0.011661487,6.00E-22,0.02648952,-37.7507783,2.6887481,0.053374853,1.01E-10
A1BG,15.2222,1.2,2.02,4.002,8.0002,4643.7854,,"[Minus], [# of exons: 7], [Gene type: NM]","chr15:60,749,144-60,752,825",NM_001081067,"A1bg, alpha-1-B glycoprotein, alpha-1B-glycoprotein, Predicted to localize to extracellular region. Orthologous to human A1BG (alpha-1-B glycoprotein).",molecular_function (GO:0003674); extracellular region (GO:0005576); biological_process (GO:0008150),A1bg,0.002499329,-400.1074598,4437.9714,9.4847039,8.82E-27,0.003638119,-274.8673144,4643.7854,18.529163,5.50E-43,0.002925992,-341.7644073,3881.126,11.391261,7.90E-27,0.004438973,-225.2773301,989.24528,3.6822609,7.41E-16
ATP6V0D2,15.2222,1.2,2.02,4.002,8.0002,6.1833133,,"[Minus], [# of exons: 8], [Gene type: NM]","chr4:19,803,985-19,849,713",NM_175406,"Atp6v0d2, ATPase, H+ transporting, lysosomal V0 subunit D2, V-type proton ATPase subunit d 2|V-ATPase subunit d 2|osteoclast-specific vacuolar ATP synthase|vacuolar proton pump subunit d 2|vacuolar proton-translocating ATPase d subunit d2, Predicted to have proton-transporting ATPase activity, rotational mechanism. Predicted to be involved in vacuolar acidification and vacuolar transport. Localizes to early endosome. Is expressed in several structures, including alimentary system; cochlea; limb; respiratory system; and skeleton. Orthologous to human ATP6V0D2 (ATPase H+ transporting V0 subunit d2).","endosome (GO:0005768); early endosome (GO:0005769); ion transport (GO:0006811); vacuolar transport (GO:0007034); vacuolar acidification (GO:0007035); proton transmembrane transporter activity (GO:0015078); membrane (GO:0016020); apical plasma membrane (GO:0016324); vacuolar proton-transporting V-type ATPase complex (GO:0016471); proton-transporting V-type ATPase, V0 domain (GO:0033179); plasma membrane proton-transporting V-type ATPase complex (GO:0033181); proton-transporting ATPase activity, rotational mechanism (GO:0046961); proton transmembrane transport (GO:1902600)",Atp6v0d2,0.1013317,-9.8685799,1.2492559,0.12331967,2.23E-05,0.15274409,-6.5468982,0.69849777,0.12026303,0.001810488,0.12153386,-8.2281597,1.7437546,0.22884938,5.92E-05,0.14165849,-7.0592312,6.1833133,0.59148099,0.003209796
CYP2C40,15.2222,1.2,2.02,4.002,8.0002,66.142915,,"[Minus], [# of exons: 9], [Gene type: NM]","chr19:39,841,563-39,841,980 chr19:39,848,314-39,848,455 chr19:39,852,404-39,852,591 chr19:39,861,249-39,861,390 chr19:39,876,970-39,877,146 chr19:39,878,260-39,878,420 chr19:39,881,656-39,881,805 chr19:39,882,005-39,882,167 chr19:39,887,045-39,887,304",NM_010004,"Cyp2c40, cytochrome P450, family 2, subfamily c, polypeptide 40, cytochrome P450 2C40|CYPIIC40|cytochrome P450, 2c40, Exhibits arachidonic acid 14,15-epoxygenase activity. Predicted to be involved in epoxygenase P450 pathway; exogenous drug catabolic process; and xenobiotic metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Is expressed in embryo; liver; and metanephros. Human ortholog(s) of this gene implicated in several diseases, including eosinophilic esophagitis; glucose metabolism disease (multiple); multiple myeloma; sickle cell anemia; and warfarin resistance. Orthologous to human CYP2C19 (cytochrome P450 family 2 subfamily C member 19) and CYP2C9 (cytochrome P450 family 2 subfamily C member 9).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); lipid metabolic process (GO:0006629); xenobiotic metabolic process (GO:0006805); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); arachidonic acid 14,15-epoxygenase activity (GO:0008404); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872)",Cyp2c40,0.076395468,-13.0897818,55.720365,3.5477158,2.41E-08,0.12894756,-7.7550904,31.518573,4.2832591,4.78E-22,0.11005545,-9.086329,66.142915,7.5748208,3.44E-13,0.11438683,-8.7422651,25.120329,2.3165549,1.72E-05
CYP2C69,15.2222,1.2,2.02,4.002,8.0002,54.104322,,"[Minus], [# of exons: 9], [Gene type: NM]","chr19:39,917,150-39,917,566 chr19:39,923,836-39,923,977 chr19:39,925,519-39,925,706 chr19:39,934,306-39,934,447 chr19:39,950,704-39,950,880 chr19:39,951,996-39,952,156 chr19:39,955,583-39,955,732 chr19:39,955,936-39,956,098 chr19:39,961,030-39,961,259",NM_001104525,"Cyp2c69, cytochrome P450, family 2, subfamily c, polypeptide 69, Predicted to have heme binding activity and monooxygenase activity. Predicted to be involved in epoxygenase P450 pathway; exogenous drug catabolic process; and xenobiotic metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in several diseases, including eosinophilic esophagitis; glucose metabolism disease (multiple); multiple myeloma; sickle cell anemia; and warfarin resistance. Orthologous to human CYP2C19 (cytochrome P450 family 2 subfamily C member 19) and CYP2C9 (cytochrome P450 family 2 subfamily C member 9).","cytoplasm (GO:0005737); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231)",Cyp2c69,0.024317112,-41.1233053,50.371406,1.1202312,1.95E-16,0.044207998,-22.6203412,24.746706,1.214762,4.30E-29,0.039347669,-25.4144662,54.104322,2.1990669,9.78E-21,0.021732556,-46.0139163,23.083176,0.39430127,8.77E-09
ECI3,15.2222,1.2,2.02,4.002,8.0002,8.8062603,,"[Minus], [# of exons: 9], [Gene type: NM]","chr13:35,038,483-35,055,678",NM_026947,"Eci3, enoyl-Coenzyme A delta isomerase 3, enoyl-CoA delta isomerase 3, peroxisomal|D3,D2-enoyl-CoA isomerase|delta(3),delta(2)-enoyl-CoA isomerase|dodecenoyl-CoA isomerase|kidney specific expressed protein 2, Exhibits dodecenoyl-CoA delta-isomerase activity. Predicted to be involved in fatty acid beta-oxidation. Localizes to peroxisome. Orthologous to human ECI2 (enoyl-CoA delta isomerase 2).",fatty-acyl-CoA binding (GO:0000062); catalytic activity (GO:0003824); dodecenoyl-CoA delta-isomerase activity (GO:0004165); peroxisome (GO:0005777); fatty acid beta-oxidation (GO:0006635); isomerase activity (GO:0016853),Eci3,0.231044,-4.3281798,2.8107315,0.56232473,0.00737549,0.34560235,-2.8934988,2.4799526,0.83777095,0.023400098,0.2148204,-4.6550515,3.922063,0.89393598,3.58E-05,0.12329018,-8.1109458,8.8062603,0.84512839,1.48E-06
FMO2,15.2222,1.2,2.02,4.002,8.0002,39.566469,,"[Minus], [# of exons: 9], [Gene type: NM]","chr1:164,804,449-164,828,889",NM_001360913 NM_001360914 NM_018881,"Fmo2, flavin containing monooxygenase 2, dimethylaniline monooxygenase [N-oxide-forming] 2|FMO 2|dimethylaniline oxidase 2|pulmonary flavin-containing monooxygenase 2, Exhibits monooxygenase activity. Involved in oxygen metabolic process. Predicted to localize to membrane. Is expressed in several structures, including alimentary system; limb; mesothelium; metanephros; and nose. Orthologous to human FMO2 (flavin containing dimethylaniline monoxygenase 2).","monooxygenase activity (GO:0004497); N,N-dimethylaniline monooxygenase activity (GO:0004499); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); NADP metabolic process (GO:0006739); xenobiotic metabolic process (GO:0006805); toxin metabolic process (GO:0009404); membrane (GO:0016020); integral component of membrane (GO:0016021); oxidoreductase activity (GO:0016491); drug metabolic process (GO:0017144); intracellular membrane-bounded organelle (GO:0043231); flavin adenine dinucleotide binding (GO:0050660); NADP binding (GO:0050661); NADPH oxidation (GO:0070995); oxygen metabolic process (GO:0072592)",Fmo2,0.13318979,-7.5080828,3.1660531,0.42345772,5.47E-05,0.21787834,-4.5897173,3.1333632,0.74919625,3.48E-05,0.25549504,-3.9139704,7.7968807,2.1443596,0.004461958,0.19165552,-5.2176948,39.566469,5.7614856,0.000250518
FMO3,15.2222,1.2,2.02,4.002,8.0002,426.63754,,"[Minus], [# of exons: 9], [Gene type: NM]","chr1:164,883,930-164,914,659",NM_008030,"Fmo3, flavin containing monooxygenase 3, dimethylaniline monooxygenase [N-oxide-forming] 3|dimethylaniline oxidase 3|hepatic flavin-containing monooxygenase 3|trimethylamine monooxygenase, Predicted to have N,N-dimethylaniline monooxygenase activity; NADP binding activity; and amino acid binding activity. Predicted to be involved in drug metabolic process. Predicted to localize to intracellular membrane-bounded organelle. Is expressed in central nervous system and retina. Human ortholog(s) of this gene implicated in hypertension; inherited metabolic disorder; and trimethylaminuria. Orthologous to human FMO3 (flavin containing dimethylaniline monoxygenase 3).","monooxygenase activity (GO:0004497); N,N-dimethylaniline monooxygenase activity (GO:0004499); endoplasmic reticulum (GO:0005783); membrane (GO:0016020); integral component of membrane (GO:0016021); oxidoreductase activity (GO:0016491); amino acid binding (GO:0016597); drug metabolic process (GO:0017144); trimethylamine monooxygenase activity (GO:0034899); intracellular membrane-bounded organelle (GO:0043231); flavin adenine dinucleotide binding (GO:0050660); NADP binding (GO:0050661)",Fmo3,0.002753018,-363.2376718,51.058582,0.12393794,3.96E-42,0.003795304,-263.4835244,44.558265,0.17505991,2.06E-98,0.003773051,-265.0374805,91.164281,0.36733761,8.97E-56,0.001070362,-934.2631295,426.63754,0.34615021,9.04E-54
H2-T22,15.2222,1.2,2.02,4.002,8.0002,108.20412,,"[Minus], [# of exons: 9], [Gene type: NM]","chr17:36,174,073-36,175,721 chr17:36,175,930-36,175,999 chr17:36,176,122-36,176,168 chr17:36,176,287-36,176,319 chr17:36,177,170-36,177,274 chr17:36,177,423-36,177,698 chr17:36,178,394-36,178,630 chr17:36,178,813-36,179,073 chr17:36,179,287-36,179,687",NM_001347382 NM_001359754 NM_001359755 NM_001359756 NM_010397,"H2-T22, histocompatibility 2, T region locus 22, histocompatibility 2, T region locus 22|MHC classIb T22|histocompatibility 2, T region locus 17, Predicted to have peptide antigen binding activity and signaling receptor binding activity. Predicted to be involved in several processes, including antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent; antigen processing and presentation of endogenous peptide antigen via MHC class Ib; and positive regulation of T cell mediated cytotoxicity. Predicted to localize to external side of plasma membrane and extracellular space. Is expressed in several structures, including genitourinary system; gut; respiratory system; sensory organ; and skeleton. Human ortholog(s) of this gene implicated in asthma; hepatitis C; and occupational asthma. Orthologous to human HLA-E (major histocompatibility complex, class I, E); HLA-F (major histocompatibility complex, class I, F); and HLA-G (major histocompatibility complex, class I, G).","positive regulation of T cell mediated cytotoxicity (GO:0001916); antigen processing and presentation of endogenous peptide antigen via MHC class Ib (GO:0002476); antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent (GO:0002486); signaling receptor binding (GO:0005102); extracellular space (GO:0005615); immune response (GO:0006955); external side of plasma membrane (GO:0009897); peptide antigen binding (GO:0042605)",H2-T22,0.20972954,-4.7680456,108.20412,22.471675,0.010495149,0.25468655,-3.926395,96.12607,24.609749,0.000626154,0.2626684,-3.8070815,80.151724,21.784469,0.017185963,0.1572524,-6.3592035,66.281356,8.5053751,0.009281019
NC_INTER_C6_42004,15.2222,1.2,2.02,4.002,8.0002,6.1389773,,"[Plus], [# Lnc isoforms: 10], [# of exons: 11], [Gene type: lncRNA]","chr6:34,129,082-34,164,221",XR_868963,"Gm13855, predicted gene 13855; lnc_inter_chr6_42004, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Gm13855 lnc_inter_chr6_42004,0.1000758,-9.9924254,1.0492807,0.095539103,6.36E-08,0.13146744,-7.6064459,0.88146361,0.12014656,1.39E-07,0.1131731,-8.8360223,1.2456594,0.14887793,1.52E-05,0.080364372,-12.443325,6.1389773,0.35985511,7.80E-07
NC_AS_C5_4727,15.2222,1.2,2.02,4.002,8.0002,7.9635267,,"[Plus], [# Lnc isoforms: 120], [# of exons: 78], [Gene type: lncRNA]","chr5:146,226,443-146,670,296",,"lnc_as_chr5_4727, ",,lnc_as_chr5_4727,0.10109934,-9.8912618,0.10360326,0.009821241,8.26E-06,0.07979312,-12.5324088,0.35492952,0.029855987,1.12E-17,0.057733747,-17.3208922,0.85159216,0.052829919,1.77E-10,0.015820872,-63.2076427,7.9635267,0.092308871,3.49E-39
NC_AS_C1_757,15.2222,1.2,2.02,4.002,8.0002,2.4932498,,"[Plus], [# Lnc isoforms: 14], [# of exons: 13], [Gene type: lncRNA]","chr1:164,913,257-164,997,319",,"Gm37273, ; lnc_as_chr1_757,754,755,756, ",,Gm37273 lnc_as_chr1_757,0.073870111,-13.5372748,0.062145711,0.003695729,0.021214431,0.028009773,-35.7018244,0.076985904,0.001934966,3.64E-06,0.027803697,-35.9664397,0.090289569,0.001946639,0.000173277,0.030105549,-33.2164682,2.4932498,0.051932161,2.93E-14
NC_INTER_C13_11602,15.2222,1.2,2.02,4.002,8.0002,3.2759514,,"[Plus], [# Lnc isoforms: 25], [# of exons: 16], [Gene type: lncRNA]","chr13:94,309,526-94,356,937",,"lnc_inter_chr13_11602, ",,lnc_inter_chr13_11602,0.070315921,-14.2215302,0.075034479,0.004389525,0.029038649,0.070973446,-14.0897766,0.18053487,0.010288446,0.030320325,0.036255423,-27.5820807,0.21868293,0.00797881,9.16E-05,0.048037302,-20.8171556,3.2759514,0.10528956,3.62E-05
NC_INTRA_C7_6001,15.2222,1.2,2.02,4.002,8.0002,3.0870944,,"[Plus], [# Lnc isoforms: 35], [# of exons: 8], [Gene type: lncRNA]","chr7:26,855,254-26,855,468 chr7:26,881,216-26,958,427 chr7:26,965,136-26,965,199",,"lnc_intra_chr7_6001, ",,lnc_intra_chr7_6001,0.023126109,-43.2411699,0.47520299,0.009867327,1.23E-16,0.021523319,-46.4612365,0.81085068,0.016229294,9.15E-17,0.032602171,-30.6728041,1.0626765,0.036461478,1.37E-13,0.035997647,-27.7795932,3.0870944,0.085272312,6.92E-15
NC_INTER_C6_5138,15.2222,1.2,2.02,4.002,8.0002,10.776651,,"[Plus], [# Lnc isoforms: 38], [# of exons: 1], [Gene type: lncRNA]","chr6:51,650,981-51,661,369",,"lnc_inter_chr6_5138, ",,lnc_inter_chr6_5138,0.062326019,-16.0446635,0.57233276,0.029618397,0.006594882,0.045614846,-21.922687,2.432025,0.10938038,1.34E-09,0.12077723,-8.2797064,2.1765953,0.26702685,0.000881208,0.05923066,-16.883148,10.776651,0.47588348,2.45E-09
NC_INTER_C10_18328,15.2222,1.2,2.02,4.002,8.0002,114.18962,,"[Plus], [# Lnc isoforms: 3], [# of exons: 3], [Gene type: lncRNA]","chr10:33,614,062-33,624,483",,"lnc_inter_chr10_18328, ",,lnc_inter_chr10_18328,0.047226697,-21.1744641,0.32010254,0.009841535,0.027734983,0.004600545,-217.3655364,6.15347,0.020799567,4.81E-13,0.010327087,-96.8327319,12.117483,0.12466642,4.26E-15,0.002974765,-336.1610187,114.18962,0.25374112,4.49E-13
NC_AS_C19_14740,15.2222,1.2,2.02,4.002,8.0002,14.963347,,"[Plus], [# Lnc isoforms: 4], [# of exons: 7], [Gene type: lncRNA]","chr19:5,406,815-5,422,847",NR_027940,"4930481A15Rik, RIKEN cDNA 4930481A15 gene; lnc_as_chr19_14740, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),4930481A15Rik lnc_as_chr19_14740,0.049428927,-20.2310684,1.4114091,0.064344766,0.000225808,0.081745003,-12.2331637,2.3694739,0.25688324,0.011337278,0.022783351,-43.8917,2.640016,0.061365465,9.64E-05,0.059531653,-16.7977866,14.963347,0.56271468,0.000508381
ACOT3,15.2222,1.2,2.02,4.002,8.0002,37.883236,,"[Plus], [# of exons: 4], [Gene type: NM]","chr12:85,393,094-85,401,350",NM_001346701 NM_134246,"Acot3, acyl-CoA thioesterase 3, acyl-coenzyme A thioesterase 3|peroxisomal acyl-CoA thioesterase 2A|peroxisomal acyl-coenzyme A thioester hydrolase 2a|peroxisomal long-chain acyl-CoA thioesterase 2, Exhibits acyl-CoA hydrolase activity. Involved in acyl-CoA metabolic process; monocarboxylic acid metabolic process; and saturated monocarboxylic acid metabolic process. Localizes to cytosol and peroxisome. Is expressed in several structures, including alimentary system; brain; genitourinary system; integumental system; and respiratory system. Orthologous to human ACOT1 (acyl-CoA thioesterase 1).",very long-chain fatty acid metabolic process (GO:0000038); long-chain fatty acid metabolic process (GO:0001676); peroxisome (GO:0005777); cytosol (GO:0005829); lipid metabolic process (GO:0006629); fatty acid metabolic process (GO:0006631); acyl-CoA metabolic process (GO:0006637); palmitoyl-CoA hydrolase activity (GO:0016290); hydrolase activity (GO:0016787); thiolester hydrolase activity (GO:0016790); saturated monocarboxylic acid metabolic process (GO:0032788); unsaturated monocarboxylic acid metabolic process (GO:0032789); acyl-CoA hydrolase activity (GO:0047617); carboxylic ester hydrolase activity (GO:0052689); myristoyl-CoA hydrolase activity (GO:0102991),Acot3,0.064151465,-15.5881084,37.883236,2.4651259,1.50E-06,0.069141803,-14.4630303,29.652593,2.1257544,8.24E-11,0.080650391,-12.3991959,27.693272,2.4100032,2.75E-05,0.10410641,-9.6055563,19.064917,1.5779462,0.00102112
SULT2A2,15.2222,1.2,2.02,4.002,8.0002,7.604032,,"[Plus], [# of exons: 4], [Gene type: NM]","chr7:14,318,855-14,319,043 chr7:14,320,096-14,320,304 chr7:14,323,574-14,323,700 chr7:14,364,771-14,364,986",NM_009286,"Sult2a2, sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 2, bile salt sulfotransferase 2|hydroxysteroid sulfotransferase|sulfotransferase 2A2|sulfotransferase, hydroxysteroid preferring 2, Predicted to have sulfotransferase activity. Predicted to be involved in sulfation. Predicted to localize to cytoplasm. Human ortholog(s) of this gene implicated in prostate cancer. Orthologous to human SULT2A1 (sulfotransferase family 2A member 1).",cytoplasm (GO:0005737); lipid metabolic process (GO:0006629); sulfotransferase activity (GO:0008146); steroid metabolic process (GO:0008202); transferase activity (GO:0016740); bile-salt sulfotransferase activity (GO:0047704); sulfation (GO:0051923),Sult2a2,0.004868489,-205.4025253,7.604032,0.034187499,2.51E-23,0.018876383,-52.976252,3.2214092,0.067828899,1.98E-23,0.006570954,-152.184909,4.5755202,0.028392343,1.00E-33,0.010461772,-95.5861025,3.1328087,0.024532153,2.69E-18
RSPH4A,15.2222,1.2,2.02,4.002,8.0002,4.4735041,,"[Plus], [# of exons: 6], [Gene type: NM]","chr10:33,624,917-33,635,827",NM_001162957,"Rsph4a, radial spoke head 4 homolog A (Chlamydomonas), radial spoke head protein 4 homolog A|radial spoke head-like protein 3|radial spokehead-like 3, Involved in maintenance of ciliary planar beating movement pattern and radial spoke assembly. Localizes to radial spoke head. Is expressed in lateral ventricle choroid plexus; lung epithelium; metencephalon part of 4th ventricle choroid plexus; and nasal cavity respiratory epithelium. Human ortholog(s) of this gene implicated in primary ciliary dyskinesia 11. Orthologous to human RSPH4A (radial spoke head component 4A).",radial spoke (GO:0001534); radial spoke head (GO:0001535); cilium movement (GO:0003341); protein binding (GO:0005515); nucleoplasm (GO:0005654); nucleolus (GO:0005730); cytoplasm (GO:0005737); cytoskeleton (GO:0005856); cilium (GO:0005929); axoneme (GO:0005930); cell projection organization (GO:0030030); axoneme assembly (GO:0035082); cell projection (GO:0042995); cilium assembly (GO:0060271); cilium movement involved in cell motility (GO:0060294),Rsph4a,0.019827886,-50.4340205,1.2630761,0.020428959,1.11E-06,0.01892483,-52.8406344,0.87442801,0.012321848,5.59E-09,0.018110506,-55.2165679,2.9121566,0.045087586,8.82E-07,0.008948845,-111.7462647,4.4735041,0.024310913,7.58E-06
SULT2A5,15.2222,1.2,2.02,4.002,8.0002,10.369042,,"[Plus], [# of exons: 6], [Gene type: NM]","chr7:14,209,316-14,253,223 chr7:14,255,934-14,256,156",NM_001184980,"Sult2a5, sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 5, sulfotransferase family 2A member 1 family member, Predicted to have 3'-phosphoadenosine 5'-phosphosulfate binding activity and sulfotransferase activity. Predicted to be involved in sulfation. Predicted to localize to cytosol. Human ortholog(s) of this gene implicated in prostate cancer. Orthologous to human SULT2A1 (sulfotransferase family 2A member 1).",alcohol sulfotransferase activity (GO:0004027); cytoplasm (GO:0005737); cytosol (GO:0005829); sulfotransferase activity (GO:0008146); transferase activity (GO:0016740); bile-salt sulfotransferase activity (GO:0047704); steroid sulfotransferase activity (GO:0050294); 3'-phosphoadenosine 5'-phosphosulfate binding (GO:0050656); sulfation (GO:0051923),Sult2a5,0.0103644,-96.484117,3.7740572,0.034615886,1.39E-15,0.01206655,-82.8737324,2.448485,0.035788325,4.72E-25,0.014252678,-70.1622522,3.6432207,0.055457667,5.39E-20,0.017458767,-57.2778127,10.369042,0.12463087,2.25E-19
SULT3A1,15.2222,1.2,2.02,4.002,8.0002,101.11857,,"[Plus], [# of exons: 7], [Gene type: NM]","chr10:33,577,528-33,599,281",NM_020565,"Sult3a1, sulfotransferase family 3A, member 1, amine sulfotransferase|sulfotransferase 3A1|sulfotransferase related gene X2|sulfotransferase-related protein SULT-X2, Exhibits sulfotransferase activity. Involved in sulfation. Predicted to localize to cytoplasm.",cytoplasm (GO:0005737); sulfotransferase activity (GO:0008146); transferase activity (GO:0016740); amine sulfotransferase activity (GO:0047685); sulfation (GO:0051923),Sult3a1,0.007453232,-134.1699887,20.067894,0.14580819,2.59E-17,0.020981884,-47.6601619,11.903749,0.26535324,5.88E-14,0.002868767,-348.5818167,39.097125,0.11239587,6.30E-50,0.005177233,-193.1533751,101.11857,0.41282303,2.36E-24
CYP2B13,15.2222,1.2,2.02,4.002,8.0002,41.95409,,"[Plus], [# of exons: 9], [Gene type: NM]","chr7:26,846,514-26,855,253 chr7:26,865,617-26,865,779 chr7:26,865,909-26,866,058 chr7:26,866,668-26,866,828 chr7:26,870,872-26,871,048 chr7:26,871,501-26,871,642 chr7:26,873,264-26,873,451 chr7:26,873,620-26,873,761 chr7:26,880,659-26,881,215",NM_007813,"Cyp2b13, cytochrome P450, family 2, subfamily b, polypeptide 13, cytochrome P450, family 2, subfamily b, polypeptide 13|cytochrome P450, 2b13, phenobarbitol inducible, type c|phenobarbital inducible, type c, Predicted to have heme binding activity and monooxygenase activity. Predicted to be involved in epoxygenase P450 pathway; exogenous drug catabolic process; and xenobiotic metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in acute myeloid leukemia. Orthologous to human CYP2B6 (cytochrome P450 family 2 subfamily B member 6).","cytoplasm (GO:0005737); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); aromatase activity (GO:0070330)",Cyp2b13,0.011015343,-90.7824683,24.026337,0.25237046,6.10E-27,0.014361341,-69.6313788,24.284297,0.36990027,2.47E-58,0.013717732,-72.8983504,33.076869,0.48569513,9.35E-25,0.015885993,-62.9485356,41.95409,0.5002191,1.00E-26
CYP2B9,15.2222,1.2,2.02,4.002,8.0002,520.35758,,"[Plus], [# of exons: 9], [Gene type: NM]","chr7:26,958,428-26,958,623 chr7:26,965,200-26,995,679",NM_010000,"Cyp2b9, cytochrome P450, family 2, subfamily b, polypeptide 9, cytochrome P450 2B9|16alphaoh-a|CYPIIB9|cytochrome P450 clone PF26|cytochrome P450, 2b9, phenobarbitol inducible, type a|cytochrome P450-16-alpha|phenobarbitol inducible, type a|testosterone 16-alpha hydroxylase, Predicted to have heme binding activity and monooxygenase activity. Involved in response to stilbenoid. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in acute myeloid leukemia. Orthologous to human CYP2B6 (cytochrome P450 family 2 subfamily B member 6).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); response to stilbenoid (GO:0035634); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); aromatase activity (GO:0070330)",Cyp2b9,0.017193791,-58.160531,28.835565,0.47773613,3.99E-23,0.023469206,-42.6090256,34.094572,0.79702028,1.01E-20,0.021325197,-46.8928846,55.263624,1.2512479,7.99E-16,0.017605551,-56.8002671,520.35758,7.2421145,7.65E-16
CYP2C37,15.2222,1.2,2.02,4.002,8.0002,95.422773,,"[Plus], [# of exons: 9], [Gene type: NM]","chr19:40,066,914-40,070,385 chr19:40,074,908-40,075,049 chr19:40,076,311-40,076,498 chr19:40,084,305-40,084,446 chr19:40,086,217-40,086,733",NM_010001,"Cyp2c37, cytochrome P450, family 2. subfamily c, polypeptide 37, cytochrome P450 2C37|CYPIIC37|cytochrome P450, 2c37, Exhibits arachidonic acid monooxygenase activity. Involved in arachidonic acid metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Is expressed in dorsal root ganglion; liver; liver lobe; and testis. Human ortholog(s) of this gene implicated in several diseases, including eosinophilic esophagitis; glucose metabolism disease (multiple); multiple myeloma; sickle cell anemia; and warfarin resistance. Orthologous to human CYP2C19 (cytochrome P450 family 2 subfamily C member 19) and CYP2C9 (cytochrome P450 family 2 subfamily C member 9).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); lipid metabolic process (GO:0006629); xenobiotic metabolic process (GO:0006805); arachidonic acid monooxygenase activity (GO:0008391); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); arachidonic acid metabolic process (GO:0019369); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); aromatase activity (GO:0070330)",Cyp2c37,0.098568658,-10.1452127,95.422773,9.2096311,1.43E-08,0.11105813,-9.0042935,50.621361,6.4176907,9.77E-15,0.14817909,-6.7485906,63.410532,9.9242045,2.44E-07,0.16359308,-6.1127279,20.163594,2.5207193,0.000129944
NT5E,15.2222,1.2,2.02,4.002,8.0002,47.332459,,"[Plus], [# of exons: 9], [Gene type: NM]","chr9:88,222,447-88,266,927",NM_011851,"Nt5e, 5' nucleotidase, ecto, 5'-nucleotidase|ecto-5'-nucleotidase, Exhibits 5'-nucleotidase activity. Involved in negative regulation of inflammatory response and nucleobase-containing small molecule biosynthetic process. Localizes to external side of plasma membrane. Is expressed in several structures, including alimentary system; brain; genitourinary system; integumental system; and musculoskeletal system. Human ortholog(s) of this gene implicated in hereditary arterial and articular multiple calcification syndrome. Orthologous to human NT5E (5'-nucleotidase ecto).","nucleotide binding (GO:0000166); nucleoplasm (GO:0005654); cytosol (GO:0005829); plasma membrane (GO:0005886); AMP catabolic process (GO:0006196); leukocyte cell-cell adhesion (GO:0007159); ferrous iron binding (GO:0008198); 5'-nucleotidase activity (GO:0008253); nucleotide catabolic process (GO:0009166); external side of plasma membrane (GO:0009897); cell surface (GO:0009986); membrane (GO:0016020); hydrolase activity (GO:0016787); hydrolase activity, acting on ester bonds (GO:0016788); anchored component of membrane (GO:0031225); ADP catabolic process (GO:0046032); adenosine metabolic process (GO:0046085); adenosine biosynthetic process (GO:0046086); metal ion binding (GO:0046872); negative regulation of inflammatory response (GO:0050728); synaptic membrane (GO:0097060)",Nt5e,0.1350803,-7.4030041,8.9906229,1.1886133,7.33E-08,0.14944907,-6.6912425,8.0342616,1.2390382,1.43E-17,0.21478159,-4.6558925,13.275354,2.9816858,7.99E-06,0.099286673,-10.0718452,47.332459,3.5825713,5.40E-18
PLPPR1,15.2222,1.2,2.02,4.002,8.0002,0.86741935,,"[~1% MAX. MULTIPLE IN BLACKLIST], [Plus], [# of exons: 8], [Gene type: NM]","chr4:49,072,334-49,353,133",NM_178756,"Plppr1, phospholipid phosphatase related 1, phospholipid phosphatase-related protein type 1|lipid phosphate phosphatase-related protein type 1|plasticity-related gene 3 protein|plasticity-related protein 3, Predicted to have lipid phosphatase activity and phosphatidate phosphatase activity. Predicted to be involved in several processes, including phospholipid dephosphorylation; phospholipid metabolic process; and signal transduction. Predicted to localize to integral component of plasma membrane and nucleoplasm. Is expressed in several structures, including ear; forebrain; forelimb bud; heart; and notochord. Orthologous to human PLPPR1 (phospholipid phosphatase related 1).",nucleoplasm (GO:0005654); integral component of plasma membrane (GO:0005887); phospholipid metabolic process (GO:0006644); signal transduction (GO:0007165); nervous system development (GO:0007399); phosphatidate phosphatase activity (GO:0008195); membrane (GO:0016020); integral component of membrane (GO:0016021); lipid phosphatase activity (GO:0042577); phospholipid dephosphorylation (GO:0046839),Plppr1,0.042359676,-23.6073572,0.022171053,0.000751805,2.78E-05,0.1223676,-8.1720976,0.043983857,0.004909845,0.000186086,0.14071611,-7.1065068,0.064157173,0.009695683,0.013303235,0.12445008,-8.0353502,0.86741935,0.075870212,7.81E-07
NC_INTRA_C7_5919,15.2222,1.2,2.02,4.002,8.0002,0.89623701,,"[~2%  IN BLACKLIST], [Plus], [# Lnc isoforms: 19], [# of exons: 8], [Gene type: lncRNA]","chr7:14,253,224-14,253,248 chr7:14,255,107-14,255,288 chr7:14,256,157-14,318,854 chr7:14,364,126-14,364,766 chr7:14,364,987-14,384,718",,"lnc_intra-as_chr7_5919, ",,lnc_intra-as_chr7_5919,0.08352371,-11.9726483,0.059750355,0.004282224,0.010086629,0.017928254,-55.7778788,0.17083932,0.003496324,9.32E-11,0.022124086,-45.1996074,0.24391437,0.005365721,6.56E-08,0.051379426,-19.4630433,0.89623701,0.032565541,2.69E-09
NC_INTRA_C15_12684,15.2222,1.2,2.02,4.002,8.0002,7.4942311,,"[~6% MAX. MULTIPLE IN BLACKLIST], [Minus], [# Lnc isoforms: 117], [# of exons: 77], [Gene type: lncRNA]","chr15:74,822,413-74,825,306 chr15:74,828,101-74,828,142 chr15:74,828,462-74,874,447 chr15:74,879,268-74,938,590 chr15:74,942,402-75,262,384",NM_001039720,"9030619P08Rik, RIKEN cDNA 9030619P08 gene, lymphocyte antigen 6 complex pseudogene; Gm28502, ; lnc_intra-as_chr15_12684,12674, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),9030619P08Rik Gm28502 lnc_intra-as_chr15_12684,0.15829948,-6.3171403,1.3674783,0.20236851,0.000577504,0.24572991,-4.0695086,2.053974,0.5502967,1.57E-08,0.29017343,-3.4462148,1.8129514,0.56030577,0.004095825,0.3899343,-2.5645346,7.4942311,2.2086336,0.015338922
CYP2C39,15.2222,1.2,2.02,4.002,8.0002,23.947828,,"[~9%  IN BLACKLIST], [Plus], [# of exons: 10], [Gene type: NM]","chr19:39,421,836-39,450,239 chr19:39,450,942-39,462,945 chr19:39,463,939-39,535,589 chr19:39,561,983-39,644,058",NM_001373937 NM_010003,"Cyp2c39, cytochrome P450, family 2, subfamily c, polypeptide 39, cytochrome P450 2C39|cytochrome P450, 2c39, Exhibits arachidonic acid 11,12-epoxygenase activity. Involved in arachidonic acid metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in several diseases, including eosinophilic esophagitis; glucose metabolism disease (multiple); multiple myeloma; sickle cell anemia; and warfarin resistance. Orthologous to human CYP2C19 (cytochrome P450 family 2 subfamily C member 19) and CYP2C9 (cytochrome P450 family 2 subfamily C member 9).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); lipid metabolic process (GO:0006629); xenobiotic metabolic process (GO:0006805); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); retinoic acid 4-hydroxylase activity (GO:0008401); arachidonic acid 11,12-epoxygenase activity (GO:0008405); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); arachidonic acid metabolic process (GO:0019369); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); caffeine oxidase activity (GO:0034875); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); aromatase activity (GO:0070330); estrogen 16-alpha-hydroxylase activity (GO:0101020)",Cyp2c39,0.17529043,-5.7048181,11.150406,1.8828749,9.44E-06,0.17706432,-5.6476653,6.7266678,1.2957897,1.90E-16,0.21338578,-4.686348,14.971539,3.3665314,1.71E-06,0.19671259,-5.0835587,23.947828,3.5968611,0.000164942
NC_INTER_C4_38016,15.1111,1.1,2.01,4.001,8.0001,13.875157,,"[Minus], [# Lnc isoforms: 30], [# of exons: 3], [Gene type: lncRNA]","chr4:61,534,830-61,674,291",,"lnc_inter_chr4_38016, ",,lnc_inter_chr4_38016,88.218643,88.2186428,0.12440454,7.8847954,1.09E-10,61.289997,61.2899972,0.14472088,9.2666539,6.08E-37,49.777938,49.7779383,0.26358693,13.875157,1.37E-35,14.98752,14.9875202,0.1772237,1.9000004,2.48E-12
DDX3Y,15.1111,1.1,2.01,4.001,8.0001,46.065341,,"[Minus], [# of exons: 17], [Gene type: NM]","chrY:597,158-623,056",NM_012008,"Ddx3y, DEAD box helicase 3, Y-linked, ATP-dependent RNA helicase DDX3Y|D1Pas1 related sequence 1|DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked|DEAD (aspartate-glutamate-alanine-aspartate) box polypeptide, Y chromosome|DEAD box protein 3, Y-chromosomal|DEAD-box RNA helicase DEAD2|mDEAD2, Predicted to have RNA binding activity and RNA helicase activity. Predicted to be involved in cell differentiation and gamete generation. Predicted to localize to P granule; cytosol; and nucleoplasm. Is expressed in several structures, including genitourinary system; heart; hemolymphoid system gland; liver; and lung. Orthologous to human DDX3Y (DEAD-box helicase 3 Y-linked).",nucleotide binding (GO:0000166); nucleic acid binding (GO:0003676); RNA binding (GO:0003723); RNA helicase activity (GO:0003724); helicase activity (GO:0004386); ATP binding (GO:0005524); nucleus (GO:0005634); nucleoplasm (GO:0005654); cytoplasm (GO:0005737); cytosol (GO:0005829); gamete generation (GO:0007276); hydrolase activity (GO:0016787); cell differentiation (GO:0030154); P granule (GO:0043186),Ddx3y,87.365316,87.3653163,0.047708991,3.1405534,7.56E-16,99.823832,99.8238324,0.059317705,6.9509695,3.37E-41,162.52403,162.5240263,0.15960822,26.164321,8.84E-47,1137.4329,1137.432911,0.05004012,46.065341,9.58E-64
LNC-LFAR1,15.1111,1.1,2.01,4.001,8.0001,324.51862,,"[Minus], [# of exons: 1], [Gene type: lncOfInterest]","chr3:130,991,365-130,992,096",,"Lnc-LFAR1, ",,Lnc-LFAR1,4.5218951,4.5218951,16.314902,70.873718,0.001994236,5.8049358,5.8049358,24.033295,144.64679,1.44E-06,4.2975101,4.2975101,52.270135,243.17966,0.005437346,6.2673155,6.2673155,65.052423,324.51862,2.23E-06
UTY,15.1111,1.1,2.01,4.001,8.0001,15.899104,,"[Minus], [# of exons: 27], [Gene type: NM]","chrY:433,587-582,202",NM_001326682 NM_001326683 NM_009484,"Uty, ubiquitously transcribed tetratricopeptide repeat containing, Y-linked, histone demethylase UTY|[histone H3]-trimethyl-L-lysine(27) demethylase UTY|male-specific histocompatibility antigen H-YDB|ubiquitously transcribed TPR protein on the Y chromosome|ubiquitously transcribed Y chromosome tetratricopeptide repeat protein|ubiquitously transcribed tetratricopeptide repeat gene, Y chromosome, Exhibits RNA polymerase II cis-regulatory region sequence-specific DNA binding activity and histone demethylase activity (H3-K36 specific). Involved in several processes, including animal organ development; cardiac muscle cell contraction; and regulation of chromatin silencing. Localizes to protein-containing complex. Is expressed in several structures, including early conceptus; forelimb bud; genitourinary system; gut; and liver. Orthologous to human UTY (ubiquitously transcribed tetratricopeptide repeat containing, Y-linked).",RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); in utero embryonic development (GO:0001701); heart morphogenesis (GO:0003007); protein binding (GO:0005515); nucleus (GO:0005634); chromatin organization (GO:0006325); heart development (GO:0007507); regulation of gene expression (GO:0010468); oxidoreductase activity (GO:0016491); chromatin DNA binding (GO:0031490); regulation of chromatin silencing (GO:0031935); protein-containing complex (GO:0032991); MLL3/4 complex (GO:0044666); establishment of protein localization (GO:0045184); metal ion binding (GO:0046872); embryonic organ development (GO:0048568); dioxygenase activity (GO:0051213); histone demethylase activity (H3-K36 specific) (GO:0051864); canonical Wnt signaling pathway (GO:0060070); histone H3-K27 demethylation (GO:0071557); histone demethylase activity (H3-K27 specific) (GO:0071558); cardiac muscle cell contraction (GO:0086003),Uty,50.629562,50.6295622,0.002964802,0.17307231,8.09E-15,99.464599,99.464599,0.010704157,1.1878137,1.43E-43,113.26395,113.2639499,0.024295114,2.7289645,6.02E-40,305.38223,305.3822266,0.069167255,15.899104,4.78E-69
IHH,15.1111,1.1,2.01,4.001,8.0001,6.2441464,,"[Minus], [# of exons: 3], [Gene type: NM]","chr1:74,991,889-74,998,246",NM_001313683 NM_010544,"Ihh, Indian hedgehog, indian hedgehog protein, Exhibits patched binding activity. Involved in several processes, including animal organ development; chordate embryonic development; and regulation of T cell differentiation. Localizes to extracellular matrix. Is expressed in several structures, including alimentary system; egg cylinder; limb; skeleton; and urinary system. Used to study Hirschsprung's disease; annular pancreas; and brachydactyly type A1. Human ortholog(s) of this gene implicated in acrocapitofemoral dysplasia; brachydactyly type A1; retinopathy of prematurity; and syndactyly type 1. Orthologous to human IHH (Indian hedgehog signaling molecule).",skeletal system development (GO:0001501); ossification (GO:0001503); branching involved in blood vessel morphogenesis (GO:0001569); osteoblast differentiation (GO:0001649); in utero embryonic development (GO:0001701); cell fate specification (GO:0001708); morphogenesis of a branching structure (GO:0001763); vasculature development (GO:0001944); heart looping (GO:0001947); positive regulation of mesenchymal cell proliferation (GO:0002053); epithelial cell morphogenesis (GO:0003382); retinal pigment epithelium development (GO:0003406); chondrocyte differentiation involved in endochondral bone morphogenesis (GO:0003413); patched binding (GO:0005113); calcium ion binding (GO:0005509); protein binding (GO:0005515); extracellular region (GO:0005576); extracellular space (GO:0005615); plasma membrane (GO:0005886); proteoglycan metabolic process (GO:0006029); proteolysis (GO:0006508); smoothened signaling pathway (GO:0007224); cell-cell signaling (GO:0007267); multicellular organism development (GO:0007275); pattern specification process (GO:0007389); peptidase activity (GO:0008233); positive regulation of cell proliferation (GO:0008284); embryo development (GO:0009790); embryonic pattern specification (GO:0009880); regulation of gene expression (GO:0010468); membrane (GO:0016020); intein-mediated protein splicing (GO:0016539); protein autoprocessing (GO:0016540); hydrolase activity (GO:0016787); cell differentiation (GO:0030154); vitelline membrane formation (GO:0030704); extracellular matrix (GO:0031012); pancreas development (GO:0031016); positive regulation of collagen biosynthetic process (GO:0032967); negative regulation of T cell differentiation in thymus (GO:0033085); negative regulation of immature T cell proliferation in thymus (GO:0033088); positive regulation of T cell differentiation in thymus (GO:0033089); multicellular organism growth (GO:0035264); chondrocyte proliferation (GO:0035988); regulation of growth (GO:0040008); embryonic digit morphogenesis (GO:0042733); camera-type eye development (GO:0043010); negative regulation of apoptotic process (GO:0043066); bone resorption (GO:0045453); negative regulation of cell differentiation (GO:0045596); positive regulation of smoothened signaling pathway (GO:0045880); positive regulation of transcription by RNA polymerase II (GO:0045944); positive regulation of alpha-beta T cell differentiation (GO:0046638); negative regulation of alpha-beta T cell differentiation (GO:0046639); metal ion binding (GO:0046872); negative regulation of eye pigmentation (GO:0048074); cell maturation (GO:0048469); embryonic digestive tract morphogenesis (GO:0048557); embryonic camera-type eye morphogenesis (GO:0048596); neuron development (GO:0048666); smooth muscle tissue development (GO:0048745); positive regulation of epithelial cell proliferation (GO:0050679); cartilage development (GO:0051216); camera-type eye photoreceptor cell fate commitment (GO:0060220); head morphogenesis (GO:0060323); somite development (GO:0061053); embryonic skeletal joint development (GO:0072498); epithelial cell-cell adhesion (GO:0090136),Ihh,5.0841548,5.0841548,0.6154153,3.111512,0.011713909,3.8976164,3.8976164,1.5054598,6.2441464,0.000765481,4.2467931,4.2467931,0.99637997,4.4681522,0.018282154,5.5704213,5.5704213,1.0910204,4.8551307,0.008218757
NAT8F5,15.1111,1.1,2.01,4.001,8.0001,14.09697,,"[Minus], [# of exons: 3], [Gene type: NM]","chr6:85,767,212-85,770,966",NM_023493,"Nat8f5, N-acetyltransferase 8 (GCN5-related) family member 5, probable N-acetyltransferase CML5|camello-like 5|camello-like protein 5, Predicted to have N-acetyltransferase activity. Involved in determination of left/right symmetry and heart development. Predicted to localize to Golgi apparatus and endoplasmic reticulum. Is expressed in brain; genitourinary system; gut; and spinal cord. Orthologous to human NAT8 (N-acetyltransferase 8 (putative)).","gastrulation with mouth forming second (GO:0001702); extracellular space (GO:0005615); endoplasmic reticulum (GO:0005783); Golgi apparatus (GO:0005794); negative regulation of cell adhesion (GO:0007162); multicellular organism development (GO:0007275); determination of left/right symmetry (GO:0007368); gastrulation (GO:0007369); heart development (GO:0007507); N-acetyltransferase activity (GO:0008080); membrane (GO:0016020); integral component of membrane (GO:0016021); transferase activity (GO:0016740); transferase activity, transferring acyl groups (GO:0016746)",Nat8f5,19.003997,19.0039968,0.70829282,10.415702,0.008988058,54.508433,54.5084326,0.19256184,11.80293,1.34E-14,28.217805,28.2178053,0.55615834,14.09697,1.36E-09,16.017175,16.0171749,0.23320263,3.3096886,0.005504285
TFF3,15.1111,1.1,2.01,4.001,8.0001,17.944204,,"[Minus], [# of exons: 3], [Gene type: NM]","chr17:31,262,251-31,266,556",NM_011575,"Tff3, trefoil factor 3, intestinal, trefoil factor 3|intestinal trefoil factor, Involved in regulation of glucose metabolic process. Localizes to secretory granule. Is expressed in several structures, including alimentary system; ear; liver and biliary system; musculoskeletal system; and nervous system. Orthologous to human TFF3 (trefoil factor 3).",extracellular region (GO:0005576); extracellular space (GO:0005615); cytoplasm (GO:0005737); regulation of glucose metabolic process (GO:0010906); secretory granule (GO:0030141); maintenance of gastrointestinal epithelium (GO:0030277); identical protein binding (GO:0042802),Tff3,28.996634,28.9966344,0.86161205,17.944204,0.000564466,16.506089,16.5060891,0.75751046,13.147058,4.07E-06,31.843853,31.8438526,0.41647627,12.424772,6.87E-06,10.367916,10.3679161,0.33730181,3.0155306,0.041173196
HSD3B5,15.1111,1.1,2.01,4.001,8.0001,45.966827,,"[Minus], [# of exons: 4], [Gene type: NM]","chr3:98,422,559-98,423,741 chr3:98,425,926-98,426,090 chr3:98,433,977-98,434,173 chr3:98,438,649-98,449,457",NM_008295,"Hsd3b5, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 5, NADPH-dependent 3-keto-steroid reductase Hsd3b5|3 beta-hydroxysteroid dehydrogenase type 5|3 beta-hydroxysteroid dehydrogenase type V|3(beta)HSDV|3-beta-HSD V|3-beta-hydroxy-5-ene steroid dehydrogenase|NADPH-dependent 3-beta-hydroxy-Delta(5)-steroid dehydrogenase|dihydrotestosterone 3-ketoreductase|hydroxysteroid dehydrogenase-5, delta<5>-3-beta|progesterone reductase, Predicted to have 3-beta-hydroxy-delta5-steroid dehydrogenase activity and steroid binding activity. Involved in response to stilbenoid. Localizes to mitochondrial inner membrane. Is expressed in several structures, including adrenal gland; gut; liver and biliary system; metanephros; and skeletal muscle. Human ortholog(s) of this gene implicated in hypertension and hypospadias. Orthologous to human HSD3B1 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1) and HSD3B2 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2).","3-keto sterol reductase activity (GO:0000253); 3-beta-hydroxy-delta5-steroid dehydrogenase activity (GO:0003854); steroid binding (GO:0005496); cytoplasm (GO:0005737); mitochondrion (GO:0005739); mitochondrial inner membrane (GO:0005743); endoplasmic reticulum (GO:0005783); lipid metabolic process (GO:0006629); steroid biosynthetic process (GO:0006694); steroid metabolic process (GO:0008202); C21-steroid hormone metabolic process (GO:0008207); membrane (GO:0016020); integral component of membrane (GO:0016021); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor (GO:0016616); hippocampus development (GO:0021766); response to stilbenoid (GO:0035634); intracellular membrane-bounded organelle (GO:0043231); 5alpha-androstane-3beta,17beta-diol dehydrogenase activity (GO:0047024); response to corticosterone (GO:0051412)",Hsd3b5,5.0428137,5.0428137,9.7315485,45.966827,3.09E-05,5.4122024,5.4122024,6.8031672,39.889679,5.40E-11,5.9593194,5.9593194,6.3050932,40.518569,8.37E-08,3.7182254,3.7182254,11.750786,31.756163,0.000523226
CIB3,15.1111,1.1,2.01,4.001,8.0001,11.414544,,"[Minus], [# of exons: 5], [Gene type: NM]","chr8:74,728,234-74,736,736",NM_001080812,"Cib3, calcium and integrin binding family member 3, calcium and integrin-binding family member 3, Predicted to have calcium ion binding activity and magnesium ion binding activity. Is expressed in skeletal muscle. Orthologous to human CIB3 (calcium and integrin binding family member 3).",magnesium ion binding (GO:0000287); calcium ion binding (GO:0005509); cellular_component (GO:0005575); biological_process (GO:0008150); metal ion binding (GO:0046872),Cib3,11.202586,11.202586,0.080838156,0.86863264,0.004572695,14.050971,14.0509709,0.41170716,6.0485609,0.000669429,10.620497,10.6204971,0.61658564,7.139309,0.029793393,6.7441926,6.7441926,2.2463963,11.414544,0.018414373
CHRM3,15.1111,1.1,2.01,4.001,8.0001,7.2010839,,"[Minus], [# of exons: 5], [Gene type: NM]","chr13:10,204,003-10,360,049 chr13:9,875,859-10,202,286",NM_033269,"Chrm3, cholinergic receptor, muscarinic 3, cardiac, muscarinic acetylcholine receptor M3|AChR M3|mm3 mAChR|muscarinic acetylcholine receptor 3, Predicted to have G protein-coupled acetylcholine receptor activity; G protein-coupled serotonin receptor activity; and acetylcholine binding activity. Involved in several processes, including cholinergic synaptic transmission; positive regulation of smooth muscle contraction; and saliva secretion. Predicted to localize to several cellular components, including basal plasma membrane; glutamatergic synapse; and integral component of synaptic membrane. Is expressed in several structures, including alimentary system; central nervous system; genitourinary system; respiratory system; and sensory organ. Used to study megacystis-microcolon-intestinal hypoperistalsis syndrome. Human ortholog(s) of this gene implicated in bladder disease; chronic obstructive pulmonary disease; prune belly syndrome; and pulmonary fibrosis. Orthologous to human CHRM3 (cholinergic receptor muscarinic 3).","regulation of vascular smooth muscle contraction (GO:0003056); negative regulation of heart rate by acetylcholine (GO:0003063); G-protein coupled receptor activity (GO:0004930); G-protein coupled serotonin receptor activity (GO:0004993); protein binding (GO:0005515); endoplasmic reticulum (GO:0005783); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); smooth muscle contraction (GO:0006939); signal transduction (GO:0007165); G-protein coupled receptor signaling pathway (GO:0007186); G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger (GO:0007187); adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway (GO:0007197); G-protein coupled acetylcholine receptor signaling pathway (GO:0007213); chemical synaptic transmission (GO:0007268); synaptic transmission, cholinergic (GO:0007271); basal plasma membrane (GO:0009925); membrane (GO:0016020); integral component of membrane (GO:0016021); G-protein coupled acetylcholine receptor activity (GO:0016907); calcium-mediated signaling (GO:0019722); cell junction (GO:0030054); dendrite (GO:0030425); neurotransmitter receptor activity (GO:0030594); asymmetric synapse (GO:0032279); regulation of ion transmembrane transporter activity (GO:0032412); acetylcholine binding (GO:0042166); axon terminus (GO:0043679); synapse (GO:0045202); postsynaptic membrane (GO:0045211); positive regulation of vasoconstriction (GO:0045907); positive regulation of smooth muscle contraction (GO:0045987); saliva secretion (GO:0046541); acetylcholine receptor signaling pathway (GO:0095500); glutamatergic synapse (GO:0098978); integral component of presynaptic membrane (GO:0099056); integral component of postsynaptic density membrane (GO:0099061); positive regulation of vascular smooth muscle contraction (GO:1904695)",Chrm3,15.82603,15.8260304,0.002392679,0.03478207,0.000250678,6.7539934,6.7539934,0.030529206,0.21940316,0.010813149,5.887526,5.887526,0.021265118,0.12387359,0.022973541,7.5801945,7.5801945,1.0738452,7.2010839,0.020340255
MUP21,15.1111,1.1,2.01,4.001,8.0001,1214.4294,,"[Minus], [# of exons: 6], [Gene type: NM]","chr4:61,808,866-61,811,875",NM_001009550,"Mup21, major urinary protein 21, major urinary protein 26, Predicted to have odorant binding activity. Predicted to localize to extracellular space.",odorant binding (GO:0005549); extracellular space (GO:0005615); biological_process (GO:0008150),Mup21,8.9033401,8.9033401,65.85828,512.12518,2.35E-07,8.0037133,8.0037133,55.779309,459.97768,5.41E-17,11.95857,11.9585702,97.390657,1214.4294,5.62E-13,13.242772,13.2427717,20.542026,219.97212,1.99E-11
GSTP1,15.1111,1.1,2.01,4.001,8.0001,4420.7043,,"[Minus], [# of exons: 7], [Gene type: NM]","chr19:4,035,411-4,037,912",NM_013541,"Gstp1, glutathione S-transferase, pi 1, glutathione S-transferase P 1|GST YF-YF|GST class-pi|GST-piB|Gst p-1|gst P1|preadipocyte growth factor, Exhibits JUN kinase binding activity; glutathione transferase activity; and kinase regulator activity. Involved in several processes, including negative regulation of cell population proliferation; negative regulation of intracellular signal transduction; and negative regulation of macromolecule metabolic process. Localizes to protein-containing complex. Is expressed in several structures, including alimentary system; central nervous system; genitourinary system; respiratory system; and sensory organ. Human ortholog(s) of this gene implicated in several diseases, including brain disease (multiple); carcinoma (multiple); hematologic cancer (multiple); neurodegenerative disease (multiple); and respiratory system disease (multiple). Orthologous to human GSTP1 (glutathione S-transferase pi 1).",response to reactive oxygen species (GO:0000302); negative regulation of acute inflammatory response (GO:0002674); glutathione transferase activity (GO:0004364); glutathione peroxidase activity (GO:0004602); fatty acid binding (GO:0005504); nucleus (GO:0005634); cytoplasm (GO:0005737); mitochondrion (GO:0005739); cytosol (GO:0005829); plasma membrane (GO:0005886); glutathione metabolic process (GO:0006749); JUN kinase binding (GO:0008432); transferase activity (GO:0016740); kinase regulator activity (GO:0019207); protein kinase binding (GO:0019901); negative regulation of interleukin-1 beta production (GO:0032691); negative regulation of tumor necrosis factor production (GO:0032720); regulation of stress-activated MAPK cascade (GO:0032872); negative regulation of stress-activated MAPK cascade (GO:0032873); positive regulation of superoxide anion generation (GO:0032930); protein-containing complex (GO:0032991); common myeloid progenitor cell proliferation (GO:0035726); S-nitrosoglutathione binding (GO:0035730); dinitrosyl-iron complex binding (GO:0035731); negative regulation of apoptotic process (GO:0043066); negative regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043124); negative regulation of JUN kinase activity (GO:0043508); negative regulation of fibroblast proliferation (GO:0048147); negative regulation of nitric-oxide synthase biosynthetic process (GO:0051771); regulation of ERK1 and ERK2 cascade (GO:0070372); negative regulation of ERK1 and ERK2 cascade (GO:0070373); negative regulation of leukocyte proliferation (GO:0070664); cellular response to lipopolysaccharide (GO:0071222); negative regulation of monocyte chemotactic protein-1 production (GO:0071638); TRAF2-GSTP1 complex (GO:0097057); negative regulation of neutrophil aggregation (GO:2000429); negative regulation of peroxidase activity (GO:2000469),Gstp1,5.5662416,5.5662416,885.44919,4420.7043,3.77E-05,5.4013137,5.4013137,758.72609,4121.4564,1.39E-07,5.7640088,5.7640088,584.41304,3503.4849,2.87E-08,6.0393853,6.0393853,413.33901,2032.5964,3.71E-07
GSTP2,15.1111,1.1,2.01,4.001,8.0001,876.17222,,"[Minus], [# of exons: 7], [Gene type: NM]","chr19:4,040,288-4,042,221",NM_181796,"Gstp2, glutathione S-transferase, pi 2, glutathione S-transferase P 2|GST YF-YF|GST class-pi|GST-piA|Gst p-2|gst P2, Exhibits glutathione transferase activity. Involved in glutathione metabolic process. Predicted to localize to several cellular components, including TRAF2-GSTP1 complex; cytosol; and mitochondrion. Is expressed in several structures, including alimentary system; cranium; eye; heart; and nervous system. Human ortholog(s) of this gene implicated in several diseases, including brain disease (multiple); carcinoma (multiple); hematologic cancer (multiple); neurodegenerative disease (multiple); and respiratory system disease (multiple). Orthologous to human GSTP1 (glutathione S-transferase pi 1).",glutathione transferase activity (GO:0004364); glutathione peroxidase activity (GO:0004602); fatty acid binding (GO:0005504); nucleus (GO:0005634); cytoplasm (GO:0005737); mitochondrion (GO:0005739); cytosol (GO:0005829); plasma membrane (GO:0005886); glutathione metabolic process (GO:0006749); transferase activity (GO:0016740); protein kinase binding (GO:0019901); S-nitrosoglutathione binding (GO:0035730); dinitrosyl-iron complex binding (GO:0035731); TRAF2-GSTP1 complex (GO:0097057),Gstp2,5.8659953,5.8659953,166.29476,835.29773,0.00022555,5.742445,5.742445,151.13687,876.17222,4.33E-09,5.8898197,5.8898197,125.80581,765.10966,8.47E-08,4.5808389,4.5808389,139.43867,511.43784,9.88E-06
MUP15,15.1111,1.1,2.01,4.001,8.0001,27.616901,,"[Minus], [# of exons: 7], [Gene type: NM]","chr4:60,079,341-60,079,594 chr4:60,080,382-60,080,427 chr4:60,080,592-60,080,693 chr4:60,081,037-60,081,147 chr4:60,151,259-60,151,332 chr4:60,152,091-60,152,224 chr4:60,152,563-60,152,730",NM_001200004,"Mup15, major urinary protein 15, major urinary protein 15|major urinary protein 13, Predicted to have odorant binding activity. Predicted to localize to extracellular space.",odorant binding (GO:0005549); extracellular space (GO:0005615); biological_process (GO:0008150),Mup15,130.54689,130.5468911,0.30310957,27.616901,0.00022555,65.872559,65.8725591,0.26825333,20.348404,9.64E-12,54.93846,54.9384599,0.46676856,26.564664,1.83E-12,14.109018,14.109018,0.89941069,9.3136547,4.82E-06
MUP20,15.1111,1.1,2.01,4.001,8.0001,4935.9257,,"[Minus], [# of exons: 7], [Gene type: NM]","chr4:61,711,269-61,715,151",NM_001012323,"Mup20, major urinary protein 20, major urinary protein 20|major urinary protein 24, Exhibits mating pheromone activity and pheromone binding activity. Involved in several processes, including olfactory learning; positive regulation of neural precursor cell proliferation; and positive regulation of neurogenesis. Localizes to extracellular region. Is expressed in liver.",mating pheromone activity (GO:0000772); pheromone activity (GO:0005186); odorant binding (GO:0005549); pheromone binding (GO:0005550); extracellular region (GO:0005576); extracellular space (GO:0005615); olfactory learning (GO:0008355); small molecule binding (GO:0036094); positive regulation of neurogenesis (GO:0050769); vocalization behavior (GO:0071625); positive regulation of neural precursor cell proliferation (GO:2000179),Mup20,96.338099,96.3380987,43.455846,3136.0086,9.10E-14,65.907976,65.9079759,45.24285,3183.5358,3.36E-44,64.344127,64.344127,72.597487,4935.9257,3.47E-34,33.008281,33.008281,17.983168,449.13982,9.19E-20
MUP7,15.1111,1.1,2.01,4.001,8.0001,866.79745,,"[Minus], [# of exons: 7], [Gene type: NM]","chr4:60,079,341-60,079,594 chr4:60,080,382-60,080,427 chr4:60,080,592-60,080,693 chr4:60,081,037-60,081,147 chr4:60,081,773-60,081,846 chr4:60,082,605-60,082,738 chr4:60,083,077-60,083,347",NM_001347129,"Mup7, major urinary protein 7, major urinary protein 7|major urinary protein gene family member 3, Predicted to have odorant binding activity. Predicted to localize to extracellular space. Is expressed in liver.",odorant binding (GO:0005549); extracellular space (GO:0005615); biological_process (GO:0008150),Mup7,73.743387,73.7433871,16.154827,866.79745,0.000943955,34.669251,34.6692511,15.739265,630.34522,2.19E-05,39.933998,39.9339983,17.675961,712.46714,4.83E-08,19.006045,19.0060452,13.796607,196.03284,3.67E-06
NC_INTER_C4_3468,15.1111,1.1,2.01,4.001,8.0001,11.516224,,"[Plus], [# Lnc isoforms: 105], [# of exons: 14], [Gene type: lncRNA]","chr4:103,054,624-103,169,216",NR_040673,"Gm12718, predicted gene 12718; lnc_inter_chr4_3468, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Gm12718 lnc_inter_chr4_3468,8.5548118,8.5548118,0.029132279,0.24372471,5.21E-06,12.501044,12.5010443,0.039785457,0.53254551,1.61E-17,7.4707667,7.4707667,0.085653474,0.67906971,3.58E-05,22.667927,22.6679266,0.68764266,11.516224,1.90E-13
NC_INTER_C19_14873,15.1111,1.1,2.01,4.001,8.0001,137.69398,,"[Plus], [# Lnc isoforms: 87], [# of exons: 1], [Gene type: lncRNA]","chr19:23,135,639-23,150,699",,"lnc_inter_chr19_14873, ",,lnc_inter_chr19_14873,19.135643,19.1356435,0.29255537,4.640555,0.000386282,19.685588,19.6855878,1.0270045,18.732842,1.25E-10,20.226491,20.2264909,2.4421899,51.477589,3.89E-11,17.79797,17.7979705,9.1496939,137.69398,3.40E-07
SCARA5,15.1111,1.1,2.01,4.001,8.0001,3.7699461,,"[Plus], [# of exons: 10], [Gene type: NM]","chr14:66,285,240-66,383,663",NM_001168318 NM_028903,"Scara5, scavenger receptor class A, member 5, scavenger receptor class A member 5|scavenger receptor class A, member 5 (putative)|testis expressed scavenger receptor, Exhibits ferritin receptor activity. Involved in several processes, including cellular response to heat; iron ion transmembrane transport; and protein homotrimerization. Localizes to cell surface and integral component of plasma membrane. Is expressed in several structures, including eye; gonad; heart; spinal cord; and vertebral pre-cartilage condensation. Orthologous to human SCARA5 (scavenger receptor class A member 5).",scavenger receptor activity (GO:0005044); protein binding (GO:0005515); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); ion transport (GO:0006811); cellular iron ion homeostasis (GO:0006879); endocytosis (GO:0006897); external side of plasma membrane (GO:0009897); cell surface (GO:0009986); membrane (GO:0016020); integral component of membrane (GO:0016021); endocytic vesicle membrane (GO:0030666); cellular response to heat (GO:0034605); iron ion transmembrane transport (GO:0034755); iron ion homeostasis (GO:0055072); protein homotrimerization (GO:0070207); ferritin receptor activity (GO:0070287),Scara5,19.812319,19.8123192,0.025863001,0.49936104,7.25E-06,8.8760048,8.8760048,0.067433533,0.66169684,4.02E-05,8.0742738,8.0742738,0.090098466,0.71072378,0.007639512,7.3156383,7.3156383,0.70430838,3.7699461,0.001900246
ALAS2,15.1111,1.1,2.01,4.001,8.0001,31.404465,,"[Plus], [# of exons: 11], [Gene type: NM]","chrX:146,981,960-147,005,165",NM_001102446 NM_009653,"Alas2, aminolevulinic acid synthase 2, erythroid, 5-aminolevulinate synthase, erythroid-specific, mitochondrial|5-aminolevulinic acid synthase 2|delta-ALA synthase 2|delta-aminolevulinate synthase 2|erythroid-specific ALAS, Exhibits 5-aminolevulinate synthase activity. Involved in several processes, including erythrocyte differentiation; heme biosynthetic process; and hemoglobin biosynthetic process. Localizes to mitochondrion. Is expressed in several structures, including alimentary system; brain; genitourinary system; hemolymphoid system gland; and liver and biliary system. Human ortholog(s) of this gene implicated in cutaneous porphyria; erythropoietic protoporphyria; hemochromatosis; sideroblastic anemia; and sideroblastic anemia 1. Orthologous to human ALAS2 (5'-aminolevulinate synthase 2).","response to hypoxia (GO:0001666); catalytic activity (GO:0003824); 5-aminolevulinate synthase activity (GO:0003870); mitochondrion (GO:0005739); mitochondrial inner membrane (GO:0005743); mitochondrial matrix (GO:0005759); porphyrin-containing compound metabolic process (GO:0006778); heme biosynthetic process (GO:0006783); cellular iron ion homeostasis (GO:0006879); biosynthetic process (GO:0009058); transferase activity (GO:0016740); transferase activity, transferring acyl groups (GO:0016746); pyridoxal phosphate binding (GO:0030170); erythrocyte differentiation (GO:0030218); tetrapyrrole biosynthetic process (GO:0033014); hemoglobin biosynthetic process (GO:0042541); erythrocyte development (GO:0048821)",Alas2,6.2365473,6.2365473,5.1352284,31.404465,1.19E-06,8.1972826,8.1972826,3.4309612,28.308513,2.55E-18,8.9308034,8.9308034,2.7184389,25.792176,2.63E-11,8.1220132,8.1220132,2.3535675,14.901288,5.10E-07
CYP4A12A,15.1111,1.1,2.01,4.001,8.0001,89.523573,,"[Plus], [# of exons: 12], [Gene type: NM]","chr4:114,971,651-115,005,420",NM_177406,"Cyp4a12a, cytochrome P450, family 4, subfamily a, polypeptide 12a, cytochrome P450 4A12A|CYPIVA12|cytochrome P450, family 4, subfamily a, polypeptide 12, Exhibits alkane 1-monooxygenase activity and arachidonic acid omega-hydroxylase activity. Involved in omega-hydroxylase P450 pathway. Predicted to localize to endoplasmic reticulum membrane and extracellular space. Is expressed in metanephros; nervous system; nose; and respiratory system. Human ortholog(s) of this gene implicated in hypertension. Orthologous to human CYP4A11 (cytochrome P450 family 4 subfamily A member 11) and CYP4A22 (cytochrome P450 family 4 subfamily A member 22).","kidney development (GO:0001822); monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); extracellular space (GO:0005615); endoplasmic reticulum (GO:0005783); endoplasmic reticulum membrane (GO:0005789); arachidonic acid monooxygenase activity (GO:0008391); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); alkane 1-monooxygenase activity (GO:0018685); arachidonic acid metabolic process (GO:0019369); heme binding (GO:0020037); intracellular membrane-bounded organelle (GO:0043231); linoleic acid metabolic process (GO:0043651); icosanoid biosynthetic process (GO:0046456); metal ion binding (GO:0046872); lauric acid metabolic process (GO:0048252); arachidonic acid omega-hydroxylase activity (GO:0052869); aromatase activity (GO:0070330); omega-hydroxylase P450 pathway (GO:0097267); laurate hydroxylase activity (GO:0102116); 16-hydroxypalmitate dehydrogenase activity (GO:0103002)",Cyp4a12a,284.71505,284.7150529,0.24804491,69.119392,1.98E-34,144.00104,144.001039,0.29452193,45.30651,2.44E-73,138.96121,138.9612081,0.6339643,89.523573,8.84E-47,143.77089,143.7708894,0.54614031,60.261868,1.82E-46
CYP4A12B,15.1111,1.1,2.01,4.001,8.0001,21.33962,,"[Plus], [# of exons: 12], [Gene type: NM]","chr4:115,084,229-115,111,639",NM_172306,"Cyp4a12b, cytochrome P450, family 4, subfamily a, polypeptide 12B, cytochrome P450 4A12B|cytochrome P450, family 4, subfamily a family|cytochrome P450, family 4, subfamily a, polypeptide 12, Exhibits arachidonic acid omega-hydroxylase activity. Involved in omega-hydroxylase P450 pathway. Predicted to localize to endoplasmic reticulum membrane and extracellular space. Is expressed in metanephros; nervous system; nose; and respiratory system. Human ortholog(s) of this gene implicated in hypertension. Orthologous to human CYP4A11 (cytochrome P450 family 4 subfamily A member 11) and CYP4A22 (cytochrome P450 family 4 subfamily A member 22).","kidney development (GO:0001822); monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); extracellular space (GO:0005615); endoplasmic reticulum (GO:0005783); endoplasmic reticulum membrane (GO:0005789); arachidonic acid monooxygenase activity (GO:0008391); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); alkane 1-monooxygenase activity (GO:0018685); arachidonic acid metabolic process (GO:0019369); heme binding (GO:0020037); intracellular membrane-bounded organelle (GO:0043231); linoleic acid metabolic process (GO:0043651); icosanoid biosynthetic process (GO:0046456); metal ion binding (GO:0046872); lauric acid metabolic process (GO:0048252); arachidonic acid omega-hydroxylase activity (GO:0052869); aromatase activity (GO:0070330); omega-hydroxylase P450 pathway (GO:0097267); laurate hydroxylase activity (GO:0102116); 16-hydroxypalmitate dehydrogenase activity (GO:0103002)",Cyp4a12b,341.93174,341.9317386,0.051889569,14.612256,4.40E-29,247.30606,247.3060572,0.04101857,11.568744,2.84E-59,183.38683,183.3868321,0.11155693,21.33962,4.56E-43,85.806407,85.8064074,0.14229592,9.3205472,1.94E-29
EIF2S3Y,15.1111,1.1,2.01,4.001,8.0001,36.763675,,"[Plus], [# of exons: 12], [Gene type: NM]","chrY:347,038-365,037",NM_001357094 NM_012011,"Eif2s3y, eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked, eukaryotic translation initiation factor 2 subunit 3, Y-linked|eIF-2-gamma Y|eukaryotic translation initiation factor 2 subunit gamma, Y-linked|spermatogenesis Y|spermatogonial proliferation factor, Is predicted to contribute to tRNA binding activity. Predicted to be involved in formation of translation preinitiation complex and positive regulation of translational fidelity. Predicted to localize to cytosol and eukaryotic translation initiation factor 2 complex. Is expressed in several structures, including brain; genitourinary system; heart; liver; and lung. Human ortholog(s) of this gene implicated in MEHMO syndrome. Orthologous to human EIF2S3 (eukaryotic translation initiation factor 2 subunit gamma).",tRNA binding (GO:0000049); nucleotide binding (GO:0000166); formation of translation preinitiation complex (GO:0001731); translation initiation factor activity (GO:0003743); GTPase activity (GO:0003924); GTP binding (GO:0005525); cytosol (GO:0005829); eukaryotic translation initiation factor 2 complex (GO:0005850); translation (GO:0006412); translational initiation (GO:0006413); hydrolase activity (GO:0016787); positive regulation of translational fidelity (GO:0045903),Eif2s3y,186.71238,186.7123832,0.019567636,3.2858013,3.35E-22,397.54267,397.5426742,0.016073507,8.2291527,2.58E-41,220.90163,220.9016251,0.17618535,36.763675,2.02E-46,646.20729,646.2072916,0.047473868,29.020886,2.72E-48
TTC39C,15.1111,1.1,2.01,4.001,8.0001,107.02735,,"[Plus], [# of exons: 14], [Gene type: NM]","chr18:12,802,042-12,865,540 chr18:12,878,459-12,878,552 chr18:12,883,448-12,883,555 chr18:12,887,129-12,887,238 chr18:12,888,101-12,895,561",NM_028341,"Ttc39c, tetratricopeptide repeat domain 39C, tetratricopeptide repeat protein 39C|TPR repeat protein 39C, Predicted to be involved in cilium assembly and otolith morphogenesis. Is expressed in adrenal medulla; clavicle; naris; nervous system; and seminiferous cord. Orthologous to human TTC39C (tetratricopeptide repeat domain 39C).",molecular_function (GO:0003674); cellular_component (GO:0005575); otolith morphogenesis (GO:0032474); cilium assembly (GO:0060271),Ttc39c,3.8578876,3.8578876,3.9773836,15.046239,0.005303112,4.5144688,4.5144688,4.5792601,23.58138,1.26E-07,4.3134217,4.3134217,5.0880817,23.423563,5.02E-06,10.145512,10.1455124,15.061712,107.02735,1.35E-10
C6,15.1111,1.1,2.01,4.001,8.0001,25.050065,,"[Plus], [# of exons: 16], [Gene type: NM]","chr15:4,677,210-4,754,045",NM_016704,"C6, complement component 6, complement component C6, Involved in in utero embryonic development; positive regulation of activation of membrane attack complex; and positive regulation of angiogenesis. Predicted to localize to extracellular space and membrane attack complex. Is expressed in embryo. Human ortholog(s) of this gene implicated in complement component 6 deficiency. Orthologous to human C6 (complement C6).",in utero embryonic development (GO:0001701); positive regulation of activation of membrane attack complex (GO:0001970); membrane attack complex (GO:0005579); extracellular space (GO:0005615); positive regulation of apoptotic process (GO:0043065); positive regulation of angiogenesis (GO:0045766); positive regulation of complement activation (GO:0045917),C6,6.0094477,6.0094477,1.0165682,5.855529,2.34E-06,2.5488028,2.5488028,2.9607906,7.6268831,0.017716007,3.0081796,3.0081796,5.1696275,15.955787,0.021964292,3.8197852,3.8197852,8.3377507,25.050065,0.000250518
GM29650,15.1111,1.1,2.01,4.001,8.0001,68.637083,,"[Plus], [# of exons: 1], [Gene type: lincRNA]","chrY:384,836-385,577",,"Gm29650, ",,Gm29650,135.59692,135.5969179,0,6.1096062,0.000301068,313.90282,313.9028215,0,21.891782,3.53E-15,98.322746,98.3227457,0.13580463,28.304853,7.05E-12,532.18804,532.1880363,0,68.637083,1.47E-15
NOX4,15.1111,1.1,2.01,4.001,8.0001,7.9731062,,"[Plus], [# of exons: 20], [Gene type: NM]","chr7:94,395,159-94,547,218",NM_001285833 NM_001285835 NM_015760,"Nox4, NADPH oxidase 4, NADPH oxidase 4|KOX-1|kidney oxidase-1|kidney superoxide-producing NADPH oxidase|renal NAD(P)H-oxidase|superoxide-generating NADPH oxidase 4, Exhibits protein tyrosine kinase binding activity and superoxide-generating NAD(P)H oxidase activity. Involved in several processes, including bone resorption; positive regulation of intracellular signal transduction; and positive regulation of nitrogen compound metabolic process. Localizes to several cellular components, including mitochondrion; nucleus; and perinuclear region of cytoplasm. Predicted to colocalize with stress fiber. Is expressed in embryo; heart; metanephros; renal cortex; and ventricle compact myocardium. Orthologous to human NOX4 (NADPH oxidase 4).","cell morphogenesis (GO:0000902); stress fiber (GO:0001725); heart process (GO:0003015); nucleus (GO:0005634); nucleoplasm (GO:0005654); mitochondrion (GO:0005739); endoplasmic reticulum (GO:0005783); plasma membrane (GO:0005886); focal adhesion (GO:0005925); superoxide metabolic process (GO:0006801); defense response (GO:0006952); cell aging (GO:0007569); negative regulation of cell proliferation (GO:0008285); gene expression (GO:0010467); positive regulation of smooth muscle cell migration (GO:0014911); membrane (GO:0016020); integral component of membrane (GO:0016021); NAD(P)H oxidase activity (GO:0016174); superoxide-generating NADPH oxidase activity (GO:0016175); apical plasma membrane (GO:0016324); oxidoreductase activity (GO:0016491); cell junction (GO:0030054); superoxide anion generation (GO:0042554); NADPH oxidase complex (GO:0043020); positive regulation of apoptotic process (GO:0043065); positive regulation of MAP kinase activity (GO:0043406); bone resorption (GO:0045453); perinuclear region of cytoplasm (GO:0048471); oxidoreductase activity, acting on NAD(P)H, oxygen as acceptor (GO:0050664); homocysteine metabolic process (GO:0050667); positive regulation of stress fiber assembly (GO:0051496); positive regulation of protein kinase B signaling (GO:0051897); cardiac muscle cell differentiation (GO:0055007); positive regulation of protein tyrosine kinase activity (GO:0061098); positive regulation of ERK1 and ERK2 cascade (GO:0070374); cellular response to glucose stimulus (GO:0071333); cell periphery (GO:0071944); modified amino acid binding (GO:0072341); reactive oxygen species metabolic process (GO:0072593); perinuclear endoplasmic reticulum (GO:0097038); protein tyrosine kinase binding (GO:1990782); positive regulation of reactive oxygen species metabolic process (GO:2000379); positive regulation of DNA biosynthetic process (GO:2000573)",Nox4,14.56425,14.5642504,0.020528378,0.31272014,1.72E-08,9.5727336,9.5727336,0.050289807,0.48129572,7.02E-10,7.3270802,7.3270802,0.16380919,1.3427275,0.00745274,11.593803,11.5938032,0.89300186,7.9731062,4.23E-07
KDM5D,15.1111,1.1,2.01,4.001,8.0001,5.3851176,,"[Plus], [# of exons: 26], [Gene type: NM]","chrY:234,231-280,254",NM_011419,"Kdm5d, lysine (K)-specific demethylase 5D, lysine-specific demethylase 5D|H-Y|[histone H3]-trimethyl-L-lysine(4) demethylase 5D|histocompatibility Y antigen|histone demethylase JARID1D|jumonji, AT rich interactive domain 1D (Rbp2 like)|jumonji/ARID domain-containing protein 1D|protein SmcY|selected mouse cDNA on the Y, Predicted to have androgen receptor binding activity and histone demethylase activity (H3-trimethyl-K4 specific). Involved in T cell antigen processing and presentation. Predicted to localize to fibrillar center. Is expressed in several structures, including early conceptus; genitourinary system; heart; liver; and lung. Orthologous to human KDM5D (lysine demethylase 5D).",fibrillar center (GO:0001650); T cell antigen processing and presentation (GO:0002457); DNA binding (GO:0003677); nucleus (GO:0005634); chromatin organization (GO:0006325); chromatin remodeling (GO:0006338); oxidoreductase activity (GO:0016491); histone demethylase activity (GO:0032452); histone demethylase activity (H3-K4 specific) (GO:0032453); histone demethylase activity (H3-trimethyl-K4 specific) (GO:0034647); histone H3-K4 demethylation (GO:0034720); metal ion binding (GO:0046872); androgen receptor binding (GO:0050681); dioxygenase activity (GO:0051213); regulation of androgen receptor signaling pathway (GO:0060765),Kdm5d,61.64555,61.6455502,0.00765265,0.46736099,6.42E-12,126.14154,126.141539,0.006047787,1.0274265,3.27E-24,204.07326,204.073255,0.008164618,2.3231133,1.60E-27,741.1737,741.1736998,0.006492429,5.3851176,1.06E-35
AOX1,15.1111,1.1,2.01,4.001,8.0001,48.538175,,"[Plus], [# of exons: 35], [Gene type: NM]","chr1:58,086,813-58,142,980 chr1:58,143,719-58,163,254",NM_009676,"Aox1, aldehyde oxidase 1, aldehyde oxidase 1|aldehyde oxidase 2|azaheterocycle hydroxylase 1|retinal oxidase, Exhibits aldehyde oxidase activity; protein homodimerization activity; and retinal oxidase activity. Involved in drug metabolic process. Localizes to cytosol. Is expressed in retina. Human ortholog(s) of this gene implicated in amyotrophic lateral sclerosis. Orthologous to human AOX1 (aldehyde oxidase 1).","aldehyde oxidase activity (GO:0004031); iron ion binding (GO:0005506); cytoplasm (GO:0005737); cytosol (GO:0005829); electron transfer activity (GO:0009055); oxidoreductase activity (GO:0016491); drug metabolic process (GO:0017144); identical protein binding (GO:0042802); protein homodimerization activity (GO:0042803); molybdopterin cofactor binding (GO:0043546); metal ion binding (GO:0046872); retinal oxidase activity (GO:0050250); flavin adenine dinucleotide binding (GO:0050660); NAD binding (GO:0051287); iron-sulfur cluster binding (GO:0051536); 2 iron, 2 sulfur cluster binding (GO:0051537); FAD binding (GO:0071949); geranial:oxygen oxidoreductase activity (GO:0102797); heptaldehyde:oxygen oxidoreductase activity (GO:0102798)",Aox1,4.1457973,4.1457973,1.6898758,7.2121405,0.014709747,3.125929,3.125929,3.4674617,11.054138,2.00E-06,3.7473043,3.7473043,4.5436054,17.880616,2.91E-06,3.3839806,3.3839806,18.732633,48.538175,4.54E-05
ELOVL3,15.1111,1.1,2.01,4.001,8.0001,173.00582,,"[Plus], [# of exons: 4], [Gene type: NM]","chr19:46,206,387-46,210,184",NM_001374665 NM_007703,"Elovl3, elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3, elongation of very long chain fatty acids protein 3|3-keto acyl-CoA synthase Elovl3|ELOVL FA elongase 3|ELOVL fatty acid elongase 3|cold inducible glycoprotein 30|cold-inducible glycoprotein of 30 kDa|elongation of very long chain fatty acids-like 3|very long chain 3-ketoacyl-CoA synthase 3|very long chain 3-oxoacyl-CoA synthase 3, Predicted to have fatty acid elongase activity. Involved in fatty acid biosynthetic process and positive regulation of cold-induced thermogenesis. Predicted to localize to integral component of endoplasmic reticulum membrane. Is expressed in brown fat; embryo; head; and skin. Orthologous to human ELOVL3 (ELOVL fatty acid elongase 3).","endoplasmic reticulum (GO:0005783); lipid metabolic process (GO:0006629); fatty acid metabolic process (GO:0006631); fatty acid biosynthetic process (GO:0006633); fatty acid elongase activity (GO:0009922); membrane (GO:0016020); integral component of membrane (GO:0016021); transferase activity (GO:0016740); fatty acid elongation, saturated fatty acid (GO:0019367); sphingolipid biosynthetic process (GO:0030148); integral component of endoplasmic reticulum membrane (GO:0030176); fatty acid elongation, monounsaturated fatty acid (GO:0034625); fatty acid elongation, polyunsaturated fatty acid (GO:0034626); very long-chain fatty acid biosynthetic process (GO:0042761); 3-oxo-arachidoyl-CoA synthase activity (GO:0102336); 3-oxo-cerotoyl-CoA synthase activity (GO:0102337); 3-oxo-lignoceronyl-CoA synthase activity (GO:0102338); very-long-chain 3-ketoacyl-CoA synthase activity (GO:0102756)",Elovl3,12.463353,12.4633526,15.3059,173.00582,2.65E-06,10.564125,10.5641246,12.516496,139.81449,2.10E-13,11.447393,11.4473933,12.085562,138.5476,6.97E-09,5.8269947,5.8269947,9.553115,45.270952,0.000533963
CLEC2H,15.1111,1.1,2.01,4.001,8.0001,77.099876,,"[Plus], [# of exons: 5], [Gene type: NM]","chr6:128,612,403-128,627,392",NM_053165,"Clec2h, C-type lectin domain family 2, member h, C-type lectin domain family 2 member H|C-type lectin-related protein F, Exhibits natural killer cell lectin-like receptor binding activity. Predicted to be involved in cellular defense response. Predicted to localize to external side of plasma membrane. Orthologous to human CLEC2D (C-type lectin domain family 2 member D).",transmembrane signaling receptor activity (GO:0004888); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); cellular defense response (GO:0006968); external side of plasma membrane (GO:0009897); membrane (GO:0016020); integral component of membrane (GO:0016021); carbohydrate binding (GO:0030246); natural killer cell lectin-like receptor binding (GO:0046703),Clec2h,7.7543792,7.7543792,0.66996944,5.4505322,0.000329631,11.98565,11.9856504,0.95363998,11.408584,1.92E-05,10.063657,10.0636573,1.724234,19.07526,0.000310652,10.355009,10.3550088,9.7679547,77.099876,0.018039418
CSPG5,15.1111,1.1,2.01,4.001,8.0001,8.3614163,,"[Plus], [# of exons: 5], [Gene type: NM]","chr9:110,146,287-110,165,080",NM_001166273 NM_013884,"Cspg5, chondroitin sulfate proteoglycan 5, chondroitin sulfate proteoglycan 5|acidic leucine-rich EGF-like domain-containing brain protein|neuroglycan C, Involved in regulation of synaptic vesicle exocytosis and trans-synaptic signaling, modulating synaptic transmission. Localizes to GABA-ergic synapse; glutamatergic synapse; and integral component of postsynaptic membrane. Is expressed in central nervous system and retina. Orthologous to human CSPG5 (chondroitin sulfate proteoglycan 5).","endoplasmic reticulum (GO:0005783); Golgi apparatus (GO:0005794); plasma membrane (GO:0005886); cytoskeleton organization (GO:0007010); multicellular organism development (GO:0007275); nervous system development (GO:0007399); membrane (GO:0016020); integral component of membrane (GO:0016021); cell junction (GO:0030054); cell differentiation (GO:0030154); Golgi-associated vesicle membrane (GO:0030660); regulation of growth (GO:0040008); synapse (GO:0045202); cell projection morphogenesis (GO:0048858); modulation of chemical synaptic transmission (GO:0050804); glutamatergic synapse (GO:0098978); GABA-ergic synapse (GO:0098982); integral component of postsynaptic membrane (GO:0099055); trans-synaptic signaling, modulating synaptic transmission (GO:0099550); glial cell projection elongation (GO:0106091); positive regulation of substrate adhesion-dependent cell spreading (GO:1900026); regulation of synaptic vesicle exocytosis (GO:2000300)",Cspg5,10.81866,10.81866,0.33062888,3.4533015,8.29E-06,5.8011667,5.8011667,0.75021787,4.2814609,7.98E-06,6.3964417,6.3964417,0.54628099,3.5995946,0.000123588,7.3997543,7.3997543,1.4138943,8.3614163,0.000185851
OBP2A,15.1111,1.1,2.01,4.001,8.0001,9.7055521,,"[Plus], [# of exons: 7], [Gene type: NM]","chr2:25,555,594-25,558,846",NM_153558,"Obp2a, odorant binding protein 2A, odorant-binding protein 2a|epididymal-specific lipocalin-13|lipocalin 13, Predicted to have small molecule binding activity. Involved in several processes, including insulin receptor signaling pathway; negative regulation of gluconeogenesis; and regulation of lipid metabolic process. Localizes to extracellular space. Orthologous to human OBP2A (odorant binding protein 2A).",extracellular region (GO:0005576); extracellular space (GO:0005615); insulin receptor signaling pathway (GO:0008286); regulation of glucose metabolic process (GO:0010906); positive regulation of fatty acid beta-oxidation (GO:0032000); small molecule binding (GO:0036094); glucose homeostasis (GO:0042593); negative regulation of gluconeogenesis (GO:0045721); negative regulation of lipid biosynthetic process (GO:0051055),Obp2a,157.76678,157.7667789,0.026078699,6.5316565,2.65E-06,112.1467,112.1467013,0.044441379,8.2091595,0.000113918,132.28103,132.2810333,0.079321905,9.7055521,0.000331845,91.623513,91.6235127,0,2.4952725,0.022524294
CYP2D12,15.1111,1.1,2.01,4.001,8.0001,58.93415,,"[Plus], [# of exons: 9], [Gene type: NM]","chr15:82,385,519-82,385,765 chr15:82,386,631-82,386,802 chr15:82,387,074-82,387,226 chr15:82,387,306-82,387,466 chr15:82,388,088-82,388,264 chr15:82,388,448-82,388,589 chr15:82,388,782-82,388,969 chr15:82,389,351-82,389,492 chr15:82,389,593-82,389,843",NM_001355665 NM_201360,"Cyp2d12, cytochrome P450, family 2, subfamily d, polypeptide 12, cytochrome P450, family 2, subfamily d, polypeptide 12|cytochrome P450, 2d12, Predicted to have heme binding activity; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; and steroid hydroxylase activity. Predicted to be involved in arachidonic acid metabolic process; exogenous drug catabolic process; and xenobiotic metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in acute lymphoblastic leukemia; acute myeloid leukemia; asthma; autoimmune hepatitis; and rhinitis. Orthologous to human CYP2D6 (cytochrome P450 family 2 subfamily D member 6).","cytoplasm (GO:0005737); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); steroid hydroxylase activity (GO:0008395); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); arachidonic acid metabolic process (GO:0019369); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231)",Cyp2d12,10.661331,10.6613315,3.6454376,37.780974,9.54E-11,11.61342,11.61342,4.7812647,58.93415,5.17E-16,11.260217,11.2602165,4.640238,55.214732,3.38E-11,10.290251,10.2902514,2.9613517,23.382291,6.31E-08
CYP2D9,15.1111,1.1,2.01,4.001,8.0001,1740.2498,,"[Plus], [# of exons: 9], [Gene type: NM]","chr15:82,282,807-82,287,257",NM_010006,"Cyp2d9, cytochrome P450, family 2, subfamily d, polypeptide 9, cytochrome P450 2D9|CYPIID9|cytochrome P450, 2d9|cytochrome P450-16-alpha|cytochrome P450CA|testosterone 16-alpha hydroxylase|testosterone 16alpha-hydroxylase, Predicted to have heme binding activity; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; and steroid hydroxylase activity. Predicted to be involved in arachidonic acid metabolic process; exogenous drug catabolic process; and xenobiotic metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Is expressed in alimentary system; liver; and urinary system. Human ortholog(s) of this gene implicated in acute lymphoblastic leukemia; acute myeloid leukemia; asthma; autoimmune hepatitis; and rhinitis. Orthologous to human CYP2D6 (cytochrome P450 family 2 subfamily D member 6).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); steroid hydroxylase activity (GO:0008395); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); arachidonic acid metabolic process (GO:0019369); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); aromatase activity (GO:0070330)",Cyp2d9,19.09773,19.0977299,88.995576,1664.0277,1.45E-15,14.867605,14.8676046,109.67642,1740.2498,8.27E-19,16.742316,16.7423164,96.437799,1714.3141,1.03E-21,18.153839,18.1538389,60.353665,856.76131,5.00E-22
LAMA3,15.1111,1.1,2.01,4.001,8.0001,0.8586928,,"[~1%  IN BLACKLIST], [Plus], [# of exons: 76], [Gene type: NM]","chr18:12,492,443-12,741,521",NM_001347461 NM_010680,"Lama3, laminin, alpha 3, laminin subunit alpha-3|epiligrin subunit alpha|kalinin subunit alpha|laminin-5 subunit alpha|laminin-6 subunit alpha|laminin-7 subunit alpha|nicein subunit alpha|nicein, 150kDa, Predicted to have integrin binding activity. Predicted to be an extracellular matrix structural constituent. Predicted to be involved in several processes, including axon guidance; hemidesmosome assembly; and integrin-mediated signaling pathway. Localizes to laminin-5 complex. Is expressed in several structures, including alimentary system; central nervous system; genitourinary system; sensory organ; and skin. Used to study junctional epidermolysis bullosa and junctional epidermolysis bullosa non-Herlitz type. Human ortholog(s) of this gene implicated in junctional epidermolysis bullosa; junctional epidermolysis bullosa Herlitz type; junctional epidermolysis bullosa non-Herlitz type; and lung small cell carcinoma. Orthologous to human LAMA3 (laminin subunit alpha 3).",morphogenesis of a polarized epithelium (GO:0001738); signaling receptor binding (GO:0005102); integrin binding (GO:0005178); extracellular matrix structural constituent (GO:0005201); extracellular region (GO:0005576); basement membrane (GO:0005604); laminin-3 complex (GO:0005608); laminin-5 complex (GO:0005610); endoplasmic reticulum (GO:0005783); adherens junction (GO:0005912); cell adhesion (GO:0007155); integrin-mediated signaling pathway (GO:0007229); axon guidance (GO:0007411); animal organ morphogenesis (GO:0009887); tissue development (GO:0009888); cell migration (GO:0016477); hemidesmosome (GO:0030056); regulation of cell adhesion (GO:0030155); regulation of cell migration (GO:0030334); hemidesmosome assembly (GO:0031581); regulation of embryonic development (GO:0045995); collagen-containing extracellular matrix (GO:0062023); cell-cell adhesion (GO:0098609),Lama3,6.0276096,6.0276096,0.01090876,0.06682399,0.000407474,4.8137563,4.8137563,0.026419457,0.12781009,4.72E-05,10.015732,10.0157323,0.031571608,0.34525276,1.59E-11,2.8903484,2.8903484,0.41611052,0.8586928,0.037784747
CYP2U1,15.1111,1.1,2.01,4.001,8.0001,13.192445,,"[~7%  IN BLACKLIST], [Minus], [# of exons: 5], [Gene type: NM]","chr3:130,993,409-131,006,145",NM_027816,"Cyp2u1, cytochrome P450, family 2, subfamily u, polypeptide 1, cytochrome P450 2U1|cytochrome P450, 2u1|long-chain fatty acid omega-monooxygenase, Predicted to have heme binding activity and monooxygenase activity. Predicted to be involved in exogenous drug catabolic process; omega-hydroxylase P450 pathway; and xenobiotic metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Is expressed in several structures, including genitourinary system; heart; liver; lung; and spleen. Human ortholog(s) of this gene implicated in hereditary spastic paraplegia 56. Orthologous to human CYP2U1 (cytochrome P450 family 2 subfamily U member 1).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); mitochondrion (GO:0005739); mitochondrial inner membrane (GO:0005743); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); steroid hydroxylase activity (GO:0008395); membrane (GO:0016020); integral component of membrane (GO:0016021); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); arachidonic acid omega-hydroxylase activity (GO:0052869); omega-hydroxylase P450 pathway (GO:0097267); fatty acid omega-hydroxylase activity (GO:0102033)",Cyp2u1,5.7139166,5.7139166,1.8261031,10.502787,0.007834938,4.960263,4.960263,2.5675375,13.192445,1.86E-05,7.6063391,7.6063391,1.5785422,12.807721,3.83E-06,7.1514907,7.1514907,2.2934721,12.425068,1.29E-07
NC_INTER_C15_12585,14.0222,0,2.02,4.002,8.0002,3.0592085,,"[Minus], [# Lnc isoforms: 10], [# of exons: 2], [Gene type: lncRNA]","chr15:60,696,171-60,702,708",,"lnc_inter_chr15_12585, ",,lnc_inter_chr15_12585,0.16748252,-5.9707724,0.026580918,0,1,0.009665012,-103.4659848,0.77727371,0,0.007291214,0.014209008,-70.3778874,2.5931604,0.025032638,1.69E-05,0.005743155,-174.1203386,3.0592085,0,0.000258588
NC_AS_CX_49461,14.0222,0,2.02,4.002,8.0002,6.9720739,,"[Minus], [# Lnc isoforms: 10], [# of exons: 9], [Gene type: lncRNA]","chrX:8,873,895-8,909,798",,"lnc_as_chrX_49461, ",,lnc_as_chrX_49461,0.084888296,-11.7801869,4.3318625,0.25777785,0.23337592,0.050400334,-19.8411382,2.9473785,0.16233488,0.000202753,0.10151231,-9.8510223,2.6280693,0.28920526,0.008301803,0.052999376,-18.8681468,6.9720739,0.24640451,0.001096631
NC_INTRA_C19_15006,14.0222,0,2.02,4.002,8.0002,96.314613,,"[Minus], [# Lnc isoforms: 123], [# of exons: 39], [Gene type: lncRNA]","chr19:39,693,745-39,693,878 chr19:39,714,613-39,714,727 chr19:39,723,533-39,763,325 chr19:39,797,503-39,797,805 chr19:39,810,279-39,810,447 chr19:39,811,832-39,813,055 chr19:39,815,592-39,841,562 chr19:39,854,486-39,854,585 chr19:39,861,396-39,861,887 chr19:39,864,806-39,866,143 chr19:39,866,283-39,867,538 chr19:39,876,322-39,876,497 chr19:39,878,641-39,878,794 chr19:39,879,447-39,880,981 chr19:39,887,305-39,917,149 chr19:39,934,977-39,935,056 chr19:39,940,894-39,940,937 chr19:39,950,168-39,950,241 chr19:39,952,377-39,953,075 chr19:39,961,260-39,965,167",,"lnc_intra_chr19_15006, ",,lnc_intra_chr19_15006,0.37346697,-2.677613,0.7739535,0.26749672,0.2410156,0.2347539,-4.2597801,3.4435174,0.88168458,2.78E-08,0.19787585,-5.0536738,8.8081169,1.8514092,1.43E-07,0.20203275,-4.9496926,96.314613,15.560246,0.000258588
NC_INTER_C1_17289,14.0222,0,2.02,4.002,8.0002,95.364727,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr1:164,879,307-164,882,466",,"lnc_inter_chr1_17289, ",,lnc_inter_chr1_17289,0.093601223,-10.6836211,0.11132084,0,1,0.002874397,-347.8990352,5.2700242,0,1.15E-13,0.00996048,-100.3967663,6.8894353,0.051905198,5.94E-08,0.001628974,-613.8831961,95.364727,0.10267818,5.22E-19
NC_INTER_CX_49549,14.0222,0,2.02,4.002,8.0002,621.33567,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrX:15,653,052-15,653,357",,"lnc_inter_chrX_49549, ",,lnc_inter_chrX_49549,0.39440514,-2.5354639,1.4617324,0.34607577,1,0.10962424,-9.1220697,27.359751,3.1066593,6.56E-05,0.015867773,-63.0208143,42.70579,0.53760171,0.006657281,0.048534429,-20.6039304,621.33567,23.690611,6.94E-13
NC_INTER_C15_12592,14.0222,0,2.02,4.002,8.0002,13.17562,,"[Minus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr15:60,740,511-60,745,792",,"lnc_inter_chr15_12592,12593, ",,lnc_inter_chr15_12592,0.16995936,-5.8837595,0.032118133,0,1,0.008152163,-122.6668291,1.201841,0,0.000216084,0.011297634,-88.5141054,1.0087289,0,0.000462325,0.001677178,-596.2396098,13.17562,0,2.62E-11
NC_INTER_C6_5253,14.0222,0,2.02,4.002,8.0002,15.028574,,"[Minus], [# Lnc isoforms: 3], [# of exons: 2], [Gene type: lncRNA]","chr6:72,007,066-72,016,856",,"lnc_inter_chr6_5253, ",,lnc_inter_chr6_5253,0.065832281,-15.1901161,0.41682216,0.021257584,0.27890885,0.018751393,-53.3293719,2.408501,0.038754789,9.46E-13,0.026684215,-37.4753386,1.5627983,0.033463419,1.86E-07,0.02764322,-36.1752356,15.028574,0.31174102,2.43E-08
NC_INTER_C6_5137,14.0222,0,2.02,4.002,8.0002,1.9362939,,"[Minus], [# Lnc isoforms: 65], [# of exons: 12], [Gene type: lncRNA]","chr6:51,617,109-51,660,247",AK031323 XR_003956432 XR_003956433 XR_869087,"Gm38811, predicted gene, 38811; lnc_inter_chr6_5137, ",,Gm38811 lnc_inter_chr6_5137,0.15928783,-6.2779434,0.20559686,0.031115158,0.070308642,0.10619656,-9.4165006,0.37483864,0.043783588,1.44E-06,0.084265805,-11.8672099,0.44352294,0.037725809,4.59E-06,0.087796776,-11.3899399,1.9362939,0.11945693,5.37E-06
NC_AS_C15_12957,14.0222,0,2.02,4.002,8.0002,8.1539375,,"[Minus], [# Lnc isoforms: 6], [# of exons: 2], [Gene type: lncRNA]","chr15:103,116,785-103,120,822",,"lnc_as_chr15_12957, ",,lnc_as_chr15_12957,0.089299915,-11.1982189,0.69379971,0.050809331,0.73330011,0.021505904,-46.4988599,1.9302227,0.033299818,2.80E-05,0.066234418,-15.0978907,1.9108632,0.1217675,0.015955582,0.050380017,-19.84914,8.1539375,0.30674094,0.000380402
NC_INTER_CX_15394,14.0222,0,2.02,4.002,8.0002,759.9355,,"[Minus], [# Lnc isoforms: 71], [# of exons: 9], [Gene type: lncRNA]","chrX:100,655,402-100,678,954",NR_001463,"lnc_inter_chrX_15394, ; Xist, inactive X specific transcripts",X chromosome (GO:0000805); nucleus (GO:0005634); chromosome (GO:0005694); dosage compensation by inactivation of X chromosome (GO:0009048); nuclear body (GO:0016604); ribonucleoprotein complex binding (GO:0043021); spongiotrophoblast differentiation (GO:0060708); inactivation of X chromosome by genetic imprinting (GO:0060819),lnc_inter_chrX_15394 Xist,0.43179808,-2.3158973,0.84733537,0.35587513,1,0.004381322,-228.2416373,81.150407,0.34890806,1.75E-71,0.006244332,-160.1452224,58.500352,0.38100955,8.84E-47,0.002314742,-432.0135644,759.9355,1.345621,4.06E-89
FBXO44,14.0222,0,2.02,4.002,8.0002,7.1242806,,"[Minus], [# of exons: 10], [Gene type: NM,NR]","chr4:147,526,908-147,534,203",NM_001161851 NM_001161852 NM_001355701 NM_001355702 NM_173401 NR_104374 NR_104375,"Fbxo44, F-box protein 44, F-box only protein 44|F-box only protein 6a, Is predicted to contribute to ubiquitin protein ligase activity. Predicted to be involved in SCF-dependent proteasomal ubiquitin-dependent protein catabolic process; glycoprotein catabolic process; and ubiquitin-dependent ERAD pathway. Predicted to localize to SCF ubiquitin ligase complex and cytoplasm. Orthologous to human FBXO44 (F-box protein 44).",protein binding (GO:0005515); cytoplasm (GO:0005737); glycoprotein catabolic process (GO:0006516); proteasomal protein catabolic process (GO:0010498); SCF ubiquitin ligase complex (GO:0019005); ubiquitin-dependent ERAD pathway (GO:0030433); SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146); ubiquitin protein ligase activity (GO:0061630),Fbxo44,0.13265783,-7.5381908,1.5455687,0.15678299,0.58545439,0.11137207,-8.9789118,2.9055908,0.36173724,0.040629431,0.082458457,-12.1273188,2.4967157,0.21595871,0.000489923,0.10725176,-9.3238566,7.1242806,0.47375841,0.004732231
ACSS3,14.0222,0,2.02,4.002,8.0002,14.264265,,"[Minus], [# of exons: 17], [Gene type: NM]","chr10:106,370,573-106,560,693",NM_001142804 NM_198636,"Acss3, acyl-CoA synthetase short-chain family member 3, acyl-CoA synthetase short-chain family member 3, mitochondrial|acetate--CoA ligase 3|propionate--CoA ligase, Predicted to have acetate-CoA ligase activity; butyrate-CoA ligase activity; and propionate-CoA ligase activity. Localizes to mitochondrion. Is expressed in central nervous system; nose; and respiratory system. Orthologous to human ACSS3 (acyl-CoA synthetase short chain family member 3).",nucleotide binding (GO:0000166); acetate-CoA ligase activity (GO:0003987); ATP binding (GO:0005524); mitochondrion (GO:0005739); mitochondrial matrix (GO:0005759); biological_process (GO:0008150); ligase activity (GO:0016874); intracellular membrane-bounded organelle (GO:0043231); butyrate-CoA ligase activity (GO:0047760); propionate-CoA ligase activity (GO:0050218),Acss3,0.3077638,-3.2492451,0.63428797,0.19037932,0.050121304,0.3106807,-3.2187387,1.0008282,0.31909099,0.000778375,0.3274388,-3.0540058,1.8742797,0.66153332,0.012840918,0.34958338,-2.8605479,14.264265,3.8579308,0.001910514
NCKAP5,14.0222,0,2.02,4.002,8.0002,5.4304105,,"[Minus], [# of exons: 18], [Gene type: NM]","chr1:127,810,213-128,727,209",NM_001081756 NM_172484 NM_176957,"Nckap5, NCK-associated protein 5, nck-associated protein 5|peripheral clock protein, Predicted to be involved in microtubule bundle formation and microtubule depolymerization. Predicted to localize to microtubule plus-end. Is expressed in central nervous system; lung; and sensory organ. Orthologous to human NCKAP5 (NCK associated protein 5).",microtubule bundle formation (GO:0001578); molecular_function (GO:0003674); microtubule depolymerization (GO:0007019); microtubule plus-end (GO:0035371),Nckap5,0.62334272,-1.6042539,0.019437609,0.010640361,1,0.33198438,-3.0121899,0.13146895,0.045555163,3.88E-05,0.24364396,-4.1043497,0.12869385,0.033631143,0.020960314,0.29359463,-3.4060568,5.4304105,1.1976722,0.002261858
SOCS2,14.0222,0,2.02,4.002,8.0002,658.57147,,"[Minus], [# of exons: 5], [Gene type: NM]","chr10:94,874,124-94,879,491",NM_001168655 NM_001168656 NM_001168657 NM_007706,"Socs2, suppressor of cytokine signaling 2, suppressor of cytokine signaling 2|CIS-2|STAT-induced STAT inhibitor 2|cytokine inducible SH2-containing protein 2|cytokine-inducible SH2 protein 2, Exhibits growth hormone receptor binding activity. Involved in several processes, including mammary gland development; negative regulation of receptor signaling pathway via JAK-STAT; and positive regulation of neuron differentiation. Predicted to localize to phosphatidylinositol 3-kinase complex. Is expressed in Sertoli cell; embryo; primary sex cord; and retina. Human ortholog(s) of this gene implicated in endometrial cancer and ovarian carcinoma. Orthologous to human SOCS2 (suppressor of cytokine signaling 2).",regulation of cell growth (GO:0001558); growth hormone receptor binding (GO:0005131); insulin-like growth factor receptor binding (GO:0005159); protein binding (GO:0005515); cytoplasm (GO:0005737); phosphatidylinositol 3-kinase complex (GO:0005942); lactation (GO:0007595); JAK pathway signal transduction adaptor activity (GO:0008269); negative regulation of signal transduction (GO:0009968); response to estradiol (GO:0032355); cellular response to hormone stimulus (GO:0032870); intracellular signal transduction (GO:0035556); regulation of growth (GO:0040008); regulation of multicellular organism growth (GO:0040014); negative regulation of multicellular organism growth (GO:0040015); positive regulation of neuron differentiation (GO:0045666); negative regulation of JAK-STAT cascade (GO:0046426); phosphatidylinositol phosphorylation (GO:0046854); 1-phosphatidylinositol-3-kinase regulator activity (GO:0046935); growth hormone receptor signaling pathway (GO:0060396); mammary gland alveolus development (GO:0060749),Socs2,0.31724912,-3.152097,50.519052,16.239953,1,0.31053582,-3.2202404,76.65852,25.961185,4.17E-06,0.22941222,-4.3589658,143.62827,35.133784,5.58E-05,0.26725489,-3.7417463,658.57147,133.29705,0.009330337
CYP26B1,14.0222,0,2.02,4.002,8.0002,15.17659,,"[Minus], [# of exons: 7], [Gene type: NM]","chr6:84,521,408-84,543,902",NM_001177713 NM_175475,"Cyp26b1, cytochrome P450, family 26, subfamily b, polypeptide 1, cytochrome P450 26B1|cytochrome P450 retinoic acid-inactivating 2|cytochrome P450, 26, retinoic acid B1|cytochrome P450RAI-2|retinoic acid B1|retinoic acid hydroxylase, Predicted to have oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen; retinoic acid 4-hydroxylase activity; and retinoic acid binding activity. Involved in several processes, including cellular response to retinoic acid; male gamete generation; and skin development. Predicted to localize to cytoplasm. Is expressed in several structures, including alimentary system; brain; genitourinary system; limb; and sensory organ. Orthologous to human CYP26B1 (cytochrome P450 family 26 subfamily B member 1).","cell fate determination (GO:0001709); establishment of T cell polarity (GO:0001768); retinoic acid binding (GO:0001972); monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); xenobiotic metabolic process (GO:0006805); inflammatory response (GO:0006954); male meiotic nuclear division (GO:0007140); spermatogenesis (GO:0007283); retinoic acid 4-hydroxylase activity (GO:0008401); proximal/distal pattern formation (GO:0009954); positive regulation of gene expression (GO:0010628); membrane (GO:0016020); sterol metabolic process (GO:0016125); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen (GO:0016709); heme binding (GO:0020037); embryonic limb morphogenesis (GO:0030326); retinoic acid catabolic process (GO:0034653); retinoic acid metabolic process (GO:0042573); intracellular membrane-bounded organelle (GO:0043231); tongue morphogenesis (GO:0043587); regulation of T cell differentiation (GO:0045580); metal ion binding (GO:0046872); retinoic acid receptor signaling pathway (GO:0048384); regulation of retinoic acid receptor signaling pathway (GO:0048385); negative regulation of retinoic acid receptor signaling pathway (GO:0048387); bone morphogenesis (GO:0060349); establishment of skin barrier (GO:0061436); cornification (GO:0070268); cellular response to retinoic acid (GO:0071300); positive regulation of tongue muscle cell differentiation (GO:2001037)",Cyp26b1,0.24376634,-4.1022891,2.5014075,0.64543795,1,0.12732887,-7.8536785,15.17659,2.077992,0.000312087,0.14145393,-7.0694393,11.195261,1.6776955,0.005864224,0.1842231,-5.4282009,5.3385293,0.76032942,0.0437964
NCMAP,14.0222,0,2.02,4.002,8.0002,13.662441,,"[Minus], [# of exons: 7], [Gene type: NM]","chr4:134,925,492-134,954,142",NM_001168498 NM_001168500 NM_001243305 NM_001243306 NM_145555 NM_181047,"Ncmap, noncompact myelin associated protein, noncompact myelin-associated protein|myelin protein of 11 kDa, Predicted to be a structural constituent of myelin sheath. Predicted to be involved in peripheral nervous system myelin formation and positive regulation of myelination. Localizes to integral component of plasma membrane. Is expressed in several structures, including alimentary system; hindlimb mesenchyme; lower urinary tract; otic capsule; and skeleton. Orthologous to human NCMAP (non-compact myelin associated protein).",plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); membrane (GO:0016020); integral component of membrane (GO:0016021); structural constituent of myelin sheath (GO:0019911); regulation of myelination (GO:0031641); positive regulation of myelination (GO:0031643); peripheral nervous system myelin formation (GO:0032290); paranode region of axon (GO:0033270); Schmidt-Lanterman incisure (GO:0043220),Ncmap,0.28830864,-3.4685052,1.213213,0.3400534,0.39529221,0.2107943,-4.7439612,2.7142998,0.66474412,4.98E-05,0.13583019,-7.3621334,3.0540778,0.44945641,0.000141016,0.22990496,-4.3496234,13.662441,2.2893359,1.41E-05
PTGDS,14.0222,0,2.02,4.002,8.0002,560.18125,,"[Minus], [# of exons: 7], [Gene type: NM]","chr2:25,322,232-25,325,269",NM_008963,"Ptgds, prostaglandin D2 synthase (brain), prostaglandin-H2 D-isomerase|PGD2 synthase|glutathione-independent PGD synthase|glutathione-independent PGD synthetase|lipocalin-type prostaglandin-D synthase|prostaglandin D2 synthase (21 kDa, brain)|prostaglandin-D2 synthase, Exhibits prostaglandin-D synthase activity and retinoid binding activity. Involved in negative regulation of male germ cell proliferation; prostaglandin biosynthetic process; and regulation of circadian sleep/wake cycle, sleep. Localizes to extracellular region. Is expressed in several structures, including alimentary system; genitourinary system; integumental system; nervous system; and sensory organ. Human ortholog(s) of this gene implicated in carotid artery disease. Orthologous to human PTGDS (prostaglandin D2 synthase).","prostaglandin biosynthetic process (GO:0001516); prostaglandin-D synthase activity (GO:0004667); retinoid binding (GO:0005501); fatty acid binding (GO:0005504); extracellular region (GO:0005576); extracellular space (GO:0005615); nucleus (GO:0005634); nucleoplasm (GO:0005654); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); rough endoplasmic reticulum (GO:0005791); Golgi apparatus (GO:0005794); lipid metabolic process (GO:0006629); fatty acid metabolic process (GO:0006631); fatty acid biosynthetic process (GO:0006633); prostaglandin metabolic process (GO:0006693); membrane (GO:0016020); isomerase activity (GO:0016853); small molecule binding (GO:0036094); mast cell degranulation (GO:0043303); regulation of circadian sleep/wake cycle, sleep (GO:0045187); negative regulation of male germ cell proliferation (GO:2000255)",Ptgds,0.36244653,-2.7590277,28.43713,8.4350007,1,0.31878046,-3.1369551,91.482035,31.475478,0.025870393,0.25007414,-3.9988142,129.84234,35.273211,0.02176475,0.30540448,-3.2743462,560.18125,122.83403,0.005313132
NC_INTER_C16_13407,14.0222,0,2.02,4.002,8.0002,11.142633,,"[Plus], [# Lnc isoforms: 106], [# of exons: 17], [Gene type: lncRNA]","chr16:65,665,173-65,754,856",,"lnc_inter_chr16_13407,13408,13409,13410,13411,13412,13413,13414,13415, ",,lnc_inter_chr16_13407,0.6763839,-1.4784503,0.060392975,0.035437762,1,0.23640071,-4.2301058,0.52297355,0.1381587,5.67E-05,0.19908618,-5.0229503,1.7785723,0.38663351,0.003061803,0.282902,-3.5347929,11.142633,2.374248,0.002754817
NC_INTER_CX_15248,14.0222,0,2.02,4.002,8.0002,18.392449,,"[Plus], [# Lnc isoforms: 12], [# of exons: 1], [Gene type: lncRNA]","chrX:9,383,433-9,391,048",,"lnc_inter_chrX_15248, ",,lnc_inter_chrX_15248,0.11318644,-8.8349804,0.046250544,0,1,0.13225896,-7.5609246,0.66178624,0.081424346,0.007418912,0.013120874,-76.214435,0.53687032,0,0.006181508,0.13823961,-7.2338166,18.392449,1.8412614,0.000330893
NC_INTER_C19_14769,14.0222,0,2.02,4.002,8.0002,5.7612175,,"[Plus], [# Lnc isoforms: 14], [# of exons: 7], [Gene type: lncRNA]","chr19:7,877,214-7,911,280",,"lnc_inter_chr19_14769, ",,lnc_inter_chr19_14769,0.056690195,-17.6397348,0.080918396,0.003098489,0.35117604,0.12090836,-8.2707266,0.1671574,0.021451852,0.001412995,0.046914699,-21.3152811,0.23585246,0.009607137,0.000289478,0.047537198,-21.0361578,5.7612175,0.20724146,2.25E-16
NC_INTER_C10_9183,14.0222,0,2.02,4.002,8.0002,31.878939,,"[Plus], [# Lnc isoforms: 19], [# of exons: 3], [Gene type: lncRNA]","chr10:94,879,872-94,893,841",NR_045338,"5730420D15Rik, RIKEN cDNA 5730420D15 gene; lnc_inter_chr10_9183, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),5730420D15Rik lnc_inter_chr10_9183,0.22764307,-4.3928418,0.78620383,0.17163523,0.055543768,0.086824747,-11.5174537,1.9657997,0.18177243,9.64E-12,0.11034729,-9.0622976,3.0761301,0.35463033,3.05E-08,0.093894436,-10.6502583,31.878939,2.2961253,1.16E-09
NC_INTER_C15_12595,14.0222,0,2.02,4.002,8.0002,4.0594822,,"[Plus], [# Lnc isoforms: 26], [# of exons: 16], [Gene type: lncRNA]","chr15:60,824,192-60,885,994",,"lnc_inter_chr15_12595,12596,12597,12598,12599, ",,lnc_inter_chr15_12595,0.041669561,-23.998333,0.060513433,0.001659471,0.27049658,0.055184501,-18.1210302,0.12861121,0.006560704,0.000319273,0.050527507,-19.7912002,0.19103596,0.009593999,0.000126249,0.019419442,-51.4947851,4.0594822,0.058023372,2.10E-09
NC_AS_C4_3281,14.0222,0,2.02,4.002,8.0002,3.6968819,,"[Plus], [# Lnc isoforms: 27], [# of exons: 9], [Gene type: lncRNA]","chr4:60,094,145-60,172,105",,"lnc_as_chr4_3281, ",,lnc_as_chr4_3281,0.32295504,-3.0964063,0.23194454,0.064003564,1,0.27825855,-3.5937799,0.49301109,0.15220123,0.002290502,0.2337102,-4.2788034,1.2386025,0.30527956,0.004714675,0.26607167,-3.7583859,3.6968819,0.73149989,0.003497365
NC_INTER_C13_11189,14.0222,0,2.02,4.002,8.0002,4.8381559,,"[Plus], [# Lnc isoforms: 2], [# of exons: 3], [Gene type: lncRNA]","chr13:35,055,917-35,067,304",AK012214 XR_003950704 XR_873227,"Gm16984, predicted gene, 16984; lnc_inter_chr13_11189, ",,Gm16984 lnc_inter_chr13_11189,0.017781544,-56.238085,0.18997456,0,0.054577352,0.007152533,-139.8106104,0.65308474,0,4.23E-07,0.026661187,-37.5077077,0.7228015,0.014370629,0.00027957,0.019633236,-50.934039,4.8381559,0.057365402,3.55E-07
NC_AS_C19_14883,14.0222,0,2.02,4.002,8.0002,33.616449,,"[Plus], [# Lnc isoforms: 30], [# of exons: 11], [Gene type: lncRNA]","chr19:23,360,457-23,430,334",,"lnc_as_chr19_14883, ",,lnc_as_chr19_14883,0.10157034,-9.8453935,0.16516027,0.013052546,1,0.012681669,-78.8539734,1.5154309,0.017037428,0.009496042,0.008792007,-113.7396781,2.1613785,0.019473844,0.015367599,0.006666953,-149.9935562,33.616449,0.17931857,0.000703548
NC_AS_C3_2128,14.0222,0,2.02,4.002,8.0002,1.137355,,"[Plus], [# Lnc isoforms: 32], [# of exons: 15], [Gene type: lncRNA]","chr3:7,576,255-7,689,237",NR_168341,"Gm16685, predicted gene, 16685; lnc_as_chr3_2128,2129,2130,2131,2132,2133,2134,2135,2136,2137,2138, ",,Gm16685 lnc_as_chr3_2128,0.83165239,-1.2024254,0.004687168,0.003892398,1,0.1487387,-6.7231996,0.067487015,0.009326589,0.008347584,0.069947322,-14.296473,0.085864745,0.006247811,0.013108641,0.17414138,-5.7424607,1.137355,0.14844089,8.86E-06
NC_INTER_C4_38000,14.0222,0,2.02,4.002,8.0002,421.46912,,"[Plus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr4:61,259,375-61,260,560",,"lnc_inter_chr4_38000, ",,lnc_inter_chr4_38000,1.5138577,1.5138577,0.22564554,0.27210472,1,0.086484891,-11.5627133,3.9444624,0.36415175,0.019934763,0.10729875,-9.3197733,6.630774,0.73405801,0.007847929,0.056243366,-17.7798748,421.46912,16.952973,5.53E-08
NC_INTER_C4_3819,14.0222,0,2.02,4.002,8.0002,27.697335,,"[Plus], [# Lnc isoforms: 4], [# of exons: 4], [Gene type: lncRNA]","chr4:144,550,258-144,561,587",,"lnc_inter_chr4_3819, ",,lnc_inter_chr4_3819,0.39613673,-2.5243809,0.45718462,0.16872853,1,0.12271392,-8.1490349,3.9042857,0.45105447,3.79E-09,0.14782234,-6.7648775,7.7437152,1.1936239,2.23E-05,0.16478856,-6.0683823,27.697335,3.7799765,0.00015577
ALDH3B3,14.0222,0,2.02,4.002,8.0002,4.3633597,,"[Plus], [# of exons: 10], [Gene type: NM]","chr19:3,958,808-3,970,438",NM_028545,"Aldh3b3, aldehyde dehydrogenase 3 family, member B3, aldehyde dehydrogenase family 3 member B3, Exhibits aldehyde dehydrogenase (NAD+) activity. Predicted to be involved in cellular aldehyde metabolic process. Localizes to cytoplasm and plasma membrane. Is expressed in olfactory epithelium; retina inner nuclear layer; retina layer; and retina outer nuclear layer. Orthologous to human ALDH3B1 (aldehyde dehydrogenase 3 family member B1).","3-chloroallyl aldehyde dehydrogenase activity (GO:0004028); aldehyde dehydrogenase (NAD) activity (GO:0004029); cytoplasm (GO:0005737); plasma membrane (GO:0005886); cellular aldehyde metabolic process (GO:0006081); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor (GO:0016620); glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity (GO:0043878)",Aldh3b3,0.12036015,-8.3083976,0.43484135,0.047404384,0.11492843,0.063845417,-15.6628313,1.0410914,0.06487341,4.15E-07,0.053354557,-18.7425416,1.3628473,0.070380219,2.88E-05,0.11897936,-8.4048195,4.3633597,0.36172912,0.000528375
HNF4G,14.0222,0,2.02,4.002,8.0002,3.3639927,,"[Plus], [# of exons: 10], [Gene type: NM]","chr3:3,508,030-3,659,800",NM_013920,"Hnf4g, hepatocyte nuclear factor 4, gamma, hepatocyte nuclear factor 4-gamma|HNF-4-gamma|nuclear receptor subfamily 2 group A member 2, Predicted to have DNA-binding transcription activator activity, RNA polymerase II-specific; RNA polymerase II cis-regulatory region sequence-specific DNA binding activity; and nuclear receptor activity. Involved in positive regulation of transcription, DNA-templated. Predicted to localize to several cellular components, including intercellular bridge; mitotic spindle; and nucleoplasm. Is expressed in several structures, including genitourinary system; gut; and nervous system. Orthologous to human HNF4G (hepatocyte nuclear factor 4 gamma).","RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0001228); DNA binding (GO:0003677); DNA binding transcription factor activity (GO:0003700); nuclear receptor activity (GO:0004879); nucleus (GO:0005634); nucleoplasm (GO:0005654); transcription factor complex (GO:0005667); cytosol (GO:0005829); regulation of transcription, DNA-templated (GO:0006355); regulation of transcription by RNA polymerase II (GO:0006357); zinc ion binding (GO:0008270); cell differentiation (GO:0030154); sequence-specific DNA binding (GO:0043565); intercellular bridge (GO:0045171); positive regulation of transcription, DNA-templated (GO:0045893); positive regulation of transcription by RNA polymerase II (GO:0045944); metal ion binding (GO:0046872); anatomical structure development (GO:0048856); mitotic spindle (GO:0072686)",Hnf4g,0.36593958,-2.7326915,0.006283226,0.002241594,1,0.24915808,-4.0135162,0.18618957,0.049331721,0.005179746,0.18024019,-5.5481521,0.18578669,0.036806728,0.017899072,0.28041184,-3.5661832,3.3639927,0.68964291,0.013200093
MEIOB,14.0222,0,2.02,4.002,8.0002,106.31259,,"[Plus], [# of exons: 14], [Gene type: NM]","chr17:24,941,327-24,976,732",NM_029197,"Meiob, meiosis specific with OB domains, meiosis-specific with OB domain-containing protein|protein expressed in male leptotene and zygotene spermatocytes 675, Exhibits chromatin binding activity; single-stranded DNA 3'-5' exodeoxyribonuclease activity; and single-stranded DNA binding activity. Involved in double-strand break repair via homologous recombination; fertilization; and meiosis I. Localizes to cytoplasm. Is expressed in genitourinary system. Human ortholog(s) of this gene implicated in spermatogenic failure 22. Orthologous to human MEIOB (meiosis specific with OB-fold).",resolution of meiotic recombination intermediates (GO:0000712); double-strand break repair via homologous recombination (GO:0000724); DNA binding (GO:0003677); chromatin binding (GO:0003682); single-stranded DNA binding (GO:0003697); nuclease activity (GO:0004518); exonuclease activity (GO:0004527); protein binding (GO:0005515); nucleus (GO:0005634); chromosome (GO:0005694); cytoplasm (GO:0005737); synapsis (GO:0007129); male meiotic nuclear division (GO:0007140); male meiosis I (GO:0007141); female meiosis I (GO:0007144); single-stranded DNA 3'-5' exodeoxyribonuclease activity (GO:0008310); fertilization (GO:0009566); hydrolase activity (GO:0016787); meiotic cell cycle (GO:0051321),Meiob,0.45743006,-2.1861265,2.4131619,1.0156412,1,0.36920461,-2.7085252,9.1212575,3.5623934,0.000173947,0.37150559,-2.6917495,17.2535,6.7692143,0.044423504,0.32774661,-3.0511376,106.31259,27.927722,0.02464152
SYTL5,14.0222,0,2.02,4.002,8.0002,3.1794114,,"[Plus], [# of exons: 17], [Gene type: NM]","chrX:9,462,747-9,575,990",NM_001290728 NM_177704,"Sytl5, synaptotagmin-like 5, synaptotagmin-like protein 5, Predicted to have neurexin family protein binding activity. Involved in exocytosis. Predicted to localize to exocytic vesicle and plasma membrane. Orthologous to human SYTL5 (synaptotagmin like 5).",protein binding (GO:0005515); phospholipid binding (GO:0005543); plasma membrane (GO:0005886); intracellular protein transport (GO:0006886); exocytosis (GO:0006887); membrane (GO:0016020); neurexin family protein binding (GO:0042043); metal ion binding (GO:0046872); exocytic vesicle (GO:0070382),Sytl5,0.47934125,-2.0861964,0.046627973,0.020604625,1,0.11857684,-8.4333501,0.12971624,0.016715308,3.97E-06,0.14005917,-7.1398396,0.47860126,0.071934224,0.00032672,0.14785721,-6.7632819,3.1794114,0.34118855,1.72E-05
RFX4,14.0222,0,2.02,4.002,8.0002,9.3193197,,"[Plus], [# of exons: 19], [Gene type: NM]","chr10:84,218,793-84,369,283",NM_001024918 NM_027689,"Rfx4, regulatory factor X, 4 (influences HLA class II expression), transcription factor RFX4|regulatory factor X 4 protein|winged-helix transcription factor RFX4, Exhibits chromatin binding activity. Involved in central nervous system development; cilium assembly; and regulation of gene expression. Localizes to nucleus. Is expressed in several structures, including central nervous system; eye; future brain; genitourinary system; and liver. Orthologous to human RFX4 (regulatory factor X4).","RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); RNA polymerase II transcription factor activity, sequence-specific DNA binding (GO:0000981); transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0001228); DNA binding (GO:0003677); chromatin binding (GO:0003682); DNA binding transcription factor activity (GO:0003700); protein binding (GO:0005515); nucleus (GO:0005634); regulation of transcription, DNA-templated (GO:0006355); regulation of transcription by RNA polymerase II (GO:0006357); dorsal spinal cord development (GO:0021516); telencephalon development (GO:0021537); cerebellar cortex morphogenesis (GO:0021696); negative regulation of smoothened signaling pathway involved in ventral spinal cord patterning (GO:0021914); forebrain development (GO:0030900); midbrain development (GO:0030901); positive regulation of transcription by RNA polymerase II (GO:0045944); cilium assembly (GO:0060271); regulation of protein processing (GO:0070613); sequence-specific double-stranded DNA binding (GO:1990837)",Rfx4,0.2676608,-3.7360719,0.15451215,0.038642814,0.14943636,0.12391153,-8.0702743,0.47139125,0.069384685,0.000187052,0.14048053,-7.118424,0.56264676,0.084849633,0.006987917,0.069159488,-14.4593321,9.3193197,0.44923262,6.21E-11
GREB1L,14.0222,0,2.02,4.002,8.0002,4.8701289,,"[Plus], [# of exons: 33], [Gene type: NM]","chr18:10,325,177-10,562,939",NM_001083628,"Greb1l, growth regulation by estrogen in breast cancer-like, GREB1-like protein, Involved in animal organ development and paramesonephric duct development. Predicted to localize to integral component of membrane. Is expressed in several structures, including brain; liver; tail unsegmented mesenchyme; thymus; and urinary system. Human ortholog(s) of this gene implicated in renal agenesis. Orthologous to human GREB1L (GREB1 like retinoic acid receptor coactivator).",metanephros development (GO:0001656); branching involved in ureteric bud morphogenesis (GO:0001658); kidney development (GO:0001822); cardiac ventricle development (GO:0003231); molecular_function (GO:0003674); cellular_component (GO:0005575); multicellular organism development (GO:0007275); membrane (GO:0016020); integral component of membrane (GO:0016021); male genitalia development (GO:0030539); uterus development (GO:0060065); epithelial tube morphogenesis (GO:0060562); paramesonephric duct development (GO:0061205); mesonephric duct development (GO:0072177),Greb1l,0.27827643,-3.5935491,0.035058524,0.008743793,0.56618793,0.32613533,-3.0662118,0.19486894,0.067027127,0.028427661,0.19827661,-5.0434592,0.33802444,0.072227061,0.017185963,0.30991684,-3.2266721,4.8701289,1.1113425,0.001360064
IGFBP1,14.0222,0,2.02,4.002,8.0002,134.65123,,"[Plus], [# of exons: 4], [Gene type: NM]","chr11:7,097,790-7,102,549",NM_008341,"Igfbp1, insulin-like growth factor binding protein 1, insulin-like growth factor-binding protein 1|IBP-1|IGF-binding protein 1|INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1 PRECURSOR (IGFBP-1) (IBP-1) (IGF-BINDING PROTEIN 1), Exhibits insulin-like growth factor binding activity. Predicted to be involved in regulation of insulin-like growth factor receptor signaling pathway. Localizes to extracellular space. Is expressed in several structures, including blastocyst; early embryo; liver; and secondary oocyte. Human ortholog(s) of this gene implicated in diabetic angiopathy. Orthologous to human IGFBP1 (insulin like growth factor binding protein 1).",insulin-like growth factor binding (GO:0005520); extracellular region (GO:0005576); extracellular space (GO:0005615); Golgi apparatus (GO:0005794); growth factor binding (GO:0019838); insulin-like growth factor I binding (GO:0031994); insulin-like growth factor II binding (GO:0031995); regulation of insulin-like growth factor receptor signaling pathway (GO:0043567),Igfbp1,0.3026926,-3.3036817,32.538442,9.2988077,0.094332133,0.15306242,-6.5332823,109.80844,18.402238,6.35E-08,0.16644032,-6.0081597,134.65123,22.809228,0.002449388,0.11257982,-8.8825865,108.18225,10.071083,0.000169855
RDH16F2,14.0222,0,2.02,4.002,8.0002,784.21766,,"[Plus], [# of exons: 4], [Gene type: NM]","chr10:127,303,532-127,314,375",NM_145424,"Rdh16f2, RDH16 family member 2, cis-retinol/3alpha hydroxysterol short-chain dehydrogenase-like, Predicted to have androstan-3-alpha,17-beta-diol dehydrogenase activity and androsterone dehydrogenase activity. Predicted to localize to endoplasmic reticulum membrane and integral component of organelle membrane. Is expressed in urinary system. Orthologous to human RDH16 (retinol dehydrogenase 16).","endoplasmic reticulum membrane (GO:0005789); integral component of organelle membrane (GO:0031301); intracellular membrane-bounded organelle (GO:0043231); androsterone dehydrogenase activity (GO:0047023); androstan-3-alpha,17-beta-diol dehydrogenase activity (GO:0047044)",Rdh16f2,0.23991467,-4.1681486,209.10377,50.617068,0.055989206,0.20179745,-4.9554641,249.00187,59.341916,5.83E-05,0.21449354,-4.6621451,289.67755,67.970076,0.001604681,0.29344591,-3.4077831,784.21766,171.31377,4.68E-05
ORM3,14.0222,0,2.02,4.002,8.0002,170.1258,,"[Plus], [# of exons: 6], [Gene type: NM]","chr4:63,017,196-63,017,347 chr4:63,017,605-63,017,747 chr4:63,017,945-63,018,015 chr4:63,018,578-63,018,685 chr4:63,018,823-63,018,926 chr4:63,019,397-63,020,545",NM_013623,"Orm3, orosomucoid 3, alpha-1-acid glycoprotein 3|AGP 3|OMD 3, Predicted to localize to extracellular space. Orthologous to human ORM1 (orosomucoid 1) and ORM2 (orosomucoid 2).",molecular_function (GO:0003674); extracellular space (GO:0005615),Orm3,0.45880727,-2.1795644,104.47196,37.631288,1,0.33669836,-2.9700174,122.17975,46.38862,0.01095863,0.27846723,-3.5910869,170.1258,50.898565,0.004780229,0.25071554,-3.9885841,165.30152,29.111782,0.022667149
PNPLA3,14.0222,0,2.02,4.002,8.0002,36.62137,,"[Plus], [# of exons: 8], [Gene type: NM]","chr15:83,998,246-83,998,699 chr15:83,998,808-84,019,951",NM_054088,"Pnpla3, patatin-like phospholipase domain containing 3, 1-acylglycerol-3-phosphate O-acyltransferase Pnpla3|acylglycerol O-acyltransferase|acylglycerol transacylase|adiponutrin|calcium-independent phospholipase A2-epsilon|iPLA2-epsilon|lysophosphatidic acid acyltransferase|patatin-like phospholipase domain-containing protein 3, Exhibits several functions, including 1-acylglycerol-3-phosphate O-acyltransferase activity; long-chain fatty acyl-CoA binding activity; and lysophosphatidic acid binding activity. Involved in glycerolipid metabolic process; long-chain fatty acid metabolic process; and response to dietary excess. Localizes to lipid droplet and membrane. Is expressed in left lung; olfactory epithelium; and right lung. Used to study non-alcoholic fatty liver disease. Human ortholog(s) of this gene implicated in coronary artery disease; fatty liver disease (multiple); liver disease (multiple); and type 2 diabetes mellitus. Orthologous to human PNPLA3 (patatin like phospholipase domain containing 3).","long-chain fatty acid metabolic process (GO:0001676); response to dietary excess (GO:0002021); 1-acylglycerol-3-phosphate O-acyltransferase activity (GO:0003841); phospholipase A2 activity (GO:0004623); triglyceride lipase activity (GO:0004806); cytoplasm (GO:0005737); lipid droplet (GO:0005811); lipid metabolic process (GO:0006629); glycerophospholipid metabolic process (GO:0006650); phosphatidic acid biosynthetic process (GO:0006654); phospholipid biosynthetic process (GO:0008654); membrane (GO:0016020); integral component of membrane (GO:0016021); lipid catabolic process (GO:0016042); transferase activity (GO:0016740); transferase activity, transferring acyl groups (GO:0016746); hydrolase activity (GO:0016787); triglyceride biosynthetic process (GO:0019432); triglyceride catabolic process (GO:0019433); lipid particle organization (GO:0034389); lysophosphatidic acid binding (GO:0035727); long-chain fatty acyl-CoA binding (GO:0036042); triglyceride acyl-chain remodeling (GO:0036153); lysophosphatidic acid acyltransferase activity (GO:0042171); mono-olein transacylation activity (GO:0051264); diolein transacylation activity (GO:0051265); lipid homeostasis (GO:0055088)",Pnpla3,0.29569115,-3.3819071,1.241908,0.31689981,0.18829633,0.21555417,-4.6392051,4.1503837,0.90034965,3.48E-05,0.19901375,-5.0247784,4.3615347,0.89937073,0.000275972,0.17651404,-5.6652716,36.62137,4.9458484,9.12E-05
NC_INTER_C10_8696,14.0222,0,2.02,4.002,8.0002,4.0053523,,"[~1%  IN BLACKLIST], [Minus], [# Lnc isoforms: 71], [# of exons: 50], [Gene type: lncRNA]","chr10:16,594,483-16,815,588",NR_038020,"Gm20125, predicted gene, 20125; lnc_inter_chr10_8696,8697, ",,Gm20125 lnc_inter_chr10_8696,0.32155771,-3.1098616,0.01361941,0.004282035,1,0.052778795,-18.9470032,0.18890927,0.008816368,0.017000746,0.052840567,-18.9248537,0.21108374,0.011799443,0.024272736,0.032543062,-30.7285164,4.0053523,0.10274458,0.000444062
NC_INTER_C7_6190,14.0222,0,2.02,4.002,8.0002,46.636175,,"[~2%  IN BLACKLIST], [Minus], [# Lnc isoforms: 73], [# of exons: 18], [Gene type: lncRNA]","chr7:55,939,302-55,997,270",XR_001778121 XR_001778122 XR_001778123 XR_001778124,"Gm45086, predicted gene 45086; lnc_inter_chr7_6190,6191, ",,Gm45086 lnc_inter_chr7_6190,0.47891801,-2.0880401,1.1275358,0.49986087,0.80721568,0.36462164,-2.742569,3.2395465,1.202465,0.016133853,0.34591749,-2.8908628,6.6702893,2.4843418,0.033976492,0.28340185,-3.5285584,46.636175,10.008763,1.10E-05
NC_INTER_C19_14770,14.0222,0,2.02,4.002,8.0002,7.2567141,,"[~44%  IN BLACKLIST], [Plus], [# Lnc isoforms: 4], [# of exons: 3], [Gene type: lncRNA]","chr19:7,918,104-7,923,575",,"lnc_inter_chr19_14770, ",,lnc_inter_chr19_14770,0.055825522,-17.9129539,0.11153901,0,1,0.003633947,-275.1829074,2.5938809,0,2.28E-14,0.026250505,-38.0945055,5.0980479,0.12914468,1.87E-12,0.066172497,-15.1120184,7.2567141,0.38258776,6.37E-06
NC_INTER_C13_11669,14.0111,0,2.01,4.001,8.0001,3.4368281,,"[Minus], [# Lnc isoforms: 16], [# of exons: 11], [Gene type: lncRNA]","chr13:104,335,078-104,392,333",NR_136924,"Gm30551, predicted gene, 30551; lnc_inter_chr13_11669, ",,Gm30551 lnc_inter_chr13_11669,3.5019893,3.5019893,0.034892465,0.11648911,0.36805394,7.4126869,7.4126869,0.039596521,0.30730232,0.000881613,7.1678092,7.1678092,0.04277038,0.35255087,0.004714675,6.4596527,6.4596527,0.67717992,3.4368281,0.000707259
NC_INTER_CX_50216,14.0111,0,2.01,4.001,8.0001,102.48455,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrX:122,678,644-122,679,742",,"lnc_inter_chrX_50216, ",,lnc_inter_chrX_50216,20.361585,20.3615845,0,0.67819357,1,102.78427,102.7842698,0,5.1799115,0.000243972,76.66344,76.66344,0.12528642,15.101962,1.64E-09,1165.5814,1165.581447,0,102.48455,1.34E-23
NC_INTER_C11_9924,14.0111,0,2.01,4.001,8.0001,22.673908,,"[Minus], [# Lnc isoforms: 236], [# of exons: 9], [Gene type: lncRNA]","chr11:81,788,231-81,848,815",XR_001780117 XR_001780118 XR_001780119 XR_003949739 XR_003949740 XR_880045 XR_880047 XR_880048 XR_880049 XR_880050 XR_880051,"Gm31522, predicted gene, 31522; lnc_inter_chr11_9924,9925, ",,Gm31522 lnc_inter_chr11_9924,4.349266,4.349266,0.042756386,0.19936471,0.23337592,5.3759612,5.3759612,0.46512931,2.5314458,5.98E-10,6.3275635,6.3275635,0.59043405,3.9079726,3.78E-07,6.4019567,6.4019567,4.4304041,22.673908,1.45E-06
NC_INTER_C8_7423,14.0111,0,2.01,4.001,8.0001,10.953423,,"[Minus], [# Lnc isoforms: 244], [# of exons: 10], [Gene type: lncRNA]","chr8:116,533,048-116,655,614",,"lnc_inter_chr8_7423,7425,7426,7427,7428,7429,7430, ",,lnc_inter_chr8_7423,2.3505968,2.3505968,0.49967423,1.0084699,1,2.8879404,2.8879404,0.57324592,1.7837549,0.006318418,3.083904,3.083904,0.84420008,2.689894,0.020691761,3.477242,3.477242,4.0569805,10.953423,0.039688327
NC_INTER_C10_8999,14.0111,0,2.01,4.001,8.0001,56.582935,,"[Minus], [# Lnc isoforms: 42], [# of exons: 8], [Gene type: lncRNA]","chr10:70,625,939-70,644,797",NR_038040,"C730027H18Rik, RIKEN cDNA C730027H18 gene; lnc_inter_chr10_8999, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),C730027H18Rik lnc_inter_chr10_8999,2.3185977,2.3185977,3.0787579,6.4802388,0.55926494,2.9906952,2.9906952,3.0231303,9.0642725,0.000371177,3.3939101,3.3939101,3.5392498,12.927879,0.000844296,2.9257665,2.9257665,24.860306,56.582935,0.005414893
NC_INTER_C19_14874,14.0111,0,2.01,4.001,8.0001,2.7651998,,"[Minus], [# Lnc isoforms: 4], [# of exons: 1], [Gene type: lncRNA]","chr19:23,135,639-23,148,356",AK021170 BC044868 XR_001782625 XR_001782626 XR_001782627 XR_001782628 XR_001782629 XR_001782630 XR_001782631 XR_001782632 XR_001782633 XR_001782634 XR_001782635,"C330002G04Rik, RIKEN cDNA C330002G04 gene; lnc_inter_chr19_14874, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),C330002G04Rik lnc_inter_chr19_14874,39.98751,39.98751,0,0.10537626,0.49196092,14.180566,14.1805664,0.02272916,0.39572129,0.001161338,11.916061,11.916061,0.049832118,0.63545809,0.004261148,6.2404211,6.2404211,0.58496343,2.7651998,0.000316709
NC_INTER_C3_2988,14.0111,0,2.01,4.001,8.0001,3.2830257,,"[Minus], [# Lnc isoforms: 80], [# of exons: 17], [Gene type: lncRNA]","chr3:149,224,946-149,327,810",AK139864 XR_376248,"Gm31121, predicted gene, 31121; lnc_inter_chr3_2988, ",,Gm31121 lnc_inter_chr3_2988,15.87389,15.8738895,0.000864749,0.018098094,0.89404335,12.615432,12.6154325,0.011564948,0.16909852,0.005815699,75.088253,75.0882531,0.002315637,0.26965247,0.00019086,37.641105,37.6411052,0.12912432,3.2830257,6.79E-09
SCP2,14.0111,0,2.01,4.001,8.0001,255.27375,,"[Minus], [# of exons: 16], [Gene type: NM]","chr4:107,716,435-107,791,152",NM_011327,"Scp2, sterol carrier protein 2, liver, sterol carrier protein 2|non-specific lipid-transfer protein|SCP-2/3-oxoacyl-CoA thiolase|SCP-2/thiolase|SCP-chi|acetyl-CoA C-myristoyltransferase|nonspecific lipid transfer protein|propanoyl-CoA C-acyltransferase|sterol carrier protein X|straight-chain acyl-CoA oxidase, Predicted to have several functions, including C-acyltransferase activity; cholesterol binding activity; and lipid transfer activity. Involved in peroxisome organization and regulation of phospholipid biosynthetic process. Localizes to endoplasmic reticulum; mitochondrion; and peroxisome. Is expressed in several structures, including central nervous system; hair follicle; intestine; liver; and retina layer. Orthologous to human SCP2 (sterol carrier protein 2).","fatty-acyl-CoA binding (GO:0000062); acetyl-CoA C-acyltransferase activity (GO:0003988); signaling receptor binding (GO:0005102); protein binding (GO:0005515); nucleus (GO:0005634); nucleoplasm (GO:0005654); cytoplasm (GO:0005737); mitochondrion (GO:0005739); peroxisome (GO:0005777); peroxisomal matrix (GO:0005782); endoplasmic reticulum (GO:0005783); cytosol (GO:0005829); fatty acid beta-oxidation (GO:0006635); acyl-CoA metabolic process (GO:0006637); steroid biosynthetic process (GO:0006694); progesterone biosynthetic process (GO:0006701); lipid transport (GO:0006869); peroxisome organization (GO:0007031); aging (GO:0007568); bile acid metabolic process (GO:0008206); lipid binding (GO:0008289); phosphatidylinositol transporter activity (GO:0008526); positive regulation of steroid biosynthetic process (GO:0010893); cholesterol binding (GO:0015485); phospholipid transport (GO:0015914); membrane (GO:0016020); transferase activity (GO:0016740); transferase activity, transferring acyl groups (GO:0016746); transferase activity, transferring acyl groups other than amino-acyl groups (GO:0016747); extrinsic component of membrane (GO:0019898); extrinsic component of mitochondrial outer membrane (GO:0031315); intracellular cholesterol transport (GO:0032367); positive regulation of intracellular cholesterol transport (GO:0032385); sterol binding (GO:0032934); inositol trisphosphate biosynthetic process (GO:0032959); protein-containing complex (GO:0032991); propanoyl-CoA C-acyltransferase activity (GO:0033814); long-chain fatty acyl-CoA binding (GO:0036042); identical protein binding (GO:0042802); positive regulation of apoptotic process (GO:0043065); intracellular membrane-bounded organelle (GO:0043231); protein-containing complex binding (GO:0044877); positive regulation of cholesterol biosynthetic process (GO:0045542); positive regulation of steroid metabolic process (GO:0045940); propionyl-CoA C2-trimethyltridecanoyltransferase activity (GO:0050632); acetyl-CoA C-myristoyltransferase activity (GO:0050633); oleic acid binding (GO:0070538); regulation of phospholipid biosynthetic process (GO:0071071); protein localization to plasma membrane (GO:0072659); intermembrane phosphotidylcholine transfer activity (GO:0120019); intermembrane cholesterol transfer activity (GO:0120020); lipid hydroperoxide transport (GO:1901373); positive regulation of cholesterol import (GO:1904109); phosphatidylethanolamine transporter activity (GO:1904121)",Scp2,1.6223449,1.6223449,118.56542,184.25802,1,2.4039274,2.4039274,57.390806,140.0746,0.008905311,3.0291308,3.0291308,80.265338,255.27375,0.022535117,3.0872513,3.0872513,64.907052,158.24144,0.00430051
TMC7,14.0111,0,2.01,4.001,8.0001,5.5796156,,"[Minus], [# of exons: 16], [Gene type: NM]","chr7:125,679,358-125,728,200",NM_172476,"Tmc7, transmembrane channel-like gene family 7, transmembrane channel-like protein 7, Predicted to have mechanosensitive ion channel activity. Predicted to be involved in ion transport. Predicted to localize to integral component of plasma membrane. Orthologous to human TMC7 (transmembrane channel like 7).",cellular_component (GO:0005575); integral component of plasma membrane (GO:0005887); ion transport (GO:0006811); mechanosensitive ion channel activity (GO:0008381); membrane (GO:0016020); integral component of membrane (GO:0016021),Tmc7,3.2281274,3.2281274,0.068135979,0.23662167,1,4.147195,4.147195,0.1723257,0.77578737,0.003716574,3.7701617,3.7701617,0.29990902,1.1861243,0.021964292,3.4653599,3.4653599,2.1256321,5.5796156,0.047606251
MCM10,14.0111,0,2.01,4.001,8.0001,51.678222,,"[Minus], [# of exons: 21], [Gene type: NM]","chr2:4,911,770-4,933,837",NM_001305259 NM_027290,"Mcm10, minichromosome maintenance 10 replication initiation factor, protein MCM10 homolog|minichromosome maintenance deficient 10, Exhibits enzyme binding activity. Involved in cell population proliferation. Predicted to localize to nucleolus; nucleoplasm; and replication fork protection complex. Is expressed in several structures, including cerebellum; early conceptus; gonad; immune system; and liver. Orthologous to human MCM10 (minichromosome maintenance 10 replication initiation factor).",DNA binding (GO:0003677); DNA replication origin binding (GO:0003688); double-stranded DNA binding (GO:0003690); single-stranded DNA binding (GO:0003697); nucleus (GO:0005634); nucleoplasm (GO:0005654); nucleolus (GO:0005730); DNA replication (GO:0006260); DNA replication initiation (GO:0006270); cellular response to DNA damage stimulus (GO:0006974); cell proliferation (GO:0008283); enzyme binding (GO:0019899); replication fork protection complex (GO:0031298); identical protein binding (GO:0042802); metal ion binding (GO:0046872),Mcm10,2.1360035,2.1360035,11.205867,23.643202,0.9403306,2.442331,2.442331,12.322717,31.953279,0.000928417,2.9528445,2.9528445,10.301854,31.790247,0.003849194,2.8581886,2.8581886,23.236747,51.678222,0.002645826
OSBPL3,14.0111,0,2.01,4.001,8.0001,2.3377205,,"[Minus], [# of exons: 25], [Gene type: NM]","chr6:50,243,326-50,406,353",NM_001163645 NM_001347213 NM_027881,"Osbpl3, oxysterol binding protein-like 3, oxysterol-binding protein-related protein 3|OSBP-related protein 3, Predicted to have cholesterol binding activity and sterol transporter activity. Predicted to be involved in lipid transport. Predicted to localize to several cellular components, including cytosol; nuclear membrane; and perinuclear endoplasmic reticulum. Is expressed in several structures, including central nervous system; genitourinary system; immune system; olfactory epithelium; and respiratory system. Orthologous to human OSBPL3 (oxysterol binding protein like 3).",nucleus (GO:0005634); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); cytosol (GO:0005829); plasma membrane (GO:0005886); lipid transport (GO:0006869); lipid binding (GO:0008289); sterol transporter activity (GO:0015248); cholesterol binding (GO:0015485); membrane (GO:0016020); nuclear membrane (GO:0031965); sterol binding (GO:0032934); cell projection (GO:0042995); intracellular membrane-bounded organelle (GO:0043231); perinuclear endoplasmic reticulum (GO:0097038),Osbpl3,5.5153099,5.5153099,0.015087289,0.085791692,0.069717561,4.9908014,4.9908014,0.053133285,0.29027639,0.000382517,4.4851471,4.4851471,0.068301609,0.32625401,0.000823919,3.9773175,3.9773175,0.82148388,2.3377205,0.011299846
HSD3B2,14.0111,0,2.01,4.001,8.0001,92.931527,,"[Minus], [# of exons: 6], [Gene type: NM]","chr3:98,515,030-98,522,338 chr3:98,523,583-98,523,707 chr3:98,527,756-98,527,815 chr3:98,528,396-98,528,466",NM_001359741 NM_153193,"Hsd3b2, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2, 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2|3 beta-hydroxysteroid dehydrogenase 2|3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type II|hydroxysteroid dehydrogenase-2, delta<5>-3-beta, Predicted to have oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor. Predicted to be involved in several processes, including C21-steroid hormone metabolic process; hippocampus development; and response to corticosterone. Predicted to localize to several cellular components, including intercellular bridge; mitochondrial envelope; and nucleolus. Is expressed in liver. Human ortholog(s) of this gene implicated in hypertension and hypospadias. Orthologous to human HSD3B1 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1) and HSD3B2 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2).","catalytic activity (GO:0003824); 3-beta-hydroxy-delta5-steroid dehydrogenase activity (GO:0003854); steroid delta-isomerase activity (GO:0004769); nucleolus (GO:0005730); cytoplasm (GO:0005737); mitochondrion (GO:0005739); mitochondrial inner membrane (GO:0005743); mitochondrial intermembrane space (GO:0005758); endoplasmic reticulum (GO:0005783); steroid biosynthetic process (GO:0006694); metabolic process (GO:0008152); C21-steroid hormone metabolic process (GO:0008207); membrane (GO:0016020); integral component of membrane (GO:0016021); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor (GO:0016616); isomerase activity (GO:0016853); hippocampus development (GO:0021766); intracellular membrane-bounded organelle (GO:0043231); intercellular bridge (GO:0045171); response to corticosterone (GO:0051412); cholesterol dehydrogenase activity (GO:0102294)",Hsd3b2,1.7232006,1.7232006,26.985855,45.435115,1,2.2164031,2.2164031,22.199605,50.009088,0.030320325,3.1045189,3.1045189,25.473698,83.702862,0.001406897,3.049082,3.049082,40.822486,92.931527,0.001516608
MUP3,14.0111,0,2.01,4.001,8.0001,11275.051,,"[Minus], [# of exons: 7], [Gene type: NM,NR]","chr4:61,744,510-61,748,351",NM_001039544 NR_149826,"Mup3, major urinary protein 3, major urinary protein 3|MUP 3|alpha-2u-globulin III|major urinary protein 25|non-group 1/group 2 MUP15, Predicted to have odorant binding activity. Involved in response to stilbenoid. Localizes to extracellular space. Is expressed in liver.",odorant binding (GO:0005549); pheromone binding (GO:0005550); extracellular region (GO:0005576); extracellular space (GO:0005615); response to stilbenoid (GO:0035634); small molecule binding (GO:0036094),Mup3,3.8659129,3.8659129,2071.3617,6910.592,0.052293295,3.7933133,3.7933133,1360.3385,5426.1478,1.37E-11,3.5427425,3.5427425,3017.4581,11275.051,1.74E-05,3.5701294,3.5701294,549.4689,1542.3907,0.016160606
GSTA2,14.0111,0,2.01,4.001,8.0001,5.3760116,,"[Minus], [# of exons: 7], [Gene type: NM]","chr9:78,178,827-78,194,952",NM_008182,"Gsta2, glutathione S-transferase, alpha 2 (Yc2), glutathione S-transferase A2|GST class-alpha member 2|glutathione S-transferase GT41A, Predicted to have glutathione binding activity and glutathione transferase activity. Involved in response to bacterium and response to stilbenoid. Predicted to localize to cytosol. Is expressed in several structures, including alimentary system; genitourinary system; heart; nervous system; and skeleton. Human ortholog(s) of this gene implicated in asthma and ovarian cancer. Orthologous to several human genes including GSTA5 (glutathione S-transferase alpha 5).",glutathione transferase activity (GO:0004364); cytosol (GO:0005829); glutathione metabolic process (GO:0006749); xenobiotic metabolic process (GO:0006805); response to bacterium (GO:0009617); transferase activity (GO:0016740); response to stilbenoid (GO:0035634); glutathione binding (GO:0043295),Gsta2,4.6317488,4.6317488,0.82403774,3.8973137,0.054463479,4.7550524,4.7550524,0.63403337,3.1805026,0.016861022,6.6899277,6.6899277,0.6109915,4.4689585,0.000195751,6.4275194,6.4275194,1.0897689,5.3760116,0.000784825
MUP12,14.0111,0,2.01,4.001,8.0001,256.56217,,"[Minus], [# of exons: 7], [Gene type: NM]","chr4:60,732,253-60,736,153",NM_001199995,"Mup12, major urinary protein 12, major urinary protein 12|MUP 1|Major urinary protein 1",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Mup12,2.8891905,2.8891905,17.080811,42.43407,1,8.7049413,8.7049413,13.60891,131.12307,1.64E-10,10.000917,10.0009165,25.285289,256.56217,1.31E-05,10.039288,10.0392877,25.593316,205.72989,6.26E-05
MUP1,14.0111,0,2.01,4.001,8.0001,91.811534,,"[Minus], [# of exons: 7], [Gene type: NM]","chr4:60,510,885-60,511,136 chr4:60,511,806-60,512,014 chr4:60,512,138-60,512,239 chr4:60,512,583-60,512,693 chr4:60,513,311-60,513,384 chr4:60,514,154-60,514,287 chr4:60,514,626-60,514,832",NM_001163010 NM_001163011 NM_031188,"Mup1, major urinary protein 1, major urinary protein 1|MUP 1|major urinary protein 10|major urinary protein 7, Exhibits insulin-activated receptor activity; pheromone activity; and pheromone binding activity. Involved in several processes, including cellular response to food; cellular response to testosterone stimulus; and negative regulation of biosynthetic process. Localizes to cytosol; extracellular space; and nucleus. Is expressed in thymus and thymus primordium.","insulin-activated receptor activity (GO:0005009); pheromone activity (GO:0005186); odorant binding (GO:0005549); pheromone binding (GO:0005550); extracellular space (GO:0005615); nucleus (GO:0005634); cytosol (GO:0005829); energy reserve metabolic process (GO:0006112); aerobic respiration (GO:0009060); cellular response to starvation (GO:0009267); positive regulation of gene expression (GO:0010628); negative regulation of lipid storage (GO:0010888); positive regulation of glucose metabolic process (GO:0010907); heat generation (GO:0031649); response to stilbenoid (GO:0035634); glucose homeostasis (GO:0042593); locomotor rhythm (GO:0045475); negative regulation of gluconeogenesis (GO:0045721); positive regulation of lipid metabolic process (GO:0045834); negative regulation of transcription, DNA-templated (GO:0045892); negative regulation of lipid biosynthetic process (GO:0051055); positive regulation of protein kinase B signaling (GO:0051897); negative regulation of insulin secretion involved in cellular response to glucose stimulus (GO:0061179); mitochondrion morphogenesis (GO:0070584); cellular response to food (GO:0071240); cellular response to testosterone stimulus (GO:0071394); cellular response to lipid (GO:0071396)",Mup1,3.1781512,3.1781512,9.833712,25.735606,1,6.9590625,6.9590625,6.8285201,53.525708,3.44E-09,5.9156273,5.9156273,15.041235,91.811534,0.000225329,4.6176976,4.6176976,15.783656,56.416774,0.005790573
NC_AS_C4_3300,14.0111,0,2.01,4.001,8.0001,24.356022,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr4:61,844,510-61,850,613",,"lnc_as_chr4_3300, ",,lnc_as_chr4_3300,3.7308009,3.7308009,0,0.017295283,1,102.86461,102.8646071,0,0.83441539,0.006307617,63.753306,63.7533065,0,0.64696917,0.017185963,166.71748,166.7174756,0.15169754,24.356022,1.19E-08
NC_INTER_C13_11670,14.0111,0,2.01,4.001,8.0001,14.948749,,"[Plus], [# Lnc isoforms: 27], [# of exons: 5], [Gene type: lncRNA]","chr13:104,381,490-104,408,110",,"lnc_inter_chr13_11670, ",,lnc_inter_chr13_11670,7.2323859,7.2323859,0.27908483,1.8436179,0.25011804,11.449373,11.4493733,0.26457496,2.7553925,0.000597476,9.9258281,9.9258281,0.38297804,3.8247667,0.016500541,13.610618,13.6106183,1.3160328,14.948749,0.000112441
NC_INTER_C2_34787,14.0111,0,2.01,4.001,8.0001,17.945127,,"[Plus], [# Lnc isoforms: 78], [# of exons: 7], [Gene type: lncRNA]","chr2:158,191,418-158,212,198",NM_175692,"lnc_inter_chr2_34787, ; Snhg11, small nucleolar RNA host gene 11, small nucleolar RNA host gene 11 (non-protein coding)",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),lnc_inter_chr2_34787 Snhg11,3.6649098,3.6649098,0.042433276,0.16703901,1,8.8903395,8.8903395,0.23243221,2.1988957,3.65E-06,7.7783124,7.7783124,0.71963066,6.1512843,0.015955582,9.381984,9.381984,2.4566286,17.945127,1.52E-05
NC_INTER_C3_2504,14.0111,0,2.01,4.001,8.0001,6.9501911,,"[Plus], [# Lnc isoforms: 95], [# of exons: 1], [Gene type: lncRNA]","chr3:85,068,714-85,087,104",,"lnc_inter_chr3_2504, ",,lnc_inter_chr3_2504,5.2023472,5.2023472,0.052108984,0.27337786,0.08319618,4.1090344,4.1090344,0.49206925,2.1271087,0.000382517,4.131799,4.131799,0.45864545,2.1416247,0.011140081,6.6400682,6.6400682,1.5082444,6.9501911,0.000503288
AOX3,14.0111,0,2.01,4.001,8.0001,161.78174,,"[Plus], [# of exons: 35], [Gene type: NM]","chr1:58,169,980-58,257,296",NM_023617,"Aox3, aldehyde oxidase 3, aldehyde oxidase 3|aldehyde oxidase 1|aldehyde oxidase homolog 1|aldehyde oxidase structural homolog 2|azaheterocycle hydroxylase 3, Exhibits aldehyde oxidase activity; electron transfer activity; and molybdenum ion binding activity. Predicted to localize to cytoplasm. Is expressed in nasal cavity. Orthologous to human AOX3P (aldehyde oxidase 3, pseudogene).","aldehyde oxidase activity (GO:0004031); iron ion binding (GO:0005506); cytoplasm (GO:0005737); electron transfer activity (GO:0009055); oxidoreductase activity (GO:0016491); molybdenum ion binding (GO:0030151); metal ion binding (GO:0046872); flavin adenine dinucleotide binding (GO:0050660); NAD binding (GO:0051287); iron-sulfur cluster binding (GO:0051536); 2 iron, 2 sulfur cluster binding (GO:0051537); FAD binding (GO:0071949); geranial:oxygen oxidoreductase activity (GO:0102797); heptaldehyde:oxygen oxidoreductase activity (GO:0102798)",Aox3,3.1214424,3.1214424,10.096919,32.217874,0.13919978,3.4529699,3.4529699,10.355125,36.558483,5.19E-08,4.4388948,4.4388948,16.777555,77.830113,1.31E-07,4.1977605,4.1977605,50.4207,161.78174,1.15E-07
CXCL1,14.0111,0,2.01,4.001,8.0001,126.39096,,"[Plus], [# of exons: 4], [Gene type: NM]","chr5:91,320,271-91,322,141",NM_008176,"Cxcl1, chemokine (C-X-C motif) ligand 1, growth-regulated alpha protein|C-X-C motif chemokine 1|GRO1 oncogene|KC/GR)-alpha|KC/GRO-alpha|alpha-chemokine|platelet-derived growth factor-inducible protein KC|secretory protein N51, Predicted to have CXCR chemokine receptor binding activity and chemokine activity. Involved in positive regulation of hematopoietic stem cell proliferation; positive regulation of neutrophil mediated killing of fungus; and positive regulation of superoxide anion generation. Localizes to extracellular space. Is expressed in several structures, including gonad; liver; lung; nervous system; and retina. Orthologous to human CXCL2 (C-X-C motif chemokine ligand 2).",response to molecule of bacterial origin (GO:0002237); acute inflammatory response (GO:0002526); cytokine activity (GO:0005125); extracellular region (GO:0005576); extracellular space (GO:0005615); chemotaxis (GO:0006935); defense response (GO:0006952); inflammatory response (GO:0006954); immune response (GO:0006955); positive regulation of cytosolic calcium ion concentration (GO:0007204); chemokine activity (GO:0008009); growth factor activity (GO:0008083); positive regulation of sodium ion transport (GO:0010765); neutrophil chemotaxis (GO:0030593); killing of cells of other organism (GO:0031640); positive regulation of superoxide anion generation (GO:0032930); positive regulation of potassium ion transport (GO:0043268); CXCR chemokine receptor binding (GO:0045236); antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844); chemokine-mediated signaling pathway (GO:0070098); positive regulation of neutrophil mediated killing of fungus (GO:0070965); cellular response to lipopolysaccharide (GO:0071222); positive regulation of hematopoietic stem cell proliferation (GO:1902035),Cxcl1,1.8788002,1.8788002,9.803025,17.457316,1,3.7159393,3.7159393,24.600379,96.036118,0.001919684,4.6809631,4.6809631,25.692283,126.39096,4.41E-06,5.0074668,5.0074668,27.558248,113.92449,0.001227814
CABYR,14.0111,0,2.01,4.001,8.0001,8.7851621,,"[Plus], [# of exons: 6], [Gene type: NM]","chr18:12,899,864-12,913,651",NM_001042418 NM_001042419 NM_001042420 NM_027687 NM_181731,"Cabyr, calcium-binding tyrosine-(Y)-phosphorylation regulated (fibrousheathin 2), calcium-binding tyrosine phosphorylation-regulated protein|calcium-binding protein 86|testis-specific calcium-binding protein CBP86, Exhibits calcium ion binding activity and protein domain specific binding activity. Localizes to cytoplasm and sperm flagellum. Used to study male infertility. Orthologous to human CABYR (calcium binding tyrosine phosphorylation regulated).",calcium ion binding (GO:0005509); protein binding (GO:0005515); nucleoplasm (GO:0005654); cytoplasm (GO:0005737); cytosol (GO:0005829); cytoskeleton (GO:0005856); cilium (GO:0005929); calcium-mediated signaling (GO:0019722); enzyme binding (GO:0019899); protein domain specific binding (GO:0019904); motile cilium (GO:0031514); sperm fibrous sheath (GO:0035686); cell projection (GO:0042995); metal ion binding (GO:0046872); sperm capacitation (GO:0048240); sperm principal piece (GO:0097228); sperm end piece (GO:0097229),Cabyr,3.122311,3.122311,0.038449333,0.11631576,1,12.261816,12.2618156,0.11536505,1.5557091,5.71E-10,13.519806,13.5198059,0.1389103,2.3550625,2.62E-10,11.597828,11.5978275,0.95865198,8.7851621,4.40E-09
UGT2B35,14.0111,0,2.01,4.001,8.0001,176.11047,,"[Plus], [# of exons: 6], [Gene type: NM]","chr5:87,429,885-87,442,299",NM_172881,"Ugt2b35, UDP glucuronosyltransferase 2 family, polypeptide B35, Predicted to have glucuronosyltransferase activity. Predicted to localize to intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in osteoporosis. Orthologous to human UGT2B15 (UDP glucuronosyltransferase family 2 member B15) and UGT2B17 (UDP glucuronosyltransferase family 2 member B17).",UDP-glycosyltransferase activity (GO:0008194); glucuronosyltransferase activity (GO:0015020); intracellular membrane-bounded organelle (GO:0043231),Ugt2b35,1.6622536,1.6622536,46.643377,72.490777,1,2.0810331,2.0810331,35.012928,74.863375,0.039184128,2.639321,2.639321,63.772701,176.11047,0.010624864,2.9638658,2.9638658,61.546068,141.78709,0.004959929
NC_INTRA_CX_15430,14.0111,0,2.01,4.001,8.0001,1.0803877,,"[~14% MAX. MULTIPLE IN BLACKLIST], [Plus], [# Lnc isoforms: 43], [# of exons: 21], [Gene type: lncRNA]","chrX:120,116,135-120,217,131 chrX:120,259,264-120,551,311",,"Gm14951, ; lnc_intra_chrX_15430,15431,15435,15427, ",,Gm14951 lnc_intra_chrX_15430,0.48585155,-2.0582419,0.008959682,0.003893667,1,2.6615836,2.6615836,0.032008683,0.096006489,0.02842136,5.8819114,5.8819114,0.013432314,0.085514293,4.60E-05,3.9344344,3.9344344,0.38383654,1.0803877,0.002414118
NC_AS_CX_15436,14.0111,0,2.01,4.001,8.0001,1.7437386,,"[~3% MAX. MULTIPLE IN BLACKLIST], [Plus], [# Lnc isoforms: 38], [# of exons: 36], [Gene type: lncRNA]","chrX:120,563,549-121,301,038",,"lnc_as_chrX_15436,15437, ",,lnc_as_chrX_15436,1.1681434,1.1681434,0.004056118,0.004312944,1,4.892995,4.892995,0.016906946,0.089655671,1.34E-09,7.4191696,7.4191696,0.011985939,0.094925981,9.07E-06,12.363303,12.3633031,0.1918111,1.7437386,4.93E-15
NC_INTER_C2_2089,13.2022,1.2,0,4.002,8.0002,7.6656445,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr2:178,879,933-178,884,826",,"lnc_inter_chr2_2089, ",,lnc_inter_chr2_2089,0.015075013,-66.3349343,0.51387033,0,0.015287837,0.11666356,-8.5716571,1.2836725,0.1329333,0.072896035,0.13395734,-7.4650629,1.6091117,0.23206834,0.010624864,0.17645314,-5.667227,7.6656445,0.98119788,0.009732523
NC_INTER_C6_5750,12.0022,0,0,4.002,8.0002,84.03189,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr6:144,197,166-144,200,005",,"lnc_inter_chr6_5750, ",,lnc_inter_chr6_5750,0.59478855,-1.6812698,0.12240892,0.072249831,1,0.34359976,-2.910363,10.706327,4.1663029,0.36790914,0.087603722,-11.4150401,2.7486297,0.23079033,0.006987917,0.31660829,-3.158477,84.03189,19.548208,0.007136374
NC_INTER_C15_12586,12.0022,0,0,4.002,8.0002,3.2665697,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr15:60,725,423-60,728,391",,"lnc_inter_chr15_12586, ",,lnc_inter_chr15_12586,0.03255581,-30.7164831,0.44469003,0,0.66557673,0.023592305,-42.3867015,0.76006359,0,0.16848747,0.012911451,-77.4506303,1.6510757,0,0.008246526,0.012528053,-79.8208655,3.2665697,0,0.003175999
NC_INTER_C15_12588,12.0022,0,0,4.002,8.0002,43.572847,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr15:60,730,060-60,731,547",,"lnc_inter_chr15_12588, ",,lnc_inter_chr15_12588,0.12107592,-8.2592807,0.17109872,0,1,0.021628217,-46.2358963,1.5921203,0,0.11428874,0.008456599,-118.2508478,4.7932825,0,1.51E-05,0.036448537,-27.4359436,43.572847,1.3118099,3.74E-05
NC_INTER_C15_12633,12.0022,0,0,4.002,8.0002,5.1971433,,"[Minus], [# Lnc isoforms: 5], [# of exons: 1], [Gene type: lncRNA]","chr15:62,555,702-62,575,557",,"lnc_inter_chr15_12633, ",,lnc_inter_chr15_12633,0.099607654,-10.0393891,0.080439349,0.005165381,1,0.21680073,-4.6125305,0.43000523,0.095445086,0.10688628,0.15090266,-6.6267882,1.0572022,0.16132787,0.008970745,0.12551288,-7.9673099,5.1971433,0.52516718,0.002754817
IRS2,12.0022,0,0,4.002,8.0002,57.451569,,"[Minus], [# of exons: 2], [Gene type: NM]","chr8:10,984,681-11,008,929",NM_001081212,"Irs2, insulin receptor substrate 2, insulin receptor substrate 2|4PS, Exhibits phosphatidylinositol 3-kinase binding activity and protein kinase binding activity. Involved in several processes, including insulin receptor signaling pathway; positive regulation of cell population proliferation; and positive regulation of insulin secretion. Localizes to cytosol; plasma membrane; and protein-containing complex. Is expressed in several structures, including brain ventricular layer; hindlimb digit skin; jaw; metanephros; and thymus primordium. Used to study type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in type 2 diabetes mellitus. Orthologous to human IRS2 (insulin receptor substrate 2).",positive regulation of mesenchymal cell proliferation (GO:0002053); negative regulation of B cell apoptotic process (GO:0002903); insulin receptor binding (GO:0005158); protein binding (GO:0005515); cytoplasm (GO:0005737); cytosol (GO:0005829); plasma membrane (GO:0005886); signal transduction (GO:0007165); brain development (GO:0007420); positive regulation of cell proliferation (GO:0008284); insulin receptor signaling pathway (GO:0008286); response to glucose (GO:0009749); negative regulation of plasma membrane long-chain fatty acid transport (GO:0010748); positive regulation of glucose metabolic process (GO:0010907); protein kinase binding (GO:0019901); protein phosphatase binding (GO:0019903); protein domain specific binding (GO:0019904); positive regulation of cell migration (GO:0030335); mammary gland development (GO:0030879); positive regulation of B cell proliferation (GO:0030890); positive regulation of fatty acid beta-oxidation (GO:0032000); positive regulation of insulin secretion (GO:0032024); cellular response to insulin stimulus (GO:0032869); protein-containing complex (GO:0032991); negative regulation of kinase activity (GO:0033673); phosphatidylinositol 3-kinase binding (GO:0043548); positive regulation of glycogen biosynthetic process (GO:0045725); positive regulation of glucose import (GO:0046326); 14-3-3 protein binding (GO:0071889),Irs2,0.68908497,-1.4511998,3.0856766,2.1786397,1,0.5224443,-1.9140796,4.95144,2.7261911,0.18555692,0.32706702,-3.0574773,5.7764257,1.986422,0.001752319,0.34646532,-2.8862917,57.451569,15.283573,0.00205379
TOX,12.0022,0,0,4.002,8.0002,20.479405,,"[Minus], [# of exons: 9], [Gene type: NM]","chr4:6,614,533-6,917,870",NM_145711,"Tox, thymocyte selection-associated high mobility group box, thymocyte selection-associated high mobility group box protein TOX|thymocyte selection-associated HMG box|thymus high mobility group box protein TOX, Exhibits chromatin DNA binding activity. Involved in several processes, including hematopoietic or lymphoid organ development; positive regulation of DNA demethylation; and regulation of lymphocyte differentiation. Localizes to nucleus. Is expressed in several structures, including genitourinary system; limb mesenchyme; nervous system; sensory organ; and skeleton. Orthologous to human TOX (thymocyte selection associated high mobility group box).","natural killer cell differentiation (GO:0001779); CD4-positive, CD25-positive, alpha-beta regulatory T cell lineage commitment (GO:0002362); NK T cell lineage commitment (GO:0002364); leukocyte differentiation (GO:0002521); DNA binding (GO:0003677); nucleus (GO:0005634); chromatin organization (GO:0006325); regulation of transcription by RNA polymerase II (GO:0006357); nervous system development (GO:0007399); positive regulation of neuron projection development (GO:0010976); cerebral cortex neuron differentiation (GO:0021895); lymphocyte differentiation (GO:0030098); chromatin DNA binding (GO:0031490); positive regulation of natural killer cell differentiation (GO:0032825); CD4-positive, alpha-beta T cell lineage commitment (GO:0043373); CD8-positive, alpha-beta T cell lineage commitment (GO:0043375); lymph node development (GO:0048535); Peyer's patch development (GO:0048541); positive regulation of DNA demethylation (GO:1901537); regulation of positive thymic T cell selection (GO:1902232); positive regulation of neural precursor cell proliferation (GO:2000179)",Tox,0.52759691,-1.8953864,0.051908528,0.026130737,1,0.39756868,-2.5152887,0.50205149,0.22490005,0.061016641,0.19476208,-5.1344698,0.53016913,0.11264447,0.004780229,0.34156798,-2.9276749,20.479405,5.1968559,0.000297596
NC_INTER_C4_37973,12.0022,0,0,4.002,8.0002,10.654364,,"[Plus], [# Lnc isoforms: 11], [# of exons: 1], [Gene type: lncRNA]","chr4:60,308,209-60,311,751",,"lnc_inter_chr4_37973, ",,lnc_inter_chr4_37973,3.7036071,3.7036071,0,0.028955007,1,0.11722373,-8.5306959,1.0208039,0.11447335,0.080080008,0.016445815,-60.805743,0.92406807,0,0.026358662,0.18395887,-5.4359976,10.654364,1.3923889,0.026805539
NC_INTER_CX_15256,12.0022,0,0,4.002,8.0002,5.3607289,,"[Plus], [# Lnc isoforms: 19], [# of exons: 12], [Gene type: lncRNA]","chrX:11,852,075-11,915,273",,"lnc_inter_chrX_15256, ",,lnc_inter_chrX_15256,0.4258101,-2.3484647,0.050008277,0.018833068,1,0.29033046,-3.4443509,0.26785138,0.080462283,0.25502818,0.22769186,-4.3919005,0.20847137,0.049861827,0.023647925,0.20816891,-4.8037912,5.3607289,0.85533424,1.44E-05
NC_INTER_C10_18327,12.0022,0,0,4.002,8.0002,15.841439,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr10:33,612,507-33,613,833",,"lnc_inter_chr10_18327, ",,lnc_inter_chr10_18327,0.1700122,-5.8819307,0.12791543,0,1,0.01498806,-66.7197769,2.3737904,0,0.10590986,0.007796723,-128.2590191,6.168883,0,0.004461958,0.021708061,-46.065838,15.841439,0.20002418,0.005386252
NC_INTER_C15_26838,12.0022,0,0,4.002,8.0002,10.303811,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr15:60,764,467-60,768,754",AK015045 AV258845 XR_001781666,"4930402D18Rik, RIKEN cDNA 4930402D18 gene; lnc_inter_chr15_26838, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),4930402D18Rik lnc_inter_chr15_26838,1,1,0,0,1,0.031688194,-31.5574938,0.37875147,0,0.80977397,0.008492248,-117.7544569,1.5012541,0,8.25E-05,0.010936565,-91.4363883,10.303811,0.05079075,9.94E-11
NC_INTER_C4_37971,12.0022,0,0,4.002,8.0002,171.1637,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr4:60,305,593-60,306,283",,"lnc_inter_chr4_37971, ",,lnc_inter_chr4_37971,0.28546505,-3.5030558,0.12291004,0,1,0.11901392,-8.4023788,2.1270924,0.23573492,1,0.01250745,-79.9523515,6.7586297,0,0.002930648,0.031180082,-32.0717569,171.1637,4.2204438,6.06E-10
PYGO1,12.0022,0,0,4.002,8.0002,4.4559052,,"[Plus], [# of exons: 3], [Gene type: NM]","chr9:72,773,452-72,800,392",NM_028116,"Pygo1, pygopus 1, pygopus homolog 1, Predicted to have methylated histone binding activity. Involved in several processes, including hematopoietic progenitor cell differentiation; protein localization to nucleus; and spermatid nucleus differentiation. Localizes to nucleus. Is expressed in several structures, including central nervous system; heart; male reproductive system; pancreas; and urinary system. Orthologous to human PYGO1 (pygopus family PHD finger 1).",kidney development (GO:0001822); hematopoietic progenitor cell differentiation (GO:0002244); protein binding (GO:0005515); nucleus (GO:0005634); spermatid development (GO:0007286); spermatid nucleus differentiation (GO:0007289); Wnt signaling pathway (GO:0016055); protein localization to nucleus (GO:0034504); methylated histone binding (GO:0035064); positive regulation of transcription by RNA polymerase II (GO:0045944); metal ion binding (GO:0046872); anatomical structure development (GO:0048856); canonical Wnt signaling pathway (GO:0060070),Pygo1,0.20091185,-4.9773073,0.53934847,0.10881705,0.25617367,0.2922778,-3.4214025,0.46855175,0.13859216,0.10688628,0.1843457,-5.4245907,0.90253265,0.1811777,0.000675352,0.2455902,-4.0718238,4.4559052,0.87039066,0.046268233
WDR63,12.0022,0,0,4.002,8.0002,1.2116615,,"[~2%  IN BLACKLIST], [Minus], [# of exons: 23], [Gene type: NM]","chr3:145,703,490-145,771,000",NM_172864,"Dnai3, dynein axonemal intermediate chain 3, dynein intermediate chain 3, axonemal|WD repeat-containing protein 63|WD repeat domain 63",cytoplasm (GO:0005737); axonemal dynein complex (GO:0005858); microtubule-based movement (GO:0007018); negative regulation of cell migration (GO:0030336); negative regulation of Arp2/3 complex-mediated actin nucleation (GO:0034316); inner dynein arm (GO:0036156); inner dynein arm assembly (GO:0036159); dynein light chain binding (GO:0045503); dynein heavy chain binding (GO:0045504); positive regulation of osteoblast differentiation (GO:0045669); cilium movement involved in cell motility (GO:0060294); Arp2/3 complex binding (GO:0071933),Wdr63,0.27548157,-3.6300069,0.027479711,0.006254073,1,0.29978665,-3.3357055,0.065058682,0.019237369,0.60081257,0.16008111,-6.2468332,0.12961731,0.020171298,0.015955582,0.21799706,-4.5872179,1.2116615,0.20870043,0.026543435
NC_INTER_C6_4887,12.0011,0,0,4.001,8.0001,2.0438211,,"[Minus], [# Lnc isoforms: 10], [# of exons: 8], [Gene type: lncRNA]","chr6:15,828,160-15,844,141",,"lnc_inter_chr6_4887, ",,lnc_inter_chr6_4887,23.265801,23.2658006,0,0.049181318,1,5.1360963,5.1360963,0.036860222,0.20608667,0.40760028,33.640169,33.6401691,0.016141345,0.46164455,9.71E-05,9.784401,9.784401,0.24228144,2.0438211,0.005313132
NC_INTER_C8_46980,12.0011,0,0,4.001,8.0001,13.715875,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr8:95,775,645-95,778,191",,"lnc_inter_chr8_46980, ",,lnc_inter_chr8_46980,1.5596262,1.5596262,0.13649604,0.24286971,1,3.1172785,3.1172785,1.3363659,4.296413,0.47593992,5.8984231,5.8984231,1.4154017,8.0908267,0.0296844,7.7568248,7.7568248,2.2398112,13.715875,0.000266699
NC_INTER_CX_15448,12.0011,0,0,4.001,8.0001,46.775768,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrX:122,551,787-122,552,029",,"lnc_inter_chrX_15448, ",,lnc_inter_chrX_15448,1,1,0,0,1,18.156352,18.1563516,0,3.5834501,1,65.480205,65.4802046,0,16.413227,0.013334891,124.11282,124.1128222,0,46.775768,0.000221178
NC_INTER_CX_50215,12.0011,0,0,4.001,8.0001,89.147194,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrX:122,674,506-122,674,706",,"lnc_inter_chrX_50215, ",,lnc_inter_chrX_50215,0.28692597,-3.4852195,0.44475767,0,1,10.923024,10.9230243,0,2.7103324,1,98.983082,98.983082,0,30.130327,0.000149387,54.597134,54.597134,1.8506449,89.147194,2.23E-06
NC_AS_C10_18831,12.0011,0,0,4.001,8.0001,30.316342,,"[Minus], [# Lnc isoforms: 29], [# of exons: 3], [Gene type: lncRNA]","chr10:76,027,026-76,033,211",NR_152752,"Gm15343, predicted gene 15343; lnc_as_chr10_18831, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),Gm15343 lnc_as_chr10_18831,2.8433427,2.8433427,3.541396,9.9569731,0.26695041,2.8809563,2.8809563,5.1769631,15.351485,0.17760152,4.7005022,4.7005022,4.4551726,22.759272,5.64E-05,4.1445706,4.1445706,9.8509563,30.316342,0.002645826
NC_INTER_CX_50214,12.0011,0,0,4.001,8.0001,10.686696,,"[Minus], [# Lnc isoforms: 4], [# of exons: 1], [Gene type: lncRNA]","chrX:122,669,995-122,671,479",,"lnc_inter_chrX_50214, ",,lnc_inter_chrX_50214,1,1,0,0,1,6.0637589,6.0637589,0.090171124,0.91184734,1,92.269308,92.2693075,0,3.8068955,0.000270678,173.13626,173.1362648,0,10.686696,2.56E-06
CYP3A25,12.0011,0,0,4.001,8.0001,651.4835,,"[Minus], [# of exons: 13], [Gene type: NM,NR]","chr5:146,788,770-146,807,308 chr5:146,810,063-146,810,162 chr5:146,813,025-146,813,077 chr5:146,814,607-146,814,700 chr5:146,821,046-146,821,193",NM_019792 NR_030782,"Cyp3a25, cytochrome P450, family 3, subfamily a, polypeptide 25, cytochrome P450 3A25|CYPIIIA25|cytochrome P450, 3a25","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); endoplasmic reticulum (GO:0005783); steroid metabolic process (GO:0008202); testosterone 16-alpha-hydroxylase activity (GO:0008390); steroid hydroxylase activity (GO:0008395); response to bacterium (GO:0009617); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); heme binding (GO:0020037); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); testosterone 6-beta-hydroxylase activity (GO:0050649); aromatase activity (GO:0070330); oxidative demethylation (GO:0070989)",Cyp3a25,1.5478308,1.5478308,50.485434,72.233561,1,2.0744152,2.0744152,93.425922,197.11423,0.15863054,3.0365419,3.0365419,202.14758,651.4835,0.002158776,3.207349,3.207349,163.15579,397.59685,0.001633428
EPHX1,12.0011,0,0,4.001,8.0001,78.650049,,"[Minus], [# of exons: 9], [Gene type: NM]","chr1:182,919,687-182,947,700",NM_001312918 NM_010145,"Ephx1, epoxide hydrolase 1, microsomal, epoxide hydrolase 1|epoxide hydratase|microsomal epoxide hydrolase, Predicted to have cis-stilbene-oxide hydrolase activity; enzyme binding activity; and epoxide hydrolase activity. Involved in cellular aromatic compound metabolic process and response to organic cyclic compound. Predicted to localize to intracellular membrane-bounded organelle and plasma membrane. Is expressed in several structures, including brain ventricle and choroid plexus; cranial ganglion; integumental system; nose; and salivary gland. Human ortholog(s) of this gene implicated in several diseases, including Leber hereditary optic neuropathy; anemia (multiple); hematologic cancer (multiple); respiratory system disease (multiple); and toxic encephalopathy. Orthologous to human EPHX1 (epoxide hydrolase 1).",catalytic activity (GO:0003824); epoxide hydrolase activity (GO:0004301); endoplasmic reticulum (GO:0005783); plasma membrane (GO:0005886); cellular aromatic compound metabolic process (GO:0006725); response to toxic substance (GO:0009636); response to organic cyclic compound (GO:0014070); membrane (GO:0016020); integral component of membrane (GO:0016021); hydrolase activity (GO:0016787); arachidonic acid metabolic process (GO:0019369); aromatic compound catabolic process (GO:0019439); enzyme binding (GO:0019899); cis-stilbene-oxide hydrolase activity (GO:0033961); diol biosynthetic process (GO:0034312); intracellular membrane-bounded organelle (GO:0043231); epoxide metabolic process (GO:0097176),Ephx1,3.0245159,3.0245159,19.207305,58.755187,0.10995214,2.5156091,2.5156091,29.249655,75.560266,0.13736426,2.8958807,2.8958807,26.26455,78.650049,0.046864184,2.9024946,2.9024946,26.189006,60.233508,0.004425112
NC_INTER_C8_6990,12.0011,0,0,4.001,8.0001,9.9069515,,"[Plus], [# Lnc isoforms: 21], [# of exons: 1], [Gene type: lncRNA]","chr8:48,053,007-48,060,781",,"lnc_inter_chr8_6990, ",,lnc_inter_chr8_6990,11.286927,11.2869271,0,0.052770072,1,6.3688189,6.3688189,0.074429394,0.59918476,0.53637312,79.062549,79.0625494,0,0.61626614,0.002930648,9.0793987,9.0793987,1.4300079,9.9069515,5.95E-06
HAO2,11.2202,1.2,2.02,0,8.0002,26.251463,,"[Minus], [# of exons: 9], [Gene type: NM]","chr3:98,678,442-98,697,153",NM_019545,"Hao2, hydroxyacid oxidase 2, hydroxyacid oxidase 2|(S)-2-hydroxy-acid oxidase, peroxisomal|HAOX2|hydroxyacid oxidase (glycolate oxidase) 3|hydroxyacid oxidase 2, kidney|medium chain alpha-hydroxy acid oxidase|medium-chain 2-hydroxy acid oxidase HAOX3|medium-chain L-2-hydroxy acid oxidase, Predicted to have FMN binding activity; identical protein binding activity; and long-chain-(S)-2-hydroxy-long-chain-acid oxidase activity. Predicted to be involved in fatty acid oxidation and mandelate metabolic process. Localizes to mitochondrion. Is expressed in several structures, including adrenal gland; genitourinary system; and nervous system. Orthologous to human HAO2 (hydroxyacid oxidase 2).",catalytic activity (GO:0003824); (S)-2-hydroxy-acid oxidase activity (GO:0003973); mitochondrion (GO:0005739); peroxisome (GO:0005777); FMN binding (GO:0010181); oxidoreductase activity (GO:0016491); mandelate metabolic process (GO:0018924); fatty acid oxidation (GO:0019395); identical protein binding (GO:0042802); very-long-chain-(S)-2-hydroxy-acid oxidase activity (GO:0052852); long-chain-(S)-2-hydroxy-long-chain-acid oxidase activity (GO:0052853); medium-chain-(S)-2-hydroxy-acid oxidase activity (GO:0052854),Hao2,0.050454605,-19.8197963,26.251463,1.4099336,0.001058249,0.087896903,-11.3769651,13.095968,1.0029267,0.004861957,0.07085121,-14.114085,25.191199,1.8372457,0.081497776,0.11534085,-8.6699551,10.69125,1.0818793,0.018039418
NC_INTRA_C19_15011,11.2202,1.2,2.02,0,8.0002,6.6700227,,"[Plus], [# Lnc isoforms: 16], [# of exons: 13], [Gene type: lncRNA]","chr19:40,070,386-40,071,864 chr19:40,074,047-40,074,145 chr19:40,083,248-40,083,593 chr19:40,084,014-40,084,172 chr19:40,086,734-40,164,168 chr19:40,167,303-40,167,517 chr19:40,169,967-40,170,291 chr19:40,184,828-40,185,551 chr19:40,185,626-40,185,645",,"lnc_intra-as_chr19_15011, ",,lnc_intra-as_chr19_15011,0.18233016,-5.4845562,0.16283558,0.028202332,0.003232271,0.22907683,-4.3653476,0.2249577,0.056588698,1.92E-05,0.34744981,-2.8781135,0.30980256,0.11312135,0.078649861,0.10815482,-9.2460051,6.6700227,0.54896404,5.75E-09
NC_INTRA_C3_2638,11.1101,1.1,2.01,0,8.0001,3.6023884,,"[Minus], [# Lnc isoforms: 11], [# of exons: 10], [Gene type: lncRNA]","chr3:98,393,275-98,422,558 chr3:98,436,065-98,436,388 chr3:98,436,750-98,436,922 chr3:98,438,545-98,438,648",,"lnc_intra_chr3_2638, ",,lnc_intra_chr3_2638,5.9958417,5.9958417,0.028791098,0.16920653,0.011918297,5.1316617,5.1316617,0.051003815,0.29385991,0.001390486,2.7938298,2.7938298,0.12165885,0.38483484,0.37430944,5.009625,5.009625,1.0401104,3.6023884,0.004577063
CYP21A1,11.1101,1.1,2.01,0,8.0001,23.61989,,"[Minus], [# of exons: 10], [Gene type: NM]","chr17:34,938,293-34,938,993 chr17:34,939,078-34,939,181 chr17:34,939,250-34,939,419 chr17:34,939,616-34,939,816 chr17:34,939,930-34,940,016 chr17:34,940,105-34,940,206 chr17:34,940,293-34,940,388 chr17:34,940,494-34,940,636 chr17:34,940,989-34,941,078 chr17:34,941,143-34,941,371",NM_009995,"Cyp21a1, cytochrome P450, family 21, subfamily a, polypeptide 1, steroid 21-hydroxylase|21-OHase|21-hydroxylase|cytochrome P-450|cytochrome P-450c21|cytochrome P450 21|cytochrome P450 XXI|cytochrome P450 hydroxylase A|cytochrome P450, 21, pseudogene|cytochrome P450, 21, steroid 21 hydroxylase|cytochrome P450, family 21, subfamily a, polypeptide 2, pseudogene|cytochrome P450-C21, Predicted to have 17-hydroxyprogesterone 21-hydroxylase activity; heme binding activity; and progesterone 21-hydroxylase activity. Predicted to be involved in progesterone metabolic process and steroid biosynthetic process. Predicted to localize to endoplasmic reticulum and membrane. Is expressed in several structures, including adrenal gland; lung; metanephros; spleen; and testis. Human ortholog(s) of this gene implicated in congenital adrenal hyperplasia. Orthologous to several human genes including CYP21A2 (cytochrome P450 family 21 subfamily A member 2).","monooxygenase activity (GO:0004497); steroid 21-monooxygenase activity (GO:0004509); steroid binding (GO:0005496); iron ion binding (GO:0005506); endoplasmic reticulum (GO:0005783); steroid biosynthetic process (GO:0006694); C21-steroid hormone biosynthetic process (GO:0006700); glucocorticoid biosynthetic process (GO:0006704); mineralocorticoid biosynthetic process (GO:0006705); steroid metabolic process (GO:0008202); lipid binding (GO:0008289); steroid hydroxylase activity (GO:0008395); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); heme binding (GO:0020037); progesterone metabolic process (GO:0042448); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); 17-hydroxyprogesterone 21-hydroxylase activity (GO:0103069)",Cyp21a1,79.227564,79.2275644,0,0.94677679,0.001420804,15.464672,15.4646721,0.17389727,3.2323407,0.000102917,10.727081,10.7270809,0.22885595,3.4717251,0.088320512,20.84962,20.8496199,1.4937274,23.61989,0.005202401
TSKU,11.1101,1.1,2.01,0,8.0001,33.985221,,"[Minus], [# of exons: 4], [Gene type: NM]","chr7:105,499,178-105,509,838",NM_001024619 NM_001168539 NM_001168540 NM_001168541,"Tsku, tsukushi, small leucine rich proteoglycan, tsukushi|tsukushin|leucine rich repeat containing 54|leucine-rich repeat-containing protein 54, Exhibits transforming growth factor beta binding activity. Involved in several processes, including cholesterol efflux; sensory organ development; and telencephalon development. Localizes to extracellular space. Is expressed in embryo and olfactory epithelium. Orthologous to human TSKU (tsukushi, small leucine rich proteoglycan).",protein binding (GO:0005515); extracellular region (GO:0005576); extracellular space (GO:0005615); plasma membrane (GO:0005886); multicellular organism development (GO:0007275); nervous system development (GO:0007399); cholesterol metabolic process (GO:0008203); regulation of gene expression (GO:0010468); negative regulation of neuron projection development (GO:0010977); corpus callosum morphogenesis (GO:0021540); lateral ventricle development (GO:0021670); hippocampus development (GO:0021766); anterior commissure morphogenesis (GO:0021960); negative regulation of Wnt signaling pathway (GO:0030178); negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512); extracellular matrix (GO:0031012); negative regulation of transforming growth factor beta1 production (GO:0032911); cholesterol efflux (GO:0033344); wound healing (GO:0042060); cholesterol homeostasis (GO:0042632); positive regulation of hair cycle (GO:0042635); camera-type eye development (GO:0043010); transforming growth factor beta binding (GO:0050431); inner ear receptor cell stereocilium organization (GO:0060122); ciliary body morphogenesis (GO:0061073); energy homeostasis (GO:0097009); negative regulation of myofibroblast differentiation (GO:1904761),Tsku,3.9756133,3.9756133,3.3563223,13.216927,0.002577863,3.0756757,3.0756757,9.4068582,31.587968,4.03E-05,2.5657686,2.5657686,7.1553135,18.77125,0.33179283,5.678759,5.678759,7.7985363,33.985221,6.23E-05
OLFM2,11.1101,1.1,2.01,0,8.0001,2.3972432,,"[Minus], [# of exons: 8], [Gene type: NM]","chr9:20,472,134-20,544,165 chr9:20,548,461-20,550,740",NM_001357635 NM_001357639 NM_173777,"Olfm2, olfactomedin 2, noelin-2, Involved in locomotory behavior and visual perception. Localizes to AMPA glutamate receptor complex; extrinsic component of synaptic membrane; and glutamatergic synapse. Is expressed in several structures, including central nervous system; eye; and orbito-sphenoid. Orthologous to human OLFM2 (olfactomedin 2).",protein binding (GO:0005515); extracellular region (GO:0005576); nucleus (GO:0005634); nucleoplasm (GO:0005654); cytoplasm (GO:0005737); visual perception (GO:0007601); locomotory behavior (GO:0007626); protein secretion (GO:0009306); membrane (GO:0016020); cell junction (GO:0030054); AMPA glutamate receptor complex (GO:0032281); synapse (GO:0045202); positive regulation of smooth muscle cell differentiation (GO:0051152); synaptic membrane (GO:0097060); glutamatergic synapse (GO:0098978); extrinsic component of synaptic membrane (GO:0099243); regulation of vascular smooth muscle cell dedifferentiation (GO:1905174),Olfm2,8.2251153,8.2251153,0.007763147,0.076377536,0.022240907,5.3590509,5.3590509,0.035514403,0.19152936,0.001512333,4.8081879,4.8081879,0.02159247,0.11749462,0.6244374,7.700852,7.700852,0.41065406,2.3972432,0.00047606
NC_AS_C10_9351,11.1101,1.1,2.01,0,8.0001,3.4527025,,"[Plus], [# Lnc isoforms: 63], [# of exons: 7], [Gene type: lncRNA]","chr10:120,943,629-120,988,278",KY467558 XR_380885 XR_872129 XR_872130 XR_872133,"Gm35696, predicted gene, 35696; lnc_as_chr10_9351,9353, ",,Gm35696 lnc_as_chr10_9351,14.121701,14.1217012,0.023535667,0.37730226,0.002384589,6.5107622,6.5107622,0.11135226,0.73128875,1.51E-05,5.8494475,5.8494475,0.095571813,0.6485939,0.45418913,4.5937206,4.5937206,0.96378371,3.4527025,0.034777911
NC_INTER_C6_5764,10.0202,0,2.02,0,8.0002,106.7554,,"[Minus], [# Lnc isoforms: 12], [# of exons: 1], [Gene type: lncRNA]","chr6:144,251,915-144,258,216",,"lnc_inter_chr6_5764, ",,lnc_inter_chr6_5764,0.62752382,-1.593565,0.070012605,0.037240701,1,0.18276674,-5.4714552,1.556134,0.27425235,0.004556547,0.15958551,-6.2662329,0.49559294,0.086058065,1,0.14735534,-6.7863166,106.7554,12.559179,1.75E-05
NC_AS_C1_782,10.0202,0,2.02,0,8.0002,5.7215557,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr1:167,423,093-167,433,788",,"Gm38325, ; lnc_as_chr1_782, ",,Gm38325 lnc_as_chr1_782,0.287143,-3.4825853,0.072529423,0.019738777,1,0.046102448,-21.6908221,0.37525855,0.015208705,0.007325553,0.34966514,-2.859879,0.53089559,0.20277488,1,0.22469308,-4.4505153,5.7215557,0.94480552,0.02464152
NC_INTER_C1_48,10.0202,0,2.02,0,8.0002,53.510771,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr1:13,370,507-13,371,567",,"lnc_inter_chr1_48, ",,lnc_inter_chr1_48,0.58301915,-1.7152095,0.58010272,0.30419255,1,0.098420767,-10.1604573,3.8647312,0.38251378,0.043709644,0.28837294,-3.4677317,1.6607714,0.46312742,1,0.10654431,-9.3857661,53.510771,3.8614643,3.33E-05
NC_INTER_C6_5772,10.0202,0,2.02,0,8.0002,67.183801,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr6:144,303,239-144,318,391",,"lnc_inter_chr6_5772, ",,lnc_inter_chr6_5772,0.4329756,-2.3095989,0.034676742,0.014709605,1,0.25808208,-3.8747363,1.4608248,0.36374678,0.005201555,0.38811263,-2.5765717,0.51857624,0.2187702,1,0.20685239,-4.8343653,67.183801,10.541571,1.43E-06
NC_INTER_C9_48997,10.0202,0,2.02,0,8.0002,44.787916,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr9:95,445,473-95,447,611",,"lnc_inter_chr9_48997, ",,lnc_inter_chr9_48997,0.088608667,-11.2855777,0.2082755,0,1,0.13988427,-7.1487666,2.3552399,0.30321428,0.030357024,0.2432758,-4.1105609,5.7511636,1.502555,0.65425738,0.27112437,-3.6883442,44.787916,8.8334117,0.044008618
NC_INTER_C1_51,10.0202,0,2.02,0,8.0002,58.580327,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr1:13,380,039-13,382,817",,"lnc_inter_chr1_51, ",,lnc_inter_chr1_51,1,1,0,0,1,0.077778035,-12.8571003,1.9823696,0.14595558,0.004051258,0.085401766,-11.7093597,1.5583327,0.11792904,0.067607446,0.14318806,-6.9838224,58.580327,5.8294852,0.000528375
NC_INTER_C13_11438,10.0202,0,2.02,0,8.0002,21.330749,,"[Minus], [# Lnc isoforms: 35], [# of exons: 3], [Gene type: lncRNA]","chr13:60,584,863-60,590,263",AK040640 XR_004938163 XR_004938164 XR_382545 XR_873555 XR_873556 XR_873558 XR_873559 XR_873560,"A530001N23Rik, RIKEN cDNA A530001N23 gene; lnc_inter_chr13_11438, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),A530001N23Rik lnc_inter_chr13_11438,0.62381069,-1.6030504,0.293065,0.16018108,1,0.18762159,-5.3298769,2.682398,0.49946734,0.012331675,0.23950885,-4.175211,2.4910997,0.63477185,0.074118079,0.17493694,-5.7163455,21.330749,2.6507795,0.039936375
NC_INTER_C1_47,10.0202,0,2.02,0,8.0002,53.322098,,"[Minus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr1:13,364,738-13,368,251",,"lnc_inter_chr1_47, ",,lnc_inter_chr1_47,0.23461444,-4.2623122,0.45151132,0.088434494,1,0.073045331,-13.690129,3.1915331,0.25370492,1.09E-07,0.2878055,-3.4745687,1.5950708,0.46599598,1,0.14524474,-6.884931,53.322098,5.618354,0.001309737
NC_INTER_C1_55,10.0202,0,2.02,0,8.0002,9.94206,,"[Minus], [# Lnc isoforms: 81], [# of exons: 20], [Gene type: lncRNA]","chr1:13,392,710-13,478,124",,"lnc_inter_chr1_55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75, ",,lnc_inter_chr1_55,0.93627859,-1.0680582,0.027512656,0.024778591,1,0.24385714,-4.1007616,0.38493385,0.10640116,0.001787367,0.22462862,-4.4517924,0.34439021,0.084718319,0.084622099,0.16382006,-6.1042585,9.94206,1.1766599,2.42E-06
SLC22A29,10.0202,0,2.02,0,8.0002,0.57777045,,"[Minus], [# of exons: 10], [Gene type: NM]","chr19:8,234,658-8,235,104 chr19:8,235,992-8,236,195 chr19:8,237,139-8,237,247 chr19:8,243,645-8,243,859 chr19:8,244,420-8,244,535 chr19:8,267,891-8,268,011 chr19:8,281,496-8,281,664 chr19:8,281,754-8,281,908 chr19:8,292,254-8,292,357 chr19:8,292,762-8,293,390",NM_001347426 NM_172776,"Slc22a29, solute carrier family 22. member 29, Predicted to be involved in organic anion transport. Is expressed in embryo; liver; metanephros; and testis. Orthologous to several human genes including SLC22A25 (solute carrier family 22 member 25) and SLC22A9 (solute carrier family 22 member 9).",organic anion transport (GO:0015711),Slc22a29,0.26729833,-3.7411382,0.27614603,0.068782569,0.058349197,0.19249586,-5.194917,0.23464019,0.044739494,0.002234386,0.29774698,-3.3585563,0.53156257,0.16840335,0.11849896,0.20781461,-4.8119812,0.57777045,0.092514927,0.016377456
PROK1,10.0202,0,2.02,0,8.0002,52.182833,,"[Minus], [# of exons: 4], [Gene type: NM]","chr3:107,034,834-107,042,625",NM_001044382 NM_001357885,"Prok1, prokineticin 1, prokineticin-1|endocrine-gland-derived vascular endothelial growth factor, Predicted to have G protein-coupled receptor binding activity. Involved in activation of MAPK activity; positive regulation of cell population proliferation; and regulation of angiogenesis. Localizes to extracellular region. Is expressed in embryo; liver; lung; metanephros; and testis. Orthologous to human PROK1 (prokineticin 1).",activation of MAPK activity (GO:0000187); angiogenesis (GO:0001525); G-protein coupled receptor binding (GO:0001664); extracellular region (GO:0005576); circadian rhythm (GO:0007623); growth factor activity (GO:0008083); positive regulation of cell proliferation (GO:0008284); positive regulation of MAPK cascade (GO:0043410); regulation of angiogenesis (GO:0045765); positive regulation of cell division (GO:0051781),Prok1,0.23593718,-4.2384163,36.542287,8.7898743,0.27283891,0.26106418,-3.8304757,24.970563,6.395988,0.02393546,0.29270646,-3.4163919,23.617937,7.3964741,0.074220501,0.17053699,-5.8638306,52.182833,6.9943987,2.82E-07
GOT1,10.0202,0,2.02,0,8.0002,71.046837,,"[Minus], [# of exons: 9], [Gene type: NM]","chr19:43,574,243-43,599,095",NM_010324,"Got1, glutamic-oxaloacetic transaminase 1, soluble, aspartate aminotransferase, cytoplasmic|cysteine aminotransferase, cytoplasmic|cysteine transaminase, cytoplasmic|cytosolic aspartate aminotransferase|glutamate oxaloacetate transaminase 1, soluble|transaminase A, Exhibits L-aspartate:2-oxoglutarate aminotransferase activity and phosphatidylserine decarboxylase activity. Involved in several processes, including dicarboxylic acid metabolic process; fatty acid homeostasis; and glycerol biosynthetic process. Localizes to cytosol. Is expressed in several structures, including alimentary system; central nervous system; genitourinary system; integumental system; and sensory organ. Human ortholog(s) of this gene implicated in amyloidosis; amyotrophic lateral sclerosis; pancreatic ductal adenocarcinoma; and transient cerebral ischemia. Orthologous to human GOT1 (glutamic-oxaloacetic transaminase 1).",catalytic activity (GO:0003824); L-aspartate:2-oxoglutarate aminotransferase activity (GO:0004069); phosphatidylserine decarboxylase activity (GO:0004609); nucleoplasm (GO:0005654); cytoplasm (GO:0005737); lysosome (GO:0005764); cytosol (GO:0005829); oxaloacetate metabolic process (GO:0006107); glycerol biosynthetic process (GO:0006114); cellular amino acid metabolic process (GO:0006520); aspartate metabolic process (GO:0006531); aspartate biosynthetic process (GO:0006532); aspartate catabolic process (GO:0006533); Notch signaling pathway (GO:0007219); transaminase activity (GO:0008483); cellular amino acid biosynthetic process (GO:0008652); biosynthetic process (GO:0009058); transferase activity (GO:0016740); glutamate catabolic process to aspartate (GO:0019550); glutamate catabolic process to 2-oxoglutarate (GO:0019551); pyridoxal phosphate binding (GO:0030170); positive regulation of transforming growth factor beta receptor signaling pathway (GO:0030511); carboxylic acid binding (GO:0031406); negative regulation of collagen biosynthetic process (GO:0032966); dicarboxylic acid metabolic process (GO:0043648); axon terminus (GO:0043679); L-cysteine:2-oxoglutarate aminotransferase activity (GO:0047801); negative regulation of cytosolic calcium ion concentration (GO:0051481); negative regulation of mitochondrial depolarization (GO:0051902); fatty acid homeostasis (GO:0055089); transdifferentiation (GO:0060290); cellular response to mechanical stimulus (GO:0071260); response to transition metal nanoparticle (GO:1990267),Got1,0.55925267,-1.7881006,52.179544,29.63675,1,0.49429295,-2.0230918,48.493628,25.010471,0.045938563,0.54042642,-1.8503906,47.9732,27.059292,1,0.32953971,-3.0345356,71.046837,18.053724,0.046235711
NC_INTER_CX_49470,10.0202,0,2.02,0,8.0002,60.617145,,"[Plus], [# Lnc isoforms: 11], [# of exons: 1], [Gene type: lncRNA]","chrX:9,333,847-9,335,924",,"lnc_inter_chrX_49470, ",,lnc_inter_chrX_49470,0.17381349,-5.7532934,0.08565386,0,1,0.076766527,-13.0265109,2.6301798,0.19521647,0.000553844,0.13114377,-7.6252191,5.3436126,0.73363112,0.55115228,0.091083982,-10.9788788,60.617145,4.2903542,6.48E-08
NC_INTER_C9_48872,10.0202,0,2.02,0,8.0002,4.9660321,,"[Plus], [# Lnc isoforms: 20], [# of exons: 2], [Gene type: lncRNA]","chr9:88,267,137-88,271,311",,"lnc_inter_chr9_48872, ",,lnc_inter_chr9_48872,0.59112659,-1.691685,0.064060843,0.024570828,1,0.015411205,-64.8878512,0.8228356,0,0.006519455,0.13533243,-7.3892117,1.210782,0.15689592,0.081497776,0.090804208,-11.0127055,4.9660321,0.36021687,0.004596853
NC_INTER_C1_987,10.0202,0,2.02,0,8.0002,19.92648,,"[Plus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr1:192,082,475-192,093,315",,"lnc_inter_chr1_987, ",,lnc_inter_chr1_987,0.17009108,-5.879203,0.01564722,0,1,0.071766292,-13.9341182,0.52365717,0.045015801,0.002640026,0.045064134,-22.190596,0.12032872,0,1,0.13365063,-7.4821945,19.92648,2.1038586,0.00286753
NC_INTER_C5_4116,10.0202,0,2.02,0,8.0002,3.960654,,"[Plus], [# Lnc isoforms: 9], [# of exons: 2], [Gene type: lncRNA]","chr5:33,807,939-33,813,770",,"lnc_inter_chr5_4116, ",,lnc_inter_chr5_4116,0.3705206,-2.6989053,0.46563712,0.15186603,1,0.17512292,-5.7102748,1.4210043,0.2446638,0.015314301,0.43747298,-2.2858555,0.58928496,0.25966796,1,0.050464049,-19.8160873,3.960654,0.13645964,0.000519828
ABHD2,10.0202,0,2.02,0,8.0002,30.78439,,"[Plus], [# of exons: 11], [Gene type: NM]","chr7:86,418,152-86,506,487",NM_018811,"Abhd2, abhydrolase domain containing 2, monoacylglycerol lipase ABHD2|2-arachidonoylglycerol hydrolase|abhydrolase domain-containing protein 2|acetylesterase|alpha/beta hydrolase fold protein|lung alpha/beta hydrolase 2|mmLABH2|triacylglycerol lipase, Predicted to have carboxylic ester hydrolase activity; hormone binding activity; and steroid hormone receptor activity. Involved in acrosome reaction; negative regulation of cell migration; and response to wounding. Localizes to acrosomal vesicle. Is expressed in several structures, including adrenal gland; alimentary system; genitourinary system; nervous system; and sensory organ. Orthologous to human ABHD2 (abhydrolase domain containing 2, acylglycerol lipase).",acrosomal vesicle (GO:0001669); steroid hormone receptor activity (GO:0003707); plasma membrane (GO:0005886); lipid metabolic process (GO:0006629); acrosome reaction (GO:0007340); acetylesterase activity (GO:0008126); response to wounding (GO:0009611); membrane (GO:0016020); integral component of membrane (GO:0016021); lipid catabolic process (GO:0016042); hydrolase activity (GO:0016787); negative regulation of cell migration (GO:0030336); cytoplasmic vesicle (GO:0031410); response to progesterone (GO:0032570); hormone-sensitive lipase activity (GO:0033878); short-chain carboxylesterase activity (GO:0034338); sperm flagellum (GO:0036126); hormone binding (GO:0042562); steroid hormone mediated signaling pathway (GO:0043401); cellular lipid metabolic process (GO:0044255); acylglycerol catabolic process (GO:0046464); acylglycerol lipase activity (GO:0047372); sperm capacitation (GO:0048240); medium-chain fatty acid biosynthetic process (GO:0051792); medium-chain fatty acid catabolic process (GO:0051793); carboxylic ester hydrolase activity (GO:0052689); sperm plasma membrane (GO:0097524),Abhd2,0.46152838,-2.166714,3.5126277,1.7333268,1,0.37782314,-2.646741,3.1045226,1.1896471,0.000734847,0.47523328,-2.1042298,1.6768531,0.83887136,0.29756043,0.4023948,-2.4851216,30.78439,9.1704591,0.036669014
ESRRG,10.0202,0,2.02,0,8.0002,8.7592483,,"[Plus], [# of exons: 12], [Gene type: NM]","chr1:189,432,885-190,038,764",NM_001243792 NM_001357534 NM_001357535 NM_001357536 NM_011935,"Esrrg, estrogen-related receptor gamma, estrogen-related receptor gamma|estrogen receptor-related protein 3|estrogen-related receptor 3|nuclear receptor subfamily 3 group B member 3, Exhibits DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. Involved in positive regulation of cold-induced thermogenesis and positive regulation of transcription by RNA polymerase II. Is expressed in several structures, including central nervous system; genitourinary system; gut; heart; and sensory organ. Orthologous to human ESRRG (estrogen related receptor gamma).","RNA polymerase II regulatory region sequence-specific DNA binding (GO:0000977); RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0001228); DNA binding (GO:0003677); DNA binding transcription factor activity (GO:0003700); steroid hormone receptor activity (GO:0003707); nuclear receptor activity (GO:0004879); steroid binding (GO:0005496); protein binding (GO:0005515); calmodulin binding (GO:0005516); nucleus (GO:0005634); regulation of transcription, DNA-templated (GO:0006355); regulation of transcription by RNA polymerase II (GO:0006357); multicellular organism development (GO:0007275); zinc ion binding (GO:0008270); identical protein binding (GO:0042802); sequence-specific DNA binding (GO:0043565); positive regulation of transcription, DNA-templated (GO:0045893); positive regulation of transcription by RNA polymerase II (GO:0045944); metal ion binding (GO:0046872); retinoic acid receptor signaling pathway (GO:0048384); sequence-specific double-stranded DNA binding (GO:1990837)",Esrrg,0.58982387,-1.6954214,0.015034171,0.008128792,1,0.37677559,-2.6540998,0.19506282,0.078706614,0.000489759,0.33744404,-2.9634543,0.11665757,0.042774125,0.47303445,0.38369093,-2.6062644,8.7592483,2.572358,0.001847572
ADCY1,10.0202,0,2.02,0,8.0002,2.1454564,,"[Plus], [# of exons: 20], [Gene type: NM]","chr11:6,963,436-7,078,508",NM_009622,"Adcy1, adenylate cyclase 1, adenylate cyclase type 1|ATP pyrophosphate-lyase 1|Ca(2+)/calmodulin-activated adenylyl cyclase|adenylate cyclase type I|adenylyl cyclase 1|barrelless, Exhibits adenylate cyclase activity. Involved in several processes, including long-term memory; modulation of chemical synaptic transmission; and positive regulation of CREB transcription factor activity. Localizes to several cellular components, including Schaffer collateral - CA1 synapse; hippocampal mossy fiber to CA3 synapse; and integral component of postsynaptic density membrane. Is expressed in several structures, including alimentary system; nervous system; renal cortex; respiratory system; and sensory organ. Human ortholog(s) of this gene implicated in autosomal recessive nonsyndromic deafness 44. Orthologous to human ADCY1 (adenylate cyclase 1).",nucleotide binding (GO:0000166); adenylate cyclase activity (GO:0004016); calmodulin binding (GO:0005516); ATP binding (GO:0005524); nucleus (GO:0005634); cytoplasm (GO:0005737); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); cAMP biosynthetic process (GO:0006171); adenylate cyclase-activating G-protein coupled receptor signaling pathway (GO:0007189); activation of adenylate cyclase activity (GO:0007190); axonogenesis (GO:0007409); long-term memory (GO:0007616); calcium- and calmodulin-responsive adenylate cyclase activity (GO:0008294); cyclic nucleotide biosynthetic process (GO:0009190); postsynaptic density (GO:0014069); membrane (GO:0016020); integral component of membrane (GO:0016021); lyase activity (GO:0016829); phosphorus-oxygen lyase activity (GO:0016849); positive regulation of CREB transcription factor activity (GO:0032793); intracellular signal transduction (GO:0035556); regulation of circadian rhythm (GO:0042752); metal ion binding (GO:0046872); rhythmic process (GO:0048511); modulation of chemical synaptic transmission (GO:0050804); Schaffer collateral - CA1 synapse (GO:0098685); hippocampal mossy fiber to CA3 synapse (GO:0098686); glutamatergic synapse (GO:0098978); integral component of postsynaptic density membrane (GO:0099061); positive regulation of long-term synaptic potentiation (GO:1900273); regulation of synaptic vesicle exocytosis (GO:2000300),Adcy1,0.1742636,-5.738433,0.30458135,0.046292149,0.32344379,0.064039384,-15.6153906,0.96017511,0.063539183,5.43E-05,0.094450517,-10.5875546,0.61225717,0.056358018,0.10243548,0.072567354,-13.7803013,2.1454564,0.12588123,8.93E-05
CYP2C50,10.0202,0,2.02,0,8.0002,95.971374,,"[Plus], [# of exons: 8], [Gene type: NM]","chr19:40,164,169-40,164,357 chr19:40,164,711-40,164,873 chr19:40,165,036-40,165,185 chr19:40,165,435-40,166,870 chr19:40,171,207-40,171,348 chr19:40,172,445-40,172,632 chr19:40,185,646-40,188,445",NM_001167875 NM_001167877 NM_134144,"Cyp2c50, cytochrome P450, family 2, subfamily c, polypeptide 50, cytochrome P450 2C50|CYPIIC50|cytochrome P450, 2c50, Exhibits arachidonic acid epoxygenase activity and linoleic acid epoxygenase activity. Involved in arachidonic acid metabolic process and linoleic acid metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Is expressed in alimentary system and liver. Human ortholog(s) of this gene implicated in several diseases, including eosinophilic esophagitis; glucose metabolism disease (multiple); multiple myeloma; sickle cell anemia; and warfarin resistance. Orthologous to human CYP2C19 (cytochrome P450 family 2 subfamily C member 19) and CYP2C9 (cytochrome P450 family 2 subfamily C member 9).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); arachidonic acid metabolic process (GO:0019369); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); linoleic acid metabolic process (GO:0043651); metal ion binding (GO:0046872); aromatase activity (GO:0070330); linoleic acid epoxygenase activity (GO:0071614)",Cyp2c50,0.2763171,-3.6190304,95.971374,26.482213,0.052556997,0.27541653,-3.6308642,55.260312,17.362593,4.98E-05,0.37464279,-2.6692093,87.225847,34.677261,0.11580362,0.37127246,-2.6934397,58.850955,16.811278,0.039838208
CYP2C38,10.0202,0,2.02,0,8.0002,25.390617,,"[~9%  IN BLACKLIST], [Minus], [# of exons: 9], [Gene type: NM]","chr19:39,464,046-39,537,565",NM_010002,"Cyp2c38, cytochrome P450, family 2, subfamily c, polypeptide 38, cytochrome P450 2C38|CYPIIC38|cytochrome P450, 2c38, Exhibits arachidonic acid 11,12-epoxygenase activity and arachidonic acid 14,15-epoxygenase activity. Involved in arachidonic acid metabolic process. Predicted to localize to cytoplasm and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in several diseases, including eosinophilic esophagitis; glucose metabolism disease (multiple); multiple myeloma; sickle cell anemia; and warfarin resistance. Orthologous to human CYP2C19 (cytochrome P450 family 2 subfamily C member 19) and CYP2C9 (cytochrome P450 family 2 subfamily C member 9).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); lipid metabolic process (GO:0006629); xenobiotic metabolic process (GO:0006805); arachidonic acid epoxygenase activity (GO:0008392); steroid hydroxylase activity (GO:0008395); retinoic acid 4-hydroxylase activity (GO:0008401); arachidonic acid 14,15-epoxygenase activity (GO:0008404); arachidonic acid 11,12-epoxygenase activity (GO:0008405); membrane (GO:0016020); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); arachidonic acid metabolic process (GO:0019369); epoxygenase P450 pathway (GO:0019373); heme binding (GO:0020037); caffeine oxidase activity (GO:0034875); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); aromatase activity (GO:0070330); estrogen 16-alpha-hydroxylase activity (GO:0101020)",Cyp2c38,0.3425038,-2.9196756,6.2016621,2.1023382,0.12955502,0.35534852,-2.8141387,3.7678304,1.4433956,9.09E-05,0.38982144,-2.5652771,9.2449544,3.7928938,0.058486018,0.303717,-3.2925387,25.390617,6.0609882,0.021053747
NC_INTER_CX_15449,10.0101,0,2.01,0,8.0001,193.88937,,"[100%  IN BLACKLIST], [Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chrX:122,647,432-122,647,635",,"lnc_inter_chrX_15449, ",,lnc_inter_chrX_15449,6.2630087,6.2630087,0,1.0104299,1,95.796644,95.7966441,0,24.640352,1.21E-05,32.438934,32.4389342,0,9.3728843,0.65829669,120.25956,120.259562,1.8232954,193.88937,1.49E-12
NC_AS_C17_13924,10.0101,0,2.01,0,8.0001,8.9444469,,"[Minus], [# Lnc isoforms: 47], [# of exons: 7], [Gene type: lncRNA]","chr17:44,154,913-44,212,677",,"lnc_as_chr17_13924,13925,13926,13927,13928, ",,lnc_as_chr17_13924,6.5586986,6.5586986,0.012185105,0.08178978,0.73330011,11.117668,11.1176677,0.066791729,0.82431249,0.048923171,7.3711921,7.3711921,0.095958535,0.7752475,0.394304,18.888301,18.8883013,0.68928775,8.9444469,0.002921869
NC_AS_C13_11022,10.0101,0,2.01,0,8.0001,1.7051957,,"[Minus], [# Lnc isoforms: 67], [# of exons: 22], [Gene type: lncRNA]","chr13:3,612,180-3,765,570",XR_382020,"Gm35190, predicted gene, 35190; lnc_as_chr13_11022,11023, ",,Gm35190 lnc_as_chr13_11022,2.6274209,2.6274209,0.015573796,0.034972469,1,9.6105786,9.6105786,0.009638198,0.098908364,2.89E-05,3.9182585,3.9182585,0.014536825,0.0621144,0.28512823,7.1680984,7.1680984,0.34890225,1.7051957,0.000181994
ADORA1,10.0101,0,2.01,0,8.0001,25.566344,,"[Minus], [# of exons: 2], [Gene type: NM]","chr1:136,095,792-136,132,034",NM_001008533 NM_001039510 NM_001282945 NM_001291928 NM_001291930,"Adora1, adenosine A1 receptor, adenosine receptor A1, Predicted to have several functions, including G protein-coupled adenosine receptor activity; G-protein beta/gamma-subunit complex binding activity; and heterotrimeric G-protein binding activity. Involved in several processes, including excitatory postsynaptic potential; negative regulation of long-term synaptic depression; and negative regulation of mucus secretion. Localizes to dendritic spine. Is expressed in several structures, including alimentary system; brain; genitourinary system; heart; and liver and biliary system. Human ortholog(s) of this gene implicated in asthma. Orthologous to human ADORA1 (adenosine A1 receptor).","activation of MAPKK activity (GO:0000186); G-protein coupled adenosine receptor activity (GO:0001609); temperature homeostasis (GO:0001659); G-protein coupled receptor binding (GO:0001664); response to hypoxia (GO:0001666); purine nucleoside binding (GO:0001883); adenosine receptor signaling pathway (GO:0001973); regulation of respiratory gaseous exchange by neurological system process (GO:0002087); negative regulation of acute inflammatory response (GO:0002674); negative regulation of leukocyte migration (GO:0002686); positive regulation of peptide secretion (GO:0002793); positive regulation of systemic arterial blood pressure (GO:0003084); negative regulation of systemic arterial blood pressure (GO:0003085); regulation of glomerular filtration (GO:0003093); G-protein coupled receptor activity (GO:0004930); protein binding (GO:0005515); endoplasmic reticulum (GO:0005783); plasma membrane (GO:0005886); protein targeting to membrane (GO:0006612); signal transduction (GO:0007165); G-protein coupled receptor signaling pathway (GO:0007186); adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway (GO:0007193); negative regulation of cell proliferation (GO:0008285); endomembrane system (GO:0012505); negative regulation of glutamate secretion (GO:0014050); postsynaptic density (GO:0014069); membrane (GO:0016020); integral component of membrane (GO:0016021); lipid catabolic process (GO:0016042); basolateral plasma membrane (GO:0016323); dendrite (GO:0030425); axolemma (GO:0030673); heat shock protein binding (GO:0031072); G-protein beta/gamma-subunit complex binding (GO:0031683); negative regulation of synaptic transmission, GABAergic (GO:0032229); positive regulation of nucleoside transport (GO:0032244); asymmetric synapse (GO:0032279); heterotrimeric G-protein binding (GO:0032795); negative regulation of neurotrophin production (GO:0032900); positive regulation of protein dephosphorylation (GO:0035307); negative regulation of renal sodium excretion (GO:0035814); vasodilation (GO:0042311); negative regulation of circadian sleep/wake cycle, sleep (GO:0042321); negative regulation of circadian sleep/wake cycle, non-REM sleep (GO:0042323); presynaptic membrane (GO:0042734); neuronal cell body (GO:0043025); negative regulation of apoptotic process (GO:0043066); terminal bouton (GO:0043195); dendritic spine (GO:0043197); positive regulation of potassium ion transport (GO:0043268); cell body (GO:0044297); calyx of Held (GO:0044305); protein-containing complex binding (GO:0044877); synapse (GO:0045202); postsynaptic membrane (GO:0045211); positive regulation of epidermal growth factor-activated receptor activity (GO:0045741); negative regulation of blood pressure (GO:0045776); positive regulation of blood pressure (GO:0045777); negative regulation of heart contraction (GO:0045822); negative regulation of hormone secretion (GO:0046888); protein heterodimerization activity (GO:0046982); presynaptic active zone (GO:0048786); negative regulation of inflammatory response (GO:0050728); cognition (GO:0050890); detection of temperature stimulus involved in sensory perception of pain (GO:0050965); negative regulation of lipid catabolic process (GO:0050995); positive regulation of lipid catabolic process (GO:0050996); regulation of sensory perception of pain (GO:0051930); negative regulation of synaptic transmission, glutamatergic (GO:0051967); fatty acid homeostasis (GO:0055089); regulation of cardiac muscle contraction (GO:0055117); excitatory postsynaptic potential (GO:0060079); relaxation of vascular smooth muscle (GO:0060087); negative regulation of mucus secretion (GO:0070256); triglyceride homeostasis (GO:0070328); regulation of cardiac muscle cell contraction (GO:0086004); integral component of postsynaptic membrane (GO:0099055); integral component of presynaptic membrane (GO:0099056); neurotransmitter receptor activity involved in regulation of presynaptic cytosolic calcium ion concentration (GO:0099582); negative regulation of long-term synaptic potentiation (GO:1900272); negative regulation of long term synaptic depression (GO:1900453); positive regulation of neuron death (GO:1901216)",Adora1,3.3716351,3.3716351,2.3640678,7.8165614,0.58077201,2.8017819,2.8017819,3.383234,9.9575667,0.00331693,2.1678386,2.1678386,2.3855687,5.5756616,1,4.2143502,4.2143502,8.3979243,25.566344,0.009209951
CYP2J9,10.0101,0,2.01,0,8.0001,20.864167,,"[Minus], [# of exons: 9], [Gene type: NM]","chr4:96,235,120-96,258,176",NM_028979,"Cyp2j9, cytochrome P450, family 2, subfamily j, polypeptide 9, cytochrome P450, family 2, subfamily j, polypeptide 9|cytochrome P450, 2j9, Predicted to have heme binding activity; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; and steroid hydroxylase activity. Predicted to be involved in exogenous drug catabolic process; organic acid metabolic process; and xenobiotic metabolic process. Localizes to endoplasmic reticulum. Is expressed in alimentary system; ductus arteriosus; nervous system; and sensory organ. Human ortholog(s) of this gene implicated in hypertension; myocardial infarction; pulmonary hypertension; renal fibrosis; and renal hypertension. Orthologous to human CYP2J2 (cytochrome P450 family 2 subfamily J member 2).","cytoplasm (GO:0005737); endoplasmic reticulum (GO:0005783); organic acid metabolic process (GO:0006082); xenobiotic metabolic process (GO:0006805); steroid hydroxylase activity (GO:0008395); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO:0016712); heme binding (GO:0020037); exogenous drug catabolic process (GO:0042738); intracellular membrane-bounded organelle (GO:0043231)",Cyp2j9,2.0082462,2.0082462,0.23675963,0.44783219,1,2.0873766,2.0873766,1.8181654,4.0565071,0.033047058,2.3125954,2.3125954,6.4637561,15.728498,0.096384078,3.018407,3.018407,8.9780322,20.864167,0.002261858
NC_INTER_CX_15335,10.0101,0,2.01,0,8.0001,3.1369097,,"[Plus], [# Lnc isoforms: 17], [# of exons: 6], [Gene type: lncRNA]","chrX:47,890,517-47,915,825",NR_131207,"Gm35612, predicted gene, 35612; lnc_inter_chrX_15335, ",,Gm35612 lnc_inter_chrX_15335,4.2504294,4.2504294,0.00351476,0.021082279,1,4.6448796,4.6448796,0.24489378,1.2370716,0.000121656,1.8334461,1.8334461,0.21245118,0.44650447,1,3.3600439,3.3600439,1.2309771,3.1369097,0.025071168
NC_INTER_CY_50499,10.0101,0,2.01,0,8.0001,24.059812,,"[Plus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chrY:2,779,621-2,783,062",,"lnc_inter_chrY_50499, ",,lnc_inter_chrY_50499,3.2025429,3.2025429,0.18126459,0.42870079,1,13.102822,13.1028225,0.12296455,1.8688203,0.000626154,6.7621131,6.7621131,0.2211889,1.8429914,0.11941699,104.95849,104.9584879,0.32269309,24.059812,9.50E-15
NC_INTER_C5_4376,10.0101,0,2.01,0,8.0001,11.530074,,"[Plus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr5:91,322,224-91,328,737",,"lnc_inter_chr5_4376, ",,lnc_inter_chr5_4376,0.42524565,-2.351582,0.054076138,0.015746758,1,4.723059,4.723059,0.46133651,2.3919559,0.000319273,1.5500059,1.5500059,0.97584585,1.7361943,1,3.7244039,3.7244039,4.2216094,11.530074,0.01326476
NC_INTER_C5_4405,10.0101,0,2.01,0,8.0001,8.4792829,,"[Plus], [# Lnc isoforms: 3], [# of exons: 1], [Gene type: lncRNA]","chr5:94,126,533-94,129,122",,"lnc_inter_chr5_4405,4406, ",,lnc_inter_chr5_4405,6.4447292,6.4447292,0,0.080383061,1,55.94658,55.9465804,0,1.1599381,0.007291214,5.0480495,5.0480495,0.46001491,2.9802112,0.078592377,11.870967,11.870967,0.90998786,8.4792829,0.00244464
C9,10.0101,0,2.01,0,8.0001,165.23788,,"[Plus], [# of exons: 12], [Gene type: NM]","chr15:6,395,346-6,448,825",NM_001368420 NM_001368421 NM_013485,"C9, complement component 9, complement component C9, Predicted to be involved in blood coagulation; cell killing; and protein homooligomerization. Predicted to localize to extracellular space and membrane attack complex. Is expressed in adrenal gland and liver lobe. Human ortholog(s) of this gene implicated in age related macular degeneration 15 and complement component 9 deficiency. Orthologous to human C9 (complement C9).","cell killing (GO:0001906); immune system process (GO:0002376); extracellular region (GO:0005576); membrane attack complex (GO:0005579); extracellular space (GO:0005615); plasma membrane (GO:0005886); immune response (GO:0006955); complement activation, alternative pathway (GO:0006957); complement activation, classical pathway (GO:0006958); blood coagulation (GO:0007596); membrane (GO:0016020); integral component of membrane (GO:0016021); cytolysis (GO:0019835); other organism cell membrane (GO:0044218); innate immune response (GO:0045087); protein homooligomerization (GO:0051260)",C9,2.5705748,2.5705748,36.640681,86.014792,0.11054869,2.4829327,2.4829327,29.225616,72.958379,0.000956971,2.1450325,2.1450325,65.226132,149.47503,0.31103114,2.5413536,2.5413536,84.224294,165.23788,0.01819642
ADGRV1,10.0101,0,2.01,0,8.0001,7.3512837,,"[~1% MAX. MULTIPLE IN BLACKLIST], [Minus], [# of exons: 90], [Gene type: NM]","chr13:81,234,067-81,772,143",NM_054053,"Adgrv1, adhesion G protein-coupled receptor V1, adhesion G-protein coupled receptor V1|G-protein coupled receptor 98|monogenic audiogenic seizure susceptibility protein 1|monogenic, audiogenic seizure susceptibility 1|neurepin|protein rueda|very large G protein-coupled receptor 1, Exhibits several functions, including G-protein alpha-subunit binding activity; adenylate cyclase inhibitor activity; and myosin binding activity. Involved in several processes, including detection of mechanical stimulus involved in sensory perception of sound; positive regulation of bone mineralization; and positive regulation of intracellular signal transduction. Localizes to several cellular components, including USH2 complex; periciliary membrane compartment; and stereocilia ankle link complex. Is expressed in several structures, including brain; eye; neural ectoderm; reproductive system; and spinal cord. Used to study Usher syndrome type 2C. Human ortholog(s) of this gene implicated in Usher syndrome type 2C and familial febrile seizures 4. Orthologous to human ADGRV1 (adhesion G protein-coupled receptor V1).",G-protein alpha-subunit binding (GO:0001965); stereocilia ankle link (GO:0002141); stereocilia ankle link complex (GO:0002142); transmembrane signaling receptor activity (GO:0004888); G-protein coupled receptor activity (GO:0004930); calcium ion binding (GO:0005509); protein binding (GO:0005515); extracellular region (GO:0005576); cytoplasm (GO:0005737); plasma membrane (GO:0005886); cell communication (GO:0007154); signal transduction (GO:0007165); cell surface receptor signaling pathway (GO:0007166); G-protein coupled receptor signaling pathway (GO:0007186); negative regulation of adenylate cyclase activity (GO:0007194); multicellular organism development (GO:0007275); nervous system development (GO:0007399); visual perception (GO:0007601); sensory perception of sound (GO:0007605); cell surface (GO:0009986); positive regulation of protein kinase A signaling (GO:0010739); adenylate cyclase inhibitor activity (GO:0010855); membrane (GO:0016020); integral component of membrane (GO:0016021); hydrolase activity (GO:0016787); myosin binding (GO:0017022); positive regulation of bone mineralization (GO:0030501); regulation of protein stability (GO:0031647); photoreceptor connecting cilium (GO:0032391); stereocilium (GO:0032420); cell projection (GO:0042995); receptor complex (GO:0043235); establishment of protein localization (GO:0045184); synapse (GO:0045202); photoreceptor cell maintenance (GO:0045494); perinuclear region of cytoplasm (GO:0048471); maintenance of animal organ identity (GO:0048496); inner ear development (GO:0048839); nervous system process (GO:0050877); response to stimulus (GO:0050896); detection of mechanical stimulus involved in sensory perception of sound (GO:0050910); sensory perception of light stimulus (GO:0050953); inner ear receptor cell stereocilium organization (GO:0060122); cellular response to calcium ion (GO:0071277); positive regulation of protein kinase C signaling (GO:0090037); self proteolysis (GO:0097264); cell-cell adhesion (GO:0098609); periciliary membrane compartment (GO:1990075); USH2 complex (GO:1990696),Adgrv1,5.0207998,5.0207998,0.047709401,0.21438688,0.69322469,6.2911332,6.2911332,0.066827716,0.48810906,0.00795835,4.5407241,4.5407241,0.093871907,0.46950021,0.28074874,5.9262154,5.9262154,1.8002084,7.3512837,0.007102703
NC_INTRA_C19_15012,1.2,1.2,0,0,0,1.1479473,,"[Minus], [# Lnc isoforms: 10], [# of exons: 15], [Gene type: lncRNA]","chr19:40,074,131-40,112,429 chr19:40,144,195-40,144,381 chr19:40,148,304-40,187,923",,"lnc_intra-as_chr19_15012, ",,lnc_intra-as_chr19_15012,0.20714665,-4.8274979,0.40612372,0.082248715,0.002873712,0.41690604,-2.398622,0.19873586,0.088736711,0.27452787,0.38765372,-2.5796219,0.39416211,0.16269535,0.094691339,0.48286167,-2.0709865,1.1479473,0.41446823,0.66002427
NC_AS_C9_8402,1.2,1.2,0,0,0,3.5999312,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr9:120,038,289-120,039,000",,"lnc_as_chr9_8402, ",,lnc_as_chr9_8402,0.01686344,-59.2998801,3.5999312,0,0.049822219,2.8818715,2.8818715,0.21869635,0.64635697,1,12.771925,12.7719248,0,1.0645525,1,1,1,0,0,1
NC_INTER_C16_13428,1.2,1.2,0,0,0,0.45177021,,"[Minus], [# Lnc isoforms: 21], [# of exons: 4], [Gene type: lncRNA]","chr16:76,215,834-76,225,131",,"lnc_inter_chr16_13428, ",,lnc_inter_chr16_13428,0.013710169,-72.9385614,0.33093319,0,0.005371317,0.048406554,-20.6583596,0.1123559,0,1,0.1120353,-8.9257582,0.2393657,0.0176012,1,0.10307319,-9.7018444,0.45177021,0.023420452,0.77670782
NC_INTER_C2_1882,1.2,1.2,0,0,0,10.212941,,"[Minus], [# Lnc isoforms: 2], [# of exons: 1], [Gene type: lncRNA]","chr2:153,411,245-153,412,989",,"lnc_inter_chr2_1882, ",,lnc_inter_chr2_1882,0.015302843,-65.3473336,1.4349037,0,0.041064707,0.16200229,-6.1727524,3.4440432,0.54082,0.46225517,0.33411993,-2.9929373,3.1252747,1.0613696,1,0.23457235,-4.263077,10.212941,1.6230615,1
NC_INTER_C17_29897,1.2,1.2,0,0,0,3.9635128,,"[Minus], [# Lnc isoforms: 4], [# of exons: 1], [Gene type: lncRNA]","chr17:46,183,385-46,185,217",,"lnc_inter_chr17_29897, ",,lnc_inter_chr17_29897,0.005717384,-174.9051633,3.9635128,0,7.52E-06,0.077780493,-12.856694,1.1603678,0.059157285,0.32094148,0.13543362,-7.3836911,1.5067153,0.23432859,1,0.43753019,-2.2855566,0.60610639,0.11885368,1
TGTP1,1.2,1.2,0,0,0,9.883602,,"[Minus], [# of exons: 2], [Gene type: NM]","chr11:48,798,831-48,805,748",NM_011579,"Tgtp1, T cell specific GTPase 1, T-cell-specific guanine nucleotide triphosphate-binding protein 1|Interferon-gamma-inducible GTPase Ifggb6 protein|T-cell specific GTPase|T-cell-specific guanine nucleotide triphosphate-binding protein 2|interferon-gamma-inducible GTPase Ifggb5, Exhibits GTPase activity. Involved in several processes, including cellular response to interferon-beta; response to interferon-alpha; and response to interferon-gamma. Predicted to localize to endoplasmic reticulum membrane. Is expressed in several structures, including genitourinary system; hemolymphoid system; integumental system; nervous system; and nose.",GTPase activity (GO:0003924); GTP binding (GO:0005525); endoplasmic reticulum membrane (GO:0005789); defense response (GO:0006952); immune response (GO:0006955); response to virus (GO:0009615); response to bacterium (GO:0009617); response to interferon-gamma (GO:0034341); response to interferon-alpha (GO:0035455); cellular response to interferon-beta (GO:0035458),Tgtp1,0.23795603,-4.2024571,8.4200541,1.8704518,0.001994236,0.47971019,-2.0845919,5.6084508,2.76224,0.78149877,0.46967422,-2.1291354,9.883602,4.8100305,1,0.62945173,-1.5886842,5.5178559,2.3486078,1
TGTP2,1.2,1.2,0,0,0,6.6990657,,"[Minus], [# of exons: 2], [Gene type: NM]","chr11:48,870,698-48,877,714",NM_001145164,"Tgtp2, T cell specific GTPase 2, T-cell-specific guanine nucleotide triphosphate-binding protein 2|Immunity related GTPase family B member 6 homologue allele 1|Immunity related GTPase family B member 6 homologue allele 2|Irgb6 homologue|OTTMUSPWKG00059379|OTTMUSPWKG00059381|OTTMUSWSBG00059278|OTTMUSWSBG00059282|interferon-gamma-inducible GTPase Ifggb6 protein, Predicted to have GTPase activity. Predicted to be involved in cellular response to interferon-beta and defense response. Predicted to localize to endoplasmic reticulum membrane. Is expressed in several structures, including genitourinary system; hemolymphoid system; integumental system; nervous system; and nose.",GTPase activity (GO:0003924); endoplasmic reticulum membrane (GO:0005789); defense response (GO:0006952); cellular response to interferon-beta (GO:0035458),Tgtp2,0.19203615,-5.207353,6.6879516,1.1680204,0.000541845,0.57128253,-1.7504474,4.1772309,2.500223,1,0.52866533,-1.8915559,6.6990657,3.6990736,1,0.6625843,-1.5092419,4.0191074,1.8109946,1
TNFAIP8L3,1.2,1.2,0,0,0,2.1235725,,"[Minus], [# of exons: 2], [Gene type: NM]","chr9:53,873,413-53,916,218",NM_001033535,"Tnfaip8l3, tumor necrosis factor, alpha-induced protein 8-like 3, tumor necrosis factor alpha-induced protein 8-like protein 3|TNF alpha-induced protein 8-like protein 3|TNFAIP8-like protein 3|tumor necrosis factor, alpha-induced protein 8-like protein 3, Exhibits phosphatidylinositol binding activity and phosphatidylinositol transfer activity. Involved in several processes, including inositol lipid-mediated signaling; positive regulation of intracellular signal transduction; and positive regulation of phosphatidylinositol 3-kinase activity. Localizes to cytoplasm and plasma membrane. Orthologous to human TNFAIP8L3 (TNF alpha induced protein 8 like 3).",nucleoplasm (GO:0005654); cytoplasm (GO:0005737); cytosol (GO:0005829); plasma membrane (GO:0005886); lipid transport (GO:0006869); phosphatidylinositol transporter activity (GO:0008526); phospholipid transport (GO:0015914); membrane (GO:0016020); regulation of lipid metabolic process (GO:0019216); phosphatidylinositol binding (GO:0035091); regulation of apoptotic process (GO:0042981); positive regulation of phosphatidylinositol 3-kinase activity (GO:0043552); inositol lipid-mediated signaling (GO:0048017); positive regulation of protein kinase B signaling (GO:0051897); positive regulation of ERK1 and ERK2 cascade (GO:0070374),Tnfaip8l3,0.081645156,-12.248124,0.10872614,0.00718785,0.006539685,0.41586359,-2.4046346,0.095116395,0.04234882,1,0.79246151,-1.2618909,0.074126757,0.065986483,1,0.5539205,-1.8053132,2.1235725,0.85798534,1
HAMP2,1.2,1.2,0,0,0,993.51543,,"[Minus], [# of exons: 3], [Gene type: NM]","chr7:31,707,391-31,709,200",NM_183257,"Hamp2, hepcidin antimicrobial peptide 2, hepcidin-2, Predicted to have hormone activity. Predicted to be involved in cellular iron ion homeostasis; defense response to bacterium; and negative regulation of iron ion transmembrane transport. Predicted to localize to extracellular space. Is expressed in liver. Human ortholog(s) of this gene implicated in anemia; hemochromatosis; hemochromatosis type 2B; and hepatocellular carcinoma. Orthologous to human HAMP (hepcidin antimicrobial peptide).",hormone activity (GO:0005179); extracellular region (GO:0005576); extracellular space (GO:0005615); cellular iron ion homeostasis (GO:0006879); killing of cells of other organism (GO:0031640); negative regulation of iron ion transmembrane transport (GO:0034760); defense response to bacterium (GO:0042742); defense response to fungus (GO:0050832),Hamp2,0.22498074,-4.444825,692.65285,149.1152,0.004572695,0.38798131,-2.5774437,696.17884,314.82495,0.58238539,0.32171837,-3.1083087,901.0848,317.84606,0.394304,0.79307151,-1.2609203,993.51543,577.69801,1
TMEM45B,1.2,1.2,0,0,0,0.84881888,,"[Minus], [# of exons: 6], [Gene type: NM]","chr9:31,233,781-31,271,823",NM_144936,"Tmem45b, transmembrane protein 45b, transmembrane protein 45B, Predicted to localize to integral component of membrane. Is expressed in central nervous system; ganglia; gut; olfactory epithelium; and vibrissa. Orthologous to human TMEM45B (transmembrane protein 45B).",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150); membrane (GO:0016020); integral component of membrane (GO:0016021),Tmem45b,0.18255426,-5.4778233,0.26090337,0.043083082,0.035482611,0.53328437,-1.8751721,0.23909021,0.13634231,1,0.54634437,-1.8303474,0.29706823,0.16865459,1,0.40337574,-2.4790782,0.84881888,0.27315437,0.88179812
SERPINB1A,1.2,1.2,0,0,0,4.402757,,"[Minus], [# of exons: 7], [Gene type: NM]","chr13:32,933,961-32,943,054",NM_025429,"Serpinb1a, serine (or cysteine) peptidase inhibitor, clade B, member 1a, leukocyte elastase inhibitor A|ovalbumin|serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1a|serine (or cysteine) proteinase inhibitor, clade B, member 1a|serine protease inhibitor EIA|serpin B1a, Predicted to have serine-type endopeptidase inhibitor activity. Involved in several processes, including negative regulation of interleukin-1 beta production; regulation of protein catabolic process; and type B pancreatic cell proliferation. Localizes to extracellular region. Is expressed in bladder wall; brain; embryo mesenchyme; gut; and liver lobe. Orthologous to human SERPINB1 (serpin family B member 1).",serine-type endopeptidase inhibitor activity (GO:0004867); protein binding (GO:0005515); extracellular region (GO:0005576); extracellular space (GO:0005615); cytoplasm (GO:0005737); inflammatory response (GO:0006954); negative regulation of peptidase activity (GO:0010466); negative regulation of endopeptidase activity (GO:0010951); cellular homeostasis (GO:0019725); peptidase inhibitor activity (GO:0030414); negative regulation of interleukin-1 beta production (GO:0032691); cytoplasmic ribonucleoprotein granule (GO:0036464); regulation of protein catabolic process (GO:0042176); type B pancreatic cell proliferation (GO:0044342); regulation of innate immune response (GO:0045088); collagen-containing extracellular matrix (GO:0062023),Serpinb1a,0.28320377,-3.5310264,2.6024934,0.69188012,0.012204131,0.754609,-1.3251896,2.1065248,1.5491987,1,0.5387843,-1.8560303,4.402757,2.4566597,1,0.36223575,-2.7606331,1.4918026,0.40481081,1
NC_INTER_C13_11294,1.2,1.2,0,0,0,0.71317898,,"[Plus], [# Lnc isoforms: 28], [# of exons: 11], [Gene type: lncRNA]","chr13:46,115,226-46,133,357",,"lnc_inter_chr13_11294, ",,lnc_inter_chr13_11294,0.032836532,-30.453886,0.26116719,0.005656535,0.000371152,0.2140109,-4.6726591,0.17964167,0.032761082,0.48356433,0.19315105,-5.177295,0.21526234,0.041727797,0.84307953,0.25584202,-3.9086621,0.71317898,0.12597319,1
NC_AS_C8_7301,1.2,1.2,0,0,0,1.1514747,,"[Plus], [# Lnc isoforms: 47], [# of exons: 40], [Gene type: lncRNA]","chr8:95,577,587-95,675,109",,"lnc_as_chr8_7301, ",,lnc_as_chr8_7301,0.2322212,-4.3062391,1.1514747,0.26488731,0.038570233,0.8337847,-1.1993504,0.52986318,0.45492408,1,0.82704132,-1.2091294,0.73525242,0.64765768,1,1.1315007,1.1315007,0.55430641,0.48464342,1
NC_AS_C5_4362,1.2,1.2,0,0,0,1.3881215,,"[Plus], [# Lnc isoforms: 6], [# of exons: 3], [Gene type: lncRNA]","chr5:89,865,010-89,903,640",,"lnc_as_chr5_4362, ",,lnc_as_chr5_4362,0.30851053,-3.2413804,1.3881215,0.41527396,0.049634875,1.4358538,1.4358538,0.24237218,0.3307028,1,0.77831651,-1.2848243,0.56259428,0.47300712,1,0.9533777,-1.0489022,1.2017369,0.77482553,1
SLC34A2,1.2,1.2,0,0,0,1.1284784,,"[Plus], [# of exons: 13], [Gene type: NM]","chr5:53,440,592-53,462,902",NM_011402,"Slc34a2, solute carrier family 34 (sodium phosphate), member 2, sodium-dependent phosphate transport protein 2B|Na(+)-dependent phosphate cotransporter 2B|Na(+)/Pi cotransporter 2B|sodium-phosphate transport protein 2B|sodium/phosphate cotransporter 2B|solute carrier family 34 member 2|type IIb Na/Picotransporter, Exhibits sodium:phosphate symporter activity. Involved in in utero embryonic development and phosphate ion transport. Localizes to apical plasma membrane and brush border. Is expressed in cortical renal tubule; incisor enamel organ; lower jaw molar; and lower jaw molar enamel organ. Human ortholog(s) of this gene implicated in pulmonary alveolar microlithiasis. Orthologous to human SLC34A2 (solute carrier family 34 member 2).",in utero embryonic development (GO:0001701); sodium:phosphate symporter activity (GO:0005436); plasma membrane (GO:0005886); brush border (GO:0005903); ion transport (GO:0006811); sodium ion transport (GO:0006814); phosphate ion transport (GO:0006817); symporter activity (GO:0015293); membrane (GO:0016020); integral component of membrane (GO:0016021); apical plasma membrane (GO:0016324); protein domain specific binding (GO:0019904); cellular phosphate ion homeostasis (GO:0030643); sodium ion binding (GO:0031402); brush border membrane (GO:0031526); microvillus membrane (GO:0031528); vesicle (GO:0031982); phosphate ion binding (GO:0042301); sodium-dependent phosphate transport (GO:0044341),Slc34a2,0.11790145,-8.4816596,0.84934548,0.091323506,3.58E-06,0.26581507,-3.7620139,1.1284784,0.30913837,0.3666952,0.33095275,-3.0215793,0.83810996,0.2801142,0.76988778,0.3110803,-3.2146041,0.85884959,0.17443064,1
ZGRF1,1.2,1.2,0,0,0,2.1173771,,"[Plus], [# of exons: 26], [Gene type: NM]","chr3:127,256,407-127,320,941",NM_197997,"Zgrf1, zinc finger, GRF-type containing 1, protein ZGRF1|GRF-type zinc finger domain-containing protein 1, Predicted to have 5'-flap endonuclease activity and RNA binding activity. Predicted to be involved in replication fork reversal. Predicted to localize to cytoplasm. Is expressed in brain ventricular layer and nose. Orthologous to human ZGRF1 (zinc finger GRF-type containing 1).",RNA binding (GO:0003723); helicase activity (GO:0004386); cytoplasm (GO:0005737); zinc ion binding (GO:0008270); membrane (GO:0016020); integral component of membrane (GO:0016021); 5'-flap endonuclease activity (GO:0017108); metal ion binding (GO:0046872); replication fork reversal (GO:0071932),Zgrf1,0.11028081,-9.0677611,0.070457287,0.006860963,0.029756167,0.4449156,-2.2476173,0.14495415,0.06581823,1,0.29243548,-3.4195577,0.54073054,0.17624432,0.79513722,0.41711197,-2.3974378,2.1173771,0.63418842,0.32619078
A2M,1.2,1.2,0,0,0,1.0081355,,"[Plus], [# of exons: 36], [Gene type: NM]","chr6:121,586,191-121,629,256",NM_175628,"A2m, alpha-2-macroglobulin, alpha-2-macroglobulin-P, Predicted to have several functions, including cytokine binding activity; growth factor binding activity; and serine-type endopeptidase inhibitor activity. Involved in stem cell differentiation. Predicted to localize to extracellular space. Is expressed in several structures, including brain; embryo mesenchyme; liver; meninges; and retina. Human ortholog(s) of this gene implicated in COVID-19; background diabetic retinopathy; neurodegenerative disease (multiple); and obstructive lung disease. Orthologous to human A2M (alpha-2-macroglobulin).","negative regulation of complement activation, lectin pathway (GO:0001869); protease binding (GO:0002020); endopeptidase inhibitor activity (GO:0004866); serine-type endopeptidase inhibitor activity (GO:0004867); signaling receptor binding (GO:0005102); protein binding (GO:0005515); extracellular region (GO:0005576); extracellular space (GO:0005615); female pregnancy (GO:0007565); negative regulation of peptidase activity (GO:0010466); growth factor binding (GO:0019838); enzyme binding (GO:0019899); interleukin-8 binding (GO:0019959); interleukin-1 binding (GO:0019966); peptidase inhibitor activity (GO:0030414); identical protein binding (GO:0042802); tumor necrosis factor binding (GO:0043120); calcium-dependent protein binding (GO:0048306); brain-derived neurotrophic factor binding (GO:0048403); nerve growth factor binding (GO:0048406); stem cell differentiation (GO:0048863)",A2m,0.091889539,-10.8826316,0.73779789,0.058690163,0.002028943,0.23060812,-4.3363607,0.80082194,0.17147713,0.24348243,0.20640519,-4.8448395,1.0081355,0.22210947,0.11617713,0.74876506,-1.3355324,0.37101551,0.20301124,1
CDX4,1.2,1.2,0,0,0,1.1629116,,"[Plus], [# of exons: 3], [Gene type: NM]","chrX:100,516,737-100,525,563",NM_007674,"Cdx4, caudal type homeobox 4, homeobox protein CDX-4|caudal type homeo box 4|caudal-type homeobox protein 4, Predicted to have DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Involved in several processes, including blood vessel development; labyrinthine layer development; and negative regulation of transcription by RNA polymerase II. Predicted to localize to nucleus. Is expressed in several structures, including embryo mesenchyme; extraembryonic component; genitourinary system; gut; and neural tube. Orthologous to human CDX4 (caudal type homeobox 4).","negative regulation of transcription by RNA polymerase II (GO:0000122); RNA polymerase II regulatory region sequence-specific DNA binding (GO:0000977); RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); RNA polymerase II transcription factor activity, sequence-specific DNA binding (GO:0000981); transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0001228); blood vessel development (GO:0001568); placenta development (GO:0001890); DNA binding (GO:0003677); DNA binding transcription factor activity (GO:0003700); nucleus (GO:0005634); regulation of transcription, DNA-templated (GO:0006355); regulation of transcription by RNA polymerase II (GO:0006357); multicellular organism development (GO:0007275); embryo development (GO:0009790); animal organ morphogenesis (GO:0009887); anterior/posterior axis specification (GO:0009948); anterior/posterior pattern specification (GO:0009952); cell differentiation (GO:0030154); positive regulation of transcription by RNA polymerase II (GO:0045944); labyrinthine layer development (GO:0060711); sequence-specific double-stranded DNA binding (GO:1990837)",Cdx4,0.015773261,-63.3984323,1.1629116,0.013293319,6.00E-06,0.033960863,-29.4456593,0.16629207,0,0.57208145,0.17782711,-5.6234395,0.27494282,0.042860112,1,3.924509,3.924509,0,0.030051219,1
NC_INTRA_C12_10884,1.2,1.2,0,0,0,1.27729,,"[~1%  IN BLACKLIST], [Minus], [# Lnc isoforms: 32], [# of exons: 31], [Gene type: lncRNA]","chr12:105,384,380-105,385,116 chr12:105,392,083-105,653,343",NR_162781,"lnc_intra-as_chr12_10884, ; Mir12183, microRNA 12183, microRNA mir-12183",,Gm51267 lnc_intra-as_chr12_10884,0.28220743,-3.5434928,1.27729,0.34478617,0.03698175,0.8786055,-1.1381672,0.50895398,0.47359576,1,1.3765636,1.3765636,0.36856022,0.53489321,1,1.5509257,1.5509257,0.13337144,0.14334692,1
NC_AS_C7_6048,1.2,1.2,0,0,0,1.5762792,,"[~9%  IN BLACKLIST], [Plus], [# Lnc isoforms: 2], [# of exons: 3], [Gene type: lncRNA]","chr7:31,707,653-31,729,453",,"Gm44662, ; lnc_as_chr7_6048, ",,Gm44662 lnc_as_chr7_6048,0.20746407,-4.8201117,1.5762792,0.32046043,0.019426564,1.1270504,1.1270504,0.64960635,0.762881,1,0.69277439,-1.4434714,1.0547762,0.79448965,1,0.85246779,-1.1730649,1.0512372,0.62361273,1
NC_INTER_C7_43800,1.1,1.1,0,0,0,14.797014,,"[Minus], [# Lnc isoforms: 1], [# of exons: 1], [Gene type: lncRNA]","chr7:7,022,951-7,023,885",,"lnc_inter_chr7_43800, ",,lnc_inter_chr7_43800,4.3451469,4.3451469,1.7790249,7.9977609,0.046228933,2.104285,2.104285,3.998986,8.6081309,1,3.4864676,3.4864676,3.9529641,14.357772,1,2.9829696,2.9829696,5.8170932,14.797014,1
NC_INTER_C1_416,1.1,1.1,0,0,0,1.746702,,"[Minus], [# Lnc isoforms: 2], [# of exons: 3], [Gene type: lncRNA]","chr1:93,299,832-93,302,653",NR_026924,"1700020N18Rik, RIKEN cDNA 1700020N18 gene; lnc_inter_chr1_416, ",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),1700020N18Rik lnc_inter_chr1_416,39.156614,39.156614,0.030063073,1.746702,0.048496588,7.1180181,7.1180181,0.10635111,0.91780183,1,13.451861,13.4518611,0.048764441,0.98670786,0.93455677,1.2857708,1.2857708,0.52481953,0.38592688,1
NC_INTER_C13_24362,1.1,1.1,0,0,0,4.8160206,,"[Minus], [# Lnc isoforms: 33], [# of exons: 1], [Gene type: lncRNA]","chr13:67,985,922-67,989,405",,"lnc_inter_chr13_24362, ",,lnc_inter_chr13_24362,8.3569078,8.3569078,0.29963465,2.2205285,0.013832706,3.6028597,3.6028597,0.89379285,3.1225159,1,6.2092711,6.2092711,0.77278375,4.8160206,0.73614783,5.3805317,5.3805317,0.85671629,3.3984513,0.98713094
2610507I01RIK,1.1,1.1,0,0,0,62.459464,,"[Minus], [# of exons: 3], [Gene type: NR]","chr11:59,011,295-59,015,933",NR_037964,"2610507I01Rik, RIKEN cDNA 2610507I01 gene",molecular_function (GO:0003674); cellular_component (GO:0005575); biological_process (GO:0008150),2610507I01Rik,20.406121,20.406121,0.26135676,5.6316822,0.005303112,2.8160397,2.8160397,4.5932281,12.756907,0.61401804,5.2990547,5.2990547,3.2185504,18.302391,0.10630322,1.7524211,1.7524211,45.306037,62.459464,1
BHLHE41,1.1,1.1,0,0,0,2.4422996,,"[Minus], [# of exons: 5], [Gene type: NM]","chr6:145,806,763-145,813,940",NM_001271768 NM_024469,"Bhlhe41, basic helix-loop-helix family, member e41, class E basic helix-loop-helix protein 41|bHLH transcriptional factor Dec2|basic helix-loop-helix domain containing, class B3|class B basic helix-loop-helix protein 3|differentially expressed in chondrocytes protein 2, Exhibits several functions, including DNA-binding transcription factor binding activity; DNA-binding transcription repressor activity, RNA polymerase II-specific; and protein dimerization activity. Involved in circadian regulation of gene expression; negative regulation of myotube differentiation; and negative regulation of transcription, DNA-templated. Predicted to localize to nucleus. Is expressed in several structures, including alimentary system; brain; heart; sensory organ; and testis. Orthologous to human BHLHE41 (basic helix-loop-helix family member e41).","negative regulation of transcription by RNA polymerase II (GO:0000122); RNA polymerase II proximal promoter sequence-specific DNA binding (GO:0000978); RNA polymerase II transcription factor activity, sequence-specific DNA binding (GO:0000981); transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0001227); DNA binding (GO:0003677); transcription corepressor activity (GO:0003714); protein binding (GO:0005515); nucleus (GO:0005634); nucleoplasm (GO:0005654); regulation of transcription, DNA-templated (GO:0006355); regulation of transcription by RNA polymerase II (GO:0006357); circadian rhythm (GO:0007623); anterior/posterior pattern specification (GO:0009952); negative regulation of myotube differentiation (GO:0010832); negative regulation of transcription by competitive promoter binding (GO:0010944); transcriptional repressor complex (GO:0017053); circadian regulation of gene expression (GO:0032922); protein homodimerization activity (GO:0042803); histone deacetylase binding (GO:0042826); bHLH transcription factor binding (GO:0043425); MRF binding (GO:0043426); negative regulation of transcription, DNA-templated (GO:0045892); protein heterodimerization activity (GO:0046982); protein dimerization activity (GO:0046983); rhythmic process (GO:0048511); regulation of neurogenesis (GO:0050767); RNA polymerase II sequence-specific DNA binding transcription factor binding (GO:0061629); E-box binding (GO:0070888)",Bhlhe41,11.754741,11.7547412,0.098071676,1.2559095,0.001580407,4.7029158,4.7029158,0.34459633,2.0447875,0.32017352,13.151366,13.1513663,0.11500445,1.8440801,0.053275689,4.3670385,4.3670385,0.77384494,2.4422996,0.45924895
CYP7B1,1.1,1.1,0,0,0,25.103979,,"[Minus], [# of exons: 6], [Gene type: NM]","chr3:17,971,950-18,038,102 chr3:18,039,328-18,046,622 chr3:18,047,360-18,057,984 chr3:18,059,801-18,060,828 chr3:18,061,947-18,088,168 chr3:18,088,949-18,104,655 chr3:18,105,028-18,107,227 chr3:18,125,076-18,129,965 chr3:18,130,189-18,143,338",NM_007825,"Cyp7b1, cytochrome P450, family 7, subfamily b, polypeptide 1, cytochrome P450 7B1|24-hydroxycholesterol 7-alpha-hydroxylase|25-hydroxycholesterol 7-alpha-hydroxylase|25/26-hydroxycholesterol 7-alpha-hydroxylase|3-hydroxysteroid 7-alpha hydroxylase|cytochrome P450, 7b1|hippocampal transcript 1 protein|oxysterol 7-alpha-hydroxylase, Exhibits oxysterol 7-alpha-hydroxylase activity. Involved in several processes, including B cell chemotaxis; bile acid biosynthetic process; and negative regulation of intracellular estrogen receptor signaling pathway. Predicted to localize to intracellular membrane-bounded organelle. Is expressed in several structures, including alimentary system; brain; genitourinary system; limb; and sensory organ. Human ortholog(s) of this gene implicated in congenital bile acid synthesis defect 3 and hereditary spastic paraplegia 5A. Orthologous to human CYP7B1 (cytochrome P450 family 7 subfamily B member 1).","monooxygenase activity (GO:0004497); iron ion binding (GO:0005506); endoplasmic reticulum (GO:0005783); lipid metabolic process (GO:0006629); steroid biosynthetic process (GO:0006694); bile acid biosynthetic process (GO:0006699); digestion (GO:0007586); memory (GO:0007613); circadian rhythm (GO:0007623); steroid metabolic process (GO:0008202); cholesterol metabolic process (GO:0008203); steroid hydroxylase activity (GO:0008395); oxysterol 7-alpha-hydroxylase activity (GO:0008396); membrane (GO:0016020); integral component of membrane (GO:0016021); oxidoreductase activity (GO:0016491); oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen (GO:0016705); heme binding (GO:0020037); negative regulation of intracellular estrogen receptor signaling pathway (GO:0033147); 25-hydroxycholesterol 7alpha-hydroxylase activity (GO:0033783); B cell chemotaxis (GO:0035754); cholesterol homeostasis (GO:0042632); intracellular membrane-bounded organelle (GO:0043231); metal ion binding (GO:0046872); 27-hydroxycholesterol 7-alpha-monooxygenase activity (GO:0047092); positive regulation of epithelial cell proliferation (GO:0050679); prostate gland epithelium morphogenesis (GO:0060740)",Cyp7b1,3.6222315,3.6222315,1.1441607,3.6860316,0.034420694,2.2170817,2.2170817,1.9199409,4.3962974,0.17195309,2.5899146,2.5899146,3.1232578,8.5942358,0.1143466,1.5214715,1.5214715,21.274606,25.103979,1
NC_INTER_C10_9349,1.1,1.1,0,0,0,18.692138,,"[Plus], [# Lnc isoforms: 11], [# of exons: 1], [Gene type: lncRNA]","chr10:120,925,673-120,934,294",XR_872127 XR_872128,"Gm40787, predicted gene, 40787; lnc_inter_chr10_9349, ",,Gm40787 lnc_inter_chr10_9349,7.5648918,7.5648918,0.15002579,1.1076507,0.004406036,3.2570406,3.2570406,1.8749611,6.2136728,0.94008527,5.1242843,5.1242843,1.1907363,6.973466,0.13774019,2.8135056,2.8135056,8.8780977,18.692138,0.84874597
SUSD4,1.1,1.1,0,0,0,2.3007424,,"[Plus], [# of exons: 10], [Gene type: NM]","chr1:184,694,175-184,826,720",NM_001356461 NM_001356462 NM_001356463 NM_001356464 NM_144796,"Susd4, sushi domain containing 4, sushi domain-containing protein 4, Predicted to be involved in negative regulation of complement activation, alternative pathway and negative regulation of complement activation, classical pathway. Predicted to localize to integral component of membrane. Is expressed in brain. Orthologous to human SUSD4 (sushi domain containing 4).","molecular_function (GO:0003674); cellular_component (GO:0005575); membrane (GO:0016020); integral component of membrane (GO:0016021); regulation of complement activation (GO:0030449); negative regulation of complement activation, alternative pathway (GO:0045957); negative regulation of complement activation, classical pathway (GO:0045959)",Susd4,8.7258235,8.7258235,0.027764875,0.25356281,0.002001472,2.2147002,2.2147002,0.11210833,0.28636241,0.75145852,2.2796116,2.2796116,0.084726403,0.20248237,1,3.1324618,3.1324618,1.0495837,2.3007424,0.061078793
PAK6,1.1,1.1,0,0,0,1.4770496,,"[Plus], [# of exons: 12], [Gene type: NM]","chr2:118,489,313-118,523,756",NM_001033254 NM_001145854,"Pak6, p21 (RAC1) activated kinase 6, serine/threonine-protein kinase PAK 6|PAK-6|p21 protein (Cdc42/Rac)-activated kinase 6|p21-activated kinase 6, Predicted to have protein serine/threonine kinase activity. Involved in learning or memory; locomotory behavior; and neuron projection morphogenesis. Predicted to localize to cell junction; cytoplasm; and nuclear lumen. Is expressed in central nervous system; retina; submandibular gland primordium; and tooth. Human ortholog(s) of this gene implicated in clear cell renal cell carcinoma. Orthologous to several human genes including BUB1B-PAK6 (BUB1B-PAK6 readthrough).",nucleotide binding (GO:0000166); fibrillar center (GO:0001650); protein kinase activity (GO:0004672); protein serine/threonine kinase activity (GO:0004674); ATP binding (GO:0005524); nucleus (GO:0005634); nucleoplasm (GO:0005654); cytoplasm (GO:0005737); protein phosphorylation (GO:0006468); learning (GO:0007612); memory (GO:0007613); locomotory behavior (GO:0007626); kinase activity (GO:0016301); phosphorylation (GO:0016310); transferase activity (GO:0016740); cell junction (GO:0030054); activation of protein kinase activity (GO:0032147); intracellular signal transduction (GO:0035556); regulation of MAPK cascade (GO:0043408); neuron projection arborization (GO:0140058); neuron projection extension (GO:1990138),Pak6,14.902125,14.9021253,0.010089682,0.16791339,0.037703059,1.7210984,1.7210984,0.18486929,0.38115066,1,1.8937897,1.8937897,0.1328449,0.24768421,1,1.5583647,1.5583647,1.4363169,1.4770496,1
CDHR2,1.1,1.1,0,0,0,0.52602694,,"[Plus], [# of exons: 32], [Gene type: NM]","chr13:54,802,824-54,838,023",NM_001033364,"Cdhr2, cadherin-related family member 2, cadherin-related family member 2|protocadherin 24|protocadherin LKC, Predicted to have cell adhesion molecule binding activity. Predicted to be involved in several processes, including cell-cell adhesion mediated by cadherin; intermicrovillar adhesion; and negative regulation of cell growth involved in contact inhibition. Predicted to localize to apical plasma membrane; cell projection membrane; and spanning component of plasma membrane. Orthologous to human CDHR2 (cadherin related family member 2).",calcium ion binding (GO:0005509); plasma membrane (GO:0005886); integral component of plasma membrane (GO:0005887); brush border (GO:0005903); cell adhesion (GO:0007155); homophilic cell adhesion via plasma membrane adhesion molecules (GO:0007156); membrane (GO:0016020); integral component of membrane (GO:0016021); apical plasma membrane (GO:0016324); cell junction (GO:0030054); cell differentiation (GO:0030154); epithelial cell differentiation (GO:0030855); brush border membrane (GO:0031526); microvillus membrane (GO:0031528); regulation of microvillus length (GO:0032532); cell projection (GO:0042995); spanning component of plasma membrane (GO:0044214); cell-cell adhesion mediated by cadherin (GO:0044331); cell adhesion molecule binding (GO:0050839); negative regulation of cell growth involved in contact inhibition (GO:0060243); intermicrovillar adhesion (GO:0090675); cell-cell adhesion (GO:0098609),Cdhr2,6.0536357,6.0536357,0.083627987,0.52602694,0.005895822,2.1223038,2.1223038,0.21322914,0.42928799,1,2.6494818,2.6494818,0.15546593,0.43146945,1,1.15817,1.15817,0.39859012,0.3195283,1